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Abstract 
Protein-protein interactions (PPIs) present a challenging target for the development of 
inhibitors, due to the large size and lipophilicity of protein binding sites. Because of this, 
work that is able to increase our understanding of how PPI inhibitors can be better 
developed is of great value. 
 
In unusual cases, approved drug compounds are able to exhibit excellent pharmacological 
(PK) profiles despite having unfavourable physical properties. New methodology was 
developed whereby the solubilising side chains found in one such compound, daclatasvir, 
could be incorporated onto aryl-bromides using palladium-catalysed C-H activation. The 
scope of the reaction was tested, and in 18 different examples the C-H activation was 
found to be successful 11 times.1 This methodology has application in the potential 
synthesis of cell-permeable PPI inhibitors. 
 
Inhibiting the PALB2/BRCA2 PPI has the potential to produce synthetic lethality in 
cancerous cells with damaged DNA repair mechanisms. Computational techniques were 
used to design small-molecule and miniprotein mimetics of BRCA2, which could 
potentially competitively inhibit PALB2/BRCA2. This resulted in the purchase of 10 
miniprotein sequences ready for testing, one of which has been proven to have significant 
helical secondary structure. The synthesis of small molecule α-helical mimetics of 
BRCA2 has also been carried out, with one compound ready for biological testing and 
the synthesis of two others close to completion. 
 
Publications:  
1 T. O. Moore, M. Paradowski and S. E. Ward, Org. Biomol. Chem., 2016, 14, 
3307–3313.  
iv 
 
 
 
List of Abbreviations 
Ac Acetyl, CH3CO 
ACPC  Aminocyclopentylcarboxylate, C6H11NO2 
AIDS  Acquired immune deficiency syndrome 
AMBER Assisted model building with energy refinement  
ANP atrial natriuretic peptides  
aPP Avian pancreatic peptide 
AR Androgen receptor 
Ar Aryl 
AUC Area-under-the-curve 
Bcl B-cell lymphoma 
BER Base excision repair  
[BMIm][PF6] 1-Butyl-3-methylimidazolium hexafluorophosphate, C8H15F6N2P 
BMS Bristol Myers-Squibb  
Boc tert-Butoxycarbonyl, C4H9O2 
BRCA1 Breast cancer 1 
BRCA2 Breast cancer 2 
brm Broad medium adsorption (IR spectroscopy) 
brs Broad singlet (1H NMR spectroscopy) 
brw Broad weak adsorption (IR spectroscopy) 
CaM Calmodulin  
Cbz Carboxybenzyl, C8H7O2 
CD Circular dichroism 
ChTx Charybdotoxin 
CMD Concerted metalation-deprotonation  
DFT  Density functional theory 
DIPEA Diisopropylethylamine, C2H5N(C3H7)2 
DMA Dimethyl acetamide, C3H7NO 
DMF Dimethyl formamide, C4H9NO 
DMSO Dimethyl sulfoxide, C2H6OS 
DNA Deoxyribose nucleic acid 
DSB Double Strand Break  
DSF Differential scanning fluorimetry  
v 
 
 
 
EDAC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, C8H17N3 
ER Oestrogen receptor 
Et Ethyl, C2H5 
F Bioavailability 
Fmoc Fluorenylmethyloxycarbonyl, C15H11O2 
FT Fourier Transform 
GPCR G-protein coupled receptor 
HBTU N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate, C11H16F6N5OP 
hCD4  Human cluster of differentiation 4  
HCV Hepatitis C 
Hdm2 Human double minute 2 homolog 
HIF Hypoxia-inducible factor  
HIV Human immunodeficiency virus 
HOBt Hydroxybenzotriazole, C6H5N3O 
HPLC High-pressure liquid chromatography 
HSA Human serum albumin 
HWE Horner-Wadsworth-Emmons 
IBX 2-Iodoxybenzoic acid, C7H5IO4 
IgG1  Immunoglobin G1 
IL-2 Interleukin-2 
iPr iso-Propyl, CH(CH3)2 
KHMDS Potassium hexamethyldisilazide, KSi2C6NH18 
KNIME Konstanz Information Miner 
LCMS Liquid-chromatography/mass-spectroscopy  
MCL-1 Induced myeloid leukemia cell differentiation protein 
Mdm2 Mouse double minute 2 homolog 
Me Methyl, CH3 
MIDA Methyliminodiacetic acid, CH3N(CH2CO2H)2 
MMFF94 Merck molecular force field 
MOE Molecular Operating Environment 
MWT Molecular weight  
NER Nucleotide excision repair  
vi 
 
 
 
NHC N-Heterocyclic carbene  
NHEJ Non-homologous end joining  
NMDA N-methyl-ᴅ-aspartate, C5H9NO4 
NMI N-methyl imidazole, C3H3N2CH3 
NMP N-methyl-2-pyrrolidone, C5H9NO 
NMR Nuclear magnetic resonance 
NOE Nuclear Overhauser effect 
NR Nuclear receptor 
NS5A  Non-structural protein 5A 
PALB2 Partner and localiser of BRCA2  
PARP Poly ADP ribose polymerase  
PEG-IFN Pegylated interferon α  
Ph Phenyl, C5H6 
PPI Protein-protein interaction 
PPII Polyproline-II 
RNA  Ribose nucleic acid 
SAR Structure activity relationship 
SEM 2-(Trimethylsilyl)ethoxymethyl, CH2OC2H4Si(CH3)3 
SMAC Second mitochondria-derived activator of caspases 
smMLCK Smooth muscle myosin light-chain kinase  
SSB Single Strand Break  
TBAC Tetrabutylammonium chloride, (C4H9)4NCl 
TBAF Tetrabutylammonium fluoride, (C4H9)4NCl 
tBu tert-Butyl, C(CH3)3 
TCEP Tris(2-carboxyethyl)phosphine, C9H15O6P 
TEMPO (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl, C9H18NO 
Tf Trifluoromethanesulfonic (triflic), CF3O2F 
TFA Trifluoroacetic acid, CF3COOH 
TFIIH Transcription factor II H  
THF Tetrahydrofuran, (CH2)4O 
TPSA Topological polar surface area 
XIAP X-linked inhibitor of apoptosis protein 
Zif286 Zinc finger 286 
 
vii 
 
 
 
Contents 
1 Introduction .............................................................................................................. 1 
1.1 The Search for a New Generation of Drug Targets ...................................... 1 
1.1.1 Protein-Protein Interactions (PPIs) Make Difficult Drug Targets .............. 2 
1.2 Assessing PPIs for Druggability ...................................................................... 3 
1.2.1 Using Computational Methods to Test PPI Druggability ........................... 4 
1.3 Designing Protein Mimetics to Inhibit PPIs ................................................... 7 
1.3.1 Using Foldamers to Inhibit PPIs ................................................................. 8 
1.3.2 Using Designed Miniproteins to Inhibit PPIs ........................................... 10 
1.3.3 Using Stapled Helices to Inhibit PPIs ....................................................... 28 
1.3.4 Using small molecule α-helical mimetics to inhibit PPIs ......................... 36 
1.3.5 Targeting PPIs using the Conventional Drug Discovery Process ............. 43 
1.4 Conclusion ....................................................................................................... 45 
2 Instilling ‘daclatasvir-like’ functional groups using palladium catalysed C-H 
activation. ....................................................................................................................... 47 
2.1 Chapter Summary .......................................................................................... 47 
2.2 The Unusual Pharmacokinetics of Daclatasvir, and potential application to 
PPIs.  .......................................................................................................................... 47 
2.3 Retrosynthetic Analysis of Daclatasvir Side-chains .................................... 50 
2.3.1 C-H Activation of Imidazoles in the 2-Position. ....................................... 51 
2.4 Synthesis of the Imidazole Reagent for C-H Activation ............................. 55 
2.4.1 Synthesis of Imidazole 19 ......................................................................... 56 
2.4.2 Peptide coupling to form amide 38 ........................................................... 60 
2.4.3 SEM Protection of Imidazole N-H to Form C-H Activation Reagents .... 63 
2.5 Optimisation of C-H Activation Conditions ................................................ 64 
2.5.2 Confirming the Optimised Conditions for Fully Functionalised Imidazole 
44  ................................................................................................................... 67 
2.5.3 SEM-group Removal to Yield Daclatasvir ............................................... 69 
2.6 Testing the Scope of the C-H activation reaction on different aryl 
dibromides .................................................................................................................. 70 
2.6.1 Incompatibility with alkynyl residues. ...................................................... 71 
2.6.2 Incompatibility with N-H residues ............................................................ 72 
2.6.3 Incompatibility of pyridyl functionality .................................................... 73 
viii 
 
 
 
2.7 Synthesis of different cores for C-H activation ............................................ 75 
2.7.1 Synthesis of bisphenylalkyne 53 ............................................................... 75 
2.7.2 Synthesis of Dibromobiphenylether 71 ..................................................... 75 
2.7.3 Synthesis of Benzoxazole 75 .................................................................... 76 
2.7.4 Synthesis of amide 56 and N-methyl amide 59 ......................................... 77 
2.7.5 Synthesis of carbazole 54 and N-methylcarbazole 57............................... 77 
2.7.6 Synthesis of Paal-Knorr products: furan 81, thiophene 82, and pyrroles 55 
and 58  ................................................................................................................... 78 
2.7.7 Synthesis of quinazoline 65 ...................................................................... 80 
2.8 Conclusion ....................................................................................................... 80 
3 Targeting PALB2 with Computational-Based Design of Inhibitors ................. 82 
3.1 Chapter Summary .......................................................................................... 82 
3.2 PALB2/BRCA2 as A Potential Target for Cancer Therapeutics ............... 82 
3.2.1 Treating Cancer through Synthetic Lethality ............................................ 84 
3.2.2 Does PALB2 Have Therapeutic Potential? ............................................... 85 
3.2.3 The Role of Bio- and Cheminformatics in Modern Drug Discovery ....... 85 
3.3 Computational Design of Small molecule BRCA2 Mimetics ..................... 88 
3.3.1 Designing a Database of Small Molecule BRCA2 Mimetics ................... 89 
3.3.2 Generating Conformers of BRCA2 Mimetics and Aligning Them to The 
BRCA2 Helix Using RDKit .................................................................................... 92 
3.3.3 Using MOE to Remove Conformers with High E_Strain ......................... 94 
3.3.4 Using MOE to Dock the Best Conformers into PALB2 to Reinforce 
Predicted Activity .................................................................................................... 94 
3.3.5 Results of Alignment and Docking Studies .............................................. 95 
3.3.6 Searching For Alternative Routes to the i+4 Position Using Docking 
Studies  ................................................................................................................... 98 
3.3.7 Choosing Candidates for Synthesis ......................................................... 100 
3.4 Design of Miniproteins to Mimic BRCA2 .................................................. 101 
3.4.1 Searching for Structurally Stable Miniproteins with Known Structures 101 
3.4.2 Analysing Structures for Suitability to Adopt the BRCA2 WFXXL Motif, 
and Designing Mutant Structures .......................................................................... 102 
3.4.3 Constructing Homology Models of Designed Miniprotein Sequences .. 102 
ix 
 
 
 
3.4.4 Superposition of Miniproteins with BRCA2 to Test for Steric 
Incompatibilities .................................................................................................... 103 
3.4.5 Selecting 10 Sequences for Synthesis ..................................................... 103 
3.4.6 Testing the Miniprotein Sequences for Helicity ..................................... 105 
3.5 Conclusion ..................................................................................................... 106 
4 The Synthesis of Small Molecule BRCA2 Mimetics ......................................... 107 
4.1 Chapter Summary ........................................................................................ 107 
4.2 Retrosynthetic Analysis of Target Cores from Computational Results .. 107 
4.2.1 Retrosynthetic Analysis to Functionalise the i, i+1 and i+4 Positions .... 108 
4.2.2 The Retrosynthetic Analysis of i, i+1 and i+4 Functionalisable Cores 
Proved Synthetically Challenging ......................................................................... 111 
4.2.3 Retrosynthetic Analysis of the i, i+1 Scaffold as a Synthetically Accessible 
Alternative ............................................................................................................. 113 
4.3 Challenges towards the Synthesis of a Pyridazine Based i, i+1 Scaffold . 114 
4.3.1 Review of Published Synthetic Routes to Pyridazines ........................... 115 
4.3.2 Synthetic Steps Attempted Towards a Pyridazine Based BRCA2 Mimetic . 
  ................................................................................................................. 118 
4.4 Synthesis of All-Hydrocarbon Indane-Based Wittig Reagents ................ 123 
4.4.1 Intramolecular Friedel-Crafts Acylation Reactions. ............................... 124 
4.4.2 Functionalisation of 6-Methoxyindanone (162) in the i+1 Position Prior to 
Wittig Functionalisation ........................................................................................ 125 
4.4.3 The Reduction of Indanones to Alcohols ................................................ 126 
4.4.4 The Conversion of Indanols to Phosphonium Salts for Wittig Chemistry ... 
  ................................................................................................................. 127 
4.5 Using the Wittig Reaction to Functionalise the i+1 position .................... 129 
4.5.1 Using the Wittig Reaction to Synthesise Reagent 178............................ 130 
4.5.2 Synthesis of Reagents for the Two-Carbon Linker i Functionalisation .. 132 
4.6 Using Heck and Sonogashira Chemistry to Functionalise the i+1 Position, 
and Hydrogenation to Give Final Compounds ..................................................... 133 
4.7 Conclusions ................................................................................................... 135 
5 Conclusion and Further Work ........................................................................... 136 
5.1 Conclusions ................................................................................................... 136 
5.2 Further Work ............................................................................................... 138 
x 
 
 
 
6 Experimental Information .................................................................................. 141 
6.1 General Information .................................................................................... 141 
6.1.1 General Software Packages ..................................................................... 142 
6.2 Chemistry Experimental Procedures ......................................................... 142 
6.3 Biochemical Procedures ............................................................................... 189 
6.3.1 Circular Dichroism .................................................................................. 189 
6.3.2 Miniprotein Refolding General Procedure .............................................. 189 
6.4 Computational Procedures .......................................................................... 189 
6.4.1 Small Molecule Mimetics: Markush Enumeration ................................. 189 
6.4.2 Small Molecule Mimetics: Conformer Generation And Alignment To 
BRCA2  ................................................................................................................. 191 
6.4.3 Small Molecule Mimetics: MOE E_Strain ............................................. 193 
6.4.4 Small Molecule Mimetics: Small Molecule Docking in MOE ............... 193 
6.4.5 Small Molecule Mimetics: 4-Substituted Indole Docking in MOE ........ 195 
6.4.6 Miniprotein Design: Homology Modelling in MOE .............................. 197 
6.4.7 Miniprotein Design: Alignment and Superposition of Miniprotein 
Homology Models to Test For Steric Incompatibilities ........................................ 198 
7 Bibliography ......................................................................................................... 200 
 
 
  
1 
 
 
1 Introduction 
1.1 The Search for a New Generation of Drug Targets 
It is no surprise that the easiest to target and best-understood proteins have often been the 
focus of drug discovery programmes. In their seminal paper published in 2002, Hopkins 
and Groom demonstrated the skew that this bias had afforded on the targets of available 
drugs,1 with over 75 % of drugs on the market designed to target either an enzyme or a 
G-protein coupled receptor (GPCR) (Figure 1.1). 
 
Figure 1.1: The target protein class of marketed drugs in 2002, adapted from a publication by Hopkins 
and Groom.1 
Enzymes and GPCRs make ideal drug targets.2 Proteins from these classes bind to small 
molecules to drive their function within the body. For example, enzymes bind to a 
substrate and catalyse a chemical transformation at the active site, while GPCRs bind to 
a chemical messenger and trigger a response within the cell. The existence of these 
endogenous small molecule ligands for the proteins provides two key benefits for the 
medicinal chemist. Firstly, it means that there must already be a pocket on the protein 
surface of the correct size and with the potential for the correct intermolecular interactions 
to bind to a drug molecule (enzyme pockets are typically 300-1000 Å2, ideal for binding 
to a drug).3 Secondly, the natural ligand can be used as a lead for drug design. Indeed, 
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before developments in biochemistry which allowed us to better understand the three-
dimensional structure of proteins, this was a commonly used practice for drug design. For 
example, the psychoactive tryptamine and amphetamine families of compounds were 
designed by using serotonin and dopamine as chemical leads respectively, both of which 
are ligands for GPCRs within the brain.4 
 
Given the relative ease with which the medicinal chemist can design drug compounds for 
enzymes and GPCRs, it is no real surprise that they comprise such a large portion of 
marketed drug classes in 2002.1 However, as time has moved on, the number of readily 
targeted proteins without marketed drugs has decreased. As a result, medicinal chemists 
are left to look towards less conventional drug targets, which provide fewer 
straightforward opportunities to develop inhibitors. In the words of Wells and 
McClendon, we are left ‘reaching for high-hanging fruit in drug discovery’.5 One such 
class of underdeveloped targets for drugs that has emerged in recent years is protein-
protein interactions (PPIs). 
 
1.1.1 Protein-Protein Interactions (PPIs) Make Difficult Drug Targets 
The interface between two proteins is not a traditional target for small molecules. Unlike 
the intrinsic pockets on enzymes and GPCRs, a PPI is much larger (typically 1500-4500 
Å2 compared to 300-1000 Å2).6,7 They are also mostly governed by lipophilic interactions 
and London dispersion forces, and usually lack the high numbers of hydrogen bond 
donors and acceptors required to achieve selectivity with small molecule ligands.8 
Finally, they are often quite flat in shape, and do not always provide an environment 
which allows a drug to be enveloped by the protein. Each of these factors cause PPIs to 
be less well suited to inhibition by small molecules than enzymes or GCPRs.9 
 
Although they may be difficult to target, PPIs could have great therapeutic potential. 
There are predicted to be around 40,000 unique PPIs in humans,10 each of which 
contribute to support cell function in some way. When considering that currently only 
around 3000 proteins exist which belong to families for which small molecule inhibitors 
have been developed, there is great potential to be gained from inhibiting just a small 
fraction of available PPIs. Unlike enzymes and GPCRs, they are involved in a large 
variety of different roles within the cell, and therefore offer a much wider range of 
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potential therapeutic effects when targeted by small molecules. For example, very few 
enzymes have been discovered to have therapeutic potential for the treatment of cancer, 
although there are notable exceptions such as receptor tyrosine kinases.11 Moreover, by 
inhibiting PPIs, there is a large amount of choice of potential drug targets for cancer, and 
with it the potential for cancer specific small-molecule drugs.12 
 
Given the huge number of PPIs from which a drug target can be selected, it stands to 
reason that if even a small proportion of them are found to be druggable, a large number 
of potential new ‘high-hanging fruit’ targets may be accessed. This brings two major 
challenges for the medicinal chemist in the search for PPI inhibitors. Firstly, a protein 
target must be selected with care, to ensure that it is both druggable and has therapeutic 
potential. Secondly, the design of potential inhibitors must be approached with creativity, 
as PPI inhibitors often differ in structure to conventional drugs. This chapter will briefly 
discuss the important considerations to take when selecting a PPI, followed by an in depth 
review into the different methods developed to design PPI inhibitors. 
 
1.2 Assessing PPIs for Druggability 
Historically, PPIs were considered to be too large and flat13 and with electrostatic and 
hydrogen bonding groups too evenly spread across the interface6,14 to allow selective 
binding of small molecules. However, using techniques such as alanine-scanning 
mutagenesis, it became increasingly clear that the affinity of many PPIs was governed by 
a small selection of key residues, known as binding ‘hot-spots’.15,16 If a small molecule 
was able to selectively bind at the site of the hot spot, then it could be possible to inhibit 
the PPI without needing a ligand with an intolerably high molecular weight. However, 
not all hot-spots are amenable to binding by a small-molecule ligand, and thus assessing 
the druggability of the PPI is very important. 
 
Assessing the druggability of PPIs in order to select a target for a drug discovery 
programme is difficult. The hot-spots are typically flat and the implicated residues 
lipophilic, meaning that conventional libraries may not show any binding to the PPI, and 
physical and computational tests may not be sufficiently sensitive to identify positive hits. 
Because of this, there has been a great deal of work into developing methods for screening 
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druggability that are more specific to PPIs.17–19 These can generally be categorised into 
either biophysical or computational screening methods. 
1.2.1 Using Computational Methods to Test PPI Druggability 
In the last two decades, advances in computing have meant that tasks that would have 
previously been performed on a supercomputer can now be carried out on the average 
desktop. This has meant that computational chemistry and bioinformatics have become 
increasingly valuable as the resource costs become negligible. Furthermore, they are also 
more scaleable than wet lab experiments, with the possibility of analysing larger fragment 
libraries quickly against many protein targets. 
 
However, there is much greater room for error in predictions made by computational 
experiments. Computational models rely on physical approximations and each of these 
increases error margins in the results obtained. Because of this, it is common practice to 
only use results obtained computationally in support, often helping to reduce the number 
of expensive biophysical experiments. There are several different approaches to 
predicting the druggability of PPIs computationally. 
 
1.2.1.1 Statistical Analysis of Existing Non-Crystallographic Data 
One approach that has traditionally proven useful for assessing the druggability of 
proteins is the statistical analysis of non-crystallographic data, normally protein 
homology analysis. This is the most basic form of computational druggability analysis, 
as it does not require three-dimensional information about the protein structure. For 
example, the protein sequence may be analysed to find domains that are shared with other 
families of proteins. If there is high homology with protein domains that have known 
inhibitors, then the target protein might also be of interest for inhibitor development. 
Online resources such as BLAST20,21 enable the user to conduct this analysis quickly and 
simply on any protein.22 Other attempts have been made to determine hot-spot residues 
through this approach. By analysing which residues are conserved between protein 
domains similar to those involved in a PPI, the Consurf algorithm attempts to determine 
which are the functional regions, and thus the likelihood of individual residues to be hot-
spots.23 
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Statistical analysis such as this has relatively low demand on computational processing 
power, and so large amounts of analysis can be carried out very quickly. However, it also 
relies on having access to a large amount of existing data, for example on known ligands, 
and pre-established druggability of protein domain families. As the field of PPI inhibition 
is not yet well established, there is little information of this kind to support their analysis, 
and thus purely statistical approaches to assessing druggability are less useful.  
 
1.2.1.2 Predicting Druggability Based on Protein Surface Topology 
A very common method for assessing the druggability of a protein is to use algorithms 
that analyse the topology of a protein surface in order assess the likelihood that a drug-
like molecule could interact at any site. However, the standard algorithms for detecting 
such pockets on a protein, such as Fpocket,24 may not be able to detect the pockets and 
hot spots at a PPI as they are too shallow or lipophilic by the normal metrics used.25 
Because of this, esoteric algorithms geared towards the detection of pockets on PPIs have 
been developed.  
 
Unfortunately by reducing the stringency of pocket definition to enable their detection at 
PPI surfaces, the error margins are increased drastically, resulting in increased false 
positives. One approach that has been taken to mitigate this is to use topological pocket 
finding algorithms in combination with statistical analysis such as that discussed above. 
Sugaya and co-workers developed a systematic method for narrowing down protein 
domains using sequential and interactome data to find PPIs which were likely to be 
druggable. They then used pocket-finding algorithms to assess the 3D structures of these 
proteins in order to further predict the druggability.26,27 This resulted in the database of 
potentially druggable PPIs ‘Dr. PIAS’.28 However, their method was unable to correctly 
predict many PPIs proven to be druggable, such as BAK/B-cell lymphoma (BCL)2. 
 
Another method for assessing pockets at a PPI interface was developed by Koes and 
Camacho. PocketQuery uses the residues embedded in the pocket by the complementary 
protein at the PPI to predict druggability.29 They developed a web-based software that 
would select clusters of three amino acid residues that were embedded into a pocket on 
the protein partner at the PPI. Rather than then using the topology of the pocket itself to 
score the PPI for druggability, the software uses the embedded residues, assessing the 
likelihood of being able to design a small molecule mimetic. This is an excellent method 
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for assessing the druggability of a PPI, however, it relies on the existence of a co-crystal 
structure of both partners of the PPI, which is usually only available in cases where a lot 
of work has already been done on the protein towards developing inhibitors. It also 
requires a lot of human input, which could provide a source of bias. 
 
1.2.1.3 Alanine Scanning Mutagenesis 
Alanine scanning mutagenesis is a computational technique that is particularly tailored 
towards assessing the druggability of PPIs due to the importance of amino acid hotspots.30 
This is the computational equivalent of biochemical experiments which use protein 
mutagenesis to discover hotspots in PPIs, by making point mutations of amino acid 
residues to alanine, and testing how these affect the strength of binding at the PPI.15  
DrugScorePPI is a software developed to carry out this experiment computationally.31 
Using the protein crystal structure, amino acids from one protein partner in the PPI are 
sequentially mutated to an alanine and the effect that this has on ΔGbinding of the two 
protein partners is predicted. This is then plotted and any outliers with a high ΔΔGbinding 
can be predicted as potential hot-spots. This is an excellent tool for predicting the 
presence of hotspots and thus the potential druggability of a PPI crystal structure,8 
however, as with PocketQuery, a co-crystal structure of both partners in the PPI must be 
available. 
 
1.2.1.4 Docking ‘Solvent’ Molecules over the Protein Surface 
One docking technique that has emerged recently in order to evaluate the druggability of 
proteins at PPIs involves the docking of small solvent-like molecules over the whole 
surface of a protein crystal structure.32–34 Regions where many binding modes of a solvent 
molecule (a ‘cluster’) are found in one confined area of the protein over a certain threshold 
are designated as hot spots. For example, FTMap34 is a web base application which can 
be used to analyse structures from the protein data-bank (PDB) and search for clusters of 
5 solvent molecules or more, which are then output as a 3D structure (Figure 1.2). This 
has the great advantage over using surface topology to search for pockets, in that it is able 
to detect flatter areas of the protein that may still have the correct electrostatics to bind a 
small molecule. Although not originally intended for the purpose of specifically testing 
for hot-spots on PPIs, this method has been shown to be particularly amenable towards 
them.35 
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Figure 1.2: The hotspots of Urokinase Type Plasminogen Activator (PDB Code: 2O8T), using FTMap. 
Each colour of molecule represents a different solvent cluster, indicating a hot-spot. Clusters of 5 or more 
are shown. 
Recently, this method was taken one step further in an attempt to predict druggability. 
Kozakov and co-workers made an attempt to mimic the pioneering work discussed 
previously by Hadjuk and coworkers,36 where indices were proposed in order to translate 
the direct result of NMR fragment binding studies into a metric of druggability. Kozokov 
analysed a series of FTMap34 outputs of proteins with known small-molecule binders, 
and created a series of criteria which must be met by the FTMap clusters to designate the 
protein as druggable.37 For PPIs they devised a separate set of criteria for proteins that 
are druggable by non-canonically large molecules. Using these, they were able to 
correctly assign 12 out of 15 PPIs with known inhibitors as druggable. Overall, this seems 
to be the most promising computational method to date with regard to predicting 
druggability of unconventional protein targets. 
 
1.3 Designing Protein Mimetics to Inhibit PPIs 
As mentioned previously, one reason PPIs make difficult targets for drug discovery 
programmes is that there is no native small-molecule ligand to the protein, such as in the 
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case of enzymes or GPCRs. Instead the native ligand for the design of PPI inhibitors is 
primarily a set of hot-spot residues on a protein, and mimicking its activity with a small 
molecule requires much more ingenuity. 
 
In order to create mimetics of one half of a PPI, it is necessary to understand the protein 
structures involved. The most common protein secondary structure at a PPI interface is 
the α-helix, which features in 62% of the PPI structures submitted in the PDB.8 Because 
of this, α-helical mimetics are hugely valuable in the development of therapeutics for 
PPIs. Fortunately, α-helices have very defined secondary structures. They consist of a 
coiled peptide backbone, with 3.6 amino acid residues per turn of the helix.38 This 
configuration allows for a hydrogen bond between the carbonyl oxygen of one amino 
acid, and the amide N-H of the amino acid four residues later, denoted as i → i+4. As a 
result, the structure is highly stable. 
 
Although the structure of the α-helix is incredibly well defined, the associated short chain 
polypeptides do not typically spontaneously exist as stable helices. The correct folding 
relies on the conformational influence of the rest of the protein. However, delivering full-
length proteins therapeutically is not an option for intracellular targets, due to lack of 
membrane permeability, and metabolic instability, combined with the high cost of 
expression of sufficiently large quantities. This has led to significant scientific 
development in identifying mimetics for α-helices to use as tool or therapeutic leads for 
the development of PPI inhibitors. 
1.3.1 Using Foldamers to Inhibit PPIs 
A foldamer is an oligopeptide containing unnatural amino acid residues which folds in 
such a way as to mimic the confirmation of biological polymers, in particular protein 
secondary structures.39 This is achieved most simply by modifying the structural elements 
of an amino acid in a small enough way that it retains the ability to fold into the same 
secondary structure when part of an oligomer. These modifications, although subtle, 
should be adequate to prevent the foldamer from being recognised by the enzymes 
involved in biological processes such as proteolysis.  
 
The most basic form of amino acid backbone modification is the insertion of a methylene 
group, to transform an α-amino acid into the respective β-amino acid (Figure 1.3). Early 
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pioneering work in this area was done by D. Seebach,40 who developed the synthesis of 
β-amino acid residues using the Wolff rearrangement. In the same work, Seebach also 
found that hexamers of β-alanine were highly resistant to peptin mediated proteolysis. 
This led to an increase of interest towards these compounds as stable in vivo therapeutic 
polypeptides. 
 
Figure 1.3: The structure of an α-amino acid residue, with some examples of β-residues 
Initially it was hypothesized that as β-polypeptides are less conformationally restricted 
they would be less likely to form secondary structures than their α-polypeptide 
counterparts. Surprisingly however, this was found not to be the case, and furthermore it 
was observed that sometimes β-amino acid foldamers had secondary structures with 
increased stability. Over the last 20 years Gellman has carried out research into how to 
tune the backbone of a synthetic foldamer to achieve the desired secondary structure.41,42 
He has found that close mimetics to the α-helical secondary structure can be achieved by 
utilising alternating α/β subunits. He discovered that by using β-amino acids containing 
hydrocarbon rings to restrict conformational rotation, he could reliably form foldamers 
with the desired ‘α-helical-like’ secondary structure. To do this, he used subunits such as 
aminocyclopentylcarboxylate (ACPC) (Figure 1.3), which could also be seen as a β- form 
of proline. The α/β-polypeptides were also found to be proteolytically stable, akin to β-
polypeptides.43  
 
This reproducible method to design foldamers that will mimic α-helices has led to the 
discovery of several biologically active foldamers that target α-helical PPIs. Gellman 
used cyclic β-amino acids in the design of a foldamer to target human cytomegalovirus.44 
He was able to develop a foldamer with an IC50 of 30 μM, an increase in potency over 
the wild type α-helix which has an IC50 of >100 μM. The technique has also been used to 
target other more conventional PPI interfaces. For example, Schepartz developed an α/β 
peptide mimicking p53 that has only slightly lower affinity than the wild type p53/mouse 
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double minute 2 homolog (Mdm2) interaction (Kd = 368 ± 76 nM and 233 ± 32 nM 
respectively).45,46 
 
Despite the success of these examples, there are still factors that prevent foldamers from 
making effective therapeutic compounds. Although their stability against proteolysis in 
the cell has increased, their large size prevents them from having good membrane 
transport properties. They are also incredibly expensive to produce, as homologation 
reactions used to synthesize β-amino acids use hazardous reagents not scalable to an 
industrial level.  
1.3.2 Using Designed Miniproteins to Inhibit PPIs 
With the development of solid phase peptide synthesis47,48 and high-pressure liquid 
chromatography (HPLC) purification49 it became possible to synthesise polypeptide 
oligomers. This meant that for the first time small protein domains or hormones could be 
used as synthetically accessible leads. However, the technique was limited by polypeptide 
chain length, as each synthetic step used instilled a greater proportion of side-products, 
and made the desired oligomer harder to purify. Due to the limited amount of published 
literature reviewing the use of miniproteins to target PPIs, an in depth review has been 
carried out here. 
 
1.3.2.1 Early Use of Designed Miniproteins to Target ANP receptors 
Several groups have attempted to mimic the action of atrial natriuretic peptides (ANPs) 
using synthetic peptide oligomers.50–54 ANP’s are a family of hormones that are released 
as part of the body’s response to raised venal blood pressure, and trigger a series of 
response measures such as vasorelaxation.55 A synthetic compound that mimics the action 
of ANPs should therefore have the potential to act as a treatment for symptoms such as 
raised blood pressure. As ANP has a chain length of 28 amino acid residues it is within 
the upper boundary of what is accessible by synthetic polypeptide chemistry, and 
therefore amenable to a drug discovery programme. 
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Figure 1.4: Development of lead compound A62225 and candidate A68828 by Geldern and coworkers,50 
using key residues identified by Bovy and coworkers.53 KL is the measured binding of the lowest affinity 
ANP receptor, presumed to be ANP-R1. 
In a successful study, Geldern and co-workers at Abbott used solid phase peptide 
synthesis to investigate the structure-activity relationship (SAR) of ANP. They took a 
sequence of amino acids, 8-15, previously identified by Bovy and co-workers as the ANP 
hotspot residues,53 combined it with other key parts of ANP, and reduced the disulfide 
ring size, to produce lead peptide A62225 (Figure 1.4). In doing so, they managed to half 
the size of the peptide from 28 to 14 residues, whilst maintaining some activity (KL = 
2000 nM). From here, they carried out SAR studies where they substituted and added 
both natural and unnatural amino acids and changed the size of disulfide ring in attempt 
to improve the efficacy. By enlarging the disulfide ring size, adding an arginine to the N-
terminus, substituting a serine for a cyclohexylalanine and capping the C-terminus with 
an –NH2 group they discovered A68828. This 15 residue peptide is much shorter than the 
28 residue ANP, however, with a KL of 140 nM it is only 65-fold less potent. Geldern and 
co-workers had shown that it was possible to synthetically create a miniprotein mimetic 
of a hormone using solid-phase synthetic techniques, allowing them to carry out SAR 
studies on oligopeptides. 
 
The solid phase synthesis techniques used to design A68828 meant that there were 
limitations to the number of compounds that could be produced given the time and 
funding available. In a seminal study by Li and co-workers, they were able to vastly 
increase the number of peptides tested using much fewer resources by employing a phage-
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display peptide screen.56 This technique involves inserting the DNA encoding a protein 
of interest into phage DNA such that the protein is displayed on the surface of the virus. 
This means that the phage will now exhibit binding affinity to any partner protein of that 
displayed.57,58 
 
This technique can be used to simultaneously test the binding affinity of many different 
proteins to a given binding partner. For example, consider that a ‘library’ of phages is 
synthesised in which point mutations have been made at three different places on the 
surface displayed protein, and each of these mutations randomly involves any one of the 
20 amino acids. This ‘library’ culture therefore consists of 320 unique phages. If this 
culture is added to a dish with the partner protein of interest fixed to the wall, any phages 
with a surface protein with high affinity will also become fixed to the dish. Low affinity 
phages can be washed away. Allowing the remaining phages to infect bacterial cells and 
propagate will generate a culture with a higher quantity of those phages displaying a high 
affinity surface protein.  
 
If this process is repeated 3 or 4 times, only the very best binding phages will remain in 
high concentrations. The DNA of these phages can then be sequenced in order to 
determine the amino acid sequence of the highest affinity proteins. 
 
Figure 1.5: Process of optimising ANP using phage display to identify a high affinity 15-residue 
miniprotein.56 
Li and co-workers used this technique to identify a very high affinity ANP miniprotein 
(Figure 1.5).56 As in previous studies hotspot residues were identified using alanine-
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scanning techniques. The disulfide ring size of ANP was reduced, and a set of residues 
randomly selected for mutation to build a phage display library. The phage display 
technique was then used to identify the amino acids best suited at each of these positions, 
to achieve the highest binding affinity. Following this, they were able to decrease the 
chain length of the enhanced peptide and point mutate at different positions in repeated 
rounds of phage display scanning, to finally achieve a 15 amino acid ANP miniprotein 
with an EC50 of 0.48 nM (compared to 140 nM for A68828). This is seven times lower 
than wild-type ANP. Due to the large number of proteins that can be tested in each phage 
display experiment it is highly efficient, and it was possible to discover an optimised 
miniprotein with much higher affinity than that from the conventional medicinal 
chemistry approach carried out by Geldern and co-workers, using far fewer 
experiments.50  
 
1.3.2.2 Designing a Protein-A Miniprotein with Defined Secondary Structure 
Although the work done by Li and co-workers was seminal towards developing 
methodology to optimise the amino acid sequence, their miniproteins did not contain 
specific secondary structure. As an estimated 62 % of all PPIs involve at least one α-
helix,8 the mimicry of secondary structure using miniproteins is important. In an 
important development, Braisted and Wells were able to design and optimise a 
miniprotein mimetic of a domain of S. aureus protein A, which contains an α-helical 
secondary structure.59 
 
In this work, the authors aimed to develop peptidic inhibitors to target the interface 
between the FC portion of immunoglobulin G1 (IgG1) and the Z-domain of 
Staphylococcus aureus ‘protein A’. From crystallographic data of the bound proteins it 
was known that the binding domain of protein A comprised of a bundle of 3 α-helices, 
with two helices bound to IgG1 and the third seemingly not involved at the protein 
interface (Figure 1.6).60 
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Figure 1.6: Crystal structure of IgG1 (purple) bound to protein A (cyan), PDB code 1FC2.60 
Due to the apparent lack of involvement of the third α-helix at the binding interface, 
Braisted and Wells hypothesised that deleting this helix would only have minimal effect 
on the protein binding energy. However, surprisingly they found that this deletion reduced 
the binding energy by 105 fold (from a Kd of 10 nM to a Kd of >1 mM). In order to remedy 
this they optimised the sequence of the truncated protein A to re-establish efficacy for 
IgG1. 
 
It had been previously shown that protein A can be displayed on the surface of M13 phage 
particles, rendering phage-display optimisation well suited for this protein.61,62 Braisted 
and Wells used site-directed mutagenesis to build phage display libraries with random 
mutations at specific positions on the truncated protein A. They first optimised residues 
that would have faced the deleted third α-helix (the exoface), and unsurprisingly found it 
beneficial that some lipophilic residues (Leu-20 and Phe-31) were replaced with charged 
residues Asp and Lys, which are much more commonly found on the solvent-exposed 
face. After this, they built a new phage-display library, mutating residues between the 
two remaining α-helices (the intraface) in order to stabilise the core of the truncated 
protein A. They found three mutations (A13R, I17A and L35I), all positioned at the open 
end of the two helices, which seem to stabilise the protein folding. Finally, once these 
changes had been made to stabilise the secondary structure of the truncated protein A, 
several phage libraries were built to optimise all 19 residues at the interface with IgG1. 
Although these residues were largely best conserved, there were a few mutations to 
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charged residues, such as N12R, for which presumably the resulting improved solubility 
outweighed any potentially negative effect on the binding to IgG1. 
 
Ultimately, the optimised truncated form of the protein A Z-domain contained 12 point 
mutations from the wild type protein, which increased the Kd more than 104 fold, from 
>1 mM to 42 nM. Perhaps more importantly, the authors were able to show that by 
optimising the structure they had increased the α-helicity in solution from 11% for the 
original truncated peptide, to 56% for the fully optimised mutant (a maximum helical 
content of 63% was calculated from the 1FC2 crystal structure). This demonstrates that 
it is possible to engineer secondary structure into artificial miniproteins. 
 
1.3.2.3 Mimicking A Zinc Finger Secondary Structure with A Designed Miniprotein 
At the same time as the Braisted and Wells work on protein A, a similar study was 
underway regarding artificially recreating secondary structure in a synthetic miniprotein. 
Here the aim was to create a zinc finger domain which could form the desired secondary 
structure without reliance on zinc presence.59 The work, carried out by Imperiali and co-
workers, began with optimisation of the naturally occurring zinc finger 286 (Zif286).63 
Rather than using a systematic phage-display library screen in order to optimise the 
structure, they employed rational design facilitated by nuclear Overhauser effect (NOE)-
derived NMR structures.64 Initially the Zif286 was modified and shortened, taking into 
consideration residues known to be key for zinc finger domain formation, and enforcing 
the β-hairpin formation using a D-serine residue (Figure 1.7, step 2). Eight point mutations 
were then made to stabilise the secondary structure further, with the aim of decreasing 
the reliance of the protein on zinc, but requiring that it retain the correct conformation. 
By using a D-proline residue instead of a D-serine residue, a type-II’ β-hairpin was 
encouraged over a type-II turn, resulting in the protein secondary structure being 
sufficiently stable to form independently of zinc ions (Figure 1.7, step 4). Finally, 
mutations at the C-terminus of the protein were used to prevent the formation of an 
unwanted trans isomer of the D-proline amide bond, visible by NMR spectroscopy. The 
final result was a 23-amino acid polypeptide with well-defined secondary structure, 
similar to that of a zinc finger, although metal independent. 
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Figure 1.7: The modification of Zif268 by rational design in order to discover a zinc-independent 
miniprotein exhibiting zinc finger-like secondary structure.  
1.3.2.4 Transferring the Human cluster of differentiation 4 (hCD4) Active Site onto a 
Naturally Occurring Miniprotein Scaffold 
Despite good progress in the design of artificial miniproteins, all examples had thus far 
involved the optimisation of an existing protein or domain with some inherent stability. 
Unfortunately however, this method is not applicable to most PPIs, as typically the hot-
spot residues are part of a domain that is too large to optimise into a stable miniprotein. 
In breakthrough work Vita and co-workers were able to transfer the hot-spot residues 
from a protein to a naturally occurring stable miniprotein and maintain some binding at 
the PPI interface.65 
 
When analysing a set of 13 scorpion toxin structures it was observed that despite 
conservation of just six cysteine residues, each of the miniproteins formed a very 
consistent secondary structure, where an α-helix was joined to a β-sheet by three disulfide 
bridges. It was therefore hypothesised that it should be possible to alter the protein 
sequences significantly while maintaining a very defined secondary structure, as long as 
the six key cysteine residues were conserved.66 
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Figure 1.8: The secondary structure of charybdotoxin (ChTx, PDB source: 2CRD), showing the 
truncated residues (red) and the mutated residues (magenta) forming the human CD4 mimetic CD4M.65 
Human cluster of differentiation 4 (hCD4) interacts with human immunodeficiency virus-
1 (HIV-1), allowing the virus to bind to the cell surface and subsequently infect the cell.67 
Blocking this interaction should therefore hinder the spread of HIV-1 around the body. 
The interaction of hCD4 with HIV-1 gp20 involves a β-hairpin at residues 35-46. Vita 
and co-workers transposed these residues onto the β-hairpin portion of scorpion venom 
charybdotoxin (ChTx, Figure 1.8), and truncated the protein by removing four 
structurally insignificant residues from the C-terminus. In doing so they created CD4M, 
a 33 residue miniprotein mimetic of the hCD4 binding domain, which could be 
synthesised using solid phase peptide chemistry.  
 
Circular dichroism (CD) of CD4M was used to assess the mix of α-helices and β-sheets 
and indicated that the desired secondary structure had formed. The IC50 of CD4M binding 
to gp20 was measured as 20 μM, and when the CD4M sequence was incorporated into a 
CD4M-human serum albumin (HSA) chimera, the IC50 improved to 0.8 nM, likely due 
to solubilisation. As such it was possible to design a miniprotein with high affinity for its 
binding partner by making significant changes to the ChTx protein sequence while 
retaining the secondary structure. This process required very little optimisation, and 
demonstrates how robust the secondary structure of scorpion venom can be as a result of 
disulfide bond formation. 
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In a further study, Vita and co-workers showed that this technique could be adapted to 
other scorpion venom toxins.68 Whereas in the first study they used the 37-amino acid 
ChTx as the surrogate structure for their miniprotein design, here they showed that the 
31-amino acid scyllatoxin could also be used. Scyllatoxin also contains the 3 disulfide 
bridges, and the resulting α-helix and β-hairpin that are conserved in scorpion venom 
proteins.69 
 
 
Figure 1.9: The secondary structure of scyllatoxin (PDB source: 1SCY), showing the truncated residues 
(red) and the initial mutated residues (magenta) forming the human CD4 mimetic CD4M3 (IC50 = 40 
μM). The further mutations (green) made to optimise this sequence to CD4M9 (IC50 = 0.4 μM) are also 
shown.65 
Similar to previous examples they made a series of mutations to incorporate the β-hairpin 
from the hCD4 binding site into scyllatoxin (Figure 1.9). This resulted in compound 
CD4M3, which had an IC50 of 40 μM. This is comparable to the previously discovered 
ChTx derivative CD4M (IC50 = 20 μM). However, CD4M3 is six amino acids shorter, 
with an overall length of 27 residues. This demonstrates how robust the technique is, as 
using an entirely new scorpion toxin ‘surrogate’ produced a miniprotein with incredibly 
similar efficacy. Vita and co-workers went on to optimise CD4M3. They tested a series 
of derivatives, employing structural and binding information to predict advantageous 
mutations, and finally arrived at CD4M9 (IC50 = 0.4 μM). This sequence has a 100-fold 
improvement in activity compared to CD4M3, a result of five different amino acid 
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mutations. Overall, a miniprotein had been designed that optimised hCD4 to roughly a 
quarter of the size, whilst improving its activity from being undetectable to 0.4 μM. 
 
1.3.2.5 Designing a DNA-Binding Miniprotein Based on Avian Pancreatic Peptide 
(aPP) 
Schepartz and Zondlo used a similar technique to Vita and co-workers to design a DNA-
binding miniprotein.70 They based their miniproteins on the structure of avian pancreatic 
peptide (aPP), a 36-amino acid protein which has a defined α-helical secondary structure 
without any disulfide bridges. This is possible due to the presence of a highly stable three 
turn polyproline II (PPII) helix,71 which binds to one face of the aPP α-helix through a 
series of lipophilic interactions. This encourages the secondary structure to form in 
solution.  
 
Figure 1.10: The structure of aPP (PDB source: 2BF9), showing the structurally important residues as 
sticks, the structurally important residues conserved in PPBR4 (magenta), and the key DNA binding 
residues in PPBR4 (green).70 
GCN4 is a protein which binds to DNA through a long α-helix, with 13 key residues 
interacting with the DNA.72,73 Schepartz and Zondlo set out to transfer different 
combinations of these key residues to the aPP α-helix, in an attempt to discover a DNA 
binding miniprotein. They began by identifying the residues that were key for the 
formation of the aPP secondary structure (Figure 1.10). They then aligned the GCN4 and 
aPP α-helical secondary structure and designed new sequences incorporating GCN4 
residues, avoiding mutation of structurally important aPP residues. Unfortunately, they 
found they could not achieve DNA binding activity by doing this, and were forced to 
make mutations which disrupted some structurally important residues on the α-helix. By 
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incorporating mutations Y27R, L28R, and V30R, they discovered PPBR4, a miniprotein 
able to bind to DNA with an IC50 of 1.5 nM. However, because of the loss of three key 
structural residues, it appeared that the α-helix did not form unaided in solution by CD 
spectroscopy. Fortunately though the influence of the PPII helix was sufficient to 
encourage the formation of the required α-helix in the presence of DNA, resulting in a 
miniprotein with very high efficacy.  
 
This work by Schepartz and Zondlo demonstrated that disulfide bond formation is not a 
prerequisite in proteins which make suitable starting points for miniprotein design. 
However, it also highlights the drastic effect of losing structurally important residues on 
the ability of a protein to form a defined secondary structure in solution. 
 
In order to restore the secondary structure of PPBR4 in solution, Schepartz carried out a 
further study, using phage display library techniques, to optimise the structure of the PPII 
helix.74,75 By stabilising the PPII helix, they aimed to re-establish the α-helical stability 
observed in aPP, thereby increasing the binding affinity of their miniproteins to DNA. 
Two phage display libraries were built. In library A, three residues were randomly 
mutated in the PPII helix region and the proline residues conserved, whereas in library B, 
four mutations were made and two of the proline residues disrupted to allow increased 
flexibility in this region of the protein (Figure 1.11). Library A produced no proteins with 
improved affinity to the PPBR4 parent protein, however, surprisingly library B produced 
several very high affinity proteins. 
 
 
Figure 1.11: Phage display libraries designed to optimise the PPII helix on PPBR4. Randomly mutated 
residues within the phage libraries are shown in green, and the optimised mutated residues in p007 in 
magenta.74 
The most active of the Library B proteins was p007, with a 100-fold increased activity 
compared to PPBR4. Despite having lost two PPII prolines, and thus most of the PPII 
secondary structure, p007 was found to adopt an α-helical conformation at room 
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temperature. It also afforded good specificity to the required DNA sequences, unlike 
PPBR4 which was less selective. 
 
1.3.2.6 Targeting Bcl-2/Bcl-XL With An aPP Derived Bak Mimetic 
Given their success in using aPP as a surrogate structure for miniprotein design of a 
GCN4 mimetic, Schepartz and co-workers set about designing a mimetic for Bak, in order 
to target Bcl-2 and Bcl-XL.76 Bcl-2 and Bcl-XL are cell death antagonists, so inhibiting 
them may encourage fragile cells to enter apoptosis. This has potential in treatment of 
cancers, as cancer cells are naturally more fragile and therefore vulnerable to the 
apoptosis-inducing effects of Bcl-2/Bcl/XL inhibition,77 and moreover Bcl-2 levels are 
elevated in 80 % of B-cell lymphomas, as well as other cancers.78 As Bak interacts with 
Bcl-2/Bcl-XL via a single face of an α-helix, it was identified as a suitable candidate for 
hot-spot transposition onto aPP.  
 
Figure 1.12: The aPP sequence aligned with Bak residues 72-87, and the most active designed 
miniprotein (PPBH3-1) discovered by phage display analysis.76 The structurally important residues are 
shown in green, the key Bak residues are shown in magenta, and the residues randomised in phage 
display libraries in grey. 
Firstly INSIGHT II was used to determine the best alignment of the aPP and Bak helices, 
by evaluating any steric clashing that could occur between each resulting miniprotein and 
Bcl-2 when they interact. A phage display library was synthesised, where six key residues 
from the Bak helix were incorporated into aPP, and then the sequence randomised in four 
other positions (Figure 1.12). This library contained three sequences with measurable 
binding to Bcl-2; the best of which being PPBH3-1, with a Kd of 52 ± 5 nM. Furthermore, 
CD spectroscopy of PPBH3-1 at 4 ºC confirmed the formation of an α-helix in solution. 
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Schepartz and co-workers had again succeeded in designing an active miniprotein 
utilising the aPP sequence to induce spontaneous secondary structure. 
 
1.3.2.7 Designing an EVH1 Binding Miniprotein to Interact Through the aPP PPII helix 
Although the α-helix of aPP shows the most versatility for integration of hotspot residues 
from different proteins, in another study Schepartz also showed that the PPII helix could 
be modified to afford binding affinity to a target.79 EVH1 domains can be found in a wide 
range of signalling proteins involved with the actin cytoskeleton.80 They recognise 
polyproline rich peptide sequences that are folded into PPII helices,81 and could 
potentially therefore have affinity for a modified aPP PPII helix. 
 
Figure 1.13: Modifications made to the PPII helix of aPP to produce the EVH1 domain binding 
miniprotein pGolemi. The structurally important residues are shown in magenta, and the residues 
important for EVH1 affinity in green.79 
To test this hypothesis, the authors identified ActA, a short peptide sequence which had 
been shown to bind EVH1 domains, in particular that of of Mena.82 They incorporated 
the ActA residues onto the aPP PPII helix (Figure 1.13) to produce pGolemi. This 
sequence had good affinity for the Mena EVH1 domain, with a Kd of 700 ± 30 nM, 10 
fold higher than the ActA sequence itself. The CD spectra of pGolemi showed strong 
PPII and α-helical secondary structure. This clearly indicates that the structural stability 
offered by miniproteins can improve the efficacy of other stable structures, such as the 
PPII helix, by restricting the conformation of the hot-spot residues, and therefore lowering 
the entropic loss on binding. 
 
1.3.2.8  Targeting p53/Hdm2 Miniprotein P53 Mimetics 
One PPI of particular interest as a potential drug target is the p53/human double minute 
2 homolog (Hdm2) interaction. p53 has many roles in DNA damage repair and can 
ultimately trigger apoptosis of a damaged cell.83 The activity of p53 is regulated by the 
antagonist Hdm2. Disrupting this interaction could therefore increase the activity of p53, 
which could lead to apoptosis of cancerous cells in conjunction with other treatments.12 
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Figure 1.14: Optimisation of aPP-p53 chimera miniprotein by phage display to improve affinity. 
Structurally important residues are shown in magenta, p53 hotspot residues in green, and the proteins 
randomised in each phage display library in grey.84 
As p53 interacts with Hdm2 through three hotspot residues on an α-helix, Schepartz and 
co-workers hypothesised that it could be possible to use aPP to produce a miniprotein 
inhibitor of p53/ Hdm2. Phage display techniques were utilised to design an appropriate 
peptide sequence.84 A phage display library was constructed based on a hybrid p53/aPP 
sequence, randomised in five positions on the α-helix near the hotspot residues (Figure 
1.14). Unfortunately, the best affinity sequence in this library only offered a two-fold 
increase in activity from the unmodified p53 α-helix. Because of this a second phage 
display library was designed, incorporating the optimised residues and randomising at a 
further four positions on the α-helix. The highest affinity miniprotein from this library 
offered a further four-fold increase in activity to 35 nM. This is likely due to a drastic 
increase in α-helicity, from 28% for the product of library one, to 54% for the library two 
product, as measured by CD spectroscopy. Both libraries contained AAAC four-peptide 
sequence adjoined to the N-terminus, to be reacted with 5-iodoacetamidofluoracein for 
fluorescence polarisation assay analysis. 
 
Li and co-workers also developed a miniprotein inhibitor of the p53/ Hdm2 interaction, 
using the scorpion venom toxin BmBKTx1 as the surrogate structure for their 
sequences.85 The short chain K+ channel toxin BmBKTx1 consists of an N-terminal α-
helix connected to a C-terminal antiparallel β-sheet by three disulfide bonds.86 The 
hotspot residues from the α-helical p53 active site can therefore be transposed onto the 
BmBKTx1 α-helix to create a p53 miniprotein mimetic.  
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Figure 1.15: Design of Stoppin-1 and Stoppin-2 based on the BmBKTx1 sequence. The α-helical 
sections are shown in magenta, β-sheets in green, key p53 hotspot residues in grey and arginine mutations 
in stoppin-2 in blue.85 
Li and co-workers utilised this to design stoppin-1, by transposing four hotspot residues 
onto the BmBKTx1 sequence and truncating the peptide by two residues at the C- and N-
termini (Figure 1.15).85 This peptide was synthesised by solid phase techniques and 
bound to Hdm2 with a Kd of 320 nM, comparable to that of the unmodified p53 sequence, 
233 nM. However, when the HTC116 cancer cell line was treated with stoppin-1, there 
was no drop in cell viability as would be expected of a p53/Hdm2 inhibitor. Li and co-
workers reasoned that this may be due to poor cell permeability of the stoppin-1, so 
modified the sequence with addition of five arginine residues to facilitate cross-
membrane transport, producing stoppin-2. Although this resulted in a slight decrease in 
efficacy, Kd 493 nM, the improved cell permeability resulted in a significant decline in 
viability of HTC116 cells exposed to stoppin-2.  
 
1.3.2.9 Designing Miniprotein Inhibitors of the Androgen Receptor (AR) Co-activator 
Interaction 
Co-activator proteins for nuclear receptors (NRs) make good targets for the design of 
mimetics. They regularly follow the same pattern of hotspot residues, binding through an 
LXXLL motif, and regulate the interaction between the NR and its respective hormone. 
Androgen receptor (AR) co-activators bind through a FXXFL motif and so also make 
good targets for miniprotein design. Regulating the binding of AR co-activators is thought 
to have potential therapeutic benefit for some cancers, such as prostate cancer.87 
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Brunsveld and co-workers took a different approach to the design of AR co-activator 
mimetics,88 where they designed inhibitors based on several different surrogate protein 
sequences. The proteins they chose to base their designs on were apamin (bee venom), κ-
heuftoxin1, CD4M3 (from work previously described by Vita and co-workers), and Om-
toxin3. From these four proteins they designed eight different sequences, each with the 
FXXLF motif installed as part of an α-helix (Figure 1.16). Occasionally an additional 
charged residue was mutated to arginine to avoid unfavourable charge-charge 
interactions. 
 
 
Figure 1.16: Design of AR co-activator FXXLF mimetics from the structure of four different 
miniproteins. α-helical (magenta) and β-sheet (green) secondary structure is shown, along with mutations 
from the original sequence (grey).88 
Of the eight analogues designed, only one, Scy-1, showed low binding affinity. All seven 
others showed moderate activity, with the best sequence, Omt-2, having a Ki of 0.5 μM. 
The high hit rate is likely due to the short length of the FXXLF binding motif, as well as 
the promiscuity of the androgen receptor, which interacts with many natural co-activators. 
The authors also found that truncating the protein to shorten the α-helix, and thus limit 
the amount of unused α-helical residues on the miniprotein, impacted the activity 
significantly. 
 
Brunsveld and co-workers had limited success in improving the activity of the best 
candidates from this series of miniproteins.89 They used rational design to introduce 
mutations with the aim to both stabilise the secondary structure of the miniprotein, and 
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improve the affinity for the hotspot residues, to develop an understanding of the SAR of 
each residue with respect to AR-coactivator affinity. Despite producing a series of 31 
sequences based on the structures of Het-2 and Omt-1, only a select few sequences 
showed improved affinity (Figure 1.17). It was found for both Het-2 and Omt-1 that 
replacing the second PXXLF phenylalanine residue with the unnatural amino acid p-
chlorophenylalanine improved activity 2-3 fold. The N o E mutation in Het-2e improved 
activity ten-fold to 0.2 μM. However, all other attempts resulted in a small to moderate 
loss in activity, suggesting that the secondary structure of the surrogate miniproteins is 
already optimised for interaction with the AR. Notably, the phage display techniques 
regularly used in  miniprotein activity studies were not employed here, and this may have 
afforded greater success. 
 
Figure 1.17: SAR studies on the AR-coactivator series developed by Brunsveld, showing the sequences 
with improved affinity. Α-helical secondary structure (magenta), FXXLF hot-spot residues (grey) and 
point mutations (blue) are labelled.89 
 
1.3.2.10 Designing Miniprotein Inhibitors of the Oestrogen Receptor (ER) Co-activator 
Interaction 
Another nuclear receptor which attracts a great deal of attention in developing miniprotein 
inhibitors is the oestrogen receptor (ER). ER co-activators interact through a five-peptide 
α-helical LXXLL motif. Design of inhibitors for the ER-co-activator interaction has 
helped to improve our understanding of the receptor function.  
 
Wittiliff and co-workers designed oligopeptide ER co-activator mimetics containing the 
LXXLL motif.90 In order to induce helicity amide or disulfide bridges were incorporated 
between residues spaced apart by one helical turn. They synthesised a series of 
oligopeptides which incorporated the LXXLL leucine residues, as well as an isoleucine 
and lysine that had been identified as important when reviewing known natural LXXLL 
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containing proteins. Of these peptides, which all had activity in the nanomolar range, the 
best was PERM-1 with a Ki to ERα of 25 nM (Figure 1.18).  
 
Figure 1.18: Crystal structure of PERM-1 bound to ERα (PDB Code: 1PGC), showing the key binding 
leucine residues in magenta, and other important residues in blue.90 
Interestingly, CD spectroscopy of PERM-1 indicates a lack of helical secondary structure 
in solution. However, crystallographic evidence clearly shows defined helical structure 
when it is bound to ERα (Figure 1.18, PDB code: 1PGC). The increase in activity between 
the five-amino acid LGGLL sequence and PERM-1 suggests that the disulfide bridge 
contributes significantly to the formation of the α-helical conformation required for 
binding. By using bridging amino acid residues spaced at one helical turn from each other, 
Wittilif and co-workers were able to produce a short, nine-amino acid, ER co-activator 
mimetic with remarkable affinity for its target. 
 
Brunsveld and co-workers also developed a miniprotein mimetic of the LXXLL motif 
based on the peptide sequence of apamin, a protein in bee venom.91 Apamin consists of 
an 18-amino acid sequence containing an α-helix, which is held by two disulfide bridges 
to a loop on the opposite face of the protein. Brunsveld and co-workers designed two 
phage display libraries in attempt to optimise the sequence to mimic ER co-activators 
(Figure 1.19). Interestingly, they opted to randomise most of the residues on the α-helix 
sequence, including the LXXLL hotspot residues, although they limited the 
randomisation to either charged/hydrophobic residues (Figure 1.19, blue) or small 
residues (Figure 1.19, pink). 
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Figure 1.19: The design of ER-Apamin-1 and ER-Apamin-2 from the apamin protein sequence, using 
two phage display libraries. The α-helical portion of apamin is shown in magenta, and the residues 
randomised by phage display in blue and grey. LXXLL hotspot residues are highlighted in bold.91 
Enrichment of the phage display libraries established two high affinity miniprotein ER 
co-activator mimetics. The first library yielded ER-Apamin-1, with an IC50 of 2.1 μM 
towards ERα. The second yielded ER-Apamin-2, with an IC50 of 1.3 mΜ. In both libraries 
the LXXLL configuration of the hotspot residues was found to be retained. There was a 
notable preference for hydrophobic amino acids, with leucine particularly favoured in 
library 2. Computational overlays with a natural LXXLL crystal structure suggested that 
ER-Apamin-2 may be able to bind via either of the overlapping LXXLL motifs. 
 
1.3.3 Using Stapled Helices to Inhibit PPIs 
There is an increasing interest in using stapled peptides to generate stable α-helices that 
can be utilised in PPI inhibition.92–95 A peptide staple refers to a covalent link between 
two residues on a polypeptide which fixes them a set distance apart. Use of a well-
designed staple of the correct size can encourage the formation of an α-helix, or stabilise 
a pre-existing one (Figure 1.20). 
 
Figure 1.20: Attaching a staple across one turn of an α-helix. 
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An early example was published by Mierke and co-workers in 1997.96 The authors 
postulated that a disulfide bridge between two cysteine residues in the i and i + 3 positions 
could bestow stabilisation similar to the i, i + 3 H-bonding observed in an α-helix. This 
technique offers the advantage that it utilises the naturally occurring amino acid, cysteine. 
As a result the desired peptides are compatible with unmodified peptide synthesis 
machines, and potentially even bacterial production, keeping the cost low. On the other 
hand, the disulfide bond would be quickly metabolised in the body, resulting in short half 
lives. 
 
A second example of peptide stapling was developed by Rosenblatt. This involves the 
formation of a lactam bridge between two amino acid residues.97 Again, naturally 
occurring amino acids can be utilised, as a lactam bridge can be formed between lysine 
and aspartic or glutamic acid, which facilitates the synthesis. However, as with the 
disulfide bridge, this results in susceptibility to degradation by biological processes, in 
this case peptins. 
 
Figure 1.21: A) A polypeptide demonstrating the i, i + 3 H-bonding observed in α-helices. B) A 
polypeptide demonstrating an i, i + 3 disulfide bridge,96 and an i, i + 4 lactam bridge.97 C) A polypeptide 
demonstrating an i, i + 4 and an i, i + 7 hydrocarbon bridge.98,99 
Probably the most popular form of peptide stapling to date is the hydrocarbon stapling 
method developed by Grubbs.98 Unlike the previous examples, this method does not use 
naturally occurring amino acids. Instead amino acids containing a hydrocarbon side chain 
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with a terminal olefin are required. Once these modified residues are incorporated into 
the polypeptide, treatment with Grubbs catalyst100–102 induces a cross metathesis reaction 
to construct the staple. The product is an all-hydrocarbon staple containing an alkene. 
These staples are much more inert to biological processes than the previous examples and 
as terminal alkenes do not exist in naturally occurring amino acids, the reaction also offers 
improved selectivity, although at the expense of requiring an increased number of 
synthetic steps.  
 
1.3.3.1 Using Stapled BH3 Helices to Inhibit Bcl-2/XL  
The BH3 domain α-helix has inspired the development of many stapled derivatives.103–
112 It consists of an α-helix which binds to many different apoptosis inducing domains 
through a single lipophilic face. In general, BH3 helices bind via a series of lipophilic 
residues spaced one helical turn apart.113,114 For example, the Bim-BH3 domain contains 
binding hotspots at Val74, Leu78 and Ile81 (Figure 1.22).115 It has been hypothesised that 
BH3 mimetics may have the ability to selectively induce apoptosis and thus be utilised 
therapeutically in reducing the viability of cancer cells. 
 
Figure 1.22: The Bim-BH3 domain showing Val74, Leu78 and Ile81 hotspot residues in magenta (PDB 
code: 2XPX).115 
In a seminal study by Walensky and coworkers,103 it was shown that by applying a ‘staple’ 
to the Bid-BH3 α-helix, it was possible to improve the helicity and thus the efficacy 
towards Bcl-2. They used the hydrocarbon stapling method, developed by Grubbs,98 and 
three different olefin-containing amino acids with varying chain length and chirality to 
make up their staples (Figure 1.23). This allowed them to design staples which bridged 
one helical turn, from the i to i + 4 positions, or two helical turns, from the i to i + 7 
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positions. Of the sequences that were synthesised, the most helical was SABHA, with a 
helicity of 87.5% in solution, compared to the unstapled Bid-BH3 sequence which has a 
helicity of 15.7%, as measured by CD spectroscopy. The longer i, i + 7 staple proved to 
be less effective, resulting in only a small increase in helicity to 35.6%. The increased 
helicity in SABHA lead to a six-fold increase in affinity for the Bcl-2 binding site, to give 
a Kd of 38.8 nM compared to 269 nM for the unstapled Bid-BH3 peptide. 
 
 
Figure 1.23: Series of stapled helices synthesised by Walensky and coworkers,103 demonstrating the 
effect of staple size and position on the α-helicity measured by CD spectroscopy. 
The SAHBA was applied to Jurkat T-cell lymphoma cells in order to test its ability to 
activate apoptosis. After 20 hours, cells treated with SAHBA demonstrated staining by 
annexin V, an apoptotic marker, whereas the control Bid-BH3 with SAHBA(G>E) peptides 
did not. In vivo studies were conducted in mice transplanted with RS4:11 leukemia cells. 
Intravenous treatment of SAHBA dosed at 10 mg.kg-1 lead to a median survival rate of 11 
days, compared to 5 days in the control. Walensky and co-workers had demonstrated that 
stapled α-helices could be used as PPI inhibitors with an observable medical effect when 
administered intravenously in mice. 
 
Alleman and co-workers were able to modify the BH3 helix staple such that the secondary 
structure became sensitive to light exposure.105 They designed a staple containing an azo 
double bond (Figure 1.24). By exposing this azo bond to light it is possible to switch 
between the trans and cis conformations, thereby changing the length of the staple. With 
the staple placed at particular locations along the polypeptide sequence, this could affect 
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whether the helicity was turned ‘on’ or ‘off’. The trans form of the staple encouraged 
helicity in an i, i+11 conformation, and the cis form in i, i+7 or i, i + 4 conformations. 
 
Figure 1.24: Using light-sensitive staples to change the helicity of a polypeptide.105 
Alleman found that by inserting the staple into the Bak and Bid BH3 helices, the affinity 
towards Bcl-XL became dependent on the extent of light exposure. For the i, i+4 and i, 
i+7 variants, where the cis conformation post irradiation promotes helix formation, a 
particularly dramatic increase in affinity was observed. Both cases exhibited at least a 20-
fold increase in affinity towards Bcl-XL after irradiation (Table 1.1). The i, i+11 variant, 
where the non-irradiated trans conformation tended towards helix formation, did not 
demonstrate as much variation in activity. The non-irradiated conformer was only two-
fold more potent than the irradiated form. Every peptide tested showed at least a two-fold 
increase in potency from their unstapled parent sequence. This phenomenon is useful in 
mechanistic studies on Bcl family proteins in vitro, where the activity can be switched on 
and off using a light source. However, it has limited potential in vivo as a therapeutic 
treatment, as the required wavelength of light cannot penetrate as deep as would be 
necessary into tissue. 
Table 1.1: The effect of light on the affinity of the different light-sensitive stapled BH3 peptides designed 
by Alleman and co-workers.105 
 Kd (nM) 
Peptide form Bak i+7 Bak i+11 Bid i+4 
parent 134r16 328r19 117r48 
dark-adapted 825r157 21r1 1275r139 
irradiated 42r9 48r10 55r4 
The development of staple stabilised BH3 helices has aided our understanding of the BH3 
interactome within the cell,104,107,109 and the structural biology of BH3 binding sites, 
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including how structural changes can affect the protein function.106,108,110,111 However, the 
stapled BH3 peptides have shown limited success in therapeutic applications due to poor 
cell membrane permeability and metabolic instability. A recent study even demonstrated 
a negligible difference in the effects of stapled peptides and their non-stapled parents.112 
 
1.3.3.2 Using a Stapled p53 Helix to Inhibit Mdm2 
Another target which attracts attention in developing stapled α-helices is the Hdm2 
binding p53 helix.116–125 p53 is a transcription factor responsible for triggering apoptosis 
in response to genetic damage, and is thus highly important in preventing cancers from 
developing.126 Hdm2 modulates p53 through a binding interaction that neutralises p53 
activity by encouraging ubiquitylation and eventual degradation.127 The interaction of p53 
with Hdm2 occurs via an α-helical segment of 16 amino acid residues and relies on the 
hotspot residues Phe19, Trp23 and Leu26, which are in an i, i+4, i+7 conformation.128 It 
is hoped that by stapling this short α-helix, to encourage secondary structure in solution, 
a stable tool compound or even a drug can be identified for use in targeting the p53/Hdm2 
PPI. 
 
Figure 1.25: The p53 transactivation domain (cyan) binding to Mdmx (grey). The hotspot residues are 
shown in magenta. (PDB code: 3DAC)128 
Bernal and co-workers used the 16-amino acid transactivation domain to design stapled 
α-helical p53 mimetics.116 They began by designing four different analogues of p53, each 
with an i, i+7 hydrocarbon staple in a different position (Figure 1.26). Of these, only 
SAH-p53-4 demonstrated significant α-helicity (59%) by CD spectroscopy, and this 
resulted in remarkable efficacy, with the Kd measured as 92 pm. However, despite this, 
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when Jurkat T-cell lymphoma cells were treated with SAH-p53-4, no cell death was 
observed. It was hypothesised that this was due to a lack of cellular uptake of the 
compound, so point mutations were made to give the peptide a positive charge at 
physiological conditions (pH 7.4) and facilitate cellular uptake.129 After making five point 
mutations, the authors discovered SAH-p53-8. Although the Kd was lower, at 55 nM, this 
stapled helix successfully promoted cell death in Jurkat T-cells due to improved cellular 
uptake.  
 
Figure 1.26: Discovery of SAH-p53-8 by modifying the Hdm2 binding helix from p53. The stapled 
residues are shown in blue and magenta, and point mutations made to basic residues for the point of cell 
permeability in green. Key binding residues are in orange.116 
In later work it was shown that SAH-p53-8 acted through specific binding to Hdm2 and 
Hdmx, thereby restoring p53 activity in cancer cells that overexpressed these proteins.117 
The crystal structure of SAH-p53-8 bound to Mdm2 shows that not only does it bind at 
the p53 site, but additional interactions are picked up between the staple and the protein, 
further increasing the affinity (Figure 1.27).122  
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Figure 1.27: Crystal structure of SAH-p53-8 bound to Mdm2, showing the interaction of the staple with 
the protein pocket.122 The staple is shown in magenta, and non-hotspot residues have been hidden for 
clarity. (PDB code: 3V3B). 
Further work has been carried out to develop stapled peptides to target Hdm2, based on 
the structure of pDI (Figure 1.28).124,130,131 PDI is an unstapled peptide sequence 
discovered by Pazgier and co-workers using phage display optimisation methods.130 The 
number of comprising amino acids is reduced compared to the wild type p53 helix, with 
12 instead of 16, while the affinity is increased from a Kd of 410 nm to 19.7 nm. Two 
different research groups simultaneously developed stapled peptides based on the 
structure of pDI. Chang and co-workers developed ATSP-7041 using an i, i+7 staple.131 
By introducing the staple and making several modifications to help boost solubility (a 
H21E mutation and two alanines incorporated at the C-terminus) and binding affinity (a 
cyclobutyl hotspot residue) they achieved an affinity of 0.9 nM. The stapled helix was 
cell-permeable and reactivated p53 function in cancer cells at low μM concentrations. In 
the second, very similar investigation, Brown and co-workers developed sMTide02A, an 
11-amino acid stapled peptide with a Kd of 6.76 nM.124 They also substituted one of the 
hotspot residues to improve binding affinity; this time Trp23 was replaced with the 6-
chloro substituted isomer, and the same H21E mutation was made to improve solubility. 
The resulting peptide could cross cell membranes and encouraged apoptosis in cancer 
cells with reduced p53 function. 
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Figure 1.28: A) Crystal structure of ATSP-7041 bound to Mdmx (PDB code: 4N5T).131 The hydrocarbon 
staple is shown in magenta, and the key residues in yellow. B) Peptide sequences of ATSP-7041131 and 
sMTide-02A124, both of which are derived from pDI.130  
The use of stapled peptides has proven to be a very effective strategy for developing cell-
permeable inhibitors of the p53/Hdm2 PPI. Optimisation of the stapled helix sequences 
has yielded several helixes with nanomolar activity, which are able to activate p53 and 
promote cell death in cancer cell lines. The stapled peptides have also been shown to 
maintain high efficacy towards Hdm2 mutants that have previously proven resistant to 
small molecule p53/Mdm2 inhibitors, such as nutlin-3a.125 
 
1.3.3.3 Further Potential of Stapled Helices as PPI Inhibitors. 
The stapling of α-helices has been highlighted as a versatile method for developing 
inhibitors of PPIs. As well as the two examples described they have also been used to 
target other oncogenic PPIs such as induced myeloid leukemia cell differentiation protein 
(MCL-1),132 notch,133 β-catenin,134–136 EED137 and eIF4G;138 targets for infectious 
diseases such as human immunodeficiency virus (HIV)-1139–142 and hepatitis-C;143 
endocrine modulators such as oestrogen receptor α;144 and neurological targets such as 
the N-methyl-ᴅ-aspartate (NMDA) receptor.145 Despite their adaptability, poor cell-
membrane permeability and high rate of metabolism by peptins has meant there has been 
little success so far in using them as therapeutic compounds.  
1.3.4 Using small molecule α-helical mimetics to inhibit PPIs 
Another approach that has been explored in the search for inhibitors of PPIs is the 
development of small molecule α-helical mimetics.92,146,147 In principle a core organic 
framework is employed that can be functionalised in order to express moieties in the same 
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positions as if they were on an α-helix (Figure 1.29). A small molecule mimetic is 
designed by selecting an appropriate scaffold that is able to display functionality in the 
same positions as hot-spot residues on the PPI α-helix.  
 
 
Figure 1.29: Examples of α-helical mimetics: i) 1,1,6-substituted indane,148 ii) terphenyl,149 iii) 
oligobenzamide,150 iv) N-alkylated oligobenzamide,151 and v) 5-6-5 imidazole-phenyl-thiazole.152 
1.3.4.1 Using 1,6-Substituted Indanes to Mimic i, i+1 Residues 
The first example of an α-helical mimetic was developed by Horwell and co-
workers.148,153 They were looking to design a mimetic with affinity for tachykinin 
neuroreceptors NK1 and NK3. These receptors bind to an α-helix via either Phe-Phe or 
Trp-Phe residues in an i, i+1 configuration. Molecular modelling studies were used to 
select a 1,6-indane structure which overlaid well with the helix and displayed the indane 
functionalities at the same vector as the i, i+1 amino acid residues (Figure 1.30, A). A 
small library of indane based i, i+1 mimetics was synthesised, and several compounds 
identified that had μM affinity for the NK1 and NK3 receptors. The most potent of these 
(1, Figure 1.30) had a measured IC50 of 2.4 μM for NH1 and 3.0 μM for NK3, 
demonstrating the potential of using α-helical scaffold mimetics towards development of 
small molecule PPI inhibitors. 
i-1 
i 
i+1 
i+2 
i+3 
i+4 
i+5 
i+6 
i+7 
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Figure 1.30: A) Alignment of Horwell’s indane scaffold with the i, i + 1 positions on an α-helix. B) 
Structure of the most efficacious indane mimetic discovered.148,153 
1.3.4.2 Development of Terphenyl i, i+3/4, i+7 Mimetics 
Although it had been shown that α-helical structure could be successfully mimicked using 
a small-molecule scaffold, this was limited to a small subset of PPIs where the hotspot 
residues are in an i, i+1 conformation. Hamilton realised that if a terphenyl scaffold was 
functionalised at each phenyl ring to display an amino acid side chain, these would align 
with the i, i+3/4 and i+7 positions on an α-helix.149 This is due to ortho-positioning of the 
functional groups on the phenyl rings, which cause the terphenyl scaffold to lose planarity 
and adopt a staggered conformation (Figure 1.31).  This is applicable to a much larger set 
of PPI targets as it is a much more common hot-spot configuration.  
 
Figure 1.31: The terphenyl functionality aligned with the i, i + 4 and i + 7 positions on an α-helix. 
The first target selected was calmodulin (CaM), which binds to an α-helical section of 
smooth muscle myosin light-chain kinase (smMLCK). Alanine scanning mutagenesis had 
i 
i+1 
A B 
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shown that smMLCK binds via three hot-spot residues (Trp800, Thr803 and Val807) in 
an i, i+3, i+7 configuration. Hamilton designed a direct mimetic of these three residues 
on the terphenyl scaffold and found that it inhibited CaM with an IC50 of 800 nM (the 
IC50 of the 20-aa smMLCK peptide is 80 nM). By changing the tryptophan mimetic to a 
1-napthyl group, they discovered compound 2 (Figure 1.32), which was able to better 
mimic the binding of smMLCK to CaM to result in an IC50 of 9 nM. This demonstrated 
the potential of using small molecule mimetics of i, i+3/4, i+7 α-helical residues to inhibit 
PPIs. 
 
Figure 1.32: Structure of smMLCK mimetic discovered by Hamilton which binds to CaM with an IC50 of 
9 nM.149 
1.3.4.3 Using Oligamides to Ease Synthesis and Enforce Conformational Structure of i, 
i+3/4, i+7 Mimetics 
Although the terphenyl structures could be used successfully in mimicking an α-helix, 
they were difficult to synthesise and their high lipophilicity resulted in poor aqueous 
solubility, meaning that they were difficult to use in cell based assays, reducing their 
value as chemical tools. In order to counteract this, in several examples benzamides have 
been used instead to mimic the α-helix i, i+3/4, i+7 positions (Figure 1.33). The amide 
bonds introduced facilitate synthesis, making the compounds amenable to solid-phase 
techniques, and also lower the pKa significantly, increasing solubility and ‘drug-
likeness’. The first example of an oligobenzamide mimetic was synthesised by 
Hamilton.154 It was calculated that the hydrogen-bonding present in an oligopicolinamide 
based molecular scaffold (Figure 1.33, i) would hold the O-functionalised side chains on 
the same side of the molecule, and induce an amount of inwards backbone bending. 
Indeed this resulted in a conformation that closely mimicked the terphenyl i, i+3/4, i+7 
mimetics. Using this scaffold they were able to design moderate μM inhibitors of the Bcl-
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XL/BAK interaction. However, the functionalised picolinic acid monomers proved 
synthetically challenging, limiting the diversity of oligomers achievable. 
 
Figure 1.33: Different structures of oligobenzamide α-helical mimetics, including i) oligopicalinamide,154 
ii) terephthalamide,155 iii) benzoylurea,156–158 iv) 3-substituted oligamide,150,159 v) 2-substituted 
oligobenzamide,160and vi) N-substituted oligobenzamide.151 
Wilson investigated the mimetic effects of simpler oligobenzamides, with monomers that 
are more synthetically accessible. He developed the synthetic methodology required to 
make 3-substituted oligamides (Figure 1.33, iv)150 and 2-substituted oligamides (Figure 
1.33, v)160 from amino benzoic acid monomers, which could be made in far fewer 
synthetic steps than the picolinic acid anologues. It was initially found that by masking 
the aniline as a nitro group he could carry out iterative peptide coupling/nitro reduction 
steps to reach the desired oligomeric product. However, although the trimer was easily 
synthesised using this methodology, the yields of the tetramer and pentamer oligomides 
were drastically lower due to the decreased solubility of the intermediates. Solid phase 
synthesis techniques using fluorenylmethyloxycarbonyl (Fmoc) protected starting 
monomers gave improved yields, but required a more lengthy synthesis of starting 
materials.161  
 
Both oligamide regioisomers afforded inhibitors for the p53/Mdm2 PPI when 
functionalised with residues to mimic the p53 i, i+4 and i+7. The 3-substituted 
oligobenzamides produced the most efficacious p53 mimetics and the most potent 
example had an IC50 of 1.0r0.11 μM, comparable to the free p5315-31 oligopeptide, with 
a measured IC50 of 1.2r0.04 μΜ.159 The 2-substituted isomers were generally less potent, 
with the most efficacious of these having an IC50 of 4.15r0.20 μM.160 N-substituted 
oligobenzamides were also developed which were amenable to solid phase synthesis.151 
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Although these contained no conformationally restricting H-bonds, they showed 
moderate activity against p53/Mdm2 of up to 2.8r0.8 μM. Wilson hypothesised that the 
differing efficacy could be due to the changing degree of backbone bending as a result of 
weaker H-bonds, meaning the side chains do not align as well to the i, i+3/4, i+7 
conformation. Of the three oligamide examples, the 2-substituted and N-substituted 
oligobenzamides exhibited the least backbone bending. Hamilton’s H-bond rich 
oligopicalinamides had more backbone bending than either of these.  
 
Hamilton et al. produced two further scaffolds, similar to the oligobenzamide α-helical 
mimetics, which relied on H-bonding to adopt the necessary conformation; the 
terephthalamide (Figure 1.33, ii)155 and benzoylurea (Figure 1.33, iii)156–158 scaffolds. 
Both of these serve to display functional groups so as to mimic the residues in the i, i+3/4 
and i+7 positions to produce a Bcl-XL/Bak inhibitor. A functionalised terephthalamide 
was able to inhibit Bcl-XL/Bak with an IC50 of 0.78r0.07 μM,155 and a benzoylurea with 
a Ki of 2.4 nM.157  
 
More recently, Hamilton et al. showed that monomers from the various oligamide 
mimetics could be combined to create hybrid compounds, to customise the degree of 
backbone bending caused by intramolecular H-bonds.162 However, these molecules 
tended to have lower efficacy for their target, and they were only able to achieve an IC50 
of 9.2r0.4 μM against p53/Hdm2. 
 
1.3.4.4 Other Examples of α-Helical Mimetic Small Molecule Scaffolds. 
Terphenyl and oligamide inspired α-helical mimetics are not the only scaffolds that have 
been developed, and some of the other examples have also afforded compounds with 
activity against PPIs (Figure 1.34).  
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Figure 1.34: Other examples of α-helical mimetic scaffolds including: i) Diphenylindane,163 ii) 
polycyclic ether,164 iii) pyridazine-based polyheterocycle,165,166 and oligooxopiperazine.167 
Hamilton et al. combined his previous work on terphenyls149 with Horwell’s indane based 
i, i+1 mimetics153 to design and synthesise a hybrid i, i+3, i+4, i+7 scaffold (Figure 1.34, 
i).163 Although the molecule was designed to mimic these positions on the p53 helix to 
interact with Hdm2, no data on the efficacy of the molecule towards its intended target 
was published. Oguri and co-workers synthesised another scaffold which mimicked the 
i, i+4 positions (Figure 1.34, ii).164 This design was based on a tetracyclic ether scaffold, 
which was selected to bestow aqueous solubility. The scaffold was functionalised with 
guanidinium groups to enable binding with the carboxylate groups on a polypeptide helix 
which contained aspartic acid residues in the i and i+4 positions. Reasonable selectivity 
was achieved over polypeptides with aspartic acid residues in different positions, and CD 
spectroscopy indicated that addition of their mimetic stabilised the helicity of the 
complementary peptide when bound. 
 
Another scaffold designed with aqueous solubility in mind was a series of pyridazine 
based scaffolds from Rebek and co-workers (Figure 1.34, iii).165,166 They attempted to 
instil a ‘wet’ edge on the face of the scaffold opposite to the lipophilic amino acid side 
chains, which contained heteroatoms to lower the clogP. As this part of the molecule is 
in theory solvent exposed when bound to the protein, this should have improved solubility 
without lowering lipophilicity. However, although some binding was detected for Bcl-XL 
by fluorescence polarisation, it was not high enough to calculate an IC50 value. 
 
Arora had more luck in his development of oxopiperazine scaffolds as α-helical mimetics 
(Figure 1.34, iv).167 These heteroatom rich molecules were found to be soluble in aqueous 
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media at μM levels. By functionalising the scaffold with larger lipophilic residues to 
mimic p53 they successfully developed compounds with affinity for Mdm2, with their 
best having a Kd of 0.3r0.01 μM. They were also able to develop potent HIF mimetics, 
the best of which bound with a Kd of 0.16r0.06 μM, making these some of the most potent 
small molecule PPI inhibitors discovered at that time. 
 
1.3.5 Targeting PPIs using the Conventional Drug Discovery Process 
Although there have been successes in targeting PPIs using carefully designed α-helical 
mimetics, very few candidates for therapeutic application have been generated using the 
methods described previously. In the meantime the pharmaceutical industry has also had 
some small successes towards a therapeutic compound inhibiting a PPI.168 As discussed 
in part 1.1, this is often a difficult and expensive process, due to the less druggable nature 
of the PPI. However, by combining traditional fragment screening to identify leads, with 
SAR to develop a candidate compound, progress has been made in some cases. Here, a 
few of the more successful case studies will be discussed. 
 
1.3.5.1 Case Study 1: p53/Mdm2 and the Nutlins 
The nutlins are named after Nutley, New Jersey, where they were discovered by Vassilev 
and co-workers at Hoffman-La Roche.169,170 A high-throughput screen using surface 
plasmon resonance identified a series of cis-imidazolines with activity against Mdm2. 
These were the racemic nutlin 1 and nutlin 2, and the separated enantiomers nutlin 3a and 
Nutlin 3b (Figure 1.35), with IC50 values of 0.26, 0.14, 0.09, and 13.60 μM, respectively. 
Crystal-structure analysis of nutlin 2 (PDB code: 1RV1) indicated that the nutlins bound 
to the same pocket on Mdm2 as the p53 α-helix. To some extent, the nutlins mimic the 
interaction of p53 protein residues with Mdm2, with a bromophenyl in both the Trp and 
Leu pockets, and an ether side chain filling the Phe pocket. The most active of the nutlins 
(3a) was taken into in vivo testing, and was well tolerated on oral administration in mice 
to give plasma levels above the in vitro IC90. This gave a 90% inhibition of tumour growth 
in mice compared to the control group. It is worth noting that nutlin 3a, breaks Lipinski’s 
rules on account of its high molecular weight (581.5 Daltons) and logP (5.19).  
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Figure 1.35: Structure of nutlins 1, 2, 3a and 3b.169,170 
1.3.5.2 Case Study 2: Targeting Bcl-XL with ABT-737 
Researchers at Abbott used nuclear magnetic resonance fragment screening, and 
subsequently structural biology, to discover compounds with high binding affinity for the 
hydrophobic groove on Bcl-XL, to act as Bcl2 inhibitors.171 Initial lead compounds 
identified from this process were highly active (Ki = 36 ± 1.6 nM), however the inhibitory 
effect was effectively nullified in the presence of HSA. After identifying the portion of 
the molecule responsible for binding to domain III of HSA, the subsequent structural 
modifications and optimisation regarding cytotoxicity effects led to the discovery of 
ABT-737 (Figure 1.36). This compound had affinity for both Bcl-2 (IC50 < 1 nM) and 
Bcl-XL (IC50 < 0.5 nM), and was maintained in 10% human albumin serum, but 
unfortunately was not orally bioavailable. However, modifications to this structure gave 
ABT-263, which retains a lot of the affinity (ABT-263 Ki = 0.4 nM, ABT-737 Ki = 0.08 
nM) and exhibits oral bioavailability in animal models.172 
 
Figure 1.36: Left: Crystal structure of ABT-737 bound to Bcl-XL (PDB: 2YXJ). Right: Structures of 
ABT-737 and ABT 263.172 
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1.3.5.3 Case Study 3: The Road to Bivalent SMAC Mimetics to Target XIAP 
The protein ‘Second mitochondria-derived activator of caspases’ (SMAC) is a regulatory 
protein which binds to X-linked inhibitor of apoptosis protein (XIAP), blocking its 
interaction with caspase 3, 7 or 9, and thereby inhibiting the apoptotic cycle. SMAC binds 
to XIAP through four residues on the N-terminus (Figure 1.37; SMAC AVPI). Early 
studies toward creating a therapeutic to target this interaction focused on developing SAR 
of the SMAC AVPI peptide. Vucic and co-workers developed compound CS3 (Figure 
1.37), which is based on the SMAC N-terminus and is highly potent, with a Ki of 
16 nM.173 The structure of SMAC mimetics dramatically changed direction when the first 
dimeric mimetics were discovered accidentally in 2005, as the result of the unintended 
homodimerisation of an alkyne group by a Glaser coupling (Figure 1.37).174 The 
compound resulted from an accidental dimerization of a terminal alkyne to form a diyne 
bridge and had higher potency even than the SMAC protein, with an estimated Kd of 0.3 
nM. From this point on new SMAC mimetics have typically incorporated this bivalent 
frame. The most successful of these is birinapant, an intravenously administered molecule 
which has been taken through to phase II testing by Tetralogic.175 
 
Figure 1.37: The structure of the N-terminus of SMAC, as well as three designed SMAC mimetics. 
1.4 Conclusion 
In conclusion, PPIs have proved a challenging target by traditional drug discovery 
methods. This is due to the fact that the protein binding site is typically large in size, flat, 
and very lipophilic in nature. As a result, typical fragment and small molecule libraries 
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designed for lead identification by high throughput screening have very low hit rates 
against PPI targets. 
 
As a result, more esoteric methods have been developed to facilitate the ab initio design 
of PPI inhibitors, primarily through the mimicry of one of the proteins at the binding site. 
As α-helices are involved at the binding site of approximately 62% of protein-protein 
interactions, a great deal of attention has been given to the development of α-helical 
mimetics. Different approaches to accomplish this include synthesising peptide foldamers 
using unnatural amino acid residues, designing structurally stable miniproteins which are 
forced into a restricted conformation in solution, covalently stapling one face of the α-
helix in order to encourage secondary structure, and designing small molecule scaffolds 
which can be functionalised as to hold functional groups in positions that mimic the α-
helical amino acid side-chains. 
 
The medicinal chemist hoping to discover a novel chemical lead for the inhibition of a 
PPI now has the choice of many different techniques, facilitating the development of tool 
compounds and drug molecules. 
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2 Instilling ‘daclatasvir-like’ functional groups using 
palladium catalysed C-H activation. 
2.1 Chapter Summary 
This chapter outlines the development of methodology to functionalise aryl bromides 
with ‘daclatasvir-like’ functional groups using C-H activation.  Daclatasvir is a hepatitis 
C anti-viral drug that has exceptionally high oral bioavailability, despite having a high 
molecular weight.  It was hypothesised that this functionalization of structurally related 
cores with ‘daclatasvir-like’ termini could be used as a strategy to improve cell 
permeation and drug-like properties of PPI inhibitors. 
 
The synthesis of the reagents required for the C-H activation chemistry is described, in 
particular optimising the conditions to reduce the amount of homo-coupling within the 
reaction. The scope of the C-H activation was then tested on 18 different aryl dibromides 
and was successful in 11 cases. The chemistry developed has applications in the late stage 
core-functionalization of HCV non-structural protein 5A (NS5A) inhibitors, as well as 
the potential to introduce improved PK to polyaryl α-helical inhibitors. 
2.2 The Unusual Pharmacokinetics of Daclatasvir, and potential 
application to PPIs. 
 
Figure 2.1: Structure of the HCV NS5A inhibitor daclatasvir. 
Although we are starting to see the development of more and more PPI inhibitors, these 
compounds consistently produce poor pharmacokinetic (PK) profiles. Due to the size and 
lipophilicity inherent in PPI inhibitors, the compounds will regularly have poor (if any) 
oral bioavailability, poor transport properties into cells, significant metabolism, 
significant excretion, and poor aqueous solubility.168,176 These factors are often governed 
by whether or not a drug meets the ‘Lipinski rule-of-five’ criteria.177,178 These state that 
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for a drug to have good oral PK properties, it must normally have MWTd500, logPd5, 
number of H-bond donors d 5, and number of H-bond acceptors d 10. PPI inhibitors 
regularly break the rules regarding molecular weight and lipophilicity.177   
 
Examples of existing drug molecules that break the rule-of-five criteria, yet still exhibit 
high oral-bioavailability and solubility, were analysed. In doing so it was hoped that 
insight would be developed into how to incorporate these physical properties into the 
design of novel PPI inhibitors. One such molecule is the HCV non-structural protein 5A 
(NS5A) inhibitor, daclatasvir.179 
 
Not only does daclatasvir exhibit exceptional potency (as low as 9 pM against NS5A 
genotype 1b), but it has also been found to have a surprisingly good pharmacokinetic 
profile.180 Despite having a molecular weight of 739 Daltons, it exhibits excellent 
bioavailability (F) of 38-108% in animal tests (Table 2.1).181 
Table 2.1: Bioavailability of Daclatasvir in animal tests.181 
 Rat Dog Monkey  
AUC 4.8 11 1.93 μM.h 
F 50 108 38 % 
 
There has been little research into what structural properties give rise to the excellent PK 
profile exhibited by daclatasvir. Based on research into other compounds of similar 
structure, it is reasonable to hypothesise that internal hydrogen bonding may be the cause 
of the high membrane permeability of the compound.182 Low energy conformations of 
daclatasvir modelled without the presence of water exhibit internal hydrogen bonding 
which causes the polar side chains to wrap inwards (Figure 2.2). This could potentially 
mask polar sites on the molecule when in a lipophilic environment, allowing inter-
membrane diffusion, without decreasing solubility in aqueous media. 
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Figure 2.2: The 3D structure of daclatasvir, conformationally minimised in MOE using LowModeMD 
calculations. 
Due to the polar nature of the side chains, they contribute only a small net gain to the 
clogP and clogD of the molecule (Table 2.2). The overall clogP over daclatasvir is only 
0.56 higher (3.62 to 4.16) than the unfunctionalised biphenyl core of the molecule, despite 
a significant contribution to molecular weight. Interestingly, due to the addition of 
imidazole rings, the side chains contribute a significant gain to the solubility forecast 
index (SFI)183,184 of daclatasvir, which is predicted to be 8.16 at physiological pH. 
Statistical analysis of known compounds indicates that only 5% of compounds with 
equivalent SFI values exhibit good solubility when tested.183 This is an indication of how 
much of an outlier the PK properties of daclatasvir are considering the large molecular 
weight.  
Table 2.2: Calculated measures of lipophilicity and solubility for daclatasvir and biphenyl. 
Compound clogP clogDpH7.4 SFIa 
N
N
H
N
H
N
NN
O
N
H
O
O
O
N
H
O
O
 
4.18 4.16 8.16 
 
3.62 3.62 5.62 
aSolubility forecast index (SFI) calculated as clogDpH7.4 plus number of aromatic rings.183 
 
It was hypothesised that the polar side chains were responsible for giving daclatasvir its 
excellent PK profile. Considering this, it was felt there could be value to instilling these 
side chains onto known PPI mimetics. For example, a terphenyl α-helical mimetic such 
as those developed by Hamilton could be functionalised in this way, potentially leading 
to greater permeability, aqueous solubility and bioavailability.149 This chapter explores 
the chemistry required to achieve this. 
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2.3 Retrosynthetic Analysis of Daclatasvir Side-chains 
 
Scheme 2.1: Synthesis of daclatasvir developed by BMS.185 
The synthetic route to daclatasvir developed by Bristol-Myers Squibb is an efficient, 
linear synthesis, reaching the product in a 31% yield over six steps (Scheme 2.1).186 1,1’-
Diacetylbisphenyl 11 is dibrominated, reacted with Boc-ʟ-proline, then transformed to 
the imidazole 14 upon reaction with ammonium acetate via an interesting rearrangement 
step. The butyloxycarbonyl (Boc) groups are then removed with acid, and the resulting 
amines subjected to amide coupling to install the valine sidechain present in the product, 
daclatasvir (10). 
 
Although this is an efficient route, and has proven to be scalable for large-scale 
production of the drug, the linearity means that the core bisphenyl functionality within 
the molecule has been incorporated within the first step. To establish methodology to 
explore α-helical mimetics with the daclatasvir side chains, a more convergent synthetic 
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route in which the aryl-imidazole bond would be formed in the final stages was required. 
Retrosynthetic analysis was therefore carried out on the structure of daclatasvir (Scheme 
2.2). There have been examples in the literature where this key bond in NS5A inhibitors 
has been formed using Suzuki cross-coupling chemistry between an imidazole-boronic 
acid, and an aryl bromide.187,188 However, the instability of the imidazole-boronic acid 
was found to be an issue. This lead us to consider a C-H activation strategy, with C-H 
activation directed to the imidazole 2-position (Scheme 2.2).189 
 
Scheme 2.2: Retrosynthetic analysis of daclatasvir using C-H activation. 
2.3.1 C-H Activation of Imidazoles in the 2-Position. 
Metal-catalysed C-H activation chemistry has gained a great deal of attention in recent 
years.189–191 It exists as an attractive alternative to conventional metal-catalysed coupling 
reactions, such as Suzuki cross-coupling. When carrying out conventional cross-coupling 
reactions, both reagents must be functionalised with reaction specific functional groups, 
such as a boronic acid and an aryl halide for a Suzuki coupling. C-H activation provides 
an atom-efficient alternative, by making use of existing C-H bonds within molecules. In 
doing so, it reduces the need for additional reaction steps to functionalise reagents with 
the necessary functionalities, potentially making the synthetic routes quicker and greener.  
 
However, the ubiquitous nature of C-H bonds brings about the problem of selectivity. In 
order to be synthetically useful, the reaction must proceed so that only the desired position 
is functionalised. Because of this, a great deal of research has been carried out into how 
to direct C-H activation to specific positions, in particular on 5 and 6-membered 
heteroaromatic rings. A few recent examples of significant C-H activations are described 
in the following paragraphs.  
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2.3.1.1 Controlling C-H Activation Using Directing Groups 
The pyridyl nitrogen lone pair has been shown to direct palladium catalysed C-H 
activation reactions on arenes.191 One of the most studied C-H activation reactions is 
palladium(II) acetate-catalysed acetoxylation using diacetoiodobenzene, pioneered by 
Sandford.192 The catalytic cycle follows the sequence of C-H activation, followed by 
oxidation by diacetoiodobenzene, and finally a reductive elimination. The cycle involves 
transitions between Pd(II) and Pd(IV) oxidation states (Scheme 2.3).193 
 
Scheme 2.3: The N-directed acetoxylation of benzoquinoline by diacetoiodobenzene catalysed by 
palladium(II) acetate, showing the catalytic cycle.193 
With modified conditions, this C-H activation can also be used for the functionalization 
of various different groups. By carrying out the reaction in alcohols as solvents, it is 
possible to functionalise with aryl ethers, such as OMe, OEt, O-iPr and OCH2CF3 in good 
yields.193 It is also possible to functionalise with a range of aryl groups using hypervalent 
bis-aryl iodonium salts as the oxidant. As well as the benzoquinoline directing group, 
Sanford has also shown that a wide range of other functional groups are able to ortho-
direct the C-H activation through ligation with the palladium metal centre (Figure 2.3).191 
 
Figure 2.3: Examples of ortho directing groups for C-H activated acetoxylation.191 
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2.3.1.2 C-H Activation on 5-Membered Heterocycles. 
Unlike for arenes, where a directing group is usually required for regioselective C-H 
activation, 5 membered heterocycles have an inherent electronic bias within the molecule 
which is often sufficient to achieve regioselective C-H activation.190 The C-H activation 
will normally occur at the most nucleophilic position on the ring. The reaction was 
traditionally predicted to proceed through electrophilic aromatic substitution, or Heck-
type mechanism (Scheme 2.4).190 However, more recently, density functional theory 
(DFT) calculations carried out by Fagnou has shown that the mechanism is more likely 
to proceed through the concerted metalation-deprotonation (CMD) mechanism, 
particularly when in the presence of a carboxylate ligand (Scheme 2.4).194 It is possible 
to C-H activate the position with selectivity to the position with the lowest pKa, by 
metalation using copper iodide, followed by a normal cross-coupling (Scheme 2.4). 
 
Scheme 2.4: Different proposed mechanisms of C-H activation on 5-membered heterocycles.190,194 
As early as 1985, the C-3 arylation of N-protected indoles by C-H activation had been 
developed by Ohta and co-workers.195 By refluxing a solution of the tosylated indole with 
a 2-chloropyrazine and potassium acetate in N,N’-dimethyl acetamide (DMA) for 12 
hours in the presence of Pd(PPh3)4, they were able to achieve C-H activation in yields of 
up to 98% (Scheme 2.5, A).196 The reaction could be explained by general ability of the 
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indole 3-position to react with electrophiles, combined with the ability for 2-
choloropyridines to undergo SNAr. 
 
Suzuki reported another early example of C-H activation on the C-3 position of an 
imidazole by intramolecular reaction with an aryl bromide (Scheme 2.5, B).197 Again the 
conditions were forcing, 150 °C in DMA. Interestingly, during the optimisation process, 
it was found that the addition of tetrabutylammonium chloride (TBAC) increased the 
yield by around 10 %. This could be due to the fact that TBAC has been shown to stabilise 
the formation of palladium nanoparticles, which act as an effective catalytic species.198 
 
Scheme 2.5: Selected C-H activation reactions, including A) Early C-3 arylation of protected indole by 
Ohta,196 B) Intramolecular C-3 arylation of imidazole by Suzuki,197 C) Arylation of SEM protected 
pyrrole by Sames,199 and D) Use of PivOH for broadly applicable C-H activation conditions by 
Fagnou.200 
Sames and co-workers breakthrough work pioneered C-H activation on N-protected 
pyrroles (normally a difficult heteroaromatic for this type of reaction). The use of a 
trimethylsilylehtoxymethyl (SEM) protecting group enabled C-H activation in the C-5 
position with a yield of 59% (Scheme 2.5, C).199 However the esoteric N-heterocyclic 
carbene palladium complex utilised as catalyst limited the applicability of the reaction. 
Nevertheless, the discovery of the SEM protecting group as facilitating the C-H activation 
of 5-membered heterocyclic rings was an important one.  
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A major breakthrough towards developing C-H activation conditions that would have 
broad applications across many different heterocycles was the introduction of pivalic acid 
as an additive (Scheme 2.5, D).200 Pivalic acid has been shown to facilitate the CMD 
transition state that occurs during the C-H activation step of the catalytic cycle (Scheme 
2.4).194 This allowed C-H activation to occur using commercially available catalyst. 
Although yields were sometimes moderate, this reaction conditions had incredibly wide 
scope.  
 
Sames developed C-H activation conditions to access each position on an imidazole ring 
(Scheme 2.6).201 He shows that it is possible to use C-H activation as an alternative to 
cross coupling on each position on the imidazole ring, by choosing appropriate conditions 
and using SEM protective group strategy to drive regioselectivity.  
 
Scheme 2.6: Strategy to access all positions on an imidazole ring developed by Sames.201 
These recent developments in imidazole C-H activation strategy were considered a viable 
option for the functionalisation of aryl groups with daclatasvir-like side chains, and thus 
synthesis of the imidazole intermediates identified in the above retrosynthesis was 
required to test the conditions, (Scheme 2.2).  
2.4 Synthesis of the Imidazole Reagent for C-H Activation  
 
Scheme 2.7: A summary of the synthesis of C-H activation reagent 39. 
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Scheme 2.7 shows the synthesis of CH-activation reagent 45 that will be discussed in 
detail in this section. Firstly, the synthesis of imidazole 25 following procedures similar 
to those reported in the literature will be described, followed by the amide coupling to 
introduce the valyl carbamate side chain, and finally the SEM protection to give the 
desired imidazole reagent 45. 
2.4.1 Synthesis of Imidazole 19 
 
Scheme 2.8: Synthesis of imidazole 19. 
The synthesis of imidazole 19 was carried out following a similar route to that described 
previously in the literature (Scheme 2.8).202,203 Firstly Boc-ʟ-proline 37 was reduced to 
the corresponding alcohol 40 using borane in tetrahydrofuran (THF). This method was 
scaled up to 20 g of starting material giving the product 40 in a 98% yield. The oxidation 
of the Boc-prolinol to the necessary aldehyde 41 was carried out with particular care due 
to the potential racemisation of the aldehyde α-carbon. The final conditions chosen 
involved a (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO)/Cu(I) catalytic system due 
to the mild nature of the reaction and the ease of scale up, which gave the product 41 in 
90% yield. The different conditions investigated are discussed in more detail in section 
2.4.1.2. The aldehyde was then cyclised to the corresponding imidazole 42 without 
purification, to reduce the chance of racemisation. This was achieved by reaction with 
glyoxal and ammonia, and gave the imidazole in a 97% yield. The final step to give 
compound 19 was the cleavage of  the Boc group using triflouroacetic acid.204 The crude 
triflouroacetate salt was purified by use of an SCX-2 ion exchange column, to give the 
free-base pyrrolidine 19 in a 97% yield. Overall, this synthetic route allowed for the 
synthesis of compound 19 in an 83% yield over 4 steps, and was successfully performed 
on a 20 g scale. 
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2.4.1.1 Rotamers around the Boc-pyrrolidine bond 
The NMR characterisation of compounds containing the Boc carbamate group was 
challenging due to the presence of rotamers at room temperature. Carbamate groups are 
known to exist in either the syn or anti conformations (Figure 2.4),205 with the syn usually 
being the thermodynamically favoured.  
 
Figure 2.4: Syn and anti carbamate rotamers 
However, because the carbamate in the compounds synthesized in this project are formed 
off a pyrrolidine ring, neither the syn or anti forms are significantly more favoured. The 
interconversion between either forms by rotation around the carbamate C-N bond is slow 
compared to the NMR timescale, and splitting of NMR peaks between rotamers is 
consistently observed. For example, in compound 41, the two carbamate rotamers (Figure 
2.5) led to a complex NMR spectrum, with splitting at both the aldehyde and tert-butyl 
peaks. 
 
Figure 2.5: Rotation around the carbamate C-N bond, and the energy profile of ration, demonstrating the 
two energetically favoured rotamers 
 
2.4.1.2 Oxidation of (S)-tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate 40 to 
(S)-tert-butyl 2-formylpyrrolidine-1-carboxylate 41 
The published synthetic route to imidazole 19 described the use of catalytic TEMPO, with 
NaOCl for the oxidation of prolinol 40 to prolinal 41. Although near-quantitative yields 
were given for this reaction in the literature, it was not possible to push the reaction past 
60% completion as measured by NMR, with the crude material containing a mixture of 
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starting material and product. As there was reluctance to purify the aldehyde using 
chromatographic techniques due to the risk of α-carbon racemisation, the crude material 
was reacted directly to form imidazole 42, but the isolated yield was low. Because of this, 
it was important to further optimise the oxidation step. 
 
Table 2.3: Conditions tested for the oxidation of Boc-prolinol 40 to the respective aldehyde. 
 Conditions Yield 
1 TEMPO, NaBr, NaOCl, NaHCO3 60% 
2 (COCl)2, DMSO, Et3N, CH2Cl2, -78 °C → r.t 98% 
3 TEMPO (5 mol%), Cu(CH3CN)4OTf (5 mol%),  
2,2'-bipyridine (5 mol%), NMI (10 mol%), acetonitrile 
90% 
 
Initially, Swern oxidation conditions were used as an alternative to the low yielding 
TEMPO oxidation (Table 2.3). This reaction was very high yielding (99%), however, the 
presence of triethylamine gave rise to concerns over the racemisation of the aldehyde α-
carbon centre (Scheme 2.9). The calculated pKa of the carbonyl α position is 16.8 
(ChemAxon MarvinSketch 6.2.0). Triethylamine used in the reaction is basic enough to 
racemise this position by catalysing the formation of the enolate form of the aldehyde 
(Scheme 2.9). Therefore, the use of milder conditions was investigated, in which the risk 
of racemisation would be mitigated. 
 
 
Scheme 2.9: Mechanism for triethylamine-mediated racemisation under Swern oxidation conditions. 
Shannon Stahl recently released conditions whereby a primary alcohol could be oxidised 
to the respective aldehyde using atmospheric oxygen.206,207 This is done using a co-
catalytic system of a bipyridyl-copper-N-methylimidazole (NMI) complex, as well as the 
stable radical species, TEMPO. Under these conditions, oxygen will oxidise the copper(I) 
to a copper(II) peroxide species. TEMPO then catalytically mediates the ability for this 
species to oxidise alcohols to aldehydes. It does this by allowing the formation of a copper 
hydroxyl species, which undergoes substitution with the alcohol, and finally provides the 
respective aldehyde by reductive elimination (Scheme 2.10).  
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Scheme 2.10: Mechanism of oxidation of alcohols using a Cu(I)/TEMOPO co-catalytic system, as 
proposed by Stahl.208 
As the conditions are very mild compared to the Swern oxidation, with NMI only having 
a pKa of 7.4, there will be a significantly lower rate of racemisation of the aldehyde 
product. Most importantly, these conditions were also found to be much easier to carry 
out on a large scale reactions. 
 
This reaction was carried out on a 10 g scale, with 90% yield. In order to confirm that 
racemisation had not occurred, the optical rotation of the starting material and product 
were measured. The product was found to have an [α]D of -94.5 deg·mL·g−1·dm−1, which 
corresponds to the literature value of -96.1 deg·mL·g−1·dm−1.209 Despite the fact that the 
yield was slightly lower than Swern conditions, this reaction was still considered 
favourable, and adopted into the synthetic route. 
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2.4.2 Peptide coupling to form amide 38 
Once compound 19 had been synthesized, the next step was to form the amide bond 
between the pyrrolidine with the valyl-carbamate side chain. The valyl carbamate 17 was 
synthesized using the Schotten-Baumann conditions described in the original Bristol 
Myers-Squibb publications.181,186 ʟ-Valine is reacted with methylchloroformate in a 
biphasic system water/dichloroethane in the presence of sodium hydroxide. The resulting 
water-soluble acid was then dried by lyophilisation to give the product in an 84% yield.  
 
Scheme 2.11: Ketene formation from an acyl chloride during amide coupling. 
To form peptide 38, many different methods of peptide coupling were analysed.210 Firstly, 
reagents that could transform the carboxylic acid group into a reactive acyl chloride were 
considered. These include thionyl chloride, phosphoryl chloride, and more commonly 
oxalyl chloride with dimethylformamide (through the Vilsmeier-Haack intermediate). 
The acyl chloride is highly reactive and the reaction is very clean and atom efficient, and 
is therefore a good option.  
 
The use of acid chlorides, however, was not favoured in this synthesis due to the risk of 
racemisation due to intermediate ketene formation (Scheme 2.11). Instead, milder 
coupling reagents were initially selected, with which the reactive intermediate is 
generated in situ before reacting directly with the amine to produce a peptide bond, thus 
preventing racemisation from occurring. The most commonly used modern example of 
these are the guanidinium (once uronium)211 salts, such as N,N,N′,N′-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (HBTU). These react with the 
carboxylic acid to produce an acyl-triazolate intermediate, which can undergo further 
reaction with an amine to produce a peptide bond (Scheme 2.12). It has been extensively 
shown that these reagents are less prone to cause racemization, despite the fact that 
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triethylamine is still present.210 It is because of this that use of HBTU was chosen as the 
first method to attempt synthesis of peptide 38.  
 
The reaction between pyrrolidine 19 and carboxylic acid 17 mediated by HBTU was 
carried out in THF at room temperature.  The reaction was found to have proceeded to 
completion by LCMS, however, problems were encountered in purifying the product. 
Under normal workup conditions, the benzotriazole side product is removed by basic 
aqueous wash, due to the high water solubility of the corresponding salts. However, it 
was found that peptide 38 also exhibited high aqueous solubility, which preclude this 
work-up option. Instead, purification of the compound was attempted by column 
chromatography. Here, two problems were encountered. Firstly, the benzotriazole side 
product was found to co-elute with amide 38. As well as this, amide 38 was not found to 
be partially unstable under silica chromatography conditions. The initial 31 g of crude 
material, which was shown to contain roughly 30% product by 1H NMR, yielded only 
1.49 g of product after the three consecutive purifications required. These difficulties 
rendered this route unviable.   
 
Scheme 2.12: Mechanism of guanidinium mediated peptide coupling. 
Because of the difficulties encountered in removing the guanidinium salt by-products in 
the HBTU reaction, the acid chloride method was reconsidered in order to form amide 
38. Using this method, there were two factors which required careful consideration. The 
first was the aforementioned risk of racemization of the valyl chiral centre. The second 
was the methyl carbamate group on the acid, which is labile under acidic conditions, 
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therefore also a risk when carrying out this reaction. Because of this, pyridine was chosen 
as a base over triethylamine. With a pKa of 5.3, as opposed to 10.6, pyridine is not basic 
enough to deprotonate next to the acid chloride to form the ketene.212 It instead facilitates 
the reaction by forming a reactive pyridinium intermediate with the acid chloride. 
 
Initial attempts to form the acid chloride using oxalyl chloride were unsuccessful, and 
product appeared to decompose upon evaporation of the solvent (CH2Cl2) under reduced 
pressure. Carrying out a literature survey it was found that previous use of this acid 
chloride had required the addition to the amine in situ without isolation of the acyl 
chloride.213 By making this modification to the reaction procedure, and adding the acid 
chloride dropwise to pyrrolidine 19 in the presence of pyridine in dichloromethane, the 
desired product was formed in excellent yield by LCMS. The reaction was then quenched 
with ammonia in isopropanol, and the resultant ammonium salt removed by filtration. 
The crude filtrate could then be lyophilized from water to remove any residual pyridine, 
and give the product in acceptable purity without the need for purification by silica 
chromatography.  
 
Figure 2.6: 13C NMR Comparison between racemic amide 38 and acid chloride coupling product, 
showing the carbonyl carbons. 
ʟ-valyl amide 38 
ᴅʟ-valyl amide 38 
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Using this specially adapted acid-chloride methodology circumvented the difficulties 
encountered during purification using the original HBTU mediated coupling procedure. 
In order to prove that no racemisation was occurring at either stereocenter during the 
reaction, the ᴅʟ-valine equivalent of amide 38 was synthesized, and compared using 
NMR spectroscopy with the single diastereomeric products from the HBTU and acid 
chloride procedures. The NMR of epimeric amide clearly showed the two different 
diastereomers. This was most clear in the carbonyl region of the 13C spectrum (Figure 
2.6). It was possible to see peaks for both diastereomers for the carbamate carbon at 171 
ppm, the valyl carbonyl at 157 ppm, and the imidazole C2 at 149 ppm, whereas only one 
epimer was visible for amide 38 obtained by using the reaction conditions developed. 
This evidence was considered conclusive showing that no significant racemization 
occurred during this reaction using the conditions proposed, and therefore it was deemed 
suitable for this synthetic route.  
 
Scheme 2.13: Final conditions to reach amide 38. 
2.4.3 SEM Protection of Imidazole N-H to Form C-H Activation Reagents 
Before the C-H activation of the imidazole could be attempted the imidazole N-H must 
be masked with a SEM group in accordance with Sames findings.199,201 Both imidazole 
42 with Boc-functionalisation, and fully functionalised imidazole 38 were protected to 
test the C-H activation conditions. Firstly the imidazole was deprotonated, using NaH in 
THF, then reacted with SEMCl, which was added dropwise. This method was used to 
produce compounds 43 (67 % yield) and 44 (47 % yield) (Scheme 2.14). 
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Scheme 2.14: SEM protection of imidazoles at the N-H position. 
2.5 Optimisation of C-H Activation Conditions 
With the completed synthesis of SEM-protected imidazoles 43 and 44, the optimisation 
of C-H activation conditions was carried out. Initial optimisation was performed on the 
reaction between Boc-pyrrolidyl SEM-imidazole 43. The initial conditions were based on 
Fagnou’s broadly applicable conditions mentioned in section 2.3.1.2 where pivalic acid 
was used as an additive to facilitate the CMD transition state.200 
 
With the completed synthesis of SEM-protected imidazoles 43 and 44, the optimisation 
of C-H activation conditions was carried out. Initial optimisation was performed on the 
reaction between Boc-pyrrolidyl SEM-imidazole 43. The initial conditions were based on 
Fagnou’s broadly applicable conditions mentioned in section 2.3.1.2 where pivalic acid 
was used as an additive to facilitate the CMD transition state.200 
 
The optimisation of the catalyst, base, additive, solvent and temperature was carried out. 
As expected, the absence of pivalic acid in experiments 6-8 lead to a significant drop in 
yields. There was little effect on changing the palladium ligands to the overall yields of 
reactions (experiments 2-5), although use of bis(diphenylphosphino)ferrocene (dppf) 
gave the best yield, and also reduced aryl bromide homo-coupling (see section 2.5.1.1). 
Changing the base did not affect the yield significantly either, although potassium 
carbonate was found to give the highest yield out of those used. Changing the solvent 
dramatically affected the yield, with DMA appearing the best of those tested. Interestingly 
dioxane, although giving a lower yield, appeared to significantly reduce aryldibromide 
homo-coupling (see section 2.5.1.1), and so was also explored further. 100 qC seemed to 
be the optimum temperature, providing the best balance between rate of reaction and side 
reactions occurring (experiments 19-22).  
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Table 2.4: Reaction data and yields for C-H activation under different conditions 
 
Experiment 
Catalyst 
/Ligand Base Acid Solvent T (°C) 
Yield 
(%)a 
1 Pd(OAc)2, 
HPCy3BF4 
K2CO3 Pivalic Acid DMA 140 61% 
2 PdCl2, 
HPCy3BF4 
K2CO3 Pivalic Acid DMA 140 49% 
3 Pd(dppf)Cl2 K2CO3 Pivalic Acid DMA 140 65% 
4 Pd(PCy3)2Cl2 K2CO3 Pivalic Acid DMA 140 57% 
5 Pd(PPh3)4 K2CO3 Pivalic Acid DMA 140 55% 
6 Pd(OAc)2, 
HPCy3BF4 
Cs2CO3 - DMA 140 42% 
7 Pd(dppf)Cl2 Cs2CO3 - DMA 140 33% 
8 Pd(PPh3)4 Cs2CO3 - DMA 140 19% 
9 Pd(dppf)Cl2 Na2CO3 Pivalic Acid DMA 140 34% 
10 Pd(dppf)Cl2 Cs2CO3 Pivalic Acid DMA 140 60% 
11 Pd(dppf)Cl2 KOAc Pivalic Acid DMA 140 56% 
12 Pd(dppf)Cl2 K3PO4 Pivalic Acid DMA 140 47% 
13 Pd(dppf)Cl2 K2CO3 Pivalic Acid DMA 140 59% 
14 Pd(dppf)Cl2 K2CO3 Pivalic Acid DMF 140 50% 
15 Pd(dppf)Cl2 K2CO3 Pivalic Acid NMP 140 29% 
16 Pd(dppf)Cl2 K2CO3 Pivalic Acid Dioxane 140 49% 
17 Pd(dppf)Cl2 K2CO3 Pivalic Acid THF 140 50% 
18 Pd(dppf)Cl2 K2CO3 Pivalic Acid IPA (wet) 140 9% 
19 Pd(dppf)Cl2 K2CO3 Pivalic Acid DMA 100 69% 
20 Pd(dppf)Cl2 K2CO3 Pivalic Acid DMA 120 61% 
21 Pd(dppf)Cl2 K2CO3 Pivalic Acid DMA 160 53% 
22 Pd(dppf)Cl2 K2CO3 Pivalic Acid DMA 80 64% 
23 Pd(dppf)Cl2 K2CO3 Pivalic Acid Dioxane 100 60% 
24 Pd(dppf)Cl2 K2CO3 Pivalic Acid Toluene 100 30% 
aYield of product determined by LCMS peak integration measured by adsorption at 254 nm. 
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In order to ensure that the LCMS profile of the reaction was indicative of the correct 
product forming, the reaction was carried out under the optimised conditions and the 
product was purified with a yield of 76% after purification. As the product contained Boc-
protected pyrrolidine, it was difficult to fully characterise using 1H NMR spectroscopy, 
due to the presence of rotamers (see section 2.4.1.1). Variable temperature NMR studies 
were carried out, and the peaks were found to fully converge at 70-80 qC (Figure 2.7), 
where the product was fully characterised as the compound 45 resulting from double C-
H activation. 
 
Figure 2.7: VT NMR of compound 45 to ensure proper assignment. 
2.5.1.1 Homo-coupling as a competing reaction, lowering the yield 
During the optimisation process of the C-H activation reaction, the major side-product 
was identified to be the product of homo-coupling between two dibromobisphenyl 
molecules which had then undergone homocoupling to form side product 47 (Scheme 
2.15). The side product was clearly distinguishable from the product on the LCMS trace 
(Figure 2.8). Despite their distinct separation on the LCMS trace, the product and the side 
product of homo-coupling were found to completely co-elute on silica gel column 
chromatography. Because of this, lowering the amount of homo-coupling during the 
reaction was considered a priority during optimisation.  
Homo-coupled side product
Mass :1036.6
Br Br Br Br
4 N
N N
N
R
SEM SEM
R
4
R= N
OO
Homo-coupling C-H Activation
18 46 47
 
Scheme 2.15: Formation of side product through homo-coupling. 
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Use of the dppf ligand, as well as conducting the reaction at or below 100 °C, gave a 
notable reduction in the amount of homo-coupling (Figure 2.8, experiments 1 and 19). 
Interestingly, when 1,4-dioxane was used as a solvent, no mass ion for the homo-coupled 
product was detectable (Table 2.4, experiment 23), although there was a significant 
overall drop in yield, which meant that DMA was still the solvent of choice for the 
reaction.  
 
 
 
 
Figure 2.8: LCMS chromatogram for experiments 1, 19 and 23. 
When the reaction was carried out in DMA at 80 °C (Table 2.4, entry 22), there was also 
less homo-coupling observed, however again there was a drop in yield. As such, the 
conditions used in experiment 19 were seemed to be the most effective overall, with a 
yield of 69% as measured by LCMS. This was found to equate to a yield of 76% of pure 
product after workup. 
2.5.2 Confirming the Optimised Conditions for Fully Functionalised Imidazole 
44 
Once the conditions were optimised for imidazole 43, a shorter optimisation process was 
carried out for imidazole 44 in order to ensure that the results observed previously 
regarding the best conditions held true. As the temperature, solvent and base were found 
to have the greatest effect on the reaction profile in the previous experiments, these were 
the only variables tested in this optimisation process (Table 2.5). 
Cross-coupling Homo-coupling 1 
19 
23 
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Table 2.5: Optimisation conditions for the C-H Activation 
 
Conditions: i) Pd(dppf)Cl2, PivOH, base, 4 hours 
Entry Base Solvent Temperature Yield 48a  49:48a 
1 K2CO3 DMF 100 °C 65%  0.13 
2 K2CO3 dioxane 100 °C 10%  0 
3 K2CO3 NMP 100 °C 38%  0.05 
4 K2CO3 THF 100 °C 25%  0.11 
5 K2CO3 DMA 100 °C 78%  0.03 
6 K2CO3 DMA 60 °C 1%  0 
7 K2CO3 DMA 80 °C 5%  0.15 
8 K2CO3 DMA 120 °C 69%  0.07 
9 Cs2CO3 DMA 100 °C 21%  0.10 
10 KOAc DMA 100 °C 3%  0.23 
11 K3PO4 DMA 100 °C 72%  0.06 
aYield of 48 and ratio of 49:48 determined by LCMS peak integration measured by adsorption at 254 nm. 
 
It was found that in general, the results obtained followed the same patterns for the yields 
of the product and by-product as when the reaction was previously optimised for 
imidazole 43. K2CO3 was still the highest yielding base, and carrying out the reaction at 
100 qC still seemed to be the best compromise between rate of reaction and side product 
formation. Gratifyingly, it was found that carrying out the reaction in DMA produced 
very little side product at all, whereas before, DMA enabled some homo-coupling of the 
aryldibromide to form side products. As a result, the overall yield by LCMS increased to 
78 %. 
 
As before, the optimised conditions were used on a larger scale to synthesise and purify 
the C-H activation product 48, so that it could be fully characterised. Whereas the LCMS 
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predicted yield was measured as 78 %, the isolated yield was calculated as 84 % (Scheme 
2.16). The lack of Boc groups also meant that no rotamers were visible by 1H NMR. 
 
Scheme 2.16: Isolated yields for optimised C-H activation reaction conditions 
2.5.3 SEM-group Removal to Yield Daclatasvir 
Once the C-H activation reaction had been optimised, conditions were tested for the 
removal of the SEM group from the product. Treatment of compound 48 with 
tetrabutlyammonium fluoride (TBAF) in ethyl acetate did not yield any product, even 
after heating at 60 qC for several days. More successful reaction conditions involved the 
use of trifluoroacetic acid (TFA) in dichloromethane, which showed quantitative 
conversion to the deprotected amine TFA salt by LCMS after eight hours. This material 
was then purified by preperative HPLC in order to obtain pure daclatasvir 10 to be fully 
characterised. 
 
Scheme 2.17: The quantitative removal of the SEM protecting groups by TFA in CH2Cl2. 
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2.6 Testing the Scope of the C-H activation reaction on different aryl 
dibromides 
With the conditions for the C-H activation and deprotection steps in hand, the scope of 
the reaction was tested. Aryl dibromide cores were selected from several examples of 
NS5A inhibitors in the literature,187,214–216 as a means of proving the methodology could 
be used to synthesise pharmaceutically-relevant compounds (Figure 2.9). Secondly, other 
aryl dibromides were chosen to give a wide range of functionalities to test the scope of 
the reaction.  
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Figure 2.9: Cores selected for synthesis from published NS5A inhibitors.187,214–216  
Overall, eighteen cores were either purchased or synthesised. The preparation of all 
synthetic intermediates is discussed in section 2.7. Of the 18 aryl dibromides tested under 
C-H activation, 11 were found to react. The results of these reactions can be seen in Table 
2.6. 
 
Overall, the reactions yielded between 42% and 80%. Generally, the larger and more 
complex the aryl dibromide, the lower the yield. Unless otherwise stated, the product of 
the C-H activation was fully characterised after removal of the SEM group by TFA in 
CH2Cl2. There are several functionalities that seem to be incompatible with the reaction, 
which are discussed below. 
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Table 2.6: Successful C-H activation reactions, with the yields of reaction. 
 
aYield of product determined by LCMS peak integration measured by adsorption at 254 nm. Characterisation was 
carried out on the fully deprotected product (see experimental section); bRatio of homo-dimer to product; cProduct 
decomposed under deprotection and characterisation was carried out on the SEM-protected product. dProduct detected  
by LCMS but purification failed. 
2.6.1 Incompatibility with alkynyl residues. 
One core that was found to be incompatible with the palladium-catalysed C-H activation 
was the alkynyl biphenyl core 53. There was found to be no observable change to the 
LCMS reaction profile when the reaction was followed during heating. This could be 
Entry Aryl Dibromide Yielda HD:Pb 
1 
 
78% 0.13 
2 
 
80% 0 
3 
 
64% 0.37 
4 
 
37% 0.72 
5 
 
0% - 
6 
 
0% - 
7 
 
42% 0.68 
8 
 
67% 0.12 
9c 
 
45% 0.26 
10c 
 
58% 0.23 
 
Entry Aryl Dibromide Yielda HD:Pb 
11 
 
0% - 
12 
 
0% - 
13 
 
67% 0 
14 
 
0% - 
15 
 
0% - 
16 
 
0% - 
17d 
 
49% 0 
18d 
 
42% 0.31 
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explained by the affinity of palladium for binding to alkyne moieties, whereby it is known 
to be able to carry out a range of reactions.217,218 For example, under similar conditions 
to those used in this reaction, the double addition of aryl-halides across the carbon-carbon 
triple bond has been observed (Scheme 2.18).219 
 
Scheme 2.18: Reactivity of biphenylalkyne reagent under similar conditions to those used in this work.219 
When the alkyne-containing reagent was added to the solution, there was a significant 
colour change from light orange to deep red, which supports the theory that the co-
ordination sphere of palladium may have changed. This is likely to affect the catalyst’s 
ability to co-ordinate with the imidazole in order to carry out the C-H activation and thus 
prevent the reaction from occurring (Scheme 2.19).  
 
Scheme 2.19: Possible co-ordination of palladium to alkyne 53, preventing the C-H reaction from 
proceeding. 
2.6.2 Incompatibility with N-H residues 
 
Figure 2.10: Methylation of N-H bonds instils compatibility with C-H activation. 
When screening different cores against the C-H activation chemistry, it was found that 
three cores that were synthesised containing an N-H bond did not react. In order to test 
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whether it was the N-H bond which was the cause of unreactivity, each core was N-
methylated. In each case, this resulted in a successful reaction (Figure 2.10). 
 
This observation was supported by wider precedent in the literature where a C-H 
activation would not occur in the presence of an N-H, but the reaction proceeded after 
masking the N-H bond. For example the intramolecular imidazole C-H activation carried 
out by Suzuki and coworkers, where alkylation of an amide with a butyl group allowed 
the reaction to proceed (Figure 2.11; A).197 The examples of reactions with an N-H 
present are nearly always intramolecular, for example Maes’ work on isocryptolepine 
synthesis (Figure 2.11; B),220 and Queiroz’s thienocarbazole synthesis (Figure 2.11; C). 
The entropic favourability of the intramolecular reaction seems to counterbalance the loss 
reactivity that results from having an N-H present in the molecule.   
 
 
Figure 2.11: Literature examples of palladium catalysed C-H activation: A) Example of C-H activation 
not compatible with presence of NH bond;197 B) Intramolecular pyridyl C-H activation, containing NH 
bond;220 C) Intromolecular thiophene C-H activation, tolerating the presence of NH functionality.221  
It therefore seems that the observation that N-H bonds are incompatible with this reaction 
is consistent with what has been reported in previous examples in the literature. 
2.6.3 Incompatibility of pyridyl functionality 
The final functionality which appeared to be incompatible with the C-H activation 
reaction was the pyridyl functionality, which was found in cores 64 and 65 (Figure 2.12). 
Aryl dibromide 64 contains a carboxylate functionality, although, as the presence of 
pivalic acid has been shown to be beneficial to the reaction, it seems unlikely that this is 
the cause of incompatibility in this case. 
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Figure 2.12: Cores with pyridyl functionality, unsuccessful at the C-H activation reaction. 
Interestingly, there was some precedent in a patent published by Pfizer that quinazoline 
65 should be compatible with the C-H activation chemistry.216 Because of this, the core 
was investigated further. The C-H activation reaction was carried out using a different 
imidazole reagent, containing a Boc functionality in place of the valyl-carbamate 
(Scheme 2.20). In this case, the reaction was found to be successful.  
 
Scheme 2.20: The C-H activation reaction was successful with a Boc, but not with a valyl carbamate 
In an attempt to explain this, both reactions were followed by LCMS analysis at regular 
intervals. In the unsuccessful reaction between quinazoline 65 and the valyl-carbamate 
imidazole reagent, the quinazoline starting material was found to be consumed, despite 
no product being formed. Instead, one predominant peak emerged as a side product. This 
side product could not be isolated and characterised, however its mass spectrum seemed 
to indicate a polymeric compound. When the equivalent reaction between quinazoline 65 
and the Boc containing imidazole was carried out, the formation of the same polymeric 
by-product was observed, however the C-H activation reaction was much quicker and the 
formation of the desired product became the dominant one. This evidence suggested that 
the larger valyl-carbamate peptide functionality on the original reaction was affecting the 
rate of C-H activation due to presence of an N-H bond, meaning that the side reaction, 
which occurred in both reactions, became the dominant product. 
 
Although it was not possible to identify the by-product, there is some precedent in the 
literature for potential reactions that may have been facilitated by the ability of the 
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quinazoline to act as a palladium ligand. The pyridine nitrogen has been shown to be a 
directing group for the C-H activation on aryl groups. Melanie Sanford and co-workers 
have done much of the work in this area. For example, it was shown that a pyridine group 
would direct the addition of a phenyl with ortho-regioselectivity to an 88% yield (Scheme 
2.21).192 Although normally an oxidising reagent is used for the C-H activation of arenes 
directed by pyridyl ligands, it demonstrates that the quinazoline may be directing C-H 
activation onto the phenyl group on 65. 
 
Scheme 2.21: Pyridyl group acting as a directing group for C-H activation.192 
2.7 Synthesis of different cores for C-H activation 
Many of the aryl-dibromides used to test the scope of the C-H activation reaction were 
not commercially available. The syntheses of these cores are described below. 
2.7.1 Synthesis of bisphenylalkyne 53  
 
Scheme 2.22: Synthesis of bisphenylalkyne 53 
Bisphenylalkyne 53 was synthesized in one step from 1-bromo-4-iodobenzene (68), using  
methodology developed by Brisbois.222 The reaction is a modified Sonogashira reaction, 
where trimethylsilyl acetylene is coupled to an aryl iodide, co-catalysed by palladium and 
copper. The presence of DBU and water then causes the labile trimethylsilyl group to 
cleave, liberating the second ethynyl hydrogen, which can undergo a second Sonogashira 
coupling. This reaction was successful with a yield of 44% after purification.  
2.7.2 Synthesis of Dibromobiphenylether 71 
 
Scheme 2.23: Synthesis of dibromobiphenyl ether 71. 
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Dibromobiphenylether 71 was produced using a simple bromination reaction, using 
bromine and sodium bromate as oxidizing agents. The reaction was carried out in a 
biphasic system of water and dichloromethane, and gave a 77% yield of the product. 
2.7.3 Synthesis of Benzoxazole 75 
 
Scheme 2.24: Synthesis of benzoxazole 75. 
The first step of this synthesis involved tin (II) chloride reduction of 4-bromo-2-
nitrophenol to the resultant aniline 73.223 This reaction gave a 97% yield after overnight 
stirring in methanol. Originally, the aminophenol 73 was reacted directly with 4-
bromobenzoic acid in the presence of by propylphosphonic anhydride224 to give 
benzoxazole 75 in one-pot. However, this reaction resulted in an intractable crude 
material, with no major product. Instead, the synthetic route summarised in Scheme 2.24 
was undertaken. 4-Bromobenzoic acid was transformed to the benzoyl chloride derivative 
using oxalyl chloride and N,N’-dimethylformamide (DMF) in dichloromethane. This was 
then reacted with aminophenol 73 to give amide 74. The temperature during the reaction 
was kept at -10 °C to control the selective formation of the amide over the less favoured 
ester. After all the starting material was consumed, any benzoic ester that had formed was 
saponified by stirring the crude material in aqueous lithium hydroxide, and then the 
resulting side products removed using aqueous work up. As a result, the product was 
obtained in 70 % yield. Amide 74 was then reacted with p-toluenesulfonic acid in 
refluxing toluene to obtain the benzoxazole 75 in 98% yield.225 
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2.7.4 Synthesis of amide 56 and N-methyl amide 59 
Scheme 2.25: Synthetic route to amide 56 and N-methylamide 59. 
In order to synthesize amide 56, p-bromobenzoic acid was firstly transformed into p-
bromobenzoyl chloride by refluxing in thionyl chloride for 2 hours, with catalytic DMF 
to catalyse the reaction through the Vilsmeier-Haack intermediate. This was then reacted 
with p-bromoaniline in the presence of triethylamine in dichloromethane at room 
temperature to give amide 56 to 54% yield. The amide was then N-methylated using 
sodium hydride and methyl iodide in THF, which after stirring for 18 hours at room 
temperature, afforded N-methylamide 59 in a 65% yield. 
2.7.5 Synthesis of carbazole 54 and N-methylcarbazole 57 
 
Scheme 2.26: Synthetic route to carbazole 54 and N-methylcarbazole 57 
Using a modified version of the conditions developed by Goto,226 the nitration of 4,4’-
dibromobiphenyl to compound 77 was successful, with a yield of 75%. Compound 77 
was then reduced and cyclised to the corresponding carbazole 54 by refluxing in 1,2-
dichlorobenzene in the presence of triphenylphosphine. Finally, carbazole 54 was 
methylated by reacting with sodium hydride, followed by methyl iodide, in THF, giving 
N-methylcarbazole 57 in 48 % yield.  
 
The mechanism for this reaction is proposed to proceed by the triphenylphosphine 
mediated transformation of the nitro group to a nitroso.227 Further reaction with 
triphenylphosphine allows cyclization of the carbazole ring with further production of 
triphenylphosphine oxide. Rearomatisation of this compound gives the carbazole product 
(Scheme 2.27). 
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Scheme 2.27: Proposed mechanism of carbazole 54 formation using triphenylphosphine.227 
2.7.6 Synthesis of Paal-Knorr products: furan 81, thiophene 82, and pyrroles 55 
and 58 
 
Scheme 2.28: Synthetic route involving Paal-Knorr synthesis of various heterocycles 
The common intermediate for the preparation of these 4 heterocyclic compounds was the 
1,4-diketone 80 (Scheme 2.28). In order to synthesize 1,4-diketone 80, p-
bromoacetophenone was brominated using elemental bromine in acetic acid, to give the 
α-bromo ketone 79 in 68% yield. The dimerization of this compound to compound 80 
was first attempted with a Wurtz-type metal-radical reaction. This was based on work 
done by Ceylan, where α-bromoacetophenones were dimerised by treatment with 
elemental zinc and catalytic iodine.228 These conditions proved unsuccessful, however, 
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and were substituted for an unusual set of conditions developed by Kulinkovich and 
coworkers,229 for the synthesis of 1,4-diketones. Under these conditions, a mixture of 4-
bromoacetophenone 78 and α-bromo ketone 79 was treated with a solution of zinc(II) 
chloride, tert-butanol and diethylamine. The proposed mechanism for this reaction is 
shown in Scheme 2.29. Zinc(II) chloride and tert-butanol form the active ClZnOtBu 
species in solution.  This facilitates the reaction between the methylketone and α-
bromomethylketone. The use of the zinc reagent as a base results in this reaction being 
entirely selective to the desired product and prevents epoxide formation occurring as a 
side reaction. When treated with diethylamine, the product rearranges to the desired 1,4-
diketone 80, through a cyclopropyl intermediate.230  
 
Scheme 2.29: Proposed mechanism for Kulinkovich’s 1,4-diketone formation.230 
Using these conditions, 1,4-diketone 80 was obtained in a 65% yield. Once this was 
achieved, the different Paal-Knorr conditions could be employed to achieve the three 
heterocyclic compounds. Furan 81 was obtained in a 74% yield by cyclocondensation 
obtained in a solution of methanol and dichloromethane saturated with HCl gas.231 
Interestingly, this reaction was found to be dependent on the temperature of the solution 
being kept below 0 °C during HCl gas saturation. This could be as a result of the higher 
solubility of HCl at lower temperatures allowing increased saturation of the solution. 
Thiophene 82 was synthesised by refluxing 1,4-diketone 80 in the presence of 
Lawesson’s reagent in toluene for 3 hours, giving the product in 75% yield.232 Finally, 
pyrrole 55 was synthesised in 62% yield by refluxing 1,4-diketone 80 in acetic acid, in 
the presence of ammonium acetate.233 Methylation of 55 was carried out with potassium 
carbonate and methyl iodide in DMF at room temperature, to give N-methylpyrrole 58 in 
47% yield. 
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2.7.7 Synthesis of quinazoline 65 
 
Scheme 2.30: Synthetic route to quinazoline 65. 
Quinazoline 71 was synthesized in a four step process reported by Pfizer.187,216 Firstly, 2-
amino-5-bromobenzonitrile was reduced to the corresponding primary amine 84 using a 
solution of borane in THF stirred over 3 days. After this, the resulting boron-nitrogen 
adducts were cleaved by HCl mediated hydrolysis to give the product in a 43% yield. 4-
Bromobenzoyl chloride, prepared from the corresponding acid and sulfuryl chloride, was 
then reacted with amine 84 to give amide 85 in excellent yield. The reduced 
nucleophilicity of the aniline due to delocalisation of the nitrogen lone pair was found to 
be sufficient so that none of the aniline-amide regioisomer was observed in the crude 
material. 85 was then transformed into dihydroquinazolinyl chloride 86 by refluxing in 
phosphoryl chloride, to give the desired product in 67% yield. Finally, intermediate 86 
was transformed into quinazoline 65 after two steps; liberation of the free base by 
treatment with aqueous sodium hydroxide and aromatisation in the presence of chloranil 
to give the desired aryl bromide core in a 66% yield. 
2.8 Conclusion 
 
Scheme 2.31: Overview of the C-H activation methodology developed. 
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In conclusion, a new methodology has been developed in order to functionalise aryl 
dibromides with ‘daclatasvir-like’ side chains using C-H activation. The scope of the 
reaction has been tested, and chemical functionalities that are incompatible with the 
reaction conditions have been identified. Care has been taken throughout the synthetic 
route to ensure that racemisation of stereogenic centres did not occur, by monitoring the 
optical rotation of the molecules, as well as identifying diastereomers by 13C NMR. This 
procedure has great potential for the development of new NS5A inhibitors and efficiently 
explore SAR, as the convergent nature of the synthesis means that the core region of the 
molecule can be diversified at a late stage. The scope of the reaction was tested, and out 
of 18 aryl dibromides tested, 11 were successful in the reaction. 
 
The methodology was also developed with the mind set of potentially improving the 
physical properties of highly lipophilic α-helical mimetics, such as Hamiltons i, i+3/4, 
i+7 terphenyl compounds, by functionalisation with ‘daclatasvir-like’ solubilising side 
chains.149 The C-H activation condition optimisation with the scope of reaction have been 
published under peer review.234 
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3 Targeting PALB2 with Computational-Based Design of 
Inhibitors 
3.1 Chapter Summary 
In this chapter computational work was carried out to design potential inhibitors of the 
partner and locator of BRCA2 (PALB2)/breast cancer 2 protein (BRCA2) PPI. The 
therapeutic potential of inhibiting the PALB2/BRCA2 interaction as a cancer treatment 
through synthetic lethality is outlined. The process by which small molecule mimetics 
were designed is described, followed by the computational alignment scoring and 
docking techniques used to predict which small molecule BRCA2 mimetics are most 
likely to inhibit the PALB2/BRCA2 interaction. The results of this work have been able 
to guide the design of BRCA2 mimetics for synthesis. 
 
Miniproteins mimicking the BRCA2 WFXXL motif were then designed. During this 
process a large number of sequences were designed based on proteins determined to be 
structurally stable in the PDB, and then homology modelling and alignment techniques 
were used to select the best candidates. Ten different sequences were purchased, and the 
α-helicity of one sequence determined to be 95% by CD spectroscopy.  
3.2 PALB2/BRCA2 as A Potential Target for Cancer Therapeutics 
Large scale PPI drug discovery programmes in pharmaceutical companies tend to focus 
on well understood interactions such as p53/Hdm2169,235,236 and the Bcl/BH3 family that 
have associated strong clinical target validation.103,171,237,238 For these targets, the large 
amount of existing research detailing fragment and small-molecule binding activity 
provides an attractive starting point for the chemical leads required. Academic research 
groups can struggle to compete with such drug discovery programmes, as they do not 
often have large research budgets or access to the equipment necessary for a chemistry 
led SAR study. However, small-scale innovation from academic groups has provided 
much of the early-stage work that has enabled large scale PPI inhibitor 
development.146,147,239–241 With this in mind, the PALB2/BRCA2 interaction was selected 
as an ideal target for an academic group. It offers potential as a cancer therapeutic target 
but there is a lack of known inhibitors in the literature.  
 
83 
 
 
PALB2 is a protein essential to the correct functioning of BRCA2 mediated repair of 
DNA double strand breaks by homologous recombination. It interacts with free BRCA2 
within the cell and localises it to the DNA damage site.242 The PPI occurs between N-
terminal amino acids 10-30 of BRCA2 and a C-terminal hydrophobic binding cleft on 
one side of a W40-type β-propeller of PALB2 (Figure 3.1).243 The binding region of 
BRCA2 forms a short α-helix that interacts with the PALB2 binding cleft predominantly 
through residues Trp31, Phe32 and Leu35, which exist in an i, i+1, i+4 configuration. 
Trp31 was identified as a hot-spot residue by mutation studies, which showed that 
BRCA2(10-40) sequences with W31R and W31C mutations exhibit a significant loss in 
activity.242  
 
 
Figure 3.1: Structure of BRCA2 bound to PALB2 (PDB code: 3EU7). The BRCA2 α-helix is shown in 
magenta, displaying the key residues Trp31, Phe32 and Leu35. The PALB2 β-propeller structure is 
shown in light blue. 
 
Although the exact role and function of PALB2 is yet to be fully understood, it is known 
that its interactions with BRCA2 and breast cancer 1 protein (BRCA1), another binding 
partner, are key to the correct functioning of homologous recombination within cells.244 
It seems that PALB2 acts as a structural link between BRCA1 and BRCA2, forming a 
multi-protein complex which is able to locate double-strand breaks and instigate 
homologous recombination.245,246  
 
Loss of function mutations of BRCA1 and BRCA2, which impair homologous 
recombination within cells, have long been known to result in susceptibility to certain 
cancers.247,248 As such it has been hypothesised that mutant forms of PALB2 will also 
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result in cancer susceptibility. Indeed, it was recently found that PALB2 mutations lead 
to a genetic predisposition to pancreatic cancers.249  Mutations in PALB2, as in BRCA1 
and BRCA2, also afford an increased risk of developing breast-cancer.250 As a result, 
there is increased interest in identifying patients at high risk of developing tumours by 
establishing whether they have mutations in PALB2 using DNA sequencing.   
3.2.1 Treating Cancer through Synthetic Lethality 
Synthetic lethality is the genetic interaction of two mutations such that neither mutation 
alone affects cell viability, but that in combination they result in cell death.251 This can 
be exploited in drug discovery to selectively target cancer cells over healthy human cells. 
The effect of one of the mutations can be mimicked using a drug to result in cell death 
only when the second mutation is already present in the cell. 
 
The best-known example of this principle is in the development of PARP inhibitors.252 
The poly ADP ribose polymerase (PARP) family of enzymes are predominantly involved 
in DNA single-strand break repair. By inhibiting them with a drug, the cell’s ability to 
repair DNA single-strand breaks is impaired, which generates an unsurmountable 
pressure in cancer cells already dysfunctional in DNA damage response pathways. 
 
PALB2, BRCA2 and BRCA1 are all proteins important for forming the Holliday 
junctions that enable homologous recombination. Some people suffer with genetically 
inherited mutation of one of these three genes, which impairs their ability to repair 
double-stranded breaks effectively. This increases the risk that they develop certain 
cancers. In fact, carriers of a BRCA1 mutation have a greater than 87% chance of 
developing breast cancer within an average life time and overall approximately 5% of 
breast cancers can be traced to this abnormality.253  
 
It was shown that sub-optimal PARP activity exhibited synthetic lethality with BRCA1 
or BRCA2 mutations.254 When either one of single-strand repair (PARP) or double-strand 
repair (BRCA1/2) are ineffective cells remain viable, albeit with an increased likelihood 
of generating cancerous mutations. However, when both DNA pathways are ineffective 
the cell is under sufficient stress to trigger apoptosis. This inspired a therapeutic strategy 
whereby cancer patients with defective BRCA containing tumours are treated with PARP 
inhibitors, which specifically target the cancer cells. 
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Olaparib (87), a PARP1 inhibitor developed by Astra-Zeneca was approved for the 
treatment of BRCA mutated ovarian cancer. It is currently undergoing phase II trials for 
the treatment of breast, prostate and colorectal cancers.255,256 There are several more 
compounds undergoing phase III trials, such as the intravenously administered rucaparib 
(88) and the orally administered niriparib (89), highlighting the potential utility of drugs 
that harness the effects of synthetic lethality.257  
 
Figure 3.2: Structures of various PARP inhibitors. 
3.2.2 Does PALB2 Have Therapeutic Potential? 
Considering its involvement in homologous recombination, it is reasonable to assume 
that inhibition of the PALB2/BRCA2 interaction will impair repair of double-strand DNA 
breaks by disrupting Holliday junction formation. Considering what is now understood 
about synthetic lethality, and the proven therapeutic use of PARP inhibitors (section 
3.2.1), inhibition of PALB2/BRCA2 may also prove synthetically lethal with other 
mutations which cause defects in alternative DNA damage repair pathways, such as in 
cases of defective single strand break (SSB) repair. Currently there are no known tool-
compounds with which this hypothesis can be tested. It is therefore important to develop 
a competitive inhibitor of the PALB2/BRCA2 interaction with which to probe cell 
viability upon loss of PALB2 function. In this work computational techniques were used 
to test the potential of small molecules and miniproteins to mimic BRCA2 and bind to 
the surface of PALB2, before the synthesis of potential inhibitors carried out. 
3.2.3 The Role of Bio- and Cheminformatics in Modern Drug Discovery 
Computational techniques relevant to drug discovery tend to be split into two fields; 
bioinformatics and chemoinformatics.258 The term bioinformatics covers computational 
methods that concern the structures of proteins and their interaction networks within the 
cell.259 Chemoinformatics examines small molecules, predicting their physiochemical 
properties, as well as mining the vast amounts of data generated in biological assays.260–
86 
 
 
263 The predictions made by computational calculations can help to guide the drug 
discovery process, reducing the number of compounds that need to be tested in order to 
achieve desirable activity against a drug target. This helps reduce the cost of drug 
discovery projects, particularly as the cost of computing decreases and the advancement 
of chemical models continues.  
 
3.2.3.1 A Summary of Bioinformatics 
The primary use of bioinformatics is in predicting the structure of proteins when there is 
no crystal structure available. The most accurate way of doing this is by homology 
modelling.264 This requires identification of a sequence with high homology (usually 
>50%) to the query sequence, for which there is an existing crystal structure. The two 
sequences are aligned and the known structure used as a template to build up the structure 
of the modelled sequence. The model can then be refined by estimating the position of 
any loops that do not fit within the original template using molecular dynamics 
calculations, or by searching for known loops with similar structures that can be employed 
as a template. Using this technique it is estimated that with the current diversity of crystal 
structures in the protein data bank it is possible to predict the structure of the majority of 
proteins with a reasonable level of accuracy.265 
 
When there are no crystal structures available with good homology to the query sequence 
it is possible to use protein threading to predict protein structure.266,267 This technique 
relies on the fact that there are a limited number of folds that a protein can adopt, and thus 
for each fold within the structure of the query sequence there is likely to be a homologous 
fold in the PDB. Each amino acid is individually placed into a position on a structure in 
the PDB and energetically analysed to determine how well it fits the template. A best-fit 
template is selected from which a model of the sequence structure can be built.267 
 
It is also theoretically possible to use ab initio calculations to predict protein secondary 
structure and folding based entirely on the protein sequence.268 This uses huge amounts 
of computational power, however, and as such, is only possible to low accuracy on short 
protein sequences.269 
 
The ability to process the large volume of data generated about proteins is key in 
bioinformatics. Large protein interaction network maps have been generated which help 
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us to understand how the loss of activity of one protein might affect others. A very popular 
service that will generate protein interaction networks is STRING.270 This exists as an 
online database which contains information on 184 million different protein-protein 
interactions.  
 
Bioinformatics can also make use of the structural properties and interaction networks of 
proteins in order to assess druggability.17,271 This is essential for helping identify 
promising targets for drug discovery programmes. A more detailed analysis on predicting 
protein druggability was carried out in the thesis introduction (Section 1.2). 
 
3.2.3.2 A Summary of Cheminformatics 
Whereas bioinformatics helps us predict information regarding proteins, cheminformatics 
is the field of computational calculations used to make predictions about small 
molecules.260 As information is generated, such as inhibitory activity against proteins, it 
is increasingly difficult to handle the accumulating data. Open databases such as 
ChEMBL272 contain over 1.5 million distinct compounds, with nearly 14 million protein 
activities recorded. The ability to effectively data mine this information to find the 
relevant entries is essential, and is a primary focus of cheminformatics. Procedural flow-
based programming environments such as Konstanz Information Miner (KNIME)273 have 
proven to be of great use when adapted to enable processing of chemical databases.274 As 
such, the ability to search chemical structures has become an important part of 
cheminformatics. 
 
Cheminformatics has also led to the development of software able to predict the chemical 
properties of molecules based on their structures with reasonable accuracy.275 Software 
suites such as MarvinSketch and ACDLabs have calculators that can predict properties 
such as molecular weight, molecular conformations, logP and pKa, facilitating both the 
design and characterisation of drug-like molecules.276,277  
 
Use of cheminformatics can also help us predict how well a small molecule ligand can 
bind to a protein.278–280 Algorithms have been designed which model the chemical force 
fields generated by both ligand and protein, such as the Merck molecular force field 
(MMFF94)281 and the assisted model building with energy refinement (AMBER)282 force 
field. These enable prediction of lipophilic and charged interactions such as hydrogen 
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bonding between the ligand and the protein. In doing so, it is possible to generate a score 
indicating how well a particular ligand binds when computationally placed into a pocket 
on the protein. This allows for the ‘virtual screening’ of compounds without any need for 
chemical synthesis.283 Although this is only a prediction and does not always perfectly 
reflect the results obtained later from biochemical screening, it enables medicinal 
chemists to direct the design of potential inhibitors, helping to reduce the number of 
compounds that must be synthesised in order to achieve high potency. Through the use 
of pharmacophores, which detail specific interactions and structural features necessary 
for good binding of lead compounds to proteins, it is possible to screen huge databases of 
compounds relatively quickly, to identify molecules that may bind in a similar way. 
 
Overall, computational chemistry has proven invaluable to the drug design process. As 
such, here a series of computational experiments were carried out in order to facilitate the 
ab initio design of BRCA2 mimetics to potentially inhibit the PALB2/BRCA2 
interaction. 
3.3 Computational Design of Small molecule BRCA2 Mimetics 
In order to design small molecule mimetics of BRCA2, a process was developed which 
used several different software packages to measure and refine structures (Figure 3.3). 
Firstly, instantJchem (ChemAxon, http://www.chemaxon.com) 284 was used to construct 
a database of potential mimetics based on existing mimetics in the literature. Conformers 
were then generated in KNIME273 using RDKit285 nodes, before being aligned to the 
BRCA2 helix from the BRCA2/PALB2 crystal structure (PDB code: 3EU7)243 and 
ranked by score. Molecular Operating Environment (MOE, Chemical Computing Group, 
Montreal, Quebec, Canada, H3A 2R7, https://www.chemcomp.com/)286,287 was used to 
check the strain energy (E_Strain) of the conformation, to remove any that were unlikely 
to form when binding. The top ranking structures could then be docked into PALB2 under 
structural restraints using MOE287, to provide further information to help predict their 
effectiveness as PALB2 binders. The results of this sequence of computational processes 
was then either fed back into the design of a new database of potential mimetics to repeat 
the process, or used to finalise the design of structures of candidates for synthesis. Each 
stage of the process will be subsequently described in greater detail. 
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Figure 3.3: The computational design sequence followed for small molecule BRCA2 mimetics. 
3.3.1 Designing a Database of Small Molecule BRCA2 Mimetics 
As outlined in section 03.2, the BRCA210-40 sequence binds to PALB2 through an α-helix. 
Structural evidence (PDB code : 3EU7)243 suggests that the key residues are Trp31, Phe32 
and Leu35, which exist in an i, i+1, i+4 conformation. Examples of molecular scaffolds 
that were designed to mimic different configurations of amino acids on an α-helix were 
discussed earlier. These existing examples tend to follow the linear i, i+3/4, i+7 
configuration that facilitates mimicry of PPIs such as p53/Hdm2 and Bcl-2/BH3. There 
are also examples of a few i, i+1 mimetics, such as the indane mimetics developed by 
Horwell.153 In order to design a set of i, i+1, i+4 mimetic scaffolds, functionalities which 
enable i to i+1, and i to i+4 spacing between residues were identified, then combined to 
create hybrid structures. 
 
3.3.1.1 Identifying i, i + 1 small molecule linkers 
Few examples of i to i+1 scaffolds could be identified from the literature. The indane 
series of α-helical mimetics contain two modes by which an i to i+1 link can be made 
Design database of potential BRCA2 mimetics
Generate conformers of database entries
Align conformers to BRCA2 helix and rank by 
score
Test E_strain to remove unlikely conformers
Confirm virtual hits by docking to PALB2
Finalise Structures
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(Figure 3.4, a and b).148 The decision was also made to incorporate the unconstrained 
phenyl ring c into the design of mimetics as well. Finally, the azabicyclooctane moiety 
utilised by Spivey and co-workers as part of their 5-residue mimetic scaffold288 was 
incorporated into potential i, i+1, i+4 mimetic designs. 
 
Figure 3.4: Examples of i, i + 1 scaffolds from published literature, including the indane series (a and 
b),148 a ring opened indane (c), and an azabicyclooctane (d).288 
3.3.1.2 Identifying i, i + 4 small molecule linkers 
Many of the α-helical mimetic scaffolds outlined earlier had the potential to be 
incorporated into the design of the i to i+4 linker required for the BRCA2 mimetics 
(Figure 3.5). The ortho-substituted phenyl group from Hamilton’s terphenyl scaffolds had 
the potential to be adapted into an i to i+4 linker (Figure 3.5, a). Oligobenzamides 
developed by Wilson, such as the N-functionalised (b)151  and ortho-phenol (c)150 
functionalised derivatives could also be incorporated into the design. Other scaffolds that 
were incorporated into i, i+1, i+4 mimetics in the database are benzoylurea (d),156 5-6-5 
imidazole-phenyl-thiazole (e and f),152 terephthalamide (g),155 and the azabicyclooctane 
based scaffold (h).288 
91 
 
 
 
Figure 3.5: Examples of i, i + 4 scaffolds from published literature, including the terphenyl scaffold 
(a),149 N-functionalised oligobenzamide (b),151 ortho-functionalised oligobenzamide (c)150, benzoylurea 
(d),156 5-6-5 imidazole-phenyl-thiazole (e and f)152, terephthalamide (g),155 and the azabicyclooctane 
based scaffold (h).288 
3.3.1.3 Design of Databases Using Known Scaffold Moieties and Markush Enumeration 
With the identification of reported i to i+1 and i to i+4 linkers, hybrid structures were 
designed in order to test computationally as BRCA2 mimetics. Initially, databases of 
structures were curated manually in instantJchem,284 using structure editors to input each 
design, resulting in structures such as those shown in Figure 3.6. 
 
Figure 3.6: Examples of hybrid i, i+1, i+4 structures designed. 
After alignment studies on the early sets of designed structures had been performed and 
the best BRCA2 mimetics established from these results, the design of sets of structures 
with smaller, iterative structural modifications was carried out. By doing so, it was hoped 
that the best scoring structures thus far could be optimised by introducing heteroatoms, 
as well as with modifications to the aliphatic residue linker lengths. During this process, 
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Markush enumeration software packages were used to generate databases of potential 
compounds. 
 
 
Figure 3.7: Use of ChemAxon nodes in KNIME to generate databases of designed BRCA2 mimetics 
from Markush structures. 
Markush structures are best known as the diagrams used within patents in order to 
describe a set of similar compounds. Variation between a large number of compounds in 
the set is represented using a small number of structural diagrams. Variables such as 
different chain lengths, different ring sizes, use of different heteroatoms at particular 
positions, and use of different functional groups are often described. Using 
ChemAxon284MarvinBeans software package, it is possible to construct a Markush 
structure, and then have the software enumerate the structure into a database of every 
possible compound that is described by the Markush variables. This process was 
completed in KNIME273 using ChemAxon nodes. By doing so the enumerated databases 
could be filtered to remove any structures with undesirable functionalities such as 
peroxide bonds, and concatenated with the output of other Markush enumerations to 
create a large database for analysis by alignment studies (Figure 3.7). 
3.3.2 Generating Conformers of BRCA2 Mimetics and Aligning Them to The 
BRCA2 Helix Using RDKit 
Once a set of potential BRCA2 mimetics had been designed, they were computationally 
analysed to determine how closely they mimicked the hotspot residues in BRCA2. This 
process was carried out in two steps. Firstly, each designed BRCA2 mimicking structure 
was used to generate a large number of rotational conformers to simulate how the shapes 
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they may potentially take in solution. These were then aligned with the hotspot residues 
of BRCA2. 
 
RDKit285 has been shown to be one of the most efficient and accurate freely available 
conformer generation tools.289 It also features KNIME273 integration, with nodes freely 
available for a number of functions on the community repository. It was therefore chosen 
as the conformer generation tool for this study. As the computational power required for 
conformer generation was relatively low, the RDKit tool was configured to generate a 
maximum of 5,000 non-duplicate conformers per structure. Although this number is 
higher than what was later found necessary to obtain good results for the alignment study, 
it still allowed completion of the analysis of a set of designed structures overnight. 
 
Figure 3.8: The process of reducing the BRCA2 helix to the key residues in PyMOL290before using 
RDKit285 Open 3D Alignment to align with BRCA2 mimetic conformers. 
PyMOL290 was used to prepare the BRCA2 helix (PDB source: 3EU7)243 by removing all 
atoms except the peptide backbone and the Trp31, Phe32 and Leu35 residues. This 
modified structure was then used as the template for the RDKit285 Open 3D Alignment 
tool, which also has integration as a freely available node in KNIME.273 This generated a 
score for the alignment of the mimetic with BRCA2. By using a KNIME workflow for 
both processes, they could be carried out in sequence, and repeated for each newly 
designed set of BRCA2 mimetics easily. 
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3.3.3 Using MOE to Remove Conformers with High E_Strain 
Once the RDKit285 nodes in KNIME273 had been utilised to identify the scaffolds which 
best aligned with BRCA2, MOE287 was used to test the conformational strain of the 
different conformers. Although the RDKit conformer generation tool generally generates 
low energy conformers, it was found that some of the conformers exhibited significant 
strain, and were deemed unlikely to form under binding conditions. The E_Strain tool in 
MOE calculates the strain that a molecular conformation is under within the chosen 
forcefield environment, as a measure of the difference in energy between a chosen 
conformation and its local rotational minima. The values are calculated in kCal.mol-1. 
AMBER10282 and MMFF94281 are two of the most commonly used forcefield 
environments for electrostatic calculations, and both can operate within MOE. Of these, 
MMFF94 is generally considered better for small molecules, so was used in this case. 
The calculated E_Strain for the BRCA2 mimetic conformers typically ranged from 7 to 
17 kCal.mol-1. Of the best aligning mimetics, conformers with an E_Strain higher than 
12 kCal.mol-1 were removed, roughly halving the number of structures.  
 
3.3.4 Using MOE to Dock the Best Conformers into PALB2 to Reinforce 
Predicted Activity 
Once the best aligning conformers had been identified, and those under high strain 
removed, docking studies in MOE were carried out in an attempt to reinforce the 
prediction that the structures would bind to the PALB2-BRCA2 interface. The docking 
was carried out using the crystal structure of BRCA2 bound to PALB2 (PDB code: 
3EU7).243 
 
The docking studies were carried out to help understand how well the different structures 
were able to behave as BRCA2 mimetics. Because of this, restrictions were applied to the 
docking calculations, to encourage them to bind with the relevant functionalities in the 
Trp31, Phe32 and Leu35 positions. This was done by generating pharmacophores using 
the BRCA2 helix that requires indole, phenyl and isopropyl groups to be near the 
positions they would be in BRCA2. However, this approach still proved to be problematic 
as the software identified interactions with the core scaffold section of the structures, as 
well as the i, i+1 and i+4 functionalities. The most common binding mode produced was 
for the tryptophan-mimicking indole to be rotated by 180°, causing the aliphatic linker in 
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the 3- position to pick up lipophilic interactions with the rear of the protein pocket (Figure 
3.9). 
 
Figure 3.9: Comparison of results between a mimetic aligned with BRCA2, and docked into PALB2 
using MOE. The binding sites of the BRCA hotspot residues have been labelled. 
By increasing the binding restrictions by optimising the number of pharmacophores, it 
was eventually possible to dock the mimetics in the ‘correct’ configuration. However, 
because of the amount of restrictions applied when docking, the results became less and 
less accurate as a prediction. Consequently, little weighting was given to the docking 
scores when choosing candidates for synthesis. 
 
3.3.5 Results of Alignment and Docking Studies 
From the results of the alignment and docking studies, several different structures were 
found to have potential as i, i+1, i+4 BRCA2 mimetics (Table 3.1). The length of the i+1 
linker to the phenyl group was found to be well tolerated with either one or two carbons, 
as each allowed alignment at different low energy conformations. The i+4 position was 
also found to not align as well with the BRCA2 helix in general. In a few cases (e.g. Table 
3.1, example 1.1), good alignment was achieved in the i+4 position, although nearly 
always with reduced alignment in the i+1 position. These examples tended to have lower 
alignment scores as well. The azabicyclooctane containing structures (e.g. Table 3.1, 
example 1.2) in general had the best i to i+1 alignment, but in no cases were able to align 
with all three residues, and often had high calculated E_Strain. In some cases (e.g. Table 
3.1, example 1.3), good overlap was achieved in each of the i, i+1 and i+4 positions, 
however this always occurred in conformations with E_Strain over the desired threshold. 
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Table 3.1: Examples of high scoring aligned i, i+1, i+4 structures. 
Example 1.1 Example 1.2 Example 1.3 
 
 
 
 
 
 
Alignment Score: 138.5 Alignment Score: 143.4 Alignment Score: 147.1 
E_Strain: 8.7 kCal.mol-1 E_Strain: 14.5 kCal.mol-1 E_Strain: 14.4 kCal.mol-1 
 
Given the high E_Strain measured in the best aligning i, i+1, i+4 mimetics, and the 
tendency for the i+4 position to align poorly with BRCA2, i, i+1 mimetics were 
investigated as an alternative. In general, these were found to align well with the BRCA2 
helix. As before, the azabicyclooctane (Table 3.2, example 2.1) containing structures 
aligned best, with low E_Strain values calculated. Indane and phenyl-based i, i+1 also 
showed good alignment with BRCA2, giving alignment scores comparable to the i, i+1, 
i+4 mimetics, despite the lower atom count. More importantly, the best aligning structures 
also were calculated to have E_Strain values nearly always under the chosen threshold of 
12 (Table 3.2, examples 2.2 and 2.3). This put them into consideration as an alternative 
to the full i, i+1, i+4 mimetics when selecting candidates for synthesis. 
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Table 3.2: Examples of high scoring aligned i, i+1 structures. 
Example 2.1 Example 2.2 Example 2.3 
   
  
 
Alignment Score: 153.0 Alignment Score: 139.1 Alignment Score: 134.0 
E_Strain: 9.0 kCal.mol-1 E_Strain: 11.3 kCal.mol-1 E_Strain: 10.8 kCal.mol-1 
 
The potential of i, i+4 mimetics to align with BRCA2 was also tested. Unsurprisingly 
given the observations of i, i+1, i+4 alignment, these were found to produce much lower 
scores from the RDKit Open 3D Align algorithm than other structures tested (Table 3.3, 
example 3.1 and 3.2) and not pursued further.  
 
In all cases, it was found that the presence of heteroatoms in the core of the molecule, as 
well as hydrocarbon linkers was well tolerated. This could be of great use when designing 
candidates for synthesis, as it may improve the inherent aqueous solubility of an all-
hydrocarbon mimetic. 
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Table 3.3: Examples of high scoring aligned i, i+4 structures. 
Example 3.1 Example 3.2 
  
  
Alignment Score: 111.2 Alignment Score: 108.8 
E_Strain: 12.0 kCal.mol-1 E_Strain: 8.8 kCal.mol-1 
3.3.6 Searching For Alternative Routes to the i+4 Position Using Docking Studies 
Given that the i+4 leucine position seemed to be the most difficult to align to with a small 
molecule mimetic, other potential options to reach this position were explored. From the 
PALB2/BRCA2 crystal structure, it seemed that the Trp31 indole 4-position points 
towards the Leu35 position. To explore this, indole analogues functionalised with 
aliphatic moieties were docked into the PALB2 structure. 
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Figure 3.10: A Markush structure indicating the indoles docked into PALB2. 
A database containing a series of different structures was created by using ChemAxon 
Markush enumeration (Figure 3.10), using filters as described before (section 3.3.1.3) to 
remove unwanted structures. A docking experiment was then set up in MOE, where 
pharmacophores were generated to ensure that the indole was locked into position in the 
Trp31 pocket. It was found by trial and error analysis that a total of 11 pharmacophores 
describing the indole atom placement was enough to lock the docked compounds in place. 
Once the methodology had been established, the functionalised indoles were docked into 
PALB2. The results demonstrated that the 4- position can indeed give access to the Leu35 
pocket (Figure 3.11). A chain length of 3-5 atoms with a terminal lipophilic group seemed 
to be best tolerated for reaching the pocket. In some cases, a terminal amino or alcohol 
group was able to pick up hydrogen bonds on the far side of the Leu35 pocket. This 
seemed to support the hypothesis that indole functionalisation could prove as an 
alternative to mimicking the i+4 position, subject to synthetic accessibility. 
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Structure 
 
 
  
 
Score -4.77 -4.71 -4.70 -4.69 -4.69 
Figure 3.11: The top hits from the docking study in MOE showed that aliphatic functionalisation in the 
indole 4-position can comfortably occupy the position of Leu35 on BRCA2. 
3.3.7 Choosing Candidates for Synthesis 
Given the results from the computational work, the subjectively best results were 
incorporated into Markush structures (Figure 3.12) as potential candidates for synthesis. 
Given the tolerance of different scaffold-to-residue linkers and potentially solubilising 
heteroatoms in the alignment and docking studies, they were included in the designs. The 
phenyl group and N-substituted imidazole were by far the most effective i+4 linkers, so 
were chosen as candidates. As the i, i+1 mimetics seemed very promising in the alignment 
and docking studies, they were also chosen as candidates for synthesis, however, it was 
decided not to pursue the i, i+4 mimetics further, due to their lower alignment scores, and 
poor overlap with BRCA2. 
 
 
Figure 3.12: Markush structure showing the structures to be analysed for synthetic accessibility. 
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3.4 Design of Miniproteins to Mimic BRCA2 
As an alternative approach to target the BRCA2/PALB2 PPI, a series of miniproteins 
were developed to mimic the BRCA2 helix. To achieve this, protein sequences were 
computationally analysed to select the best candidates to act as mimetics (Figure 3.13). 
An in depth review on the development of miniproteins was discussed in the thesis 
introduction (section 1.3.2). 
 
Figure 3.13: The design sequence followed for the development of BRCA2 miniprotein mimetics. 
3.4.1 Searching for Structurally Stable Miniproteins with Known Structures 
In order to design miniproteins, sequences must be found with structural information 
available. In order to achieve this, the PDB advance search function was used to find 
structures that matched chosen criteria. The criteria selected for were for a disulfide bond 
count > 1, a chain length < 31, the number of α-helices > 0, and the number of chains = 
1. This returned a total of 87 different protein structures. To these was added the aPP 
sequence used by Schepartz as the parent structure for the design of many different 
miniproteins.70,75 APP did not match the search criteria due to its lack of disulfide bonds, 
but had been proven to be a good template for miniprotein design in several examples. 
This gave a total of 94 different structures that were analysed for their suitability to adopt 
Search for structurally stable miniproteins on the PDB
Analyse each structure for potential α-helical i, i+1, i+4 mutation 
sites
Make point mutations to incorporate WFXXL residues in each 
sequence
Align and create homology models of the sequences based on the 
parent miniprotein structure
Check for steric clashes when ‘docked’ in place on PALB2 and 
eliminate unsuitable structures
Choose best miniproteins for synthesis
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the BRCA2 WFXXL motif. The PDB search contained all other structures used for the 
design of miniproteins that were discussed in section 1.3.2. 
 
3.4.2 Analysing Structures for Suitability to Adopt the BRCA2 WFXXL Motif, 
and Designing Mutant Structures 
Once the 94 different structures had been obtained, they were individually subjected to 
analysis in PyMOL290 by manually visualising each structure to determine whether or not 
they could adopt the WFXXL motif. For this to be allowed, possible mutations had to be 
made in the solvent exposed face of an α-helix in an i, i+1, i+4 configuration. None of 
these mutations could be at the position of a disulfide-forming cysteine residue, in order 
to have as limited effect on the protein secondary structure as possible. In each case when 
it was possible to mutate in an i, i+1, i+4 configuration, the new structure was recorded. 
This resulted in a total of 53 different sequences being designed, using a total of 43 
different miniprotein templates obtained from the PDB. 
 
3.4.3 Constructing Homology Models of Designed Miniprotein Sequences 
 
 
Figure 3.14: Creating a BRCA2 miniprotein mimetic from Om-toxin (Pdb Code: 1WQD)291 using 
homology modelling. 
Once the 53 different miniprotein sequences containing the WFXXL motif had been 
designed, homology modelling was used to construct the predicted 3D structures. This 
was carried out using homology modelling tools in MOE (Figure 3.14).287 Firstly the 
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modified sequences were imported into MOE and aligned to the sequence from the 
structure of the parent miniprotein. The homology modelling tool was then used under 
Amber10,282 with a maximum of 10 iterations. The best model of each was then exported 
for further analysis. 
3.4.4 Superposition of Miniproteins with BRCA2 to Test for Steric 
Incompatibilities 
Once the 53 homology models had been constructed, they were tested for steric 
incompatibilities with PALB2. For this to be done, firstly the WFXXL motif in each 
homology model was aligned with the equivalent residues in the BRCA2 helix. Each 
miniprotein was then superposed to BRCA2, locked to the position of the Trp31, Phe32 
and Leu35 residues.  
   
Figure 3.15: Left: Superposed WFXXL miniprotein based on 1WQD291, with minimal steric clashing. 
Right: Superposed WFXXL miniprotein based on 2RTZ, showing significant steric clashing denoted by 
orange disks. 
The ‘Contacts’ tool in MOE was then used to search for residues that were involved in 
steric clashes with PALB2 (Figure 3.15). Areas of significant steric clash were indicated 
by the clustering of orange ‘steric-clash’ disks. If a miniprotein was involved in a large 
amount of steric clashing when it was superposed to the BRCA2 position, then it was 
discarded as an option for synthesis. Using this technique, 22 of the 53 structures tested 
appeared to have little to no steric clashing with PALB2. 
3.4.5 Selecting 10 Sequences for Synthesis 
The set of 22 sequences that were able to fit in the PALB2 pocket without a significant 
steric clash were filtered down to a set of 10 sequences to be synthesised. Firstly, any 
sequence where a mutation had been made to a proline residue for part of the WFXXL 
motif was taken out of consideration as loss of a proline is likely to affect the way that 
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the protein folded. By doing this, the number of sequences was reduced from 22 to 15. 
Of these 15 peptides, 10 were selected based on the diversity of the different structures. 
For example, in any case where more than one miniprotein had been designed from the 
same parent sequence, only one was selected. The result was a set of 10 distinct 
miniproteins, all bearing the WFXXL motif. 
 
Figure 3.16: Structures of the 10 miniproteins selected for synthesis. 
Of the miniproteins selected, the amino acid count was between 14 and 35. Of these, two 
were based on parent structures had had previously been used for the design of 
miniproteins. Avian pancreatic peptide (aPP, PDB code: 2BF9) has been used by 
Schepartz and co-workers to design miniproteins for a series of different targets.75 Om-
toxin3 (Pdb code: 1WQE) has been used by Brunsveld and co-workers to develop binders 
of oestrogen receptors.88,89  
Table 3.4: The sequences of the 10 miniproteins selected for synthesis 
PDB 
Code 
Miniprotein Sequence 
Amino 
acid count 
Disulfide 
count 
1D5Q CNLWFCQLSCKSLGLKGGCQGSFCTCG 27 3 
1EDP CSCSSLMDWFCVLFCHL 17 2 
1KCO VQCPHFCYELDYELCPWFCYLX 21 2 
1WQD DPCYEVCLQQHGNVWFCELACKHPVEY 27 2 
2LDE CSCTDMSWFECLNFCHKDVIWVNRN 25 2 
1WQE NDPCEEVCIQHTGDVWFCELACQ 23 2 
2BF9 GPSQPTYPGDDAPWFDLLRFYNDLQQYLNVVTRHRX 35 0 
2LR9 FNWFCCLIPACRRNHKKFCX 19 2 
2M61 CCRWFCGLGCHPCCX 14 3 
2RTY FSCDHWFCALRCLAQRRKGGKCKNGDCVCR 30 3 
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The other eight sequences are based on unique templates. Most of the examples contain 
two disulfide bonds, with three different examples of structures stabilised by three 
disulfide bonds, and one (aPP) with no disulfide bonds at all. The sequences were bought 
from PeptideSynthetics (Peptide Protein Research Ltd.) ready to be tested. 
3.4.6 Testing the Miniprotein Sequences for Helicity 
Once the peptide sequences had been bought, the helicity was assessed by circular 
dichroism to ensure that they had folded correctly before their affinity for PALB2 was 
tested in a biochemical assay. For the aPP based miniprotein which contained no disulfide 
bonds, this could be done using the purified sequence dissolved in water. The other nine 
proteins were submitted to oxidative folding conditions to ensure that they had formed 
disulfide bonds correctly, before they could be tested under circular dichroism. 
 
The CD spectrum of the aPP (2BF9) based miniprotein showed a characteristically α-
helical profile, with a peak at 192 nm, and two troughs at 209 and 222 nm respectively 
(Figure 3.17). The K2D3 online CD prediction service292 predicted the miniprotein to 
have 95% helicity based on the recorded spectrum. This suggests that the miniprotein was 
folding in solution as hoped, and thus could act as a potential α-helical mimetic of 
BRCA2. 
 
Figure 3.17: CD Spectrum of the aPP based miniprotein (2BF9), showing a characteristically α-helical 
profile. 
The 9 miniproteins with disulfide bridges were then treated with tris(2-
carboxyethyl)phosphine (TCEP) in a 2:1 mixture of phosphate buffer (pH 8.0) and 
trifluoroethanol to reduce any pre-existing disulfide bonds. Dimethylsulfoxide (DMSO) 
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was then added to quench the remaining TCEP, and the proteins were stirred in air for 48 
hours to allow disulfide reformation. Unfortunately, the folded proteins were not purified 
due to time constraints, and thus the resulting CD spectra not reported in this thesis. 
 
3.5 Conclusion 
In conclusion, computational chemistry has been used for the design of both small 
molecule mimetics of BRCA2, and miniprotein mimetics containing the WFXXL binding 
motif. The small molecule mimetics designs were primarily scored by their ability to align 
with the BRCA2 helix, using RDKit nodes in KNIME to carry out many calculations in 
sequence. Docking studies were also used to evaluate the structures, but with less effect. 
This resulted in an understanding of which small molecules could be synthesised in order 
to obtain efficacy towards PALB2, allowing the progression of synthetic chemistry 
towards achieving this goal. 
 
Miniproteins were also designed computationally, and analysed by use of homology 
modelling in MOE. This allowed a set of 10 miniproteins to be chosen from 94 initial 
candidates taken from the PDB. The 10 selected miniproteins were bought, and circular 
dichroism spectroscopy of one miniprotein showed that significant helicity was forming 
in solution. This suggests that the hot-spot residues are held at the correct configuration 
to have efficacy towards PALB2 in a biochemical assay. 
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4 The Synthesis of Small Molecule BRCA2 Mimetics 
4.1 Chapter Summary 
This chapter outlines the synthetic steps taken towards the synthesis of BRCA2 small 
molecule α-helical mimetics. The structures identified as potential mimetics in 
computational work outlined in chapter 3 are retrosynthetically analysed. Due to the 
synthetic complexity of the i, i+1, i+4 mimetics, the synthesis of i, i+1 mimetics is carried 
out. Initial synthesis towards a pyridazine containing scaffold design is unsuccessful due 
to difficulties experienced in selective pyridazine ring formation. Synthesis of all-
hydrocarbon indane-based i, i+1 mimetics is more successful. The late-stage 
functionalisation of the i position is carried out using Wittig chemistry, and the i, i+1 
position with the Sonogashira reaction and Ullman condensation. Overall, one i, i+1 
mimetic is obtained, and two further mimetics are within two synthetic steps of a 
complete synthesis.  
4.2 Retrosynthetic Analysis of Target Cores from Computational 
Results 
Computational studies outlined in section 3.3 investigated the ability for different small 
molecule scaffolds to align with the BRCA2 hotspot residues that interact with PALB2. 
Small molecules that align well may be able to act as competitive ligands, inhibiting the 
PALB2/BRCA2 interaction. In this chapter, retrosynthetic analysis of the optimal 
structures from the computational study will be carried out. The progress towards 
synthesis of the most structurally accessible of these structures will then be described.  
 
Before synthesis was attempted, retrosynthetic analysis was carried out on the results of 
the computational studies. This was performed with the intention of selecting cores which 
could be accessed synthetically in the fewest number of steps, with easy diversification 
of the i, i+1 or i+4 positions. Compounds containing stereogenic centres were initially 
synthesised in racemic form with the ultimate aim of separating via chiral HPLC methods. 
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Figure 4.1: Potential methodology for functionalisation of an indane based scaffold in the i, i+1 and i+4 
positions. 
4.2.1 Retrosynthetic Analysis to Functionalise the i, i+1 and i+4 Positions 
The results of computational alignment studies between small molecule mimetics and 
BRCA2 (section 3.3) suggested that by functionalising an indane in the 1, 4 and 6 
positions, would give optimal overlay with the BRCA2 i, i+1 and i+4 hotspot positions. 
This structure was analysed to identify the best chemical methodology that could be used 
in order to selectively functionalise at these positions (Figure 4.1) 
 
Functionalisation of the indane 1-position had previously been carried out by Horwell 
and co-workers using Wittig chemistry, followed by hydrogenation of the subsequent 
double bond.153 This methodology was considered for the i, i+1, i+4 mimetics (Scheme 
4.1). 
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Scheme 4.1: Retrosynthetic cutting of the indole linking bond in the i position of the scaffold. 
In the synthetic route described by Horwell,153 the i position was functionalised with a 
phenyl group through Wittig chemistry,293 to mimic phenylalanine. Application to indoles 
presented a challenge. The high acidity of the N-H bond, (pKa calculated using 
MarvinSketch284 to be as low as 13.5 if the indole was electron deficient) meant it would 
deprotonate under the basic conditions of a Wittig294,295 or Horner-Wadsworth-Emmons 
(HWE) reaction,296,297 possibly affecting the result of the reaction. Because of this, 
protecting group chemistry would likely have to be employed. The stability of the 
phosphonium reagents, as well as the organohalide intermediates towards their synthesis, 
was also likely to be an issue. In the case where the chain length between the indole ring 
and the phosphorus is a single carbon atom, there is potential for elimination. This led to 
the possibility of switching the functional groups in the Wittig reaction, resulting in an 
indane phosphonium salt, and a carbaldehyde functionalised indole. By doing this, the 
indole reagent is likely to have increased stability. 
 
Scheme 4.2: Retrosynthetic cutting of the phenyl group linking chain in the i+1 position of the scaffold. 
Retrosynthetic analysis of the i+1 phenyl group was then carried out (Scheme 4.2). The 
computational studies indicated that a chain length of one or two atoms between the 
phenyl group and the central scaffold provided the best overlap with BRCA2. 
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Synthesising compounds with a hydrocarbon chain length of one carbon atom appeared 
to be challenging. There are limited examples of transition metal-catalysed cross-
coupling reactions at sp3 hybridised carbon centres. Often the reagents required, such as 
benzylboronic acid derivatives, exhibit poor reactivity or are unstable. There are some 
examples in which this has been solved by using less reactive and thus more stable 
reagents, such as alkyltrifluoroboranes.298 However, due to their lower reactivity, highly 
specific conditions are required for their reaction, such as expensive ruthenium based 
catalysts in the presence of ultraviolet light.299,300  Because of this, one-atom linkers 
containing a heteroatom were considered because of more established reaction 
conditions.  
 
The synthesis of biphenylethers is very well precedented using Ullmann condensation 
conditions.301–303 This involves heating an aryl-halide with a phenol to high temperatures 
in the presence of a copper catalyst. These conditions can also be used to form C-N bonds, 
with the potential to produce a one atom aniline linker in the i+1 position. More recently, 
the development of the Buchwald-Hartwig reaction has allowed the formation of C-N and 
C-O bonds using milder conditions under palladium catalysis.304–306 Both of these 
reactions would be suitable for the synthesis of single heteroatom linkers needed for 
BRCA2 mimetics. 
 
For two atom linkers, it is possible to form this bond with an unsaturated two-carbon 
chain using palladium chemistry, which can then be hydrogenated to form the desired 
functionality. The Heck reaction can be used to cross-couple aryl-halides with terminal 
alkenes, such as styrene.307 This involves heating the two reagents to high temperatures 
in the presence of a palladium catalyst and a base. The milder Sonogashira reaction308,309 
relies on the acidity of a terminal alkyne C-H bond. A copper/palladium co-catalytic 
system is employed, whereby the alkyne forms a cupric intermediate, facilitating 
transmetallation to the palladium during the catalytic cycle. This allows the reaction to be 
carried out at lower temperatures than the Heck reaction. The products of the reactions 
could then be hydrogenated to give the saturated ethylene as the desired two-atom linker. 
111 
 
 
 
Scheme 4.3: Retrosynthetic cutting of the isopropyl group linking chain in the i+4 position of the 
scaffold. 
Retrosynthetic analysis of the i+4 position suggested that disconnection at the aryl-aryl 
bond would be the best strategy, as it gave access to cross coupling reactions (Scheme 
4.3). In particular, the Suzuki-Miyaura reaction allows the coupling between aryl halides 
and phenylboronic acid derivatives.310,311 This reaction allows for the stereoselective 
cross-coupling of aryl rings using a palladium catalyst. As the aryl boronic acids required 
for i+4 functionalisation are commercially available, the Suzuki-Miyaura reaction was 
the preferred choice. 
 
4.2.2 The Retrosynthetic Analysis of i, i+1 and i+4 Functionalisable Cores Proved 
Synthetically Challenging 
Given the analysis of methodology which would allow functionalisation of the i, i+1 and 
i+4 positions during the synthesis of BRCA2 mimetics, the synthetic accessibility of 
different scaffold cores was analysed (Scheme 4.4). It was important to design the 
scaffolds so that there could be differentiation in the regioselectivity of cross coupling 
reactions to the i+1 and i+4 positions. One solution to this could be the use of N-
methyliminodiacetyl (MIDA) boronates.312 The MIDA group attenuates the reactivity of 
boron towards palladium, allowing other palladium catalysed reactions to be performed 
elsewhere in the molecule without reacting at this position. When the MIDA group is 
cleaved, the boron becomes reactive towards palladium, thus allowing iterative cross 
coupling reactions to take place. 
 
Figure 4.2: The reactivity of the 1 and 5 positions in dichloropyrimidines. 
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If a pyrimidine containing scaffold were used, it should be possible to differentiate 
between the i+1 and i+4 positions due to the differing reactivity of chlorides in this 
configuration (Figure 4.2).313 The i+4 position should be the most reactive, and thus the 
first to react under cross coupling conditions.  
 
Scheme 4.4: Retrosynthetic analysis of i, i+1, i+4 scaffolds to produce cores with the potential for late 
stage diversification in each position. 
Unfortunately, no straightforward or cost effective route that enabled the synthesis of 
these reagents could be devised. The standard route to form the indanone ring structure 
is via an intramolecular Friedel-Crafts acylation from a 3-phenylpropanoic acid. In the 
case of the all-hydrocarbon MIDA boronate containing indanone, it was difficult to buy 
starting materials that would lead to this structure within a small number of synthetic 
steps. There was also no literature precedent that suggested the electron poor pyrimidine 
ring would be able to undergo Friedel-Crafts acylation to form the ring. It also did not 
appear retrosynthetically that it would be possible to construct the pyrimidine ring onto a 
preformed cyclopentone based reagent. Due to the synthetic inaccessibility of the i, i+1, 
i+4 cores, the simpler i, i+1 scaffold was considered for synthesis. 
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4.2.3 Retrosynthetic Analysis of the i, i+1 Scaffold as a Synthetically Accessible 
Alternative 
 
Scheme 4.5: Retrosynthetic analysis of i, i+1 scaffolds to produce cores with the potential for late stage 
diversification in each position. 
The simplified structure of the i, i+1 scaffold appeared much easier to access synthetically 
based on retrosynthetic analysis. For a heteroatom containing scaffold, a pyridazine was 
chosen. In this configuration, the heteroatoms would be pointing away from the lipophilic 
pocket on PALB2, allowing them to have a positive influence on the physicochemical 
properties of the compound without having a negative effect on electrostatic interactions 
with the protein.  
 
 
Scheme 4.6: Indanone 95 can be accessed synthetically in one step from commercially available starting 
materials. 
Retrosynthetic analysis suggested it was possible to reach the all hydrocarbon 
bromoindanone intermediate 95 in one synthetic step from commercially available 3-(4-
bromophenyl)propanoic acid (98) in one step, using Friedel-Crafts chemistry. 
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Scheme 4.7: Retrosynthetic analysis of pyridazine 97 
There was far less precedent for the synthesis of the pyridazine-based heteroatom 
containing intermediate 87. As stated previously, there was no literature evidence to 
suggest that the ketone ring could be formed using an intramolecular Friedel-Crafts 
reaction on heteroatom containing rings, such as a pyridazine. Because of this, a strategy 
was developed to form the pyridazine ring from a pre-constructed cyclopentone (Scheme 
4.7). It was predicted that by functionalising cyclopentadione 101 through an aldol 
condensation, and carefully reacting the intermediate with hydrazine, pyridazinone 99 
may be produced. This could then be transformed to the chlorinated compound 97, ready 
to be functionalised in the i and i+1 positions. 
 
The i, i+1 mimetics were predicted to have much greater synthetic accessibility than their 
i, i+1, i+4 counterparts. The computational alignment studies described in chapter 3 did 
not highlight that a significant gain was made in terms of binding potential from the i+4 
position in comparison to the i and i+1 positions. On top of this, significant gains in 
molecular weight had to be made as part of incorporating an i+4 group into the mimetic 
design, potentially reducing solubility in aqueous media. This led to the decision to pursue 
the synthesis of i, i+1 mimetics as a priority, in the hope that it would provide quicker 
results on the efficacy of small molecule mimetics towards PALB2. 
 
4.3 Challenges towards the Synthesis of a Pyridazine Based i, i+1 
Scaffold 
Compared to other nitrogen containing heterocycles such as pyridine and pyrimidine, 
there is less literature precedent for synthetic routes to pyridazines. This may be 
influenced by the lack of naturally occurring pyridazines, and possibly by the toxicity of 
hydrazine as a reagent. 
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4.3.1 Review of Published Synthetic Routes to Pyridazines 
The first example of a pyridazine synthesis was published in 1886 by Emile Fischer.314 
The most common route to a pyridazine is through the reaction of hydrazine with a 1,4-
diketone moiety (Scheme 4.8).315 If an unsaturated 1,4-diketone is reacted with hydrazine, 
it will be transformed directly into a pyridazine with the loss of two molecules of water, 
via a double condensation reaction (Scheme 4.8, A). However, often this reaction route 
can be difficult, due to the reliance on the cis conformation in order to form the ring. In 
cases where it may be difficult to selectively obtain the cis isomer, it is possible to 
synthesise the dihydropyridazine by reacting hydrazine with a saturated 1,4-diketone 
(Scheme 4.8, B). The resulting compound may then spontaneously oxidise to the 
aromatised pyridazine. If this does not occur, then an oxidant such as chloranil can be 
used in order to induce aromatisation. 
 
Scheme 4.8: General synthesises of pyridazines from saturated and unsaturated 1,4-diketone 
compounds.315 
There are several other methods that have been published which offer variations on the 
standard pyridazine synthesis. The Schmidt pyridazinone synthesis involves the three-
component reaction between an α-dicarbonyl compound, a malonate ester and hydrazine 
(Scheme 4.9).316 Although there are many pathways that this reaction could follow, it is 
likely that the malonate ester reacts with the α-dicarbonyl compound via an aldol 
condensation, eliminating water and forming intermediate 109. This can then react with 
hydrazine to form a hydrazone at the ketone position, followed by addition elimination 
with the adjacent ester to form a pyridazinone ring (110). 
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Scheme 4.9: A) Schmidt pyridazinone synthesis from α-dicarbonyl compounds and malonate esters.316 B) 
Modified step-wise Schmidt synthesis by Evans and Schweizer allowing direct synthesis of 
pyrizadines.317 
Evans and Schweizer developed a modified version of the Schmidt pyridazine synthesis, 
where they used a step-wise approach for the direct synthesis of pyridazines (Scheme 4.9, 
B).317 They first prepared and isolated the biphenyl α-diketomonohydrazone 111. They 
were then able to react this with 1,3-dicarbonyl 112 to form a bishydrazone. This was 
then transformed into the pyridazine on heating; the final step proceeds through an aldol 
condensation and the subsequent elimination of water to give 114. 
 
Scheme 4.10: A) Carboni-Lindsey reaction to form pyridazines from 2,3,4,5-tetrazines and alkynes.318 B) 
Modification of the Carboni-Lindsey reaction to proceed using a keto-enolate by Haddadin and co-
workers.319 
The Carboni-Lindsey reaction forms a pyridazine through a very different reaction path. 
A 1,4-substituted 2,3,5,6-tetrazine is reacted with an alkyne through a 4+2 cycloaddition 
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reaction, forming the adduct 117. A second pericyclic rearrangement then occurs, causing 
the loss of nitrogen gas, and resulting in a tetrasubstituted pyridazine ring (Scheme 4.10, 
A).318 
 
This reaction was modified by Haddadin and co-workers, by deprotonating a ketone and 
then reacting with 2,3,5,6-tetrazine.319 The enolate reacts at the 2,3,5,6-tetrazine 1-
position, forming the intermediate 120. The negative charge then acts as a nucleophile at 
the carbonyl position, forming a ring system 121, similar to the intermediate in the 
Carboni-Lindsey reaction. Once this is formed, nitrogen is eliminated as before through 
a 4+2 sigmatropic rearrangement, forming a dihydropyridazine ring. Water is then 
eliminated, forming the pyridazine product 118. 
 
Scheme 4.11: A) South and co-workers pyridazine formation from 1-carbethoxy-3-phenyl-4-
haloazodienes and electron rich olephins.320 B) Strategy for the synthesis of pyridazines developed by 
Herdewijn and coworkers using diaza-Wittig chemistry.321,322 
South and co-workers developed a technique for the synthesis of pyridazines using 1-
carbethoxy-3-phenyl-4-haloazodienes (Scheme 4.11, A).320 By reacting them with an 
electron rich alkene, such as the O-alkylated enol 124, they found it was possible to form 
the hexahydropyridazine containing compound 125. This compound then had the 
potential to form a pyridazine when treated with a base, through the elimination of 
hydrogen chloride, ethanol, carbon dioxide and ethane.  
 
Herdewijn and coworkers developed methodology to form pyridazine rings using diaza-
Wittig chemistry (Scheme 4.11, B).321,322 They outlined a synthetic route to reach aldol 
127, where the functionality R could be diversified by the aldol reaction with an aldehyde. 
This could then be oxidised using 2-iodoxybenzoic acid (IBX) to the corresponding 
aldehyde. Treatment of this intermediate with a phosphine causes the aza-Wittig reaction 
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to proceed, driven by the formation of the phosphine oxide. The resulting compound is a 
4-hydroxypyridazine. 
 
Scheme 4.12: Unexpected functional group cleavage observed by Wu and coworkers during pyridazine 
synthesis when using a large excess of hydrazine.323 
Wu and co-workers observed an unusual functional group cleavage when they were 
synthesising pyridazines using unsaturated 1,4-dicarbonyl compounds. They had formed 
the 1,4-dicarbonyl precursors to pyridazines (132) by reacting benzophenone with 1,3-
dicarbonyl compounds (131) in the presence of iodine and copper (II) oxide. However, 
they found that when they reacted this intermediate with a large excess (15 equivalents) 
of hydrazine in tert-butanol, rather than forming the pyridazine ring with a 3-substituted 
hydrazone, the functional group was cleaved, forming the disubstituted pyridazine 133. 
 
Given the different synthetic routes available to pyridazine rings, the synthesis of 
pyridazine-containing BRCA2 mimetic scaffolds was attempted. 
  
4.3.2 Synthetic Steps Attempted Towards a Pyridazine Based BRCA2 Mimetic 
Several different unsuccessful attempts were carried out to synthesise a pyridazine that 
could be functionalised into an i, i+1 mimetic. The unsuccessful synthetic routes are 
described below. 
 
4.3.2.1 Attempted Route 1 
 
Scheme 4.13: The first attempted synthetic route to pyridazine 97. 
The first attempt at synthesising a pyridazine scaffold targeted chloro-substituted 
pyridazine 97, from which substitution could be carried out in the i and i+1 positions as 
discussed previously (Scheme 4.13). It was hoped that after the condensation reaction 
between 1,3-cyclopentadione and glyoxylic acid, the resulting compound 135 could be 
treated with one equivalent of hydrazine to give the quinazolinone 136. Treatment of this 
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with phosphorus oxychloride (POCl3) would then give the desired compound 97. The 
initial aldol condensation to form 135 did not give any product; however, when catalytic 
pyrrolidine was used in order to allow the reaction to proceed through a Knoevenagel 
condensation, the product was clearly visible by LCMS. Full purification and 
characterisation was not possible due to the hydrophilicity of the product, which 
precluded its extraction from aqueous media with organic solvents. Because of this, the 
product was treated with hydrazine without purification. However, no product was 
obtained, and instead a polymeric compound was observed by mass spectroscopy, and 
the route was abandoned. 
4.3.2.2 Attempted Route 2 
 
Scheme 4.14 The second attempted synthetic route to pyridazine 97. 
A new route was designed using ethyl glyoxylate to produce compound 100 (Scheme 
4.14). It was hoped that the increased reactivity of esters towards hydrazine would 
counterbalance the problems faced in the previous attempt. The ozonolysis of diethyl 
fumarate was initially carried out to prepare ethylglyoxylate, however, no product was 
obtained, possibly due to the loss of product on workup due to its low boiling point of 
110 qC.324 Instead, the oxidative diol cleavage of diethyl ʟ-(+)-tartrate by reaction with 
periodic acid was performed. To avoid evaporation of product, crude material was taken 
onto the next step without workup. A single peak with the mass of the hydroxyl acetal 
could be observed by LCMS. This was reacted under Knoevenagel conditions with 1,3-
cyclopentadione in the presence of proline, to give the product 100, which was directly 
reacted with one equivalent of hydrazine. However, a mixture of unidentified compounds 
was formed. This could potentially be due to the instability of unsaturated 1,4-dicarbonyl 
compounds for forming pyridazines observed by Wu and co-workers323 (section 4.3.1), 
as well as the problem of selectivity with multiple carbonyl groups in one molecule. This 
route was not taken further. 
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4.3.2.3 Attempted Route 3 
 
Scheme 4.15: Third first attempted synthetic route to pyridazine 97. 
In order to counterbalance the problem of selectivity, synthesis of the saturated compound 
138 was attempted (Scheme 4.15). It was hoped that by doing so, the pyridazine could 
form after the formation of a hydrazone at either carbonyl, due to free rotation around the 
central bond. This may allow formation of the dihydropyridazinone, which could then be 
oxidised to the respective pyridazine 136. However, problems were experienced in the 
alkylation of 1,3-cyclopentadione in the α-carbon 2-position. 
 
Scheme 4.16: The different products achieved from the attempted substitution reaction between 
cyclopentadione and ethyl bromoacetate, depending on the metal counterion present. 
The reaction was attempted with potassium carbonate, potassium hydroxide, lithium 
hydroxide, lithium methoxide and trimethylamine as different bases. In most cases, it was 
found that the product from the reaction was the undesired enol ether 141 of 1,3-
cyclopentadione and ethyl bromoacetate, resulting from O-alkylation, rather than the C- 
alkylated product (Scheme 4.16). Interestingly, when a lithium salt was used as a base, 
self-condensation of cyclopentadione occurred producing dimer 142. This was potentially 
due to the ability of lithium ions to act as a Lewis acid, increasing the electrophilic nature 
of the carbonyl group. As the desired product 138 was not obtained, the synthetic route 
was abandoned. 
121 
 
 
  
4.3.2.4 Attempted Route 4 
 
Scheme 4.17: The fourth attempted synthetic route employing a more step-wise approach to pyridazinone 
136. 
In the light of the difficulties encountered in synthesis of pyridazines, a more step-wise 
approach was adopted (Scheme 4.17), in order to try and gain control over the selective 
addition of hydrazine to the carbonyl group required for pyridazine formation. This was 
attempted by the use of a Boc-protected hydrazide already in place on the glyoxylate 
reagent 146. To synthesize the key intermediate, initially diethyl ʟ-(+)-tartrate was 
transformed into the dihydrazide 144 by refluxing in ethanol in the presence of hydrazine. 
Some difficulty was encountered in functionalising this compound with Boc-protecting 
groups. Direct reaction of the dihydrazide 144 with Boc-anhydride in organic and in 
aqueous solvents under heating did not result in the Boc-protected product. The use of 
pyridine and of trimethylamine also yielded nothing. Using catalytic iodine as a Lewis 
acid was found to allow the reaction to proceed, giving the product in 54 % yield. 
 
However, when the product was treated with periodic acid in diethyl ether to attempt 
oxidative diol cleavage, decomposition occurred, and effervescence was observed. When 
the reaction mixture was concentrated, only a small amount of unidentifiable material 
remained, suggesting that the starting material had decomposed to gaseous side products. 
Analysing the pKa of Boc-protected hydrazide 145 in MarvinSketch possibly helped 
develop an understanding of what had happened (Scheme 4.18). 
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Scheme 4.18: Proposed mechanism for the decomposition of compound 145 observed when reacted with 
periodate species, with the pKa of different positions of Boc-hydrazide 145 as predicted by 
MarvinSketch.284 
According to MarvinSketch, the point on the molecule with the lowest pKa is a hydrazide 
nitrogen, which has a predicted pKa of 9.0. Considering this, it is highly possible that 
during the reaction with periodate, the cyclic intermediate can form between one of the 
alcohol groups, and the hydrazide nitrogen, giving 149. When the pericyclic oxidation 
occurs, this results in the cyanate containing compound 151, which would tautomerise to 
compound 152. This could then decompose to carbon monoxide, nitrogen, carbon dioxide 
and 2-methyl propane, as indicated in Scheme 4.18. 
 
In an attempt to prevent this from happening, the reaction was attempted with sodium 
periodate in water, and silica-adsorbed sodium periodate in dichloromethane. However, 
in each case, the same result was observed. Because of this, this synthetic route was 
abandoned. 
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4.3.2.5 Attempted Route 5 
 
Scheme 4.19: The fifth attempted synthetic route to a pyridazine core, with early functionalisation of the 
i+1 position. 
In a final attempt to synthesize a pyridazine containing i, i+1 mimetic, a synthetic route 
was designed that had a pre-functionalised i+1 position, containing a benzyl moiety. It 
was hoped that this would affect the formation of the pyridazine, as the ketone would be 
much more reactive than the esters from previous routes. However, as before, the 
alkylation of 1,3-cyclopentadione 101 was not successful due to the formation of the enol 
ether, and the synthetic route abandoned. 
 
The inclusion of heteroatoms in the i, i+1 mimetic scaffold was desirable for effective 
tool compounds due to the expected increase in aqueous solubility, whilst still being 
compatible with the lipophilic PALB2 binding site as predicted by computational work 
detailed in chapter three. However, the synthesis of pyridazine-based i, i+1 scaffolds had 
proven problematic, with no fully synthesised mimetics produced after many different 
approaches were attempted. The synthesis of all-hydrocarbon indane-containing cores 
was more established in the literature. In order to achieve testable compounds, the focus 
was moved onto the synthesis of all-hydrocarbon i, i+1 mimetics, with the potential of 
returning to heteroatom containing cores as part of later SAR studies. 
4.4 Synthesis of All-Hydrocarbon Indane-Based Wittig Reagents 
The synthesis of all-hydrocarbon indanes to be used as the scaffold of i, i+1 mimetics was 
carried out, with the aim of functionalising the i position using Wittig or HWE chemistry 
(Scheme 4.20). The indanone functionality required for this was synthesised by 
intramolecular Friedel-Crafts acylation of a 3-phenylpropionic acid. The resulting ketone 
had the potential to react as the electrophile in a Wittig/HWE reaction. The ketone was 
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also converted into the respective phosphonium compound via the alcohol, allowing it to 
act as the nucleophile in the Wittig/HWE reaction too.  
 
Scheme 4.20: General scheme for the synthesis of ketones and phosphonium salts for use in Wittig 
chemistry. 
4.4.1 Intramolecular Friedel-Crafts Acylation Reactions. 
Intramolecular Friedel-Crafts acylation reactions were carried out on three different 3-
phenylpropionic acids, with different functionalities in the phenyl of the phenyl ring, to 
act as synthetic handles for i+1 functionalisation. Two propionic acids, 3-(4-
bromophenyl)propionic acid (98) and 3-(4-methoxyphenyl)propionic acid (161) were 
obtained from commercial suppliers. The third acid, 3-(4-carboxyphenyl)propionic acid 
(160) was synthesised in two steps (Scheme 4.21). 
 
Scheme 4.21: Preparation of dicarboxylic acid 160 from 4-iodobenzoic acid. 
4-Iodobenzoic acid (158) was coupled with acrylic acid under a palladium-catalysed 
Heck reaction in water. The product 159 was precipitated from the water by acidification, 
and obtained in 82% yield. The resulting carbon-carbon double bond from the Heck 
reaction was hydrogenated using Raney nickel in water, with hydrazine as a source of 
hydrogen. This gave the desired propionic acid 160 after 1 hour in 90% yield. 
 
Once the three propionic acids had been obtained, they were subjected to Friedel-Crafts 
acylation conditions. 3-(4-Carboxyphenyl)propionic acid (160) was transformed into the 
indanone 163 by following published methodology.153 It was reacted with aluminium 
trichloride in a melt with sodium chloride for 2 hours, giving the product in 83 % yield 
after workup.  
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Scheme 4.22: The optimised conditions for three different Friedel-Crafts reactions to form indanones. 
When 3-(4-bromophenyl)propionic acid (98) was reacted under these conditions, no 
product was obtained. However, using recently published conditions325 and employing 
triflic acid as a catalyst to generate the carbonium ion required for acylation, the desired 
reaction occurred giving the product in  67% yield. The ease of acylation was heavily 
influenced by the electron density within the aromatic ring. For the electron poor 
bromophenyl derivative (98), 15 equivalents of triflic acid and forcing conditions (48 
hours heating) were required to push the reaction to completion. However, for the electron 
rich anisole 161, only three equivalents of triflic acid and four hours of heating were 
required to achieve the same yield. 
4.4.2 Functionalisation of 6-Methoxyindanone (162) in the i+1 Position Prior to 
Wittig Functionalisation 
 
Scheme 4.23: The synthesis of i+1 functionalised indanone 165, from 6-methoxyindanone 162. 
In the case of 6-methoxyindanone 162, the decision was made to functionalise in the i+1 
position before carrying out i functionalisation using Wittig chemistry. There was 
concern over whether the indole N-H would interfere with the Ullman conditions 
employed for aryl ether synthesis. Protecting group chemistry was considered, but there 
was no immediate solution which would not require multiple steps, and the exchange of 
protecting groups mid synthesis. 
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6-Methoxyindanone 162 was functionalised in two steps. Firstly, the anisole group was 
demethylated by refluxing with aluminium trichloride in toluene for 30 minutes. This 
gave the phenol 164 in 85% yield after purification. This was then coupled with 2-
bromopyridine using an Ullmann condensation reaction. Picolinic acid has been shown 
to be a broadly applicable ligand for use in copper catalysed Ullmann condensation.326,327 
Use of these conditions gave the desired product 165 in 58% yield after 3 hours. 
 
Scheme 4.24: The proposed catalytic cycle for an Ullman condensation to form an aromatic ether, 
involving an unusual Cu(III) oxidation state.328 
The Ullmann condensation was first reported in 1905, and involves the use of catalytic 
copper to form aryl-heteroatom bonds.301,302 Originally used for the formation of aryl 
ethers, it has since been developed to be used for a range of C-O and C-N bonds. The 
proposed mechanism of the reaction is similar to that of palladium catalytic cycles 
(Scheme 4.24).328 Initially, a deprotonated heteroatom salt becomes co-ordinated to a 
copper(I) species, through a transmetallation reaction. The oxidative addition of an aryl 
halide to the copper can now occur, producing a highly unusual copper(III) species. 
Reductive elimination of both organic ligands forms a carbon-heteroatom bond, giving 
the product and completing the catalytic cycle. 
4.4.3 The Reduction of Indanones to Alcohols 
 
Scheme 4.25: The reduction of two different indanones to their respective alcohols using sodium 
borohydride. 
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The indanones synthesised were reduced to the corresponding alcohol by portion-wise 
addition of sodium borohydride in methanol, with no purification required. This was 
carried out on two different indanones. 6-Bromoindanone 95 was reduced to racemic 6-
bromoindanol 166 in a 90 % yield after one hour. The 2-pyridyl functionalised indanone 
165 was also reduced to alcohol 167, in a 98% yield after 30 minutes.  
4.4.4 The Conversion of Indanols to Phosphonium Salts for Wittig Chemistry 
 
Scheme 4.26: One-step conversion of alcohols to their respective phosphonium salt, using 
triphenylphosphonium hydrobromide. 
Once the indanols 166 and 167 had been synthesised, they were transformed into the 
respective triphenylphosphonium salts. Initially, this was attempted in one step, using 
triphenylphosphonium hydrobromide (Scheme 4.26).329 This reagent acts as a source of 
hydrogen bromide (HBr), to convert the alcohol to the respective bromide. The bromide 
can then undergo a condensation reaction with triphenylphosphine, forming the 
phosphonium bromide salt as the product. The reaction gave the desired phosphonium 
salts at 21% and 20% yields for 94 and 168, respectively. The reaction was found to only 
be effective on a large scale, with smaller scale (approximately 200 mg) reactions only 
yielding 3-4%. Although the yield of 20% was adequate to get enough material for the 
next step, a stepwise approach was tested in an attempt to improve the yield (Scheme 
4.27). 
 
In the step-wise approach, the indanol was reacted to the respective 1-bromoindane using 
phosphorus tribromide in dichloromethane. These conditions allowed the conversion of 
bromoindanol 166 to the corresponding bromide in a 94% yield after two hours. When 
the bromide was heated with triphenylphosphine in toluene at reflux, the phosphonium 
salt 94 was obtained in 57% yield. This yield, which equates to 54% over two steps, is an 
improvement on the 21% achieved for the one step method using triphenylphosphonium 
hydrobromide on the same indanol. Conversion of 1,6-dibromoindane to the diethyl 
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phosphonate ester was attempted using a Michaelis-Arbuzov reaction.330 None of the 
desired product could be detected in the crude mixture by LCMS or 1H NMR. However, 
the less sterically hindered benzylbromide 171 could be converted to the phosphonium 
salt 172 by reacting with triphenylphosphine in toluene under reflux with a higher yield 
of 92%. 
 
 
Scheme 4.27: Stepwise conversion of alcohols to the respective phosphonium salt, by conversion to the 
bromide, then reaction with triphenylphosphine. 
 
The bromination of indanol 166 and 167 resulted in several problems (Scheme 4.28). 
Depending on the conditions used, three different brominated products were obtained. 
Initially, Appel reaction conditions were used in an attempt to form the bromoindane. 
However, the predominant component after column chromatography was identified as 
the tetrabromoindole 174 by 1H NMR. The coupling constants of the three indane protons 
identified as being in an AAB system.  
The use of phosphorus tribromide as an alternative to Appel conditions appeared to solve 
this problem, producing the desired product 169 in 96% without purification required. 
However, it was found that when the reaction was repeated on a day with high levels of 
sunshine in the lab, the only isolated product was the tribromoindane 173. 1H NMR 
analysis of the methylene protons at the indane 2-position suggested that only the (R,R) 
or (S,S) trans diastereomers were present. This was potentially due to benzyl radicals 
produced in the presence of light energy. 
Synthesis of the i+1 functionalised bromoindole 175 was not achieved, and so the single-
step method was used in this case. 
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Scheme 4.28: The effect of reaction conditions on the isolated product of indanol bromination. 
4.5 Using the Wittig Reaction to Functionalise the i+1 position 
With the synthesis of the indanone and indane phosphonium salts complete, Wittig 
chemistry could be employed to functionalise the scaffolds in the i position with an indole 
moiety. 
 
Scheme 4.29: General reaction scheme of a Wittig reaction. 
Conditions were explored for the functionalisation of the i position of the scaffolds 
synthesised, using Wittig chemistry. For these reactions, the phosphonium and carbonyl 
synthetic handles could be placed in one of two different pairings (Scheme 4.30). For the 
mimetics with a 1-carbon linker, it was considered best to react the indane as a 
phosphonium salt. This is because of the high risk of elimination of triphenylphosphine 
from 3-triphenylphosphomethyl indole. 
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Scheme 4.30: The synthetic handles can be placed in two different pairings for the Wittig reaction. 
4.5.1 Using the Wittig Reaction to Synthesise Reagent 178 
Initial attempts to perform a Wittig reaction on phosphoindane 94 were unsuccessful 
(Scheme 4.31). Phosphoindane 94 was reacted with indole-3-carbaldehyde 176, using 
potassium carbonate with 18-crown-6 in dichloromethane, however only starting 
materials could be detected in the crude material after being stirred overnight. 
 
Scheme 4.31: The failed Wittig reaction in the presence of the indole N-H bond. 
It was hypothesised that the indole N-H bond was interfering with the reaction. With a 
pKa calculated to be 13.5 (MarvinSketch),284 it is the most acidic proton in both reagents. 
Because the negative charge would be delocalised to the aldehyde, the deprotonated 
species would be significantly less electrophilic. In order to circumvent this problem, the 
N-H bond was masked with an electron withdrawing carboxybenzyl (Cbz) protecting 
group. 
 
Scheme 4.32: The protection of the indole N-H bond with a Cbz group. 
To protect the indole-3-carboxaldehyde, it was deprotonated with sodium hydride, then 
reacted with carboxybenzyl chloride (CbzCl) in tetrahydrofuran overnight, giving the 
product 179 in 52% yield. 
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Table 4.1: Different conditions tested for the Wittig reaction between compounds 94 and 179. 
 
 Conditions Yield 
1 K2CO3, 18-crown-6, CH2Cl2, r.t, 3 days 10% 
2 BuLi, THF, -78 °C to r.t, 6 hours Trace by TLC, not isolatable 
3 DBU, THF, reflux, overnight 0% 
4 DBU, ethanol, r.t., overnight Trace by TLC, not isolatable 
5 LiHMDS, THF, 0 °C to r.t., overnight Trace by TLC, not isolatable 
6 NaH, THF, r.t., overnight 22% 
 
Once the protected indole had been synthesised, it was submitted to the same Wittig 
conditions as used before, and the desired product was obtained in a 10% yield. In an 
attempt to increase the yield, six different sets of alternative reaction conditions were 
screened (Table 4.1). Of these, the only other set of conditions that gave product was the 
use of sodium hydride in THF. This could be due to the large amount of steric hindrance 
around the benzylic position, which had less effect on the smaller bases such as sodium 
hydride. 
 
Scheme 4.33: Different successful Wittig reactions to functionalise the i position of BRCA2 mimetics. 
On scale-up of the optimal Wittig conditions in Table 4.1, the yield was found to improve 
from 22% to 49%. The Wittig reactions of i+1 functionalised phosphonium salt 168, and 
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benzylphosphonium salt 172 were also attempted. In both of these cases, the reaction 
conditions with sodium hydride were found to be ineffective. Instead, the reaction was 
carried out using potassium carbonate and 18-crown-6 and was found to be successful in 
both cases. The i+1 functionalised phosphonium salt was reacted overnight at room 
temperature with N-Cbz protected indole 179 to give the product 181 in 22% yield. The 
lower yield could be due to the increased electron density provided by the aryl ether 
increasing the pKa and causing destabilisation of the phosphonium ylid. For the benzylic 
phosphonium bromide 172, reaction with N-Cbz protected indole 179 afforded the 
product as approximately a 1:1 mixture of both cis and trans isomers in 56% yield. 
Although it was difficult to separate the isomers by column chromatography, small 
fractions of each isomer were obtained and fully characterised. As the stereochemistry of 
each double bond was to be subsequently lost at a later stage by hydrogenation, 
determination of the exact stereochemistry of other Wittig products was not attempted. 
 
4.5.2 Synthesis of Reagents for the Two-Carbon Linker i Functionalisation 
 
Scheme 4.34: Synthesis towards reagents for a 2 chain linker in the i position, with reversed synthetic 
handles. 
It was possible to predict the most stable pairing for the Wittig synthetic handles when 
designing the synthetic route for the one carbon linker due to possible elimination of the 
indole phosphonium salt. For the two carbon linker, however, it was less clear which 
pairing would be the most effective. As a result, the synthesis of an indole functionalised 
with an aldehyde and with a phosphonium salt were planned, so that both could be tested 
(Scheme 4.34). Indole 185 was synthesised from 1,2-dihydrofuran using a Fischer indole 
synthesis, giving the product in 47% yield. The alcohol group was then transformed to 
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the corresponding bromide by using Appel conditions with carbon tetrabromide and 
triphenylphosphine in dichloromethane. This gave the product 186 in 73% yield after 
purification. Unfortunately, due to time constraints, the completion of the synthesis of 
both aldehyde 188 and phosphonium 190 were not completed. 
4.6 Using Heck and Sonogashira Chemistry to Functionalise the i+1 
Position, and Hydrogenation to Give Final Compounds 
Once the i position had been functionalised, the Heck reaction and Sonogashira coupling 
reactions were investigated as a means of functionalising in the i+1 position.  
 
Scheme 4.35: A general reaction scheme for a Heck reaction307,331 and Sonogashira reaction.308 
Initially, the Heck reaction was used for the attempted functionalisation of the i+1 
position (Scheme 4.36). The reaction was attempted with both styrene and 4-
vinylpyridine. Palladium(o-tolyl)3 was used as it has been shown to be a widely applicable 
ligand for the Heck reaction. Unfortunately, no product was detectable in the crude 
reaction mixture, despite the consumption of starting material. Instead, a complicated 
mixture of unidentifiable side products was produced in both cases. 
 
Scheme 4.36: Failed heck reaction conditions using styrene and 4-vinylpyridine to form heck product 
193. 
The Sonogashira reaction was used as an alternative to the Heck reaction (Scheme 4.37). 
Comparatively forcing conditions were chosen. When the reaction was carried out at 
room temperature no reaction was observed, probably due to the insolubility of the 
starting material. However, when the reaction mixture was heated to 80 qC, the starting 
material began to dissolve, allowing the reaction to occur. As a result, the product 194 
was obtained in 24% yield.  
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Scheme 4.37: The successful Sonogashira reaction between bromoindane 180 and ethynyl benzene to 
give 194, as well as the reaction between phenylbromide 182 and ethynyl benzene that was not carried 
out due to time constraints. 
After the i+1 functionalisation by Sonogashira coupling, the final stage of the synthesis 
was palladium catalysed hydrogenation. This would potentially deprotect the N-Cbz 
group, as well has saturate the i alkene bond and the i+1 alkyne bond. Compound 194 
was stirred in THF in the presence of palladium on charcoal, with a hydrogen atmosphere 
overnight. The crude material was then purified by preparative HPLC, to give the product 
196 in a yield of 18%. 
 
Scheme 4.38: Prospective hydrogenations to give BRCA2 mimetics. 
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4.7 Conclusions 
In conclusion, synthetic routes were designed for the synthesis of small molecule BRCA2 
mimetics, based on the results of computational studies. Due to the difficulty in designing 
a short synthetic route of i, i+1, i+4 mimetics, the synthesis of the simplified i, i+1 
mimetics was performed instead. 
Difficulty was encountered with the synthesis of pyridazine containing scaffolds to serve 
as a backbone for the i, i+1 mimetics. The problems seemed to arise from the high 
reactivity of hydrazine rendering selective reaction with the desired carbonyl groups 
unachievable. A step-wise approach was attempted, but abandoned when the reaction was 
unsuccessful. After many failed synthetic routes, the synthesis of pyridazine containing 
cores was abandoned. 
The synthesis of an all-hydrocarbon i, i+1 scaffold was more successful, and several 
indanes were formed using an intramolecular Friedel-Crafts acylation, followed by 
subsequent conversion to the triphenylphosphonium salt via the alcohol. This allowed for 
late-stage functionalisation in the i and i+1 positions. 
Functionalisation in the i position was carried out by Wittig chemistry. By protecting 
indole-3-carboxaldehyde with an N-Cbz group, the aldehyde group was rendered 
electrophilic enough to undergo a Wittig reaction with a triphenylphosphonium salt. It 
was subsequently reacted to form three different i, i+1 mimetic scaffolds with tryptophan 
(indole) functionalisation in the i position. 
Functionalisation in the i+1 position was carried out using a Sonogashira coupling 
reaction. This was performed on one scaffold, and subsequently hydrogenated to produce 
the fully synthesised BRCA2 i, i+1 mimetic, ready for testing. Two other mimetics also 
are within two synthetic steps of the end of the synthetic route, but were not able to be 
synthesised due to time constraints.  
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5 Conclusion and Further Work 
5.1 Conclusions 
This thesis has investigated the processes by which protein α-helices can be mimicked by 
designed structures.  
 
In the introduction the identification of PPI targets for inhibitor design, and in particular 
how modern computational methods have been able to predict the druggability of a PPI 
with increasing accuracy, was covered. The different methods that have been used to 
design α-helical mimetics were then described. This covered: using unnatural amino acid 
residues to create protein-mimicking foldamers, using naturally occurring and highly 
stable short peptide structures as surrogates for the design of miniproteins, placing a 
covalent linker at a set position in a peptide sequence to form a stapled helix, and by the 
design of small molecule scaffolds that are able to be functionalised to mimic the position 
of amino acid residues in an α-helix. In particular, the use of miniproteins to inhibit PPIs 
was reviewed in depth due to a lack of existing published reviews in the literature. This 
helped develop an understanding of the ways in which an inhibitor for a novel PPI target 
could be developed. It also highlighted aspects of α-helical mimetic research, in particular 
the solubility and cell permeability of PPI inhibitors, which were in need of further 
scientific development.  
 
Scheme 5.1: Overview of the C-H activation methodology developed. 
In unusual cases, approved drug compounds are able to exhibit excellent pharmacological 
(PK) profiles despite having unfavourable physical properties. It was hypothesised that it 
may be possible to incorporate structural features from these compounds into PPI 
inhibitors in order for them to also adopt better PK profiles. This hypothesis was explored 
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in chapter 2. The HCV NS5A inhibitor, daclatasvir, was identified as having good oral 
bioavailability alongside a high molecular weight of 739 Daltons. This property was 
attributed to a pair of symmetrical polar side chains within the structure of daclatasvir. 
Methodology which would allow the functionalisation of small molecule PPI inhibitors 
with poor PK profiles with ‘daclatasvir-like’ side chains could be of use for the 
development of membrane permeable PPI inhibitors. C-H activation was identified as 
potential methodology for the formation of the required C-C bonds. This reaction was 
attempted and proved successful, and the conditions optimised in order to reduce the 
amount of homo-coupling leading to inseparable side products. The scope of the 
optimised conditions was tested and of 18 different aryl dibromide cores investigated, 11 
were able to undergo C-H activation (Scheme 5.1). This methodology was shown to have 
the potential to synthesise a range of ‘daclatasvir-like’ compounds as potential NS5A 
inhibitors, resulting in a peer-reviewed publication.234 It can be used to functionalise a 
wide range of aryl bromides with solubilising side chains, and could potentially help 
towards synthesis of PPI inhibitors with good PK profiles. 
 
Figure 5.1: Structures of the 10 miniproteins selected for synthesis. 
The PALB2/BRCA2 PPI was identified as a potential candidate as a target of cancer 
therapeutics through synthetic lethality with damaged DNA break repair mutations. 
However, there are no published inhibitors of the PALB2/BRCA2 interaction. It was 
hypothesised that the methods reviewed to mimic α-helical secondary structure could be 
used to develop tool compounds to probe the therapeutic value of a PALB2/BRCA2 
inhibitor in cell-based assays. A series of miniproteins containing the WFXXL hot-spot 
motif presented by BRCA2 were designed using computational techniques to test for 
compatibility when binding to PALB2 (Figure 5.1). Upon purchasing the protein 
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sequences, CD spectroscopy of one of the sequences suggested that the WFXXL motif 
had not disrupted α-helicity, which was calculated to be 95% in solution. The miniprotein 
sequences are now ready for testing in a biochemical assay. 
 
 
Figure 5.2: Markush structure showing the structures to be analysed for synthetic accessibility. 
Small molecule i, i+1, i+4 and i, i+1 were designed by using a series of computational 
studies to analyse the ability of small molecule scaffolds to align with BRCA2. This gave 
an understanding of which small molecules were the most effective BRCA2 mimetics, 
and therefore be able to inhibit the BRCA2/PALB2 interaction (Figure 3.12). Due to the 
synthetic complexity, higher molecular weight, and less ‘drug-like’ structures of i, i+1, 
i+4, the synthesis of i, i+1 mimetics was carried out. Although the synthesis of pyridazine 
based i, i+1 mimetics was unsuccessful, the synthesis of hydrocarbon scaffolds had more 
success and allowed the development of methodology to functionalise in the i and i+1 
positions. This resulted in the complete synthesis of one all-hydrocarbon BRCA2 
mimetic, as well as progress towards the synthesis of several others. These compounds 
can then be tested in a biochemical assay in order to determine whether or not mimicking 
the BRCA2 helix has resulted in efficacy towards PALB2. 
 
Figure 5.3: Functionalisation of hydrocarbon i, i+1 α-helical mimetic scaffolds was carried out using 
Wittig, Sonogashira and Ullman chemistry. 
5.2 Further Work 
This thesis has led to a number of areas where further work can be done. The synthesis 
of BRCA2 i, i+1 mimetics with a one-carbon i linker was not completed, and three 
synthetic steps are required in order to synthesise two more mimetics (Figure 5.4), 
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including one with a one-atom i+1 linker. This would be of value for understanding the 
potential SAR of these molecules based on the determined efficacy towards PALB2. 
 
Figure 5.4: Final steps to the completion of mimetics with a one-carbon linker in the i position. 
The synthesis and activity of BRCA2 mimetics with a two-atom i linker has not been 
explored. The synthetic route to these compounds from 3-(2-bromoethyl)-indole 
derivatives (187) has been designed, however the synthesis was not carried out (Figure 
5.5). This synthetic route should hopefully be compatible with the established 
methodology and give further understanding of the SAR of these compounds. 
 
Figure 5.5: Synthesis of mimetics with a two-carbon linker in the i position. 
Once the activity of the BRCA2 miniproteins has been established, it could be optimised 
by sequence modifications. This could be done either by the rational mutation of certain 
residues that have potential for picking up further interaction at the binding site,89 or by 
using phage display methods on a library of generated sequences.91 It is also possible to 
regulate the cellular uptake of miniproteins by incorporating basic residues such as 
arginine,332 facilitating active transport into cells. This could be explored in the case of 
any miniprotein which demonstrates good activity against PALB2, and lead towards the 
development of a tool compound. 
 
Finally, the hypothesis of whether incorporation of ‘daclatasvir-like’ side chains into 
small molecule mimetics would increase the solubility and bioavailability is yet to be 
tested. Mimetics with known activity against PPIs, such as Hamilton’s terphenyl 
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compounds,149 could be synthesised with daclatasvir-like side chains incorporated and 
PK profiles determined in order to fully test this hypothesis. 
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6 Experimental Information 
6.1 General Information 
All reactions were conducted under an atmosphere of nitrogen unless otherwise stated. 
Anhydrous solvents were used as purchased or were purified under nitrogen as follows 
using activated molecular sieves. 
Thin layer chromatography was performed on glass plates pre-coated with Merck silica 
gel 60 F254. Visualisation was achieved with U.V. fluorescence (254 nm) or by staining 
with a phosphomolybdic acid dip or a potassium permanganate dip. Flash column 
chromatography was carried out using pre-packed columns filled with Aldrich silica gel 
(40-63 µm) on an ISCO Combiflash Rf, or a Biotage Isolera Prime. 
Proton nuclear magnetic resonance spectra were recorded at 500 MHz on a Varian 500 
spectrometer (at 30 °C), using residual isotopic solvent (CHCl3, δH = 7.27 ppm, DMSO 
δH = 2.50 ppm, 3.33 ppm (H2O), MeOH δH = 3.31 ppm, 4.87 ppm (H2O)) as an internal 
reference. Chemical shifts are quoted in parts per million (ppm). Coupling constants (J) 
are recorded in Hertz (Hz).  
Carbon nuclear magnetic resonance spectra were recorded at 125 MHz on a Varian 500 
spectrometer and are proton decoupled, using residual isotopic solvent (CHCl3, δC = 
77.00 ppm, DMSO δC = 39.52 ppm, MeOH δC = 49.00 ppm) as an internal reference. 
Carbon spectra assignments are supported by DEPT editing and chemical shifts (δC) are 
quoted in ppm. 
Infrared spectra were recorded on a Perkin Elmer FT-IR One spectrometer as either an 
evaporated film or liquid film on sodium chloride plates. Absorption maxima are reported 
in wave numbers (cm-1). Only significant absorptions are presented in the data, with key 
stretches identified in brackets. 
LCMS data was recorded on a Waters 2695 HPLC using a Waters 2487 UV detector and 
a Thermo LCQ ESI-MS. Samples were eluted through a Phenomenex Lunar 3µ C18 50 
mm × 4.6 mm column, using acetonitrile and water (3:7 to 7:3) acidified by 0.01% formic 
acid. 
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HPLC analysis and purification was performed on an Agilent 1100 series HPLC 
spectrometer, using a Phenominex Luna 10 µ C18 150 mm × 15 mm column, eluted using 
acetonitrile and water (3: 7 to 7: 3) 
High resolution mass spectrometry (HRMS) spectra were recorded on Bruker Daltonics 
Apex III ESI-MS, with an Apollo ESI probe using a methanol spray. Only molecular ions, 
fractions from molecular ions and other major peaks are reported as mass/charge (m/z) 
ratios. 
Microwave reactions were performed using a Biotage Initiator 8+ microwave reactor. 
6.1.1 General Software Packages 
Calculation of molecular weight, pKa, logP, logD and NMR spectra predictions were 
carried out using MarvinSketch (ChemAxon Kft, 1031 Budapest, Hungary, 
https://www.chemaxon.com). 
Drawing of chemical structures was carried out using ChemDraw Prime 15.1.0.144 
(PerkinElmer Informatics Inc, Massachusetts 02451, USA, 
http://www.cambridgesoft.com/). 
Visualisation and rendering of three-dimensional protein and small-molecule images was 
carried out using PyMOL 1.7.6.6 (Schrodinger, LLC, Cambridge, Cambridgeshire, CB1 
2JD, https://www.pymol.org). 
6.2 Chemistry Experimental Procedures 
A. General Procedure for C-H activated cross coupling for compound without 
deprotection 
The appropriate aryl dibromide (0.10 mmol), (S)-tert-butyl 2-(1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (44, 100 mg, 
0.24 mmol), pivalic acid (6.1 mg, 0.06 mmol), K2CO3 (41 mg, 0.30 mmol) and 
Pd(ddpf)Cl2 (7.3 mg, 0.01 mmol) were placed in a sealed reaction vial. The reaction vial 
was placed under reduced pressure then purged with nitrogen, repeating the process 5 
times. The content of the sealed vial was dissolved in dimethylacetamide (1 mL), and the 
solvent was deoxygenated by bubbling with nitrogen for 20 minutes. The solution was 
then irradiated in a microwave at 100 °C for 4 hours. The resulting solution was quenched 
with water (15 mL), and extracted with EtOAc (2 × 10 mL). The organic phase was 
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washed with concentrated sodium bicarbonate solution (2 × 15 mL) water (2 × 15 mL), 
and brine (2 × 15 mL), before being concentrated under reduced pressure to afford a solid 
which was purified by mass-directed auto purification (30% to 70% acetonitrile in water 
over 25 minutes). 
 
Dimethyl (2S,2'S)-1,1'-((2S,2'S)-2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(1-((2-
(trimethylsilyl) ethoxy)methyl)-1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-
diyl))bis(3-methyl-1-oxobutane-2,1-diyl)dicarbamate (48) 
 
1H NMR (500 MHz, CD3OD) 7.79 (4H, d, J = 7.8 Hz, 3-CH), 7.59 (4H, d, J = 7.8 Hz, 2-
CH), 7.04 (2H, s, 6-CH), 5.79 (2H, d, J = 10.9 Hz, 8-CHA), 5.32 (2H, d, J = 10.9 Hz, 8-
CHB), 5.24 (2H, s, 12-CH), 4.22 (2H, d, J = 7.5 Hz, 17-CH), 4.11 − 4.03 (2H, m, 15-
CHA), 3.95 − 3.86 (2H, m, 15-CHB), 3.66 (6H, s, 22-CH3), 3.61 − 3.44 (4H, m, 10-CH2), 
2.37 (4H, m, 13-CHA, 14-CHA), 2.21 − 1.96 (6H, m, 13-CHB, 14-CHB, 18-CH), 0.90 (16H, 
m, 19-CH3, 9-CH2), -0.03 (18H, s, 11-Si(CH3)3); 13C NMR (126 MHz, CD3OD) 171.7 
(16-CO), 158.0 (21-CO), 150.9 (7-NCN), 140.0 (1-C), 133.1 (5-C), 129.4 (2-CH), 128.8 
(4-C), 127.0 (3-CH), 125.4 (6-CH), 72.1 (8-CH2), 65.6 (10-CH2), 58.3 (17-CH), 53.2 (12-
CH), 51.3 (22-CH3), 47.6 (15-CH2), 31.6 (13-CH2), 30.1 (18-CH), 24.7 (14-CH2), 18.4 
(19-CH3), 17.30 (9-CH2), -2.84 (11-Si(CH3)3); IR (neat, νmax, cm-1) 3276 (brw), 2959 (m), 
1719 (s), 1631 (s), 1507 (m), 1441 (s), 1248 (s), 1189 (m), 1178 (s), 1033 (m), 820.21 (s), 
693 (m); HRMS (ESI): calcd. for C52H78N8NaO8Si2 [M+H]+ 1021.5368, found 
1012.5373; [α]D -39.4 ° (c 0.6 in CHCl3, T 21.0 °C) 
 
144 
 
 
Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-(furan-2,5-diylbis(4,1-phenylene))bis(1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-
diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate (199) 
 
1H NMR (500 MHz, CDCl3) δ 7.80 (d, J = 8.0 Hz, 4H, 7/9/13/15-CH), 7.49 (d, J = 8.0 
Hz, 4H, 6/10/12/16-CH), 7.05 (s, 2H, 2/3-CH), 6.82 (s, 2H, 18/21-CH), 5.79 (d, J = 10.6 
Hz, 2H, 29/23-CHH), 5.29 (d, J = 9.1 Hz, 2H, 45/53-NH), 5.24 – 5.16 (m, 4H, 23/29-
CHH, 35/39-CH), 4.35 (dd, J = 9.2, 6.4 Hz, 2H, 44/52-CH), 3.98 – 3.87 (m, 4H, 38/42-
CH2), 3.67 (s, 6H, 47/55-CH3), 3.59 – 3.46 (m, 4H, 24/30-CH2), 2.55 – 2.42 (m, 2H, 
37/41-CHH), 2.39 – 2.26 (m, 4H, 36/40-CH2), 2.15 – 1.91 (m, 4H, 37/41-CHH, 48/56-
CH), 1.01 – 0.87 (m, 10H, 50/58-CH3, 25/31-CH2), 0.80 (d, J = 6.7 Hz, 6H, 49/57-CH3), 
0.00 (s, 18H, 26/27/28/32/33/34-CH3); 13C NMR (126 MHz, CDCl3) δ 170.9 (43/51-CO), 
157.1 (46/54-CO), 153.3 (8/14-C), 151.6 (1/4-C), 150.7 (19/22-C), 133.8 (5/11-C), 132.8 
(17/20-C), 129.3 (7/9/13/15-CH), 124.0 (6/10/13/15-CH), 108.0 (18/21-CH), 88.3 (2/3-
CH), 65.9 (24/30-CH2), 57.6 (44/52-CH), 52.9 (35/39-CH), 52.2 (47/55-CH3), 47.6 
(38/42-CH2), 31.8 (36/40-CH2), 31.1 (48/56-CH), 25.2 (37/41-CH2), 19.3 (49/57-CH3), 
18.0 (25/31-CH2), 17.3 (50/58-CH3), -1.4 (26/27/28/32/33/34-CH3); IR (neat, νmax, cm-1) 
2955 (m), 1719 (s), 1640 (s), 1503 (m), 1440 (m), 1249 (s), 1188 (m), 1082 (s), 1030 (w), 
837 (s), 697 (w); HRMS (ESI): calcd. for C56H81N8O7Si2 [M+H]+ 1065.5660, found 
1065.5642; [α]D -102.1 ° (c 0.3 in CHCl3, T 22.5 °C) 
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Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-(thiophene-2,5-diylbis(4,1-phenylene))bis(1-
((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-
diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate (200) 
 
1H NMR (500 MHz, CDCl3) δ 7.71 (d, J = 7.9 Hz, 4H, 7/9/13/15-CH), 7.47 (d, J = 7.9 
Hz, 4H, 6/10/12/16-CH), 7.38 (s, 2H, 2/3-CH), 7.12 (s, 2H, 18/21-CH), 5.81 (d, J = 10.6 
Hz, 2H, 23/29-CHH), 5.29 – 5.14 (m, 6H, 23/29-CHH, 35/39-CH, 45/53-NH), 4.39 – 
4.31 (m, 2H, 44/52-CH), 4.21 – 4.05 (m, 2H, 38/42-CHH), 3.99 – 3.84 (m, 2H, 38/42-
CHH), 3.66 (s, 6H, 47/55-CH3), 3.59 – 3.43 (m, 4H, 24/30-CH2), 2.58 – 2.28 (m, 6H, 
37/41-CHH, 36/40-CH2), 2.17 – 1.93 (m, 4H, 37/41-CHH, 48/56-CH), 1.01 – 0.85 (m, 
10H, 50/58-CH3, 25/31-CH2), 0.79 (d, J = 6.7 Hz, 6H, 49/57-CH3), 0.00 (s, 18H, 
26/27/28/32/33/34-CH3); 13C NMR (126 MHz, CDCl3) δ 171.4 (43/51-CO), 157.1 
(46/44-CO), 150.3 (19/22-C), 143.2 (1/4-C), 134.5 (5/11-C), 134.1 (8/14-C), 132.9 
(17/20-C), 129.7 (6/10/12/16-CH), 125.9 (7/9/13/15-CH), 124.8 (2/3-CH), 118.4 (18/21-
CH), 72.9 (23/29-CH2), 66.4 (24/30-CH2), 57.7 (44/52-CH), 52.8 (35/39-CH), 52.2 
(47/55-CH3), 47.7 (38/42-CH2), 31.7 (36/40-CH2), 30.6 (48/56-CH), 25.4 (37/41-CH2), 
19.4 (50/58-CH3), 18.0 (25/31-CH2), 17.2 (49/57-CH3), -1.4 (26/27/28/32/33/34-CH3); 
IR (neat, νmax, cm-1) 3681 (brw), 2967 (m), 2844 (m), 1718 (m), 1637 (m), 1508 (w), 
1455 (m), 1429 (m), 1055 (s), 1033 (s), 1015 (s), 838 (m); HRMS (ESI): calcd. for 
C56H81N8O6Si2S [M+H]+ 1081.5431, found 1081.5449; [α]D -69.1 ° (c 1.2 in CHCl3, T 
22.7 °C) 
 
B. General Procedure for C-H activated cross coupling and subsequent SEM-
removal 
The appropriate aryl dibromide (0.10 mmol), (S)-tert-butyl 2-(1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (7, 100 mg, 
0.24 mmol), pivalic acid (6.1 mg, 0.06 mmol), K2CO3 (41 mg, 0.30 mmol) and 
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Pd(ddpf)Cl2 (7.3 mg, 0.01 mmol) were placed in a sealed reaction vial. The reaction vial 
was placed under reduced pressure then purged with nitrogen, repeating the process 5 
times. The contents of the sealed vial were dissolved in dimethylacetamide (1 mL), and 
the solvent was deoxygenated by bubbling with nitrogen for 20 minutes. The solution 
was then irradiated in a microwave at 100 °C for 4 hours. The resulting solution was 
quenched with water (15 mL), and extracted with EtOAc (2 × 10 mL). The organic phase 
was washed with saturated sodium bicarbonate solution (2 × 15mL) water (2 × 15 mL), 
and brine (2 × 15 mL), before being concentrated under reduced pressure. The resulting 
solid material was then redissolved in dichloromethane (0.5 mL) before addition of 
trifluoroacetic acid (0.50 mL, 6.5 mmol). The solution was stirred under an inert 
atmosphere for 4 hours, before being diluted with dichloromethane (15 mL). The solution 
was then washed with saturated sodium bicarbonate solution (2 × 30 mL), with care taken 
to release any overpressure from gas formation. The organic phase was concentrated 
under reduced pressure to afford a solid which was purified by mass-directed auto 
purification. 
 
Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-([1,1'-biphenyl]-4,4'-diyl)bis(1H-imidazole-
5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate 
(10) 
 
1H NMR (500 MHz, CD3OD) 7.73 (4H, d, J = 8.1 Hz, 3/5/9/11-CH), 7.66 (4H, d, J = 8.1 
Hz, 2/6/8/12-CH), 7.37 (2H, s, 14/18-CH), 5.19 (2H, dd, J = 8.0, 6.3 Hz, 21/25-CH), 4.24 
(2H, d, J = 7.4 Hz, 30/38-CH), 4.05 – 3.95 (2H, m, 24/28-CHA), 3.92 – 3.84 (2H, m, 
24/28-CHB), 3.66 (6H, s, 33/41-CH3), 2.41 – 2.17 (6H, m, 22/26-CH2, 23/27-CHA), ), 2.11 
– 2.04 (4H, m, 23/27-CHA, 34/42-CH), 0.93 (12H, dd, J = 22.0, 6.8 Hz, 35/36/43/44-
CH3); 13C NMR (126 MHz, CD3OD) 172.0 (32/40-CO), 158.0 (15/19-C), 149.6 (32/40-
CO), 139.0 (4/10-C), 136.1 (17/13-C), 130.9 (1/7-C), 126.6 (2/6/8/12-CH), 125.0 
(3/5/9/11-CH), 116.2 (14/18-CH), 58.4 (21/25-CH), 54.8 (30/38-CH), 51.3 (33/41-CH3), 
47.4 (24/28-CH2), 30.9 (22/26-CH2), 30.1 (34/42-CH), 24.7 (23/27-CH2), 18.4 
(35/36/43/44-CH3), 17.0 (35/36/43/44-CH3); IR (neat, νmax, cm-1) 2964 (w), 2875 (w), 
147 
 
 
1705 (s), 1632 (s), 1446 (s), 1393 (s), 1258 (w), 1035 (m), 829 (m), 773 (m); HRMS 
(ESI): calcd. for C40H51N8O6 [M+H]+ 739.3926, found 739.3937; [α]D -170.0 ° (c 0.6 in 
CHCl3, T 22.2 °C) 
 
Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-(1,4-phenylene)bis(1H-imidazole-5,2-
diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate 
(201) 
 
1H NMR (500 MHz, CD3OD) 7.88 (4H, s, 2/3/5/6-CH), 7.48 (2H, s, 8/12-CH), 5.29 – 
5.19 (2H, m, 15/19-CH), 4.29 – 4.17 (2H, m, 24/32-CH), 4.14 – 3.97 (2H, m, 18/22-CHA), 
3.93 – 3.77 (2H, m, 18/22-CHB), 3.66 (6H, s, 27/35-CH3), 2.60 – 2.46 (16/20-CHA, m, 
2H), 2.32 – 1.95 (8H, m, 16/20-CHB, 17/21-CH2, 28/36-CH), 0.96 – 0.85 (12H, m, 
29/30/37/38-CH3); 13C NMR (126 MHz, CD3OD) 172.7 (23/31-CO), 158.1 (9/13-C), 
149.4 (23/34-CO), 147.5 (7/11-C), 126.0 (1/4-C), 118.7 (2/3/5/6-CH), 115.3 (8/12-CH), 
58.5 (24/32-CH), 53.7 (15/19-CH), 53.2 (18/22-CH2), 51.4 (27/35-CH3), 29.8 (28/36-
CH), 24.9 (16/20-CH2), 18.4 (17/21-CH2), 16.7 (29/30/37/38-CH3); IR (neat, νmax, cm-1) 
3284 (brw), 2962 (w), 1711 (s), 1625 (s), 1521 (s), 1444 (s), 1370 (w), 1264 (s), 1192 
(m), 1098 (m), 1037 (m), 846 (m), 734 (s); HRMS (ESI): calcd. for C34H47N8O6 [M+H]+ 
663.3613, found 663.3608; [α]D -288.6 ° (c 0.3 in CHCl3, T 22.6 °C) 
 
Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-((E)-ethene-1,2-diylbis(4,1-
phenylene))bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-
oxobutane-2,1-diyl))dicarbamate (202) 
 
1H NMR (500 MHz, CD3OD) 8.16 (2H, s, 1/2-CH), 7.92 (4H, d, J = 8.4 Hz, 5/7/11/13-
CH), 7.82 (4H, d, J = 8.4 Hz, 4/8/10/14-CH), 7.66 (2H, s, 16/20-CH), 5.24 (2H, dd, J = 
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8.1, 6.2 Hz, 23/27-CH), 4.26 (2H, d, J = 7.3 Hz, 32/40-CH), 4.09 – 4.02 (2H, m, 26/30-
CHA), 3.97 – 3.81 (2H, m, 26/30-CHB), 3.67 (6H, s, 35/43-CH3), 2.52 – 2.41 (2H, m, 
24/28-CHA), 2.32 – 2.02 (8H, m, 24/28-CHB, 25/29-CH2, 36/44-CH), 0.98 – 0.86 (12H, 
m, 37/38/45/46-CH3); 13C NMR (126 MHz, CD3OD) 172.4 (31/39-CO), 163.2 (17/19-
C), 158.1 (15/19-C), 149.6 (34/42-CO), 133.0 (3/9-C), 128.5 (6/12-C), 125.0 (1/2-CH), 
123.7 (5/7/11/13-CH), 123.0 (4/8/10/14-CH), 115.8 (16/20-CH), 58.5 (23/27-CH), 54.4 
(32/40-CH), 51.4 (35/43-CH3), 47.5 (26/30-CH2), 30.9 (24/28-CH2), 30.0 (36/44-CH), 
24.8 (25/29-CH2), 18.4 (37/38/45/46-CH3), 16.9 (37/38/45/46-CH3); IR (neat, νmax, cm-
1) 2966 (w), 2876 (w), 1701 (s), 1631 (s), 1521 (m), 1443 (m), 1264 (w), 1201 (s), 1132 
(m), 1033 (w), 799 (w), 719 (m); HRMS (ESI): calcd. for C42H53N8O6 [M+H]+ 765.4083, 
found 765.4118; [α]D -538.3 ° (c 0.3 in CHCl3, T 22.6 °C) 
 
Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-(naphthalene-2,6-diyl)bis(1H-imidazole-5,2-
diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate 
(203) 
 
1H NMR (500 MHz, CD3OD) 7.64 – 7.54 (4H, m, 1/4/6/9-CH), 7.41 (2H, s, 12/16-CH), 
7.20 – 7.13 (2H, m, 3/8-CH), 5.19 (2H, t, J = 7.0 Hz, 19/23-CH), 4.24 (2H, d, J = 7.3 Hz, 
28/36-CH), 4.06 – 3.97 (2H, m, 22/26-CHA), 3.92 – 3.83 (2H, m, 22/26-CHB), 3.66 (6H, 
s, 31/39-CH3), 2.43 – 2.32 (2H, m, 20/24-CHA), 2.31 – 1.97 (8H, m, 20/24-CHB, 21/25-
CH2, 32/40-CH), 0.97 – 0.85 (12H, m, 33/34/41/42-CH3); 13C NMR (126 MHz, CD3OD) 
172.2 (27/35-CO), 158.0 (13/17-C), 149.4 (30/38-CO), 136.7 (5/10-C), 135.6 (11/15-C), 
130.0 (2/7-C), 127.8 (3/8-CH), 126.7 (1/6-CH), 124.8 (4/9-CH), 115.9 (12/16-CH), 58.4 
(19/23-CH), 54.6 (28/36-CH), 51.4 (31/39-CH3), 47.5 (22/26-CH2), 30.9 (20/24-CH2), 
30.1 (32/40-CH), 24.7 (21/25-CH2), 18.4 (33/34/41/42-CH3), 16.9 (33/34/41/42-CH3); 
IR (neat, νmax, cm-1) 3287 (brw), 2962 (w), 2875 (w), 1711 (s), 1628 (w), 1517 (m) 1443 
(m), 1370 (w), 1264 (m), 1181 (m), 1131 (m), 1035 (m), 947 (w), 841 (m), 775 (m), 732 
(s); HRMS (ESI): calcd. for C38H49N8O6 [M+H]+ 713.3770, found 713.3779; [α]D -222.1 
° (c 0.6 in CHCl3, T 22.1 °C) 
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Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-(oxybis(4,1-phenylene))bis(1H-imidazole-5,2-
diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate 
(204) 
 
1H NMR (500 MHz, CD3OD) 8.13 (2H, s, 20/36-NH), 7.68 (4H, d, J = 8.0 Hz, 3/5/9/11-
CH), 7.48 (2H, s, 14/18-CH), 7.08 (4H, d, J = 8.0 Hz, 2/6/8/12-CH), 5.20 (2H, t, J = 7.1 
Hz, 21/25-CH), 4.24 (2H, d, J = 7.2 Hz, 27/35-CH), 4.09 – 3.99 (2H, m, 24/28-CHA), 3.92 
– 3.82 (2H, m, 24/28-CHB), 3.66 (6H, s, 30/38-CH3), 2.50 – 2.35 (2H, m, 22/26-CHA), 
2.31 – 1.97 (8H, m, 22/26-CHB, 23/27-CH2, 31/39-CH)), 0.97 – 0.87 (12H, m, 
32/33/40/41-CH3); 13C NMR (126 MHz, CD3OD) 172.3 (29/34-CO), 163.5 (15/19-C), 
158.1 (29/37-CO), 156.9 (1/7-C), 149.1 (13/17-C), 134.9 (4/10-C), 126.6 (3/5/9/11-CH), 
118.9 (2/6/8/12-CH), 114.8 (14/16-CH), 58.4 (21/25-CH), 54.3 (27/35-CH), 51.4 (30/38-
CH3), 47.5 (24/28-CH2), 30.9 (22/26-CH2), 30.0 (31/39-CH), 24.8 (23/27-CH2), 18.4 
(32/33/40/41-CH3), 16.8 (32/33/40/41-CH3); IR (neat, νmax, cm-1) 3294 (brw), 2962 (w), 
2875 (w), 1712 (m), 1627 (s), 1497 (m), 1424 (m), 1237 (s), 1199 (m), 1198 9m), 1130 
(m), 1033 (m), 798 (m), 733 (s), 701 (m); HRMS (ESI): calcd. for C40H51N8O7 [M+H]+ 
755.3875, found 755.3882; [α]D -114.3 ° (c 0.6 in CHCl3, T 22.0 °C) 
 
Methyl N‐[(2S)‐1‐[(2S)‐2‐{5‐[4‐(5‐{2‐[(2S)‐1‐[(2S)‐2‐[(methoxycarbonyl)amino]‐3‐
methylbutanoyl]pyrrolidin‐2‐yl]‐1H‐imidazol‐5‐yl}‐1,3‐benzoxazol‐2‐yl)phenyl]‐
1H‐imidazol‐2‐yl}pyrrolidin‐1‐yl]‐3‐methyl‐1‐oxobutan‐2‐yl]carbamate (205) 
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1H NMR (500 MHz, CD3OD) δ 8.33 – 8.20 (2H, m, 10/12-CH), 8.02 (1H, d, J = 8.3 Hz, 
6-CH), 7.94 – 7.84 (2H, m, 9/13-CH), 7.83 – 7.70 (2H, m, 3-CH, 4-CH), 7.72 – 7.59 (2H, 
m, 15-CH, 19-CH), 5.27 – 5.18 (2H, m, 22/26-CH), 4.25 (2H, dd, J = 7.3, 7.3 Hz, 31/39-
CH), 4.13 – 3.98 (2H, m, 25/40-CHH), 3.95 – 3.84 (2H, m, 25/40-CHH), 3.66 (6H, s, 
34/42-CH3), 2.57 – 2.35 (2H, m, 23/27-CHH), 2.32 – 2.02 (8H, m, 23/27-CHH, 24/28-
CH2, 35/43-CH), 0.99 – 0.89 (12H, m, 36/37/44/45-CH3); 13C NMR (126 MHz, CD3OD 
3) δ 173.7 (30/38-CO), 165.0 (1-C), 159.5 (33/41-CO), 152.9 (2-C), 152.4 (16/20-C), 
152.0 (7-C), 151.5 (14/18-C), 150.3 (5-C), 136.6 (8-C), 136.0 (11-C), 129.3 (10/12-CH), 
126.5 (9/13-CH), 124.5 (4-CH), 118.0 (19-CH), 117.5 (6-CH), 116.4 (15-CH), 112.5 (3-
CH), 59.9 (31/39-CH), 55.4 (22/44-CH), 52.8 (34/42-CH3), 49.0 (25/40-CH2), 32.4 
(24/28-CH2), 31.5 (35/43-CH), 26.3 (23/27-CH2), 19.8 (36/44-CH3), 18.3 (37/45-CH3); 
IR (neat, νmax, cm-1) 3284 (brw), 2966 (w), 2875 (w), 1699 (m), 1628 (s), 1517 (m), 1424 
(m), 1368 (w), 1265 (m), 1180 (s), 1132 (s), 1039 (m), 825 (m), 798 (m), 732 (s); HRMS 
(ESI): calcd. for C41H50N9O7 [M+H]+ 780.3828, found 780.3804; [α]D -446.6 ° (c 0.3 in 
CHCl3, T 22.4 °C) 
 
Methyl N‐[(2S)‐1‐[(2S)‐2‐(5‐{4‐[(4‐{2‐[(2S)‐1‐[(2S)‐2‐[(methoxycarbonyl)amino]‐3‐
methylbutanoyl]pyrrolidin‐2‐yl]‐1H‐imidazol‐5‐yl}phenyl)(methyl)carbamoyl] 
phenyl}‐1H‐imidazol‐2‐yl)pyrrolidin‐1‐yl]‐3‐methyl‐1‐oxobutan‐2‐yl]carbamate 
(206) 
 
1H NMR (500 MHz, CDCl3) δ 7.51 – 7.39 (m, 2H, 5/7-CH), 7.35 – 7.26 (m, 2H, 10/14-
CH), 7.26 – 7.20 (m, 2H, 4/8-CH), 7.15 – 7.04 (m, 2H, 16/20-CH), 6.98 (d, J = 8.2 Hz, 
2H, 11/13-CH), 5.58 (s, 2H, 33/41-NH), 5.18 (s, 2H, 23/27-CH), 4.30 (dd, J = 8.1, 8.1 
Hz, 2H, 32/40-CH), 3.90 – 3.77 (m, 2H, 26/30-CHH), 3.74 – 3.63 (m, 8H, 26/30-CHH, 
35/43-CH3), 3.46 (s, 3H, 1-CH3), 2.35 – 2.11 (m, 4H, 24/25/28/29-CHH), 2.09 – 1.85 (m, 
6H, 24/25/28/29-CHH, 36/44-CH), 0.88 – 0.77 (m, 12H, 37/38/45/46-CH3); 13C NMR 
(100 MHz, CDCl3) δ 172.6 (31/39-CO), 170.2 (2-CO), 157.1 (34/42-CNO), 148.5 (17/21-
CN2), 143.6 (9-C), 138.5 (15/19-CN), 134.3 (3-C), 132.3 (6-C), 129.3 (4/8-CH), 127.1 
(11/13-CH), 125.5 (5/7-CH), 124.6 (12-C), 123.9 (10/14-CH), 115.3 (16/20-CH), 57.7 
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(32/40-CH), 54.2 (23/27-CH), 52.3 (35/43-CH3), 47.8 (26/30-CH2), 38.4 (1-CH3), 30.8 
(36/44-CH), 28.4 (24/28-CH2), 25.2 (25/29-CH2), 19.2 (38/46-CH3), 17.437/45-CH3); IR 
(neat, νmax, cm-1) 3227 (brw), 2958 (w), 1698 (s), 1630 (s), 1532 (m), 1445 (m), 1396 (m), 
1203 (m), 1137 (m), 1038 (w), 847 (w); HRMS (ESI): calcd. for C41H50N9O7 [M+H]+ 
796.4141, found 796.4240; [α]D -243.3 ° (c 0.6 in CHCl3, T 22.4 °C) 
 
(S)-2-(Methoxycarbonylamino)-3-methylbutanoic acid (17)203 
 
To a stirred solution of ʟ-valine (20.0 g, 171 mmol) in water (150 mL) and toluene (150 
mL) was added NaOH (13.7 g, 341 mmol). The solution was cooled to 0 °C, and methyl 
chloroformate (14.5 mL, 188 mmol) was added dropwise over 10 minutes. The solution 
was allowed to warm to room temperature and stirred for 16 hours. The solution was 
diluted with EtOAc (200 mL) to dissolve any precipitate, and the organic phase was 
separated. The aqueous phase was acidified with aqueous HCl (1 M, 100 mL), and 
extracted with EtOAc (2 × 200 mL). The combined organic phases were concentrated 
under reduced pressure, and the resultant white paste dissolved in warm water (500 mL). 
The solution was freeze dried, and the resulting white powder dried under reduced 
pressure at 70 °C for 16 hours to give the product as a white powder (25.7 g, 84%). 
 
1H NMR (500 MHz, DMSO-d6) 12.54 (1H, brs, 1-COOH), 7.27 (1H, d J = 8.4 Hz, 6-
NH), 3.84 (1H, dd, J = 8.4, 5.9 Hz, 3-CH), 3.53 (3H, s, 8-CH3), 2.08 – 1.96 (1H, m, 4-
CH), 0.97 – 0.77 (6H, m, 5-CH(CH3)2); 13C NMR (126 MHz, DMSO-d6) 173.7 (2-CO), 
157.4 (7-CO), 60.0 (3-CH), 51.8 (8-CH3), 30.0 (4-CH), 19.6 (5-CH(CH3)2), 18.4 (5-
CH(CH3)2); IR (neat, νmax, cm-1) 3397 (m), 2965 (m), 1732 (s), 1664 (s), 1551 (s), 1395 
(m), 1306 (s), 1255 (s), 1179 (s), 1104 (s), 1019 (s), 892 (s), 778 (s), 735 (m); HRMS 
(ESI): calcd. for C7H13NNaO4 [M+Na]+ 198.0737, found 198.0738 
 
(S)-2-(Pyrrolidin-2-yl)-1H-imidazole (19)203 
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To a solution of (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate (42, 10.0 g, 
42.1 mmol) in dichloromethane (200 mL) at 0 °C, was added dropwise trifluoroacetic 
acid (24 mL, 316 mmol). The solution was allowed to warm to room temperature, and 
stirred for a further 16 hours, before being concentrated under reduced pressure. The 
crude material was then purified by adsorption onto an ion exchange column in methanol 
(SCX-2, 2 × 50 g silica), followed by elution by ammonia in methanol (2.0 M), and 
concentration under reduced pressure to give amine 19 as a brown oil (5.6 g, 97%). 
 
1H NMR (500 MHz, CDCl3) 7.44 (1H, s, 9-NH), 6.89 (2H, s, 6,7-CH), 4.25 (1H, t, J = 
7.4 Hz, 1-CH), 3.02-2.95 (1H, m, 4-CHA), 2.93-2.86 (1H, m, 4-CHB), 2.17-2.06 (1H, m, 
2-CHA), 2.03-1.94 (1H, m, 2-CHB), 1.86-1.69 (2H, m, 3-CH2); 13C NMR (126 MHz, 
CDCl3) 150.1 (5-C), 121.7 (6,7-CH), 56.1 (1-CH), 46.5 (4-CH2), 32.0 (2-CH2), 25.5 (3-
CH2); IR (neat, νmax, cm-1) 2971 (brm), 1648 (m), 1531 (m), 1408 (s), 1342 (m), 1065 
(m), 748 (s); HRMS (ESI): calcd. for C7H12N3 [M+H]+ 138.1026, found 138.1026 
 
Methyl (S)-1-((S)-2-(1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-
ylcarbamate (38) 
 
To a solution of (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (17, 1.25 g, 6.98 
mmol) in dichloromethane (20 mL) and a drop of dimethylformamide at 0 °C was added 
dropwise oxalyl chloride (0.67 mL, 7.0 mmol). The solution was allowed to warm to 
room temperature, and stirred for 3 hours. This solution was then added dropwise to a 
solution of (S)-2-(pyrrolidin-2-yl)-1H-imidazole 19 (870 mg, 6.35 mmol) and pyridine 
(1.9 mL, 19 mmol) in dichloromethane (30 mL) at 0 °C. The solution was allowed to 
warm to room temperature and stir for 16 hours. The solution was then neutralized by the 
slow addition of ammonia (2 M) in isopropanol (20 mL) dropwise. The resultant 
precipitate was removed by vacuum filtration, and the filtrate was concentrated under 
reduced pressure to give a brown solid, which was lyophilized from ice to remove residual 
water and pyridine, and afforded the product as a brown, glass foam (1.82 g, 97%). 
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1H NMR (500 MHz, CDCl3) 11.50 (1H, s, 8-NH), 7.21 (1H, d, J = 8.4 Hz, 14-NH), 6.92 
(1H, s, 6-CH), 6.72 (1H, s, 7-CH), 5.05 (1H, dd, J = 7.7, 3.5 Hz, 1-CH), 4.04-3.98 (1H, 
m, 10-CH), 3.80-3.64 (2H, m, 4-CH2), 3.53 (3H, s, 16-CH3), 2.19-1.80 (5H, m, 2-CH2, 3-
CH2, 11-CH), 0.90-0.75 (6H, m, 12-CH3, 13-CH3); 13C NMR (500 MHz, CDCl3) 170.8 
(9-CO), 157.2 (15-CO), 148.9 (5-CH), 127.3 (6-CH), 115.9 (7-CH), 58.4 (10-CH), 54.4 
(1-CH), 51.9 (16-CH3), 47.2 (4-CH2), 30.9 (3-CH2), 30.2 (11-CH), 24.7 (2.CH2), 19.4 
(12-CH3, 13-CH3), 18.9 (12-CH3, 13-CH3); IR (neat, νmax, cm-1) 3151 (brw), 2970 (w), 
1703 (m), 1632 (m), 1520 (m), 1446 (m), 1362 (m), 1520 (m), 1446 (m), 1362 (m), 1261 
(m), 1183 (m), 1099 (m), 835 (s), 741 (s); HRMS (ESI): calcd. for C14H23N4O3 [M+H]+ 
295.1765, found 295.1761 
 
(S)-tert-Butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate (40)206  
 
To a solution of (S)-1-(3,3-dimethylbutanoyl)pyrrolidine-2-carboxylic acid 37 (20.0 g, 
92.9 mmol) in THF (200 mL) at -10 °C was added dropwise BH3.SMe2 solution (2.0 M 
in THF, 60.4 mL). The solution was allowed to warm to room temperature and stirred for 
a further 16 hours. After cooling to 0 °C, MeOH (80 mL) was added dropwise to quench 
the reaction. The solution was then concentrated under reduced pressure, and the resulting 
yellow oil was dissolved in EtOAc (150 mL), washed with saturated aqueous NaHCO3 
solution (2 × 100 mL) and brine (2 × 100mL). The organic phase was then dried over 
magnesium sulfate and concentrated under reduced pressure, to give alcohol 40 as a pale 
yellow oil (18.2 g, 98%). 
 
1H NMR (500 MHz, CDCl3) 4.69 (1H, s, 9-OH), 3.91 (1H, s, 1-CH), 3.66 (2H, s, 8-CH2), 
3.44-3.35 (1H, m, 4-CHA), 3.31-3.22 (1H, m, 4-CHB), 2.00-1.90 (1H, m, 2-CHA), 1.88-
1.68 (2H, m, 3- CH2), 1.58-1.48 (1H, m, 2-CHB), 1.42 (9H, s, 7-CH3); 13C NMR (126 
MHz, CDCl3) 156.9 (5-CO), 80.0 (6-C(CH3)3), 67.3 (8-CH2), 60.1 (1-CH), 47.5 (4-CH2), 
28.6 (2-CH2), 28.4 (7-C(CH3)3) 23.7 (3-CH2). IR (neat, νmax, cm-1) 3405 (brm), 2974 (m), 
2877 (w), 1666 (s), 1391 (s), 1252 (w), 1163 (s), 1105 (m), 1049 (m), 772 (m); HRMS 
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(ESI): calcd. for C10H19NNaO3 [M+Na]+ 224.1257, found 224.1258; [α]D -49.9 ° (c 1.3 
in CHCl3, T 21.0 °C) 
 
(S)-tert-Butyl 2-formylpyrrolidine-1-carboxylate (41)206 
 
Swern Oxidation: 
To a solution of oxalyl chloride (8 mL, 92.6 mmol) in dry dichloromethane (150 mL) 
at -78 °C under nitrogen was added dropwise DMSO (13.2 mL, 185.2 mmol). To this 
solution was added dropwise (S)-tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate 
40 (17.4 g, 84.2 mmol), and allowed to stir for 30 minutes. Triethylamine (60 mL, 421 
mmol) was added to the solution dropwise over 30 minutes, before being allowed to warm 
to room temperature. The reaction was then quenched with deionized water (150 mL), 
and stirred for a further 15 minutes. The layers were allowed to separate, before extracting 
the aqueous phase with dichloromethane (150 mL). The combined organic phases were 
washed with saturated aqueous NaHCO3 solution (2 × 150 mL) and brine (2 × 150 mL), 
before being dried over magnesium sulfate and concentrated under reduced pressure to 
yield aldehyde 41 as a pale orange oil (16.7 g, 99% yield). 
 
Aerobic Oxidation: 
To a stirred solution of  tert-butyl (2S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 40 
(6.06 g, 30.1 mmol)  in acetonitrile (100 mL) at was added (2,2,6,6-tetramethylpiperidin-
1-yl)oxidanyl (TEMPO, 235 mg, 1.51 mmol), 2,2'-bipyridyl (235 mg, 1.51 mmol) , 
and  tetrakisacetonitrile copper(I) triflate (567 mg, 1.51 mmol).  1-methylimidazole (0.24 
mL, 3.01 mmol) was then added to the solution, and stirred for 36 hours in an open flask, 
replacing solvent as it evaporated. The solution was then diluted with water (150 mL) and 
extracted with diethyl ether (3 u 150 mL). The combined organic phases were washed 
with brine (2 u 100 mL) and dried over MgSO4, before being concentrated to dryness 
under reduced pressure. The crude material was then passed through a silica plug (approx. 
30 g silica), eluted with a 1:1 mixture of petrol ether:diethyl ether, and concentrated under 
reduced pressure to give the product as a light orange oil (5.40 g, 90%). 
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1H NMR (500 MHz, CDCl3) 9.53 (0.4H, s, 8-CHO), 9.44 (0.6H, s, 8-CHO), 4.17 (0.4H, 
t, J = 5.6 Hz, 1- CH), 4.03 (0.6H, t, J = 5.6 Hz, 1- CH), 3.63-3.37 (2H, m, 4-CH2), 2.15-
1.73 (4H, m, 2-CH2, 3-CH2), 1.49-1.36 (9H, m, 7-C(CH3)3); 13C NMR (126 MHz, CDCl3) 
200.5 (8-CHO), 200.3 (8-CHO), 154.9 (5-CO), 153.9 (5-CO), 80.5 (7-C(CH3)3), 80.1 (7-
C(CH3)3), 65.0 (1-CH), 64.8 (1-CH), 46.8 (4-CH2), 46.7 (4-CH2), 28.2 (C(CH3)3), 27.9 
(2-CH2), 26.7 (2-CH2), 24.6 (4-CH2), 23.9 (4-CH2); IR (neat, νmax, cm-1) 2976 (m), 2880 
(w), 1735 (m), (1687 (s), 1390 (s), 1256 (m), 1160 (s), 1119 (m), 911 (w), 858 (w), 772 
(m); [α]D -94.5 ° (c 0.6 in CHCl3, T 24.2 °C)  
 
(S)-tert-Butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate (42)203 
 
To a solution of (S)-tert-butyl 2-formylpyrrolidine-1-carboxylate 41 (16.7 g, 84.2 mmol) 
in methanol (150 mL) and glyoxal solution (40 % wt. in water, 35.6 mL, 353.0 mmol) at 
0 °C was added dropwise ammonia solution (35 % wt. in water, 31.0 mL, 555 mmol). 
The solution was allowed to warm to room temperature and stirred for 15 hours. The 
solution was concentrated under reduced pressure, and the resultant residue was extracted 
with EtOAc (2 × 150 mL). Any precipitate was removed by filtration, and the organic 
phase was washed with concentrated aqueous NaHCO3 solution (2 × 100 mL), and brine 
(2 × 100 mL). The solution was then dried over magnesium sulfate and concentrated 
under reduced pressure to give imidazole 42 as a brown solid (19.4 g, 97%).  
 
1H NMR (500 MHz, CDCl3) 6.95 (2H, s, 6/7-CH), 4.94 (1H, dd, J = 7.6, 2.6 Hz, 1-CH), 
3.43 - 3.34 (1H, m, 3-CH2), 2.95 - 2.88 (1H, m, 2-CHA), 2.17 - 2.08 (2H, m, 2-CHB, 4-
CHA), 1.95 (1H, ddd, J = 8.9, 6.0, 4.2 Hz, 4-CHB), 1.48 (9H, s, 10-C(CH3)3); 13C NMR 
(126 MHz, CDCl3) 156.4 (8-CO), 148.9 (5-NCNH), 80.2 (9-C(CH3)3), 53.9 (1-CH), 47.2 
(3-CH2), 28.5 (10-C(CH3)3), 28.1 (2-CH2), 24.8 (4-CH2); IR (neat, νmax, cm-1) 2977 (w), 
2877 (w), 1687 (s), 1390 (s), 1161 (s), 1101 (s), 966 (w), 890 (m), 760 (m), 694 (w); 
HRMS (ESI): calcd. for C12H20N3O2 [M+H]+ 238.1550, found 238.1551; [α]D -159.4 ° 
(c 1.4 in CHCl3, T 24.6 °C) 
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(S)-tert-Butyl 2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-
1-carboxylate (43)216 
 
To a solution of (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate (42, 2.50 g, 
10.5 mmol) in dry THF (100 mL) at 0 °C under an atmosphere of nitrogen was added 
portion-wise NaH (60% in mineral oil, 0.50 g, 12 mmol), and stirred for one hour. 
2-(Trimethylsilyl)ethoxymethyl chloride (2.1 mL, 12 mmol) was added to the solution 
dropwise, which was then allowed to warm to room temperature and stir for a further 
22 hours. The resulting solution was quenched with deionized water (150 mL) and 
extracted with EtOAc (2 × 150 mL). The combined organic phases were washed with 
water (150 mL), and brine (2 × 150 mL), before being dried over MgSO4 and concentrated 
under reduced pressure to give a brown oil. The crude material was purified by flash 
chromatography (50 g silica, EtOAc:Pet. Ether, 25% to 100%) to give the protected 
imidazole 43 as a pale brown oil (2.61 g, 67%).  
 
1H NMR (500 MHz, CDCl3) 7.18 - 7.09 (1H, m, 7-CH), 6.78 (1H, d, J = 5.7 Hz, 6-CH), 
5.60 (0.4H, d, J = 10.9 Hz, 8-CH2), 5.37 (0.6H, d, J = 10.9 Hz, 8-CH2), 5.25 (1H, d, J = 
10.9 Hz, 8-CH2), 4.97 - 4.82 (1H, m, CH), 3.50 - 3.32 (4H, m, 4-CH2, 12-CH2), 2.28 - 
2.02 (2H, m, 2-CHA, 3-CHA), 1.90 - 1.75 (2H, m, 2-CHB, 3-CHB), 1.36 (4H, s, 11-CH3), 
1.12 (5H, s, 11-CH3), 0.91 – 0.77 (2H, m, 13-CH2), -0.04 (9H, s, 14-CH3); 13C NMR (126 
MHz, CDCl3) 153.5 (9-CO), 150.1 (5-C), 126.9 (6-CH), 120.4 (7-CH), 78.5 (10-C), 74.4 
(8-CH2), 65.5 (12-CH2), 52.5 (1-CH), 46.7 (4-CH), 32.8 (3-CH2), 28.4 (11-CH3), 23.5 (2-
CH3), 17.7 (13-CH2), -0.95 (14-CH3); IR (neat, νmax, cm-1) 2975 (brw), 1683 (s), 1478 
(w), 1386 (s), 1248 (m), 1159 (m), 1103 (s), 986 (w), 913 (m), 883 (s), 761 (m), 729 (m), 
697 (m), 664 (w). 
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Methyl (S)-3-methyl-1-oxo-1-((S)-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-
imidazol-2-yl)pyrrolidin-1-yl)butan-2-ylcarbamate (44) 
 
To a stirred suspension of NaH (305 mg, 7.63 mmol) in dry THF (100 mL) at 0 °C, was 
added dropwise a solution of methyl (S)-1-((S)-2-(1H-imidazol-2-yl)pyrrolidin-1-yl)-3-
methyl-1-oxobutan-2-ylcarbamate (38, 1.35 g, 4.54 mmol) in dry THF (20 mL), and the 
resulting solution was allowed to stir for one hour. To this solution was added dropwise 
2-(trimethylsilyl)ethoxymethyl chloride (1.35 mL, 7.63 mmol) in dry THF (5 mL), before 
warming to room temperature and stirring for 16 hours. The reaction was quenched with 
deionized water (100 mL), and extracted with EtOAc (2 × 100 mL). The combined 
organic phases were washed with water (100 mL) and brine (2 × 100 mL), before being 
dried over MgSO4 and concentrated under reduced pressure to give an orange oil (2.03 
g). The crude material was purified by flash chromatography (25 g silica, 
EtOAc:petroleum ether, 30% to 100%), to give protected imidazole 44 (0.91 g, 47%) as 
a pale brown oil. 
 
1H NMR (500 MHz, DMSO-d6) 7.17 (1H, s, 16-NH), 7.10 (1H, d, J = 1.2 Hz, 7-CH), 
6.77 (1H, d, J = 1.2 Hz, 6-CH), 5.71 (1H, d, J = 10.9 Hz, 8-CHA), 5.24 (1H, d, J = 10.9 
Hz, 8-CHB), 5.11 (1H, dd, J = 8.2, 3.8 Hz, 1-CH), 3.99 (1H, dd, J = 8.4, 8.4 Hz, 13-CH), 
3.88 - 3.80 (1H, m, 4-CHA), 3.74 – 3.66 (1H, m, 4-CHB), 3.56 - 3.45 (5H, m, 9-CH2, 18-
CH3), 2.37 - 2.27 (1H, m, 3-CHA), 2.14 - 2.05 (1H, m, 2-CHA), 1.98 - 1.88 (2H, m, 2-
CHA, 3-CHB), 1.84 - 1.73 (1H, m, 14-CH), 0.92 - 0.69 (8H, m, 10-CH2, 15-CH3), -0.04 
(9H, s, 11-CH3); 13C NMR (126 MHz, DMSO d6) 170.4 (12-CO), 157.2 (17-CO), 149.3 
(5-C), 127.0 (6-CH), 120.3 (7-CH), 74.6 (8-CH2), 65.4 (9-CH2), 58.3 (13-CH), 51.9 (1-
CH), 51.8 (18-CH3), 47.2 (4-CH2), 31.5 (2-CH2), 30.3 (14-CH), 24.9 (3-CH2), 19.1 (15-
CH3), 17.7 (10-CH2), -0.9 (11-CH3); IR (neat, νmax, cm-1) 3261 (w), 2955 (w), 1716 (s), 
1619 (s), 1522 (m), 1444 (m), 1248 (m), 1091 (s), 1033 (m), 834 (s), 725 (m); HRMS 
(ESI): calcd. for C20H36N4NaO4 [M+H]+ 447.2398, found 447.2395; [α]D 32.1 (c 0.6 in 
CHCl3, T 20.5 °C). 
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(2S,2'S)-tert-Butyl 2,2'-(5,5'-(biphenyl-4,4'-diyl)bis(1-((2-(trimethylsilyl)ethoxy)-
methyl)-1H-imidazole-5,2-diyl))dipyrrolidine-1-carboxylate (45) 
 
4,4'-Dibromobiphenyl (18, 178 mg, 0.57 mmol), (S)-tert-butyl 2-(1-((2-
(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate (43, 500 mg, 
1.36 mmol), pivalic acid (35 mg, 0.34 mmol), K2CO3 (236 mg, 1.71 mmol) and 
Pd(ddpf)Cl2 (42 mg, 0.057 mmol) were placed in a sealed reaction vial. The reaction vial 
was placed under reduced pressure then purged with nitrogen, repeating the process 5 
times. The content of the sealed vial was dissolved in dimethylacetamide (5 mL), and the 
solvent was deoxygenated by bubbling with nitrogen for 20 minutes. The solution was 
then irradiated in a microwave reactor at 100 °C for 4 hours. The resulting solution was 
quenched with water (50 mL), and extracted with EtOAc (2 × 35 mL). The organic phase 
was washed with brine (3 × 50 mL), then passed through a silica plug, eluted with 
MeOH:CH2Cl2 (1:9). The filtrate was concentrated under reduced pressure to give a dark 
brown oil (0.62 g). The crude material was purified by flash chromatography (25 g silica, 
MeOH:CH2Cl2, 1% to 8%) to give compound 45 as a brown solid (382 mg, 76%). 
 
1H NMR (500 MHz, CDCl3) 7.75 - 7.63 (4H, m, 3-CH), 7.59 - 7.47 (4H, m, 2-CH), 7.13 
- 7.05 (2H, m, 6-CH), 5.75 (1H, d, J = 10.8 Hz, 8-CH2), 5.38 (1H, d, J = 10.8 Hz, 8-CH2), 
5.25 - 5.18 (2H, m, 8-CH2), 5.18 - 4.84 (2H, m, 12-CH), 3.83 - 3.35 (8H, m, 9-CH2, 15-
CH2), 2.54 - 1.82 (8H, m, 13-CH2, 14-CH2), 1.42 (10H, s, 18-CH3), 1.24 (8H, s, 18-CH3), 
0.99 - 0.79 (4H, m, 10-CH2), -0.01 (18, s, 11-CH3); 13C NMR (126 MHz, CDCl3) 154.6 
(16-CO), 151.5 (7-C), 139.8 (1-C), 139.5 (5-C), 132.8 (4-C), 129.5 (2-CH), 127.1 (3-
CH), 126.7 (6-CH), 79.4 (17-C), 72.3 (8-CH2), 65.6 (9-CH2), 52.7 (12-CH), 46.8 (15-
CH2), 32.4 (14-CH2), 28.5 (18-CH3), 24.0 (13-CH2), 17.9 (10-CH2), -1.44 (11-CH3); IR 
(neat, νmax, cm-1) 2951 (brw), 1697 (s), 1390 (s), 1248 (m), 1163 (m), 1079 (s), 832 (s), 
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761 (m), 694 (m); HRMS (ESI): calcd. for C48H73N6O6Si2 [M+H]+ 885.5125, found 
885.5125 
 
1,2-Bis(4-Bromophenyl)ethyne (53)222 
 
To a solution of 1-bromo-4-iodo benzene 68 (1.0 g, 3.5 mmol), Pd(PPh3)Cl2 (74 mg, 
0.21 mmol), and CuI (67 mg, 0.35 mmol) in benzene under N2 gas, was added dropwise 
DBU (3.2 mL, 21 mmol), trimethylsilyl acetylene (0.25 mL, 1.8 mmol), and H2O (25 μL, 
1.41 mmol). The solution was stirred at room temperature for 20 hours, before being 
diluted with water (75 mL) and diethyl ether (75 mL). The phases were separated, and 
the organic phase was washed with aqueous HCl (1M, 3 × 50 mL), before being dried 
over MgSO4, and concentrated under reduced pressure. The crude material was purified 
by flash chromatography (10 g silica, petroleum ether, 100%), to give the product as a 
pale yellow solid (0.26 g, 44%). 
 
1H NMR (500 MHz, CDCl3) 7.50 (4H, d, J = 8.4 Hz, 4-CH), 7.39 (4H, d, J = 8.4 Hz, 3-
CH); 13C NMR (126 MHz, CDCl3) 133.0 (3-CH), 131.7 (4-CH), 122.8 (2-C), 121.9 (5-
C), 89.4 (1-C). 
 
2,7-Dibromo-9H-carbazole (54)333 
 
 A stirred solution of 4-bromo-1-(4-bromophenyl)-2-nitro-benzene (77, 1.5 g, 4.2 mmol) 
and triphenylphosphine (5.00 g, 19.1 mmol) in 1,2-dichlorobenzene (10 mL) was 
refluxed at  180 °C for 20 hours. The solution was allowed to cool to room temperature, 
and then concentrated under reduced pressure to form a dark oil. This was then washed 
with a mixture of ethyl acetate:petroleum ether (1:9, 100 mL) under stirring for 3 hours, 
forming a dark precipitate, which was removed by filtration. The filtrate was concentrated 
under reduced pressure, and purified by column chromatography (0 to 10% ethyl acetate: 
petroleum ether (40-60°C), followed by crystallization from chloroform, to give the 
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product as a white solid (278 mg, 20%). 
 
1H NMR (500 MHz, DMSO-d6) 8.06 (1H, s, 1-NH), 7.88 (2H, d, J = 8.2 Hz, 6-CH, 9-
CH), 7.37 (2H, dd, J = 8.2 Hz, 1.9, 5-CH, 10-CH), 7.27 (2H, d, J = 1.9, 3-CH, 12-CH); 
13C NMR (126 MHz, DMSO-d6) 140.3 (2-C, 13-C), 123.3 (5-CH, 10-CH), 121.8 (4-CBr, 
11-CBr), 121.4 (6-CH, 9-CH), 119.7 (7-C, 8-C), 113.8 (3-CH, 12-CH). 
 
2,5-Bis(4-bromophenyl)-1H-pyrrole (55)334 
 
A stirred solution of 1,4-bis(4-bromophenyl)butane-1,4-dione (80, 500 mg, 1.28 mmol) 
and ammonium acetate (346 mg, 4.48 mmol) in acetic acid (10 mL) was allowed to reflux 
for 21 hours. The solution was then allowed to cool to room temperature, and 
concentrated under reduced pressure. The resulting brown solid was washed with 
concentrated aqueous potassium carbonate (30 mL), before being crystallized from acetic 
acid to give the product as a white, crystalline solid (301 mg, 62%). 
 
1H NMR (500 MHz, DMSO-d6) 11.34 (1H, s, 5-NH), 7.72 (4H, d, J = 8.1 Hz, 7-CH, 11-
CH, 13-CH, 17-CH), 7.55 (4H, d, J = 8.1, 8-CH, 10-CH, 14-CH, 16-CH), 6.65 (2H, s, 2-
CH, 3-CH); 13C NMR (126 MHz, DMSO-d6) 132.8 (1-C, 4-C), 132.0 (6-C, 12-C), 131.9 
(8-CH, 10-CH, 14-CH, 16-CH), 126.4 (7-CH, 11-CH, 14-CH, 16-CH), 119.0 (9-CBr, 15-
CBr), 109.0 (2-CH, 3-CH). 
 
4-Bromo-N-(4-bromophenyl)benzamide (56)335 
 
 A suspension of 4-bromobenzoic acid (1.00 g, 4.97 mmol) in thionyl chloride (5.0 mL, 
69 mmol) with a drop of DMF was heated under reflux under stirring. The solution was 
allowed to reflux for 2 hours, then concentrated under reduced pressure, to give a light 
orange oil, which solidified upon cooling to a crystalline solid (1.09 g) 
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To a stirred solution of 4-bromoaniline (777 mg, 4.52 mmol) and triethylamine (1.9 mL, 
13.6 mmol) in dichloromethane (30 mL) at 0 °C was added dropwise a solution of the 
crystalline solid produced in the first part of the experiment in dichloromethane (10 mL). 
After addition, the solution was allowed to warm to room temperature, and allowed to stir 
for a further three hours. The solution was then cooled to −78 °C, and the resulting white 
precipitate was collected by vacuum filtration, and washed with cold dichloromethane (2 
x 20 mL) to give the produce as a fine, white, crystalline powder (872 mg, 54%). 
 
1H NMR (500 MHz, DMSO-d6) 1H NMR (500 MHz, DMSO-d6) δ 10.40 (1H, s, 1-NH), 
7.90 (2H, d, J = 8.2 Hz, 4-CH), 7.75 (4H, d, J = 8.2 Hz, 5-CH, 8-CH), 7.53 (2H, d, J = 
8.2 Hz, 9-CH). 13C NMR (126 MHz, DMSO-d6) δ 165.1 (2-CO), 138.8 (7-C), 134.2 (3-
C), 131.9 (9-CH), 131.9 (5-CH), 130.3 (4-CH), 125.9 (6-CBr), 122.8 (8-CH), 116.0 (10-
CBr). 
 
2,7-Dibromo-9-methyl-9H-carbazole (57)336 
 
A solution of 2,7-dibromo-9H-carbazole (54, 200 mg, 0.62 mmol) in dry N,N-
dimethylformamide (2 mL) at room temperature was added dropwise to sodium hydride 
(32 mg, 0.8 mmol) previously washed with ether. After 15 minutes of 
stirring, iodomethane (48 μL, 0.77 mmol) was added to the solution, and allowed to stir 
for a further 18 hours. The solution was quenched with water (20 mL), and extracted with 
ethyl acetate (2 × 20 mL). The combined organic phases were then washed with brine (2 
× 20 mL), dried over magnesium sulfate, and concentrated under reduced pressure. The 
crude material was purified by flash column chromatography, eluted with petroleum ether 
and ethyl acetate (0 to 10 %), then recrystallized from a 1:1 mixture of petroleum ether 
and ethyl acetate, to give the product as a white, crystalline solid (101 mg, 48%). 
 
1H NMR (500 MHz, CDCl3) 7.88 (2H, d, J = 8.2 Hz, 9-CH, 6-CH), 7.54 (2H, d, J = 1.7 
Hz, 3-CH, 12-CH), 7.36 (2H, dd, J = 8.2, 1.7 Hz, 5-CH, 10-CH), 3.78 (3H, s, 1-CH3); 13C 
NMR (126 MHz, CDCl3) 141.9 (2-C, 13-C), 122.6 (6-CH, 9-CH), 121.4 (5-CH, 10-CH), 
121.2 (4-CBr, 11-CBr), 119.7 (7-C, 8-C), 111.9 (3-CH, 12-CH), 29.3 (1-CH3). 
162 
 
 
 
2,5-Bis(4-bromophenyl)-1-methyl-1H-pyrrole (58)337 
 
A solution of 2,5-bis(4-bromophenyl)-1H-pyrrole (55, 300 mg, 0.800 mmol), 
iodomethane (0.10 mL, 1.59 mmol), and potassium carbonate (330 mg, 2.39 mmol) in 
N,N-dimethylformamide (5 mL) was stirred under an inert atmosphere of nitrogen for 48 
hours. The solution was then quenched with water (20 mL), and extracted with ethyl 
acetate (2 × 20 mL). The combined organic phases were washed with brine (2 × 30 mL), 
dried over magnesium sulfate, and concentrated under reduced pressure. The crude solid 
was purified by flash column chromatography eluting with Petroleum Ether: Ethyl 
Acetate (0 to 10 %), then recrystallized from ethyl acetate, to give the product as a white, 
crystalline solid (146 mg, 47%). 
 
1H NMR (500 MHz, CDCl3) δ 7.56 (4H, d, J = 8.4 Hz, 5-CH), 7.34 (4H, d, J = 8.4 Hz, 
6-CH), 6.32 (2H, s, 3-CH), 3.58 (3H, s, 1-CH3); 13C NMR (126 MHz, CDCl3) δ 136.1 (2-
C), 132.2 (4-C), 131.6 (5-CH), 130.1 (6-CH), 121.0 (7-CBr), 109.2 (3-CH), 34.2 (1-CH3). 
 
4-Bromo-N-(4-bromophenyl)-N-methylbenzamide (59)338 
 
 A solution of 4-bromo-N-(4-bromophenyl)benzamide (56, 250 mg, 0.700 mmol)  in 
dry tetrahydrofuran (5 mL)  was added to  sodium hydride (42 mg, 1.1 mmol)   washed 
with ether. After 90 minutes, iodomethane (0.26 mL, 4.2 mmol) was added to the 
solution, and allowed to stir for a further 18 hours. The solution then was quenched with 
water (30 mL), and extracted with diethyl ether (2 × 30 mL). The combined organic phase 
was dried over magnesium sulfate and concentrated under reduced pressure to give the 
crude material as an oil. The crude material was purified by column chromatography, 
eluted with petroleum ether and ethyl acetate (10 to 30 %) to give the product as a 
crystalline solid (168 mg, 65%). 
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1H NMR (500 MHz, CDCl3) 7.40 − 7.31 (4H, m, 4-CH, 8-CH, 10-CH, 14-CH), 7.17 (2H, 
d, J = 8.4 Hz, 11-CH, 13-CH), 6.90 (2H, d, J = 8.6 Hz, 5-CH, 7-CH), 3.46 (3H, s, 15-
CH3); 13C NMR (126 MHz, CDCl3) 169.4 (2-CO), 143.7 (9-CN), 134.3 (3-C), 132.5 (10-
CH, 14-CH), 131.2 (11-CH, 13-CH), 130.3 (5-CH, 7-CH), 128.3 (4-CH, 8-CH), 124.4 
(6-CBr), 120.3 (12-CBr), 38.4 (15-CH3); IR (neat, νmax, cm-1) 3059 (w), 2925 (w), 1640 
(m), 1588 (m), 1484 (s), 1354 (m), 1296 (m), 1183 (m), 1068 (m), 1005 (m), 834 (s), 735 
(s), 688 (m); HRMS (ESI): calcd. for C14H12Br2NO [M+H]+ 369.9260, found 369.9276 
 
7-Bromo-3-(4-bromophenyl)quinoline-4-carboxylic acid (64)339 
 
A solution of 5-bromoisatin (2.00 g, 8.85 mmol), 1-(4-bromophenyl)ethanone (1.76 g, 
8.85 mmol) and potassium hydroxide (1.48 g, 26.6 mmol) in ethanol (100 mL) was heated 
at 60 °C for 15 hours. The solution was then concentrated under reduced pressure to give 
a red residue, which was redissolved in water (200 mL) and petroleum ether (150 mL). 
The precipitate was removed by filtration, and the filtrate separated. The aqueous phase 
was acidified with 1 M HCl, to give an orange precipitate. This precipitate was then 
triturated in a mixture of hot ethanol (90 mL) and water (10 mL) to give the product as a 
pale brown solid (621 mg, 17%). 
 
1H NMR (500 MHz, DMSO-d6) δ 9.05 (1H, s, 8-CH), 8.42 (1H, s, 6-CH), 8.18 (2H, d, J 
= 8.1 Hz, 11-CH), 8.01 (1H, d, J = 8.9 Hz, 3-CH), 7.89 (1H, d, J = 8.9 Hz, 2-CH), 7.73 
(2H, d, J = 8.1 Hz, 12-CH); 13C NMR (126 MHz, DMSO-d6) δ 155.6 (14-COOH), 147.4 
(7-C), 137.6 (4-C), 133.3 (2-CH), 132.4 (12-CH), 132.0 (3-CH), 129.6 (11-CH), 129.0 
(8-CH), 125.9 (1-CBr), 124.2 (13-CBr), 120.9 (5-C), 119.7 (6-CH). 
 
6-Bromo-2-(4-bromophenyl)quinazoline (65)340 
 
164 
 
 
6-Bromo-2-(4-bromophenyl)-3,4-dihydroquinazolin-1-ium chloride (86, 569 mg, 1.42 
mmol) was stirred in an emulsion of aqueous sodium hydroxide (30 mL) and 
dichloromethane (30 mL) at room temperature for 2 hours. The resulting solution was 
extracted with ethyl acetate (2 × 75 mL), and dried over magnesium sulfate, before being 
concentrated under reduced pressure. This residue was taken up in toluene (10 mL), and 
chloranil (350 mg, 1.42 mmol) was added. The solution was refluxed under an inert 
atmosphere for 18 hours, then concentrated under reduced pressure. The solid residue was 
taken up in dichloromethane (250 mL), and the remaining precipitate removed by vacuum 
filtration. The filtrate was washed with aqueous sodium hydroxide solution (3 M, 100 
mL) and water (2 × 100 mL), and dried over magnesium sulfate, before being 
concentrated under reduced pressure to give quinazoline 65 as an off-white solid (341 mg, 
66%) 
 
1H NMR (500 MHz, CDCl3) 9.39 (1H, s, 10-CH), 8.50 (2H, d, J = 8.6 Hz, 12-CH, 16-
CH), 8.10 (1H, d, J = 2.0 Hz, 8-CH), 8.02 − 7.93 (2H, m, 5-CH, 6-CH), 7.67 (2H, d, J = 
8.6 Hz, 13-CH, 15-CH); 13C NMR (126 MHz, CDCl3) 160.4 (2-C), 159.4 (10-CH), 149.4 
(4-C), 137.8 (1-CH), 136.5 (9-CH), 131.9 (13-CH, 15-CH), 130.4 (5-CH), 130.2 (12-CH, 
16-CH), 129.2 (8-CH), 125.8 (11-C), 124.5 (14-CBr), 121.0 (7-CBr). 
 
4,4'-Oxybis(bromobenzene) (71)341 
 
To a solution of diphenyl ether (0.50 mL, 3.2 mmol), and NaBrO3 (158 mg, 1.05 mmol) 
in dichloromethane (2.5 mL) and water (2.5 mL), was added dropwise bromine (0.20 ml, 
3.5 mmol). The solution was then stirred at room temperature for 2 hours, until no starting 
material was visible by TLC. The solution was diluted with dichloromethane (10 mL) and 
water (10 mL), and 1 M aqueous sodium thiosulfate solution was added until the solution 
had turned colourless. The organic phase was washed with water (2 × 10 mL) and brine 
(2 × 10 mL), before being dried over MgSO4, and concentrated under reduced pressure 
to the product as an off-white solid (792 mg 77%). 
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1H NMR (500 MHz, CDCl3) 7.46 (4H, d, J = 8.8 Hz, 3/5/9/11-CH), 6.89 (4H, d, J = 8.8 
Hz, 2/6/8/12-CH), 13C NMR (126 MHz, CDCl3) 156.0 (1/7-CO), 132.8 (3/5/9/11-CH), 
120.6 (2/6/8/12-CH), 116.2 (4/10-CBr) 
 
2-Amino-4-bromophenol (73)342 
 
A suspension of tin(II) chloride (5.9 g, 23 mmol) in concentrated aqueous HCl (37 %, 
11 mL) and MeOH (20 mL) was cooled to 0 °C. 4-bromo-2-nitrophenol (72, 1.0 g, 4.6 
mmol) was then added to the solution in one portion, and allowed to stir for 6 hours, 
whereby the solution had gone colourless. The solution was then diluted with ethyl acetate 
(60 mL), and neutralised with concentrated aqueous NaHCO3 solution. The white 
precipitate was then removed by filtration, and washed with ethyl acetate (120 mL). The 
filtrate was separated, and the aqueous phase extracted with ethyl acetate (3 × 50 mL). 
The combined organic phase was dried over MgSO4, and concentrated under reduced 
pressure, to give the product as a light brown solid (836 mg, 97%). 
 
1H NMR (500 MHz, CDCl3) 9.21 (1H, s, 7-OH), 6.71 (1H, d, J = 2.4 Hz, 3-CH), 6.55 
(1H, d, J = 8.3 Hz, 6-CH), 6.48 (1H, dd, J = 8.3, 2.4 Hz, 5-CH), 4.76 (2H, s, 8-NH2); 13C 
NMR (126 MHz, CDCl3) 143.7 (1-COH), 139.3 (2-CNH2), 118.5 (5-CH), 116.4 (3-CH), 
116.1 (6-CH), 111.1 (4-CBr). 
 
4-Bromo-N-(5-bromo-2-hydroxyphenyl)benzamide (74) 
 
A solution of 4-bromobenzoic acid (1.0 g, 5 mmol), and 3 drops of dimethylformamide 
in sulfuryl chloride (7 mL) was refluxed at 80 °C for 3 hours. The solution was then 
concentrated under reduced pressure to yield a yellow, crystalline solid (1.03 g).  
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To a stirred solution of 2-amino-4-bromophenol (73, 568 mg, 3.02 mmol) and pyridine 
(0.8 mL, 10 mmol) in dry THF (20 mL) at −10 °C, was added dropwise a solution of the 
yellow solid (676 mg, 3.3 mmol) in dry THF (6 mL). The solution was allowed to stir at 
−10 °C for 6 hours, before being quenched with concentrated aqueous NaHCO3 solution 
(30 mL), and diluted with ethyl acetate (40 mL). The aqueous phase was extracted with 
ethyl acetate (30 mL), and the combined organic phases were washed with HCl (1 M, 50 
mL), and brine (50 mL), before being concentrated under reduced pressure to give a 
brown solid. This crude material was dissolved in a solution of NaOH (150 mg, 3.8 mmol) 
in water (10 mL) and THF (20 mL), and allowed to stir at room temperature for 20 hours. 
The resulting solution was diluted with ethyl acetate (100 mL), and the organic phase was 
washed with HCl (1 N, 2 × 150 mL), concentrated aqueous NaHCO3 solution (2 × 150 
mL), and brine (2 × 100 mL). The solution was dried over MgSO4 and concentrated under 
reduced pressure, to give the product as a light brown, crystalline solid (787 mg, 70%). 
 
1H NMR (500 MHz, DMSO-d6) 10.11 (1H, s, 8-NH), 9.57 (1H, s, 7-OH), 8.00 - 7.81 
(3H, m, 5-CH, 11-CH), 7.74 (2H, d, J = 8.6 Hz, 12-CH), 7.19 (1H, dd, J = 8.6, 2.5 Hz, 3-
CH), 6.88 (1H, d, J = 8.6 Hz, 2-CH); 13C NMR (126 MHz, DMSO-d6) 164.9 (9-CO), 
149.3 (1-COH), 133.7 (3-CH), 132.0 (12-CH), 130.2 (11-CH), 128.8 (10-C), 128.3 (13-
CBr), 127.7 (5-CH), 126.9 (6-CNH), 126.0 (2-CH), 109.9 (4-CBr); IR (neat, νmax, cm-1) 
3182 (brm), 1631 (s), 1587 (s), 1519 (s), 1481 (s), 1409 (s), 1320 (s), 1283 (s), 1104 (s), 
1068 (s), 1009 (s), 930 (m), 870 (s), 844 (s), 812 (s), 752 (m), 723 (m), 688 (m); HRMS 
(ESI): calcd. for C13H10Br2N1O2 [M+H]+ 371.9053, found 371.9056. 
 
5-bromo-2-(4-bromophenyl)benzo[d]oxazole (75) 
 
To a solution of p-toluenesulfonic acid monohydrate (80 mg, 0.42 mmol) in toluene (5 
mL) was added 4-bromo-N-(5-bromo-2-hydroxyphenyl)benzamide (74, 50 mg, 0.13 
mmol), and heated at 110 °C for 5 hours. The resulting solution was diluted with water 
(15 mL) and ethyl acetate (15 mL). The aqueous phase was extracted with ethyl acetate 
(15 mL), before the combined organic phase was washed with NaHCO3 solution (2 × 20 
mL) and brine (2 × 20 mL). The solution was then dried over MgSO4, and concentrated 
under reduced pressure to give the product as a light brown solid (45 mg, 98%). 
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1H NMR (500 MHz, CDCl3) 8.11 (2H, d, J = 8.6 Hz, 10-CH), 7.91 (1H, d, J = 1.9 Hz, 5-
CH), 7.69 (2H, d, J = 8.6 Hz, 9-CH), 7.54 - 7.42 (2H, m, 2-CH, 3-CH); 13C NMR (126 
MHz, CDCl3) 163.2 (7-C), 149.8 (6-C), 143.6 (1-C), 132.3 (10-CH), 129.1 (9-CH), 128.4 
(3-CH), 126.7 (8-C), 125.6 (11-CBr), 123.1 (5-CH), 117.5 (4-CBr), 111.8 (2-CH); IR 
(neat, νmax, cm-1) 3084 (w), 2919 (w), 1587 (m), 1546 (m), 1474 (s), 1446 (s), 1423 (m), 
1397 (s), 1260 (s), 1069 (s), 1008 (s), 891 (m), 830 (s), 797 (s), 750 (m), 726 (s), 679 (m); 
HRMS (ESI): calcd. for C13H8Br2NO [M+H]+ 351.8967, found 351.8967. 
 
4,4'-Dibromo-2-nitro-1,1'-biphenyl (77)333 
 
A mixture of nitric acid (68%, 5.0 mL, 110 mmol) and glacial acetic acid (3mL) was 
added dropwise to a stirred solution of 1-bromo-4-(4-bromophenyl)benzene (18, 2.00 g, 
6.41 mmol) in  acetic anhydride (20 mL) and  dichloromethane (4 mL) at 0 °C. The 
solution was allowed to warm to room temperature and stir for 1 hour. The solution was 
then neutralised with aqueous NaOH (3 M) and extracted with dichloromethane (2 × 40 
mL). The organic phase was dried over MgSO4 and concentrated under reduced pressure. 
The resulting material was recrystallized from ethanol to yield the product as a light 
yellow solid (1.72 g, 75%). 
 
1H NMR (500 MHz, DMSO-d6) 8.27 (1H, d, J = 2.0 Hz, 2-CH), 7.98 (1H, dd, J = 8.2, 
2.0 Hz, 4-CH), 7.66 (2H, d, J = 8.1 Hz, 8-CH, 12-CH), 7.51 (1H, d, J = 8.2 Hz, 5-CH), 
7.30 (2H, d, J = 8.1 Hz, 9-CH, 11-CH); 13C NMR (126 MHz, DMSO-d6) 149.5 (1-CNO2), 
136.2 (4-CH), 135.7 (6-C), 133.9 (5-CH), 133.5 (7-C), 132.2 (8-CH, 12-CH), 130.4 (9-
CH, 11-CH), 127.2 (2-CH), 122.6 (10-CBr), 121.7 (3-CBr). 
 
2-Bromo-1-(4-bromophenyl)ethanone (79)343 
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To a stirred solution of 4-bromoacetophenone (78, 6.00 g, 30.3 mmol) in acetic acid (45 
mL) was added dropwise bromine (1.55 mL, 30.3 mmol). The solution was allowed to 
stir at room temperature for a further three hours, until a colour change from dark brown 
to yellow had occurred. The solution was then diluted with ethyl acetate (100 mL), and 
washed with sodium thiosulfate solution (2 M, 2 × 50 mL), sodium bicarbonate solution 
(saturated, 2 × 50 mL), and water (2 × 50 mL). The solution was then dried over 
magnesium sulfate and concentrated under reduced pressure to give a white solid. The 
crude material was then recrystallized from a 10:1 mixture of petrol ether and ethyl 
acetate to give the product as a white, crystalline solid (5.75 g, 68% yield). 
 
1H NMR (500 MHz, CDCl3) 7.85 (2H, d, J = 8.6 Hz, 2-CH, 6-CH), 7.65 (2H, d, J = 8.6 
Hz, 3-CH, 5-CH), 4.40 (2H, s, 8-CH2); 13C NMR (126 MHz, CDCl3) 190.4 (7-CO), 132.7 
(1-C), 132.2 (3-CH, 5-CH), 130.4 (2-CH, 6-CH), 129.3 (4-CBr), 30.3 (8-CH2). 
 
1,4-Bis(4-bromophenyl)butane-1,4-dione (80)228 
 
Zinc(II) chloride (3.91 g, 28.7 mmol) was dried by melting at 350 °C for 25 minutes, until 
gas evolution had ceased. After cooling to room temperature, the solidified material was 
then stirred in a solution of toluene (13.5 mL), diethylamine (2.2 mL, 22 mmol) and tert-
butanol (2.1 mL, 22 mmol) for 2.5 hours, until all solid material had dissolved. To this 
solution was added 4-bromoacetophenone (78, 4.26 g, 21.5 mmol), followed by 2-bromo-
1-(4-bromophenyl)ethanone (79, 4.00 g, 14.3 mmol), and the reaction vessel was sealed 
under an inert atmosphere and stirred for a further 3 hours. The solution was then allowed 
to stand for 3 days, causing a precipitate to form. The reaction mixture was then quenched 
with sulfuric acid (5 % in water, 20 mL), and the precipitate collected by vacuum filtration. 
The precipitate was washed with toluene (20 mL), water (20 mL) and methanol (20 mL) 
to give the product as a crystalline, white solid (3.67 g, 65%). 
 
1H NMR (500 MHz, CDCl3) 7.90 (4H, d, J = 8.5 Hz, 2-CH, 6-CH, 12-CH, 16-CH), 7.63 
(4H, d, J = 8.5 Hz, 3-CH, 5-CH, 12-CH, 16-CH), 3.41 (4H, s, 8-CH2, 9-CH2); 13C NMR 
(126 MHz, CDCl3) 197.5 (7-CO, 10-CO), 135.4 (1-C, 11-C), 131.9 (3-CH, 5-CH, 12-CH, 
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16-CH), 129.6 (2-CH, 6-CH, 12-CH, 16-CH), 128.4 (4-CBr, 14-CBr), 32.4 (8-CH2, 9-
CH2). 
 
2,5-Bis(4-bromophenyl)furan (81)344 
 
A stirred solution of 1,4-bis(4-bromophenyl)butane-1,4-dione (80, 250 mg, 0.635 mmol) 
in methanol (3.0 mL) and dichloromethane (7.0 mL) at 0 °C was saturated with HCl gas, 
produced from the reaction of concentrated sulfuric acid with sodium chloride. The 
solution was allowed to warm to room temperature and stirred for a further three hours. 
The solution was then concentrated under reduced pressure give a brown solid, which 
was washed with concentrated aqueous potassium carbonate solution (30 mL). The 
remaining crude material was then crystallized from a 3:7 mixture of chloroform and 
diethyl ether to give 2,5-bis(4-bromophenyl)furan (81) as a white, crystalline solid (177 
mg, 74%). 
 
1H NMR (500 MHz, DMSO-d6) 7.77 (4H, d, J = 8.6 Hz, 6-CH, 10-CH, 13-CH, 15-CH), 
7.63 (4H, d, J = 8.6 Hz, 7-CH, 9-CH, 13-CH, 15-CH), 7.14 (2H, s, 2-CH, 3-CH); 13C 
NMR (126 MHz, DMSO-d6) 152.4 (1-CH, 4-CH), 132.3 (7-CH, 9-CH, 13-CH, 15-CH), 
129.6 (5-C, 11-C), 125.9 (6-CH, 10-CH, 12-CH, 16-CH), 121.1 (8-CBr, 14-CBr), 109.6 
(2-CH, 3-CH). 
 
2,5-Bis(4-bromophenyl)thiophene (82)345 
 
A stirred solution of 1,4-bis(4-bromophenyl)butane-1,4-dione (80, 250 mg, 0.64 mmol) 
and Lawesson’s reagent (308 mg, 0.76 mmol) in toluene (5.0 mL) was allowed to reflux 
for 3 hours. The solution was then allowed to cool to room temperature, before adding 
diethyl ether (10.0 mL) and further cooling the solution to −78 °C. After allowing the 
solution to sit for 10 minutes, the resulting precipitate was collected by vacuum filtration, 
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and washed with chilled (−78 °C) diethyl ether (10 mL), to give 2,5-bis(4-
bromophenyl)thiophene (82) as a white, crystalline solid (188 mg, 75%). 
 
1H NMR (500 MHz, CDCl3) 7.55 - 7.46 (8H, m, 6-CH, 7-CH, 9-CH, 10-CH, 12-CH, 13-
CH, 15-CH, 16-CH), 7.27 (2H, s, 2-CH, 3-CH); 13C NMR (126 MHz, CDCl3) 142.7 (1-
C, 4-C), 133.1 (5-C, 11-C), 132.0 (7-CH, 9-CH, 13-CH, 15-CH), 127.1 (6-CH, 10-CH, 
12-CH, 16-CH), 124.5 (2-CH, 3-CH), 121.5 (8-CBr, 14-CBr). 
 
2-(Aminomethyl)-4-bromoaniline (84)340 
 
To a solution of 2-amino-5-bromobenzonitrile (83, 2.00 g, 10.2 mmol) in dry THF (20 
mL) at 0 °C was added dropwise a solution of borane in THF (1 M, 12.5 mL, 12.5 mmol). 
The solution was then allowed to warm to room temperature, and stir for a further 72 
hours. The solution was quenched dropwise with ethanol (10 mL), before hydrochloric 
acid (4 M, 10 mL) was added, and the solution was allowed to stir for a further 16 hours. 
The solution was then concentrated under reduced pressure, and tert-butyl acetate (20 
mL) was added, before basifying the aqueous phase with sodium hydroxide tablets. The 
organic phase was then separated and washed with water (2 × 15 mL), before being dried 
over magnesium sulfate, and concentrated under reduced pressure to give a light brown 
solid. This crude material was then purified by column chromatography (25 g silica, 
MeOH:CH2Cl2, 0% to 15%) to give the product as a white, crystalline solid (874 mg, 
43%). 
 
1H NMR (500 MHz, DMSO-d6) 7.18 (1H, d, J = 2.4 Hz, 5- CH), 7.04 (1H, dd, J = 8.4, 
2.4 Hz, 3-CH), 6.54 (1H, d, J = 8.4 Hz, 2-CH), 5.21 (2H, s, 9-NH2), 3.56 (2H, s, 7-CH2), 
1.75 (2H, brs, 8-NH2); 13C NMR (126 MHz, DMSO-d6) 146.3 (1-CNH2), 130.4 (5-CH), 
129.7 (3-CH), 117.7 (6-CH), 116.7 (2-CH), 107.0 (4-CBr), 43.0 (7-CH2). 
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N-(2-Amino-5-bromobenzyl)-4-bromobenzamide (85)340 
 
4-Bromobenzoic acid (1.00 g, 5.00 mmol) was suspended in thionyl chloride (5 mL), and 
a drop of DMF was added. The solution was heated to reflux, and stirred for 2 hours, until 
no more effervescence was observed. The solution was then cooled to room temperature 
and concentrated under reduced pressure to give an orange, crystalline solid (1.097 g). 
 
To a stirred solution of 2-(aminomethyl)-4-bromoaniline 84 (730 mg, 3.63 mmol) and 
triethylamine (0.70 mL, 5.4 mmol) in dichloromethane (10 mL) at 0 °C was added 
dropwise a solution of the previously formed orange solid (800 mg, 3.64 mmol) in 
dichloromethane (5 mL). The solution was allowed to warm to room temperature and stir 
for a further 2.5 hours. The reaction was quenched with water (15 mL), causing 
precipitation of a white solid upon formation of an emulsion. The white solid was 
redissolved using ethyl acetate (100 mL), the phases separated, and the organic phase 
washed with potassium carbonate solution (conc., 2 × 50 mL) and water (2 × 50 mL). The 
solution was then dried over magnesium sulfate, and concentrated under reduced pressure 
to yield amide 85 as an oil, which later solidified to an off-white solid (1.31 g, 94%) 
 
1H NMR (500 MHz, DMSO-d6) 9.01 (1H, s, 8-NH), 7.82 (2H, d, J = 8.4 Hz, 13-CH, 17-
CH), 7.69 (2H, d, J = 8.4 Hz, 14-CH, 16-CH), 7.14 − 7.07 (2H, m, 3-CH, 5-CH), 6.59 
(1H, d, J = 8.4 Hz, 3-CH), 5.31 (2H, s, 9-NH2), 4.29 (2H, d, J = 6.0 Hz, 7-CH2); 13C NMR 
(126 MHz, DMSO-d6) 166.0 (10-CO), 146.0 (1-CNH2), 133.5 (11-C), 131.9 (14-CH, 16-
CH), 131.6 (5-CH), 130.7 (3-CH), 129.8 (13-CH, 17-CH), 125.6 (15-CBr), 124.7 (6-C), 
117.0 (2-CH), 106.7 (4-CBr). 
 
6-Bromo-2-(4-bromophenyl)-3,4-dihydroquinazolin-1-ium chloride (86)340 
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A solution of N-(2-amino-5-bromobenzyl)-4-bromobenzamide 85 (1090 mg, 2.84 mmol) 
in phosphoryl chloride (7 mL) was refluxed for 2.5 hours. The solution was then 
concentrated under reduced pressure, and the residue was neutralized by washing with 
concentrated aqueous sodium bicarbonate (30 mL). The solid material was extracted with 
ethyl acetate (50 mL), and the precipitate was removed by vacuum filtration. The filtrate 
was dried over magnesium sulfate, before being concentrated under reduced pressure to 
give the product as an off-white, crystalline solid (767 mg, 67%). 
 
1H NMR (500 MHz, DMSO-d6) 12.64 (1H, s, 1-NH), 11.10 (1H, s, 3-NH), 7.98 − 7.83 
(4H, m, 12-CH, 13-CH, 15-CH, 16-CH), 7.58 − 7.48 (2H, m, 6-CH, 8-CH), 7.40 (1H, d, 
J = 8.5 Hz, 5-CH), 4.85 (2H, s, 10-CH2); 13C NMR (126 MHz, DMSO-d6) 157.5 (2-C), 
132.4 (13-CH, 15-CH), 132.0 (4-C), 131.9 (6-CH), 131.3 (12-CH, 16-CH), 129.8 (8-CH), 
128.5 (11-C), 126.3 (9-C), 121.0 (14-CBr), 119.8 (5-CH), 119.2 (7-CBr), 42.1 (10-CH2); 
HRMS (ESI): calcd. for C14H10Br2N4 [M+H]+ 364.9283, found 364.9283. 
 
(6-Bromo-2,3-dihydro-1H-inden-1-yl)triphenylphosphonium bromide (94) 
 
Single Step Method 
A solution of 6-bromoindan-1-ol (166, 107 mg, 0.500 mmol) and triphenylphosphonium 
bromide (172 mg, 0.500 mmol) in toluene (5 mL) was refluxed overnight at 110 °C, 
forming a white precipitate. The solution was cooled to room temperature, and the white 
precipitate was collected by vacuum filtration. Recrystallization of this white precipitate 
from chloroform gave the product as a white solid (56 mg, 21%). 
 
Two Step Method 
To a solution of 6-bromoindan-1-ol (166, 2.00 g, 9.39 mmol) in dichloromethane (5 mL) 
at 0 °C was added dropwise a solution of phosphorus tribromide (1.76 mL, 18.8 mmol) 
in dichloromethane (8 mL). The solution was allowed to warm to room temperature and 
stir for a further 2 hours. This solution was then quenched with saturated NaHCO3 
solution, and the phases separated. The aqueous phase was extracted with 
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dichloromethane (2 x 5 mL), dried, and concentrated under reduced pressure to give the 
benzyl bromide as a light brown oil (2.45 g) 
 
To a solution of 1,6-dibromoindane from the previous step (6.06 g, 22.0 mmol) in toluene 
(60 mL) was added triphenylphosphine (5.76 g, 22.0 mmol) and the solution was refluxed 
for 4 days. The solution was then cooled to room temperature and filtered, and the 
precipitate was washed with diethyl ether (2 x 30 mL), before being triturated in boiling 
chloroform. Drying in the vacuum oven for 20 hours yielded the product as a white solid 
(6.32 g, 51% over 2 steps). 
 
1H NMR (500 MHz, CDCl3) δ 7.93 – 7.83 (6H, m, 12/14/18/20/24/26-CH), 7.81 – 7.75 
(3H, m, 13/19/25-CH), 7.70 – 7.62 (6H, m, 11/15/17/21/23/27-CH), 7.34 – 7.28 (1H, m, 
6-CH), 6.92 – 6.86 (2H, m, 5-CH, 8-CH), 3.43 – 3.20 (1H, m, 3-CHH), 2.74 – 2.63 (1H, 
m, 3-CHH), 2.44 – 2.27 (1H, m, 2-CHH), 1.69 – 1.52 (1H, m, 2-CHH). 1H NMR (500 
MHz, DMSO-d6) δ 7.91 (3H, t, J = 7.1 Hz, 13/19/25-CH), 7.85 – 7.68 (m, 12H, 
11/15/17/21/23/27-CH, 12/14/18/20/24/26-CH), 7.45 (1H, dd, J = 8.3, 1.9 Hz, 6-CH), 
7.12 (1H, d, J = 8.3 Hz, 5-CH), 6.76 (1H, d, J = 1.9, 8-CH), 6.33 – 6.17 (1H, m, 1-CH), 
3.06 – 2.83 (1H, m, 3-CHH), 2.78 – 2.65 (1H, m, 3-CHH), 2.48 – 2.31 (1H, m, 2-CHH), 
1.63 – 1.53 (1H, m, 2-CHH); 13C NMR (126 MHz, DMSO-d6) δ 145.9 (4-C), 145.8 (4-
C), 137.3 (9-C), 135.7 (13/19/25-CH), 135.6 (13/19/25-CH), 134.4 (12/14/18/20/24/26-
CH), 134.3 (12/14/18/20/24/26-CH), 132.4 (6-CH), 130.8 (11/15/17/21/23/27-CH), 
130.8 (11/15/17/21/23/27-CH), 129.0 (8-CH), 128.9 (8-CH), 127.8 (5-CH), 127.7 (5-
CH), 119.9 (7-CBr), 119.8 (7-CBr), 118.1 (10/16/22-C), 117.5 (10/16/22-C), 79.7 (1-C), 
30.7 (3-CH2), 27.4 (2-CH2); IR (neat, νmax, cm-1) 3317 (m), 2979 (w), 1754 (m), 1673 (s), 
1493 (s), 1393 (w), 1369 (m), 1244 (s), 1156 (s), 1125 (s), 1172 (m), 878 (w), 754 (m); 
HRMS (ESI): calcd. for C27H23BrP [M]+ 457.0715, found 457.0714. 
 
6-Bromo-2,3-dihydro-1H-inden-1-one (95)346 
 
To a cooled suspension of 3-(4-bromophenyl)propanoic acid (2.29 g, 10.0 mmol)  in 
dichloromethane (5 mL)  at 0 °C was added dropwise trifluoromethanesulfonic acid (13.3 
mL, 150 mmol). The solution was warmed to room temperature, then heated in the 
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microwave at 80 °C for 1 hour. The resulting brown solution was poured into ice (150 
mL), causing a large exotherm when mixing. The ice/water solution was neutralised with 
saturated NaHCO3 solution and then extracted with CH2Cl2 (3 x 70 mL). The combined 
organic phase was dried over MgSO4 and concentrated under reduced pressure to yield 
an off-white powder (1.83 g) Purification by flash chromatography (PE:EtOAc, 0-20%, 
20g silica) yielded the product as a crystalline white powder (182 mg, 70%).  
 
1H NMR: (500 MHz, CDCl3) δ 7.89 (1H, d, J = 1.9 Hz, 8-CH), 7.69 (1H, dd, J = 8.2, 1.9 
Hz, 6-CH), 7.37 (1H, d, J = 8.2 Hz, 5-CH), 3.13 – 3.07 (2H, m, 3-CH2), 2.75 – 2.70 (2H, 
m, 2-CH2); 13C NMR: (126 MHz, CDCl3 ) δ 205.1 (1-CO), 153.5 (4-C), 138.9 (9-C), 
137.3 (6-CH), 128.2 (5-CH), 126.7 (8-CH), 121.6 (7-CBr), 36.5 (2-CH2), 25.5 (3-CH2); 
LCMS (acetonitrile/water, 30-90%, 20 mins) Retention time: 15.28 min, m/z: 210.9 
[M+H]+. 
 
(2R,3R)-2,3-Dihydroxysuccinohydrazide (144)347 
 
To a solution of diethyl (2R,3R)-2,3-dihydroxybutanedioate (0.83 mL, 4.85 mmol) in 
ethanol (10mL) was added hydrazine hydrate (0.94 mL, 19.4 mmol), and heated to reflux 
for 16 hours. The solution was cooled to room temperature and the precipitate collected 
by vacuum filtration, and dried under vacuum to give the product as a white solid (698 
mg, 81%). 
 
1H NMR (500 MHz, DMSO-d6) δ 8.76 (2H, s, 7/8-NH), 5.36 (2H, s, 3/4-OH), 4.25 
(2H, s, 1/2-CH); LCMS (acetonitrile/water, 10-90%, 10 mins) Retention time: 0.66 
min, m/z: 366.1 [M+H]+. 
 
Di-tert-butyl 2,2'-((2R,3R)-2,3-dihydroxysuccinyl)bis(hydrazinecarboxylate) (145) 
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To a stirred suspension of tert-butoxycarbonyl tert-butyl carbonate (144, 2.45 g, 11.23 
mmol) and (2R,3R)-2,3-dihydroxybutanedihydrazide (1.00 g, 5.61 mmol) in acetonitrile 
(40 mL) and water (10 mL) at room temperature was added a single crystal of iodine. The 
solution was allowed to stir overnight. If there was still undissolved starting material, 
several more crystals of iodine were added and the solution allowed to continue stirring. 
The solution was then concentrated under reduced pressure, giving a white slurry. This 
slurry was then triturated in dichloromethane (approx. 25 mL) by sonication. The solid 
was then collected by filtration, and dried under vacuum, giving the product as a white 
solid (989 mg, 47 %). 
 
1H NMR: (500 MHz, DMSO-d6) δ 9.36 (2H, s, 7/8-NH), 8.70 (2H, s, 9/10-NH), 5.37 
(2H, d, J = 7.6 Hz, 3/4-OH), 4.30 (2H, d, J = 7.6 Hz, 1/2-CH), 1.39 (18H, s, 
15/16/17/18/19/20-CH3); 13C NMR (126 MHz, DMSO-d6) δ 171.6 (5/6-CO, 155.5 
(11/12-CO), 79.6 (13/14-C), 72.8 (1/2-CH), 28.5 (15/16/17/18/19/20-CH3); IR (neat, 
νmax, cm-1) 3332 (m), 2979 (w), 1754 (m), 1714 (m), 1674 (s), 1494 (s), 1393 (w), 1369 
(m), 1296 (s), 1245 (s), 1158 (s), 1127 (s), 1173 (m), 879 (w), 794 (m), 755 (m), 676 (m); 
HRMS (ESI): calcd. for C14H26N4NaO8 [M+Na]+ 401.1648, found 401.1643. 
 
(E)-4-(2-Carboxyvinyl)benzoic acid (159)348 
 
Acrylic acid (6.22 mL, 90.72 mmol) was added dropwise to a solution of potassium 
carbonate (16.7 g, 121 mmol) and palladium(II) acetate (136 mg, 0.600 mmol) in water 
(150 mL). To this solution was then added 4-iodobenzoic acid (15.0 g, 60.5 mmol), 
forming a slurry. This slurry was then heated at 80 °C for 4 hours under vigorous stirring, 
before being cooled to room temperature. The solution was filtered through Celite then 
acidified with 1 M HCl, causing formation of a fine, white precipitate. The precipitate 
was removed by vacuum filtration, and dried in a vacuum oven at 80 °C to give the pure 
product as a fine white powder (10.6 g, 82%). 
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1H NMR (600 MHz, DMSO-d6) δ 12.82 (2H, s,  8-COOH, 12-COOH), 7.93 (2H, d, J = 
8.3 Hz, 2H, 2/8-CH), 7.78 (2H, d, J = 8.3 Hz, 3/5-CH), 7.62 (1H, d, J = 16.0 Hz, 9-CH), 
6.62 (1H, d, J = 16.0 Hz, 10-CH); LCMS (acetonitrile/water, 30-90%, 20 mins) Retention 
time: 7.44 min, m/z: 191.0 [M-H]-. 
 
4-(2-Carboxyethyl)benzoic acid (160)349 
 
To a solution of sodium hydroxide (3.6 g, 90 mmol) and 4-[(E)-2-carboxyvinyl]benzoic 
acid (159, 8.65 g, 45.0 mmol) in  water (250 mL) was added a small spatula of Raney 
nickel, and the solution was heated to 90 °C. Hydrazine hydrate (45.0 mL, 925 mmol) 
was then added to the solution dropwise, causing the evolution of gas. After 1 hour, gas 
evolution had ceased. The Raney nickel was removed by filtration, giving a colourless 
solution. The solution was then acidified by concentrated HCl, resulting in the formation 
of a white precipitate. The white precipitate was collected by vacuum filtration and 
washed with water (30 mL) and ethanol (20 mL). The product was then dried in the 
vacuum oven, giving the product as a white solid (7.82 g, 90%). 
 
1H NMR (500 MHz, DMSO-d6) δ 7.83 (2H, d, J = 8.0 Hz, 2/6-CH), 7.33 (2H, d, J = 8.0 
Hz, 3/5-CH), 2.87 (2H, t, J = 7.5 Hz, 9-CH2), 2.55 (2H, t, J = 7.5 Hz, 10-CH2).  
 
6-Methoxy-2,3-dihydro-1H-inden-1-one (162)350 
 
Trifluoromethanesulfonic acid (6.6 mL, 75 mmol) was added to a cooled (0 °C) solution 
of 3-(4-methoxyphenyl)propionic acid (2.7 g, 15 mmol) in dichloromethane (15mL)  in 
a 20 mL microwave vial. The vial was sealed and the tube heated to 80 °C overnight. The 
solution was cooled to room temperature and poured into ice (approx. 60 mL). The 
mixture was extracted with dichloromethane (3 x 20 mL), and washed with brine (2 x 20 
mL), before being dried over magnesium sulfate and concentrated under reduced 
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pressure. The crude material was purified by column chromatography (0 to 40%), and 
then recrystallized from hexanes to give the product as a light yellow, crystalline solid 
(856 mg, 35%). 
 
 1H NMR (500 MHz, CDCl3) δ 7.35 (1H, d, J = 7.7 Hz, 5-CH), 7.20 – 7.16 (2H, m, 6-
CH, 8-CH), 3.83 (3H, s, 10-CH3), 3.10 – 3.02 (2H, m, 3-CH2), 2.74 – 2.67 (2H, m, 2-
CH2).  
 
3-Oxo-2,3-dihydro-1H-indene-5-carboxylic acid (163)153 
 
4-(2-Carboxyethyl)benzoic acid (160, 250 mg, 1.29mmol), aluminium trichloride (1.25 
g, 9.37 mmol)  and sodium chloride (250 mg, 4.28 mmol) were placed in a 25 mL round 
bottom flask fitted with a condenser, and heated to 180 °C. After one hour, a liquid had 
formed. The liquid was cooled to room temperature and ice water (7.5 mL) and 6M HCl 
(7.5 mL) was added, followed by ethyl acetate (20 mL). The layers were separated and 
the aqueous layer was washed with ethyl acetate (3 x 20 mL). The combined organic 
layers were then washed with 1 M HCl (20 mL), water (2 x 20 mL) and brine (20 mL), 
dried over MgSO4, and concentrated under reduced pressure to give the product as a white 
solid (192 mg, 85%). 
 
1H NMR (500 MHz, DMSO-d6 ) δ 13.15 (1H, s, 11-COOH), 8.19 (1H, dd, J = 8.0, 1.6 
Hz, 6-CH), 8.10 (1H, d, J = 1.6 Hz, 8-CH), 7.70 (1H, d, J = 8.0 Hz, 5-CH), 3.20 – 3.13 
(2H, m, 3-CH2), 2.73 – 2.66 (2H, m, 2-CH2).  
 
6-Hydroxy-2,3-dihydro-1H-inden-1-one (164)351 
 
6-Methoxyindan-1-one (162, 5.0 g, 31 mmol) and aluminium trichloride (12.3 g, 92.0 
mmol) were dissolved in toluene (100 mL) and heated to reflux, whereby a large about 
of gas was released. Once gas production had ceased (approx. 3 hours) the reaction was 
cooled to room temperature and poured into ice, forming a precipitate. The precipitate 
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was dissolved in ethyl acetate, and the organic phase separated, before being washed with 
water (2 x 30 mL), dried over MgSO4, and concentrated under reduced pressure. The 
resulting residue was washed with CH2Cl2 to give the product as a brown, crystalline 
solid (4.04 g, 88%). 
 
1H NMR (500 MHz, CDCl3) δ 7.35 (1H, d, J = 8.2, 5-CH), 7.22 (1H, d, J = 2.5 Hz, 8-
CH), 7.16 (1H, dd, J = 8.3, 2.5 Hz, 6-CH), 5.98 (1H, s, 10-OH), 3.10 – 3.03 (2H, m, 3-
CH2), 2.75 – 2.69 (2H, m, CH2).  
 
6-(Pyridin-2-yloxy)-2,3-dihydro-1H-inden-1-one (165) 
 
6-Hydroxyindan-1-one (164, 3.89 g, 26.3 mmol), 2-picolinic acid (650 mg, 5.2 mmol), 
copper iodide (500 mg, 2.6 mmol), and tribasic potassium phosphate (11.2 g, 52.5 
mmol) were placed into a 25 mL round bottom flask and the air replaced with nitrogen. 
Dimethyl sulfoxide (8mL) and 2-bromopyridine (3.76 mL, 39.4 mmol) were added, and 
the solution heated to 100 °C under stirring. After 3 hours, the reaction mixture was 
poured into water (30 mL) and ethyl acetate (30 mL). The fractions were filtered through 
a celite plug, and the organic phase washed with water (2 x 50 mL), and brine (2 x 30 
mL), before being dried over MgSO4 and concentrated under reduced pressure. The crude 
material was purified by column chromatography (EtOAc, PE, 0% to 50%), to the product 
at a white solid (3.40 g, 58%) 
 
1H NMR (500 MHz, CDCl3) δ 8.17 (1H, dd, J = 5.0, 1.5 Hz, 14-CH), 7.71 (1H, ddd, J = 
8.2, 7.2, 2.0 Hz, 12-CH), 7.53 – 7.47 (2H, m, 5-CH, 8-CH), 7.40 (1H, dd, J = 8.2, 2.4 Hz, 
6-CH), 7.01 (1H, ddd, J = 7.1, 4.9, 0.9 Hz, 13-CH), 6.97 (1H, dd, J = 8.3, 0.9 Hz, 11-CH), 
3.14 (2H, t, J = 5.7 Hz, 3-CH2), 2.74 (2H, t, J = 6.1 Hz, 2-CH2); 13C NMR (126 MHz, 
CDCl3) δ 206.1 (1-CO), 163.3 (10-C), 153.8 (9-C), 151.0 (7-C), 147.6 (14-CH), 139.5 
(12-CH), 138.5 (4-C), 128.2 (6-CH), 127.6 (5-CH), 118.8 (13-CH), 115.5 (8-CH), 111.9 
(11-CH), 36.9 (2-CH2), 25.4 (3-CH2); IR (neat, νmax, cm-1) 3054 (w), 2928 (w), 1698 (s), 
1590 (m), 1465 (s), 1423 (s), 1266 (m), 1229 (s), 1175 (m), 990 (w), 913 (m), 861 (s), 
782 (s), 740 (m), 697 (m); MS (EI): m/z 78 (13%), 168 (7 %), 169 (12 %), 196 (11 %), 
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197 (26 %), 224 (100%), 225 (65%, mass ion), 226 (22%); LCMS (acetonitrile/water, 
30-70%, 4 mins) Retention time: 2.05 min, m/z: 226.2 [M+H]+. 
 
6-Bromo-2,3-dihydro-1H-inden-1-ol (166)352 
 
To a suspension of 6-bromoindan-1-one (95, 2.53 g, 12.0 mmol) in methyl alcohol (30 
mL) was added portion-wise sodium borohydride (454 mg, 12.0 mmol), keeping the level 
of effervescence under control. After 1 hour, the effervescence had ceased, and the 
reaction mixture was concentrated under reduced pressure. The residue was taken up in 
ethyl acetate (30 mL) and water (30 mL), and the phases separated. The aqueous phase 
was extracted with a further 30 mL of ethyl acetate, before the combined organic phases 
were dried over MgSO4, and concentrated under reduced pressure to give the product as 
a white, crystalline solid (2.39 g, 93%). 
 
1H NMR (500 MHz, CDCl3) δ 7.54 (1H, d, J = 1.8 Hz, 8-CH), 7.37 (1H, dd, J = 8.0, 1.8 
Hz, 6-CH), 7.12 (1H, d, J = 8.0 Hz, 5-CH), 5.22 (1H, t, J = 6.3 Hz, 10-OH), 3.05 – 2.93 
(1H, m , 3-CHH), 2.84 – 2.70 (1H, m, 3-CHH), 2.59 – 2.43 (1H, m 2-CHH), 2.02 – 1.89 
(1H, m, CHH).  
 
6-(Pyridin-2-yloxy)-2,3-dihydro-1H-inden-1-ol (167) 
 
To a suspension of 6-(2-pyridyloxy)indan-1-one (165, 3.00 g, 13.3 mmol)  in methanol 
(25 mL)  was added portion-wise sodium borohydride (504 mg, 13.3 mmol), keeping the 
level of effervescence under control. The solution was allowed to stir for 45 minutes, by 
which point effervescence had ceased, and concentrated under reduced pressure. The 
residue was taken up in ethyl acetate (30 mL) and water (30 mL), and the phases 
separated. The aqueous phase was extracted with a further 30 mL of ethyl acetate, before 
the combined organic phases were washed with brine (30 mL) dried over MgSO4, and 
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concentrated under reduced pressure to give the product as a light brown oil (2.97 g, 
98%). 
 
1H NMR (500 MHz, CDCl3) δ 8.15 (1H, dd, J = 5.0, 2.1 Hz, 14-CH), 7.66 (1H, ddd, J = 
8.3, 7.2, 2.0 Hz, 12-CH), 7.23 (1H, d, J = 8.1 Hz, 5-CH), 7.15 (1H, d, J = 2.2 Hz, 8-CH), 
7.01 (1H, dd, J = 8.1, 2.3 Hz, 6-CH), 6.96 (1H, ddd, J = 7.2, 5.0, 0.9 Hz, 13-CH), 6.89 
(1H, d, J = 8.3 Hz, 11-CH), 5.19 (1H, t, J = 6.3 Hz, 1-CHOH), 3.05 – 2.97 (1H, m, 3-
CHH), 2.84 – 2.73 (1H, m, 3-CHH), 2.54 – 2.46 (1H, m, 2-CHH), 2.32 (1H, s, 15-OH), 
2.00 – 1.90 (1H, m, 2-CHH); 13C NMR (126 MHz, CDCl3) δ 164.0 (10-C), 153.1 (7-C), 
147.6 (14-CH), 146.8 (9-C), 139.4 (4-C), 139.3 (12-CH), 125.7 (5-CH), 121.3 (6-CH), 
118.2 (13-CH), 117.1 (8-CH), 111.5 (11-CH), 76.3 (1-CHOH), 36.4 (2-CH2), 29.3 (3-
CH2); IR (neat, νmax, cm-1) 3323 (brw), 2935 (w), 2851 (w). 1590 (m), 1466 (s), 1424 (s), 
1243 (s), 1167 (m), 1143 (m), 1048 (m), 921 (w), 857 (m), 822 (w) 776 (s); MS (EI): m/z 
78 (23%), 198 (23%), 199 (17%), 226 (99%), 227 (100%, mass ion) 228 (17%); LCMS 
(acetonitrile/water, 30-70%, 4 mins) Retention time: 1.64 min, m/z: 228.1 [M+H]+. 
 
Triphenyl(6-(pyridin-2-yloxy)-2,3-dihydro-1H-inden-1-yl)phosphonium bromide 
(168) 
 
A solution of 6-(2-pyridyloxy)indan-1-ol (167, 1.91 g, 8.39 mmol) and 
triphenylphosphonium bromide (3.45 g, 10.1 mmol)  in  toluene (30 mL)  was refluxed 
overnight at  110 °C, forming a white precipitate. The solution was cooled to room 
temperature, and the white precipitate was collected by vacuum filtration. The solid 
material was triturated in ether to give the product as a light pink solid (906 mg, 20%). 
 
1H NMR (500 MHz, CDCl3) δ 8.06 (1H, d, J = 4.7 Hz, 14-CH), 7.96 – 7.80 (7H, m, 
17/19/23/25/29/31-CH, 12-CH), 7.74 – 7.66 (3H, m, 18/24/30-CH), 7.64 – 7.54 (6H, m, 
16/20/22/26/28/32-CH), 7.13 – 7.05 (1H, m, 13-CH), 7.05 – 6.84 (3H, m, 5-CH, 6-CH, 
11-CH), 6.59 (1H, s, 8-CH), 3.43 – 3.20 (1H, m, 3-CHH), 2.82 – 2.65 (1H, m, 2-CHH), 
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2.50 – 2.32 (1H, m, 3-CHH), 1.78 – 1.63 (1H, m, 2-CHH).13C NMR (126 MHz, CDCl3) 
δ 162.1 (10-C), 152.6 (4-C), 145.1 (14-CH), 142.8 (9-C), 142.3 (12-CH), 134.8 
(18/24/30-CH), 134.4 (17/19/23/25/29/31-CH), 134.3 (17/19/23/25/29/31-CH), 130.4 
(16/20/22/26/28/32-CH), 130.3 (16/20/22/26/28/32-CH), 126.2 (5-CH), 121.9 (6-CH), 
119.6 (8-CH), 118.8 (13-CH), 118.3 (15/21/27-C), 117.7 (15/21/27-C), 112.5 (11-CH), 
39.9 (1-C), 39.6 (1-C), 30.6 (2-CH2), 27.7 (3-CH2); IR (neat, νmax, cm-1) 3442 (w), 2827 
(w), 1733 (w), 1584 (m), 1486 (m), 1462 (m), 1423 (s), 1234 (s), 1110 (s), 993.4 (m), 
948.6 (m), 883 (m), 842 (m), 784 (m), 706 (s), 752 (s), 725 (s), 693 (s); HRMS (ESI): 
calcd. for C32H27NOP [M]+ 472.1825, found 472.1814; LCMS (acetonitrile/water, 30-
70%, 4 mins) Retention time: 1.20 min, m/z: 472.1 [M]+. 
 
(3-Bromobenzyl)triphenylphosphonium bromide (172) 
 
To a solution of  3-bromobenzyl bromide (1.00 g, 4.00 mmol)  in  toluene (13 mL)  was 
added  triphenylphosphine (1.05 g, 4.00 mmol)  and the solution was refluxed for 16 
hours, forming a white precipitate. The white precipitate was collected by vacuum 
filtration, and washed with diethyl ether (2 x 15 mL), and allowed to dry to give the 
product as a white, crystalline powder (1.89 g, 92 %). 
 
1H NMR (500 MHz, CDCl3) δ 7.83 – 7.73 (9H, m, 10/12/16/18/22/24-CH, 11/17/23-
CH), 7.67 – 7.59 (6H, m, 9/13/15/21/19/25-CH), 7.35 – 7.28 (2H, m, 4-CH, 6-CH), 7.02 
– 6.94 (2H, m, 2-CH, 5-CH), 5.57 (2H, d, J = 14.7 Hz, 7-CH2); 13C NMR (126 MHz, 
CDCl3) δ 135.0 (11/17/23-CH), 134.9 (11/17/23-CH), 134.5 (10/12/16/18/22/24-CH), 
134.4 (10/12/16/18/22/24-CH), 134.0 (2-CH), 131.3 (6-CH), 130.6 (4-CH), 130.2 (5-
CH), 130.2 (9/13/15/21/19/25-CH), 130.1 (9/13/15/21/19/25-CH), 129.8 (1-C), 122.2 (3-
CBr), 118.0 (8/14/20-C), 117.3 (8/14/20-C), 30.5 (7-CH2), 30.2 (7-CH2); IR (neat, νmax, 
cm-1) 3054 (w), 2844 (w), 2777 (w), 1727 (s), 1456 (m), 1390 (s), 1308 (m), 1247 (s), 
1217 (s), 1075 (m), 996 (m), 867 (s), 810 (m), 740 (s), 696 (s); HRMS (ESI): calcd. for 
C25H21BrP [M]+ 431.0559, found 431.0553. 
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Benzyl 3-formyl-1H-indole-1-carboxylate (179)353 
 
To a suspension of sodium hydride (220 mg, 16.5 mmol) in tetrahydrofuran (15 mL) at 0 
°C was added portion-wise indole-3-carboxaldehyde (2.2 g, 15 mmol) over 20 minutes. 
The solution was allowed to warm to room temperature and stir for a further 20 minutes. 
The solution was then cooled to 0 °C and benzyl chloroformate (2.36 mL, 16.5 mmol) was 
added, before the solution was allowed to warm to room temperature and stir overnight. 
The solution was diluted with water (50 mL) and EtOAc (50 mL), and the aqueous phase 
was further extracted with ethyl acetate (2 x 50 mL). The combined organic phase was 
washed with saturated NaHCO3 solution (40 mL) and brine (2 x 40 mL), before being 
dried over magnesium sulphate and concentrated under reduced pressure to give a brown 
oil (5.092 g). The crude material was recrystallized from to give the product as a white 
crystalline solid (2.311 g, 55%). 
 
1H NMR (500 MHz, Chloroform-d) δ 10.10 (1H, s, 9-CO), 8.30 (1H, d, J = 7.9 Hz, 4-
CH), 8.26 (1H, s, 1-CH), 8.20 (1H, d, J = 8.1 Hz, 7-CH), 7.55 – 7.50 (2H, m, 13/17-CH), 
7.48 – 7.37 (m, 5H, 5-CH, 6-CH, 14/16-CH, 15-CH), 5.52 (2H, s, 11-CH2); LCMS 
(acetonitrile/water, 30-70%, 10 mins) Retention time: 2.62 min, m/z: 280.0 [M+H]+. 
 
(E/Z)-Benzyl 3-((6-bromo-2,3-dihydro-1H-inden-1-ylidene)methyl)-1H-indole-1-
carboxylate (180) 
 
To a stirred suspension of (6-bromoindan-1-yl)-triphenyl-phosphonium bromide (94, 
1.62 g, 3.00 mmol) in tetrahydrofuran (15 mL) at 0 °C was added sodium hydride (132 
mg, 3.3 mmol). The solution was stirred for a further 20 minutes before adding benzyl 3-
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formylindole-1-carboxylate (179, 920 mg, 3.3 mmol). The solution was then allowed to 
warm to room temperature and stir for a further 18 hours. The solution was then 
concentrated under reduced pressure, giving a light brown precipitate. This precipitate 
was washed with water (40 mL) and CH2Cl2 (30 mL) before triturating in ethyl acetate 
(30 mL) to give the product as a fine white powder (671 mg, 49 %). 
 
1H NMR (500 MHz, CDCl3) δ 8.19 (1H, s, 14-CH), 7.82 – 7.74 (2H, m, 15-CH, 17-CH), 
7.71 (1H, s, 11-CH) 7.55 – 7.50 (2H, m, 22/26-CH), 7.48 – 7.30 (6H, m, 23/25-CH, 16-
CH, 24-CH, 8-CH, 6-CH), 7.16 (1H, d, J = 7.9 Hz, 5-CH), 7.08 (1H, s, 10-CH), 5.51 (2H, 
s, 20-CH2), 3.21 – 2.77 (4H, m, 2-CH2, 3-CH2); 13C NMR (126 MHz, CDCl3) δ 151.0 
(19-CO), 145.0 (1-C), 144.4 (4-C), 143.3 (9-C), 135.2 (21-C), 135.0 (18-C), 130.7 (6-
CH), 130.4 (13-C), 128.8 (23/25-CH), 128.7 (16-CH), 128.4 (22/26-CH), 126.7 (5-CH), 
125.2 (24-CH), 123.2 (8-CH), 122.4 (11-CH), 120.8 (17-CH), 119.2 (7-CBr), 118.9 (15-
CH), 117.7 (12-C), 115.3 (14-CH), 108.4 (10-CH), 68.8 (20-CH2), 31.7 (3-CH2), 30.2 (2-
CH2); IR (neat, νmax, cm-1) 3052 (w), 2919 (w), 1726 (s), 1455 (s), 1400 (s), 1366 (s), 
1352 (s), 1309 (s), 1259 (s), 1250 (s), 1219 (s), 1173 (m), 1091 (m), 1034 (m), 961 (m), 
867 (m), 795 (m), 758 (s), 741 (s), 691 (s); HRMS (ESI): calcd. for C26H20BrNNaO2 
[M+Na]+ 480.0570, found 480.0572. 
 
(E/Z)-Benzyl 3-((6-(pyridin-2-yloxy)-2,3-dihydro-1H-inden-1-ylidene)methyl)-1H-
indole-1-carboxylate (181) 
 
To a stirred suspension of triphenyl-[6-(2-pyridyloxy)indan-1-yl]phosphonium bromide 
(168, 750 mg, 1.36 mmol) in dichloromethane (4 mL) and 18-crown-6 (3.6 mg, 0.01 
mmol) in a screw-top reactivial under nitrogen gas was added potassium carbonate (1.87 
g, 13.6 mmol). The solution was stirred for half an hour, and benzyl 3-formylindole-1-
carboxylate (179, 417 mg, 1.49 mmol) was added. The solution was then allowed to stir 
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room temperature overnight (approximately 18 hours). The solution was then diluted with 
water (20 mL) and dichloromethane (20 mL). The aqueous phase was washed with 
dichloromethane (20 mL), and the combined organic phases were washed with brine (20 
mL) and dried over magnesium sulfate, filtered, and concentrated under reduced pressure. 
The resulting residue was purified by column chromatography (PE/EtOAc, 0% to 20%), 
causing a crystalline solid to form in the product fraction test tubes. This was collected 
by vacuum filtration, giving the product as a light yellow crystalline solid (132 mg, 21%). 
 
1H NMR (500 MHz, CDCl3) δ 8.24 (1H, dd, J = 5.1, 2.0 Hz, 14-CH), 8.19 (1H, s, 19-
CH), 7.76 – 7.67 (3H, m, 8-CH, 12-CH, 16-CH), 7.53 (2H, d, J = 7.3 Hz, 27/31-CH), 
7.47 – 7.29 (7H, m, 22-CH, 28/30-CH, 21-CH, 29-CH, 5-CH, 20-CH), 7.06 – 6.98 (3H, 
m, 15-CH, 6-CH, 13-CH), 6.96 (1H, d, J = 8.3 Hz, 11-CH), 5.52 (2H, s, 25-CH2), 3.18 – 
3.13 (2H, m, 3-CH2), 3.10 – 3.06 (2H, m, 2-CH2); 13C NMR (126 MHz, CDCl3) δ 164.2 
(10-C), 153.4 (7-C), 151.0 (24-CO), 147.8 (14-CH), 144.3 (4-C), 143.8 (9-C), 142.7 (1-
C), 139.3 (12-CH), 135.2 (26-C), 135.0 (23-C), 130.5 (18-C), 128.8 (28/30-CH), 128.7 
(21-CH), 128.4 (27/31-CH), 126.2 (5-CH), 125.0 (29-CH), 123.1 (20-CH), 122.2 (16-
CH), 121.5 (6-CH), 119.4 (17-C), 119.0 (8-CH), 118.2 (13-CH), 115.3 (19-CH), 112.8 
(22-CH), 111.3 (11-CH), 107.9 15-CH), 68.8 (25-CH2), 32.1 (2-CH2), 30.2 (3-CH2); IR 
(neat, νmax, cm-1) 3034 (w), 2929 (w), 1726 (s), 1591 (m), 1470 (s), 1458 (s), 1429 (s), 
1399 (s), 1306 (m), 1240 (s), 1214 (s), 1073 (m), 1014 (m), 913 (w), 852 (m), 745 (s); 
HRMS (ESI): calcd. for C62H48N4NaO6 [2M+Na]+ 967.3466, found 967.3432; MS (EI): 
m/z 91 (23%), 243 (76%), 337 (58%), 368 (12%), 428 (11%), 472 (70%). 
 
(E/Z)-Benzyl 3-(3-bromostyryl)-1H-indole-1-carboxylate (182) 
 
To a stirred suspension of (3-bromophenyl)methyl-triphenyl-phosphonium bromide (172, 
102 mg, 0.200 mmol) in  dichloromethane (0.4 mL) and  18-crown-6 (1 mg, 0.01 
mmol) in a screw-top reactivial under nitrogen gas was added  potassium carbonate (276 
mg, 2.00 mmol). The solution was stirred for half an hour, before benzyl 3-formylindole-
1-carboxylate (179, 61 mg, 0.22 mmol) was added. The solution was then allowed to stir 
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at ambient temperatures overnight (approx. 18 hours). The solution was then diluted with 
water (20 mL) and CH2Cl2 (20 mL). The aqueous phase was washed with CH2Cl2 (20 
mL), and the combined organic phases were washed with brine (20 mL) and dried over 
MgSO4, before being filtered and concentrated under reduced pressure. The resulting 
residue was purified by column chromatography (PE/EtOAc, 0% to 10%) to give trans 
and cis isomers of the product. The combined weight of both isomers was 44 mg, as a 
white crystalline solid (56% yield). 
 
(cis isomer) 
1H NMR (500 MHz, CDCl3) δ 8.14 (1H, d, J = 8.2 Hz, 28-CH), 7.46 (1H, s, 2-CH), 7.42 
(1H, s, 9-CH), 7.40 – 7.25 (8H, m, 20/24-CH, 21/23-CH, 13-CH, 15-CH, 4-CH, 6-CH), 
7.22 – 7.13 (2H, m, 22-CH, 14-CH), 7.03 (1H, t, J = 7.8 Hz, 5-CH), 6.66 – 6.58 (2H, m, 
7-CH, 8-CH), 5.37 (2H, s, 18-CH2); 13C NMR (126 MHz, CDCl3) δ 150.3 (17-CO), 139.9 
(1-C), 138.0 (16-C), 135.0 (19-C), 131.5 (2-CH), 130.2 (4-CH), 129.8 (5-CH), 129.8 (7-
CH), 128.7 (21/23-CH), 128.6 (22-CH), 128.2 (20/24-CH), 127.1 (6-CH), 124.9 (15-CH), 
123.7 (9-CH), 123.7 (11-C), 123.0 (14-CH), 122.4 (3-CBr), 121.1 (8-CH), 119.8 (13-C), 
117.4 (10-C), 115.1 (12-CH), 68.7 (18-CH2); IR (neat, νmax, cm-1) 3034 (w), 1739 (s), 
1589 (w), 1566 (w), 1456 (s), 1395 (m), 1350 (m), 1255 (s), 1221 (s), 1074 (m), 1018 
(w), 747 (m), 697 (m); HRMS (ESI): calcd. for C24H19BrNO2 [M+H]+ 434.0579, found 
434.0574 
 
(trans isomer) 
1H NMR (500 MHz, CDCl3) δ 8.24 (1H, d, J = 8.0 Hz, 12-CH), 7.88 (1H, dd, J = 7.6, 1.4 
Hz, 15-CH), 7.78 (1H, s, 9-CH), 7.67 (1H, d, J = 1.8 Hz, 2-CH), 7.50 (2H, d, J = 7.1 Hz, 
20/24-CH), 7.46 – 7.29 (7H, m, 21/23-CH, 13-CH, 14-CH, 4-CH, 5-CH, 6-CH), 7.25 – 
7.16 (2H, m, 7-CH, 22-CH), 7.11 (1H, d, J = 16.5 Hz, 8-CH), 5.47 (2H, s, 18-CH2); 13C 
NMR (126 MHz, CDCl3) δ 150.7 (17-CO), 139.8 (1-C), 136.2 (16-C), 135.0 (19-C), 
130.2 (4-CH), 130.1 (5-CH), 129.8 (2-CH), 128.9 (22-CH), 128.8 (21/23-CH), 128.5 
(20/24-CH), 127.7 (8-CH), 125.2 (14-CH), 124.8 (6-CH), 123.9 (15-C), 123.4 (9-CH), 
123.0 (11-C), 122.9 (3-CBr), 121.2 (7-CH), 120.0 (13-CH), 119.5 (10-CH), 115.5 (12-
CH), 68.9 (18-CH2); IR (neat, νmax, cm-1) 3035 (w), 2983 (w), 1739 (s), 1455 (m), 1393 
(m), 1356 (m), 1247 (s), 1095 (m), 1004 (m), 956 (m), 910 (m), 747 (m), 696 (s); LRMS 
(EI): m/z 91 (100%), 217 (34%), 387 (66%), 389 (65%), 431 (46%, mass ion), 433 (48%, 
mass ion). 
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2-(1H-Indol-3-yl)ethanol (185)354 
 
Phenylhydrazine (7.7 mL, 78 mmol) was added to 1M HCl solution (80 mL), and 
topped up with water (20 mL) and sulfuric acid (2.71 mL, 48.2 mmol). To this solution 
was added N,N-dimethylacetamide (100 mL), and heated to 100 °C. 2,3-dihydrofuran 
(6.04 mL, 78.3 mmol) was added dropwise over 5 mins to the solution. The solution was 
then stirred at 100 °C for 2 hours, developing a red colour. The solution was extracted 
with ethyl acetate (3 x 100 mL), and the combined organic phase was washed with 0.5 
M LiCl solution (100 mL), water (2 x 100 mL) and brine (2 x 100 mL). The organic phase 
was then dried over magnesium sulfate, and concentrated under reduced pressure to give 
an orange oil. The orange oil was purified by column chromatography (PE:EtOAc, 0-
65%, 100 g silica) to give the product as a light orange, crystalline solid (5.89 g, 47%). 
 
1H NMR (500 MHz, DMSO-d6) δ 10.74 (1H, s, 1-NH), 7.50 (1H, d, J = 7.9 Hz, 5-CH), 
7.32 (1H, d, J = 8.1 Hz, 8-CH), 7.14 – 7.10 (1H, m, 2-CH), 7.04 (1H, d, J = 7.7 Hz, 6-
CH), 6.96 (1H, d, J = 7.4 Hz, 7-CH), 4.58 (1H, t, J = 5.4 Hz, 12-OH), 3.65 (2H, td, J = 
7.3, 5.4 Hz, 11-CH2), 2.84 (2H, d, J = 7.3 Hz, 10-CH2). 
 
3-(2-Bromoethyl)-1H-indole (186)355 
 
To a solution of triphenylphosphine (680 mg, 2.6 mmol) and 2-(1H-indol-3-yl)ethanol 
(185, 320 mg, 2.0 mmol) in dichloromethane (3 mL) at 0 °C was added dropwise a 
solution of tetrabromomethane (860 mg, 2.6 mmol) in dichloromethane (2 mL). The 
solution was allowed to warm to room temperature and stir for a further 3 hours. The 
solution was then concentrated under reduced pressure, giving a brown oil. This crude 
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mixture was purified by column chromatography (P:E/EtOAc, 0-25%), giving 329 mg of 
a light brown solid. The brown solid was then recrystallized from PE (100-120 °C 
fraction), to give the product as a crystalline, off-white solid (329 mg, 73%). 
 
1H NMR (500 MHz, Chloroform-d) δ 8.01 (1H, s, 1-NH), 7.62 (1H, d, J = 7.5 Hz, 5-CH), 
7.39 (1H, d, J = 7.5 Hz, 8-CH), 7.24 (1H, dd, J = 7.5 Hz, 6-CH), 7.17 (1H, dd, J = 7.5 Hz, 
7-CH), 7.10 (1H, s, 2-CH), 3.67 (2H, t, J = 7.7 Hz, 11-CH2Br), 3.37 (2H, t, J = 7.7 Hz, 
10-CH2).  
 
(E/Z)-Benzyl 3-((6-(phenylethynyl)-2,3-dihydro-1H-inden-1-ylidene)methyl)-1H-
indole-1-carboxylate (194) 
 
In a screw cap reaction vial with a septum was added a solution of 
bis(triphenylphosphine)palladium(II) dichloride (2.81 mg, 0.01 mmol),  copper iodide 
(1.5 mg, 0.010 mmol), triethylamine (139 μL, 1.00 mmol)  and benzyl 3-[(E/Z)-(6-
bromoindan-1-ylidene)methyl]indole-1-carboxylate (180, 92 mg, 0.20 mmol), before 
being purged with nitrogen. Phenylacetylene (26 μL, 0.24mmol) was then added, and the 
sealed vial was heated to 70 °C. The solution was allowed to stir overnight before being 
cooled to room temperature. The solution was diluted with ethyl acetate (20 mL) and 
water (20 mL), and the aqueous phase further extracted with ethyl acetate (10 mL). The 
combined organic phase was then washed with saturated sodium bicarbonate solution (2 
x 20 mL), 1M HCl solution (2 x 20 mL), and brine (20 mL), before being concentrated 
onto silica and purified by flash column chromatography (0% to 25% EtOAc:PE). 
Precipitate from the chromatographic elute were collected by vacuum filtration to give 
the product as a white crystalline solid (23 mg, 24%).  
 
1H NMR (500 MHz, Chloroform-d) δ 8.20 (1H, s, 22-CH), 7.85 (1H, s, 8-CH), 7.80 (1H, 
d, J = 7.8 Hz, 25-CH), 7.73 (1H, s, 19-CH), 7.58 (2H, d, J = 7.8 Hz, 13/17-CH), 7.53 (2H, 
d, J = 7.3 Hz, 30/34-CH), 7.48 – 7.33 (7H, m, 5-CH, 31/33-CH, 6-CH, 32-CH, 14/16-
CH), 7.32 – 7.27 (1H, m, 15-CH), 7.18 – 7.31 (1H, m, 18-CH), 5.52 (2H, s, 28-CH2), 3.20 
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– 3.14 (2H, m, 3-CH2), 3.09 – 3.02 (2H, m, 2-CH2); 13C NMR (126 MHz, CDCl3) δ 151.0 
(27-CO), 146.7 (4-C), 143.8 (9-C), 142.3 (1-C), 135.2 (29-C), 131.6 (13/17-CH), 131.3 
(6-CH), 130.5 (26-C), 128.8 (31/33-CH), 128.7 (5-CH), 128.4 (14/16-CH), 128.3 (30/34-
CH), 128.1 (24-CH), 125.3 (15-CH), 125.1 (32-CH), 123.4 (7-C), 123.2 (23-CH), 123.1 
(8-CH), 122.2 (21-C), 121.6 (12-C), 119.4 (20-C), 119.0 (25-CH), 115.3 (22-CH), 107.9 
(18-CH), 89.8 (10-C), 88.8 (11-C), 68.8 (28-CH2), 31.6 (2-CH2), 30.7 (3-CH2); IR (neat, 
νmax, cm-1) 3049 (w), 2915 (w), 1727 (s), 1543 (w), 1455 (s), 1392 (s), 1352 (m), 1396 
(m), 1249 (s), 1218 (s), 1076 (m), 1013 (m), 867 (m), 754 (s), 740 (s), 698 (m), 613 (m); 
HRMS (ESI): calcd. for C68H50N2NaO4 [2M+Na]+ 981.3663, found 981.3656; LRMS 
(EI): m/z 91 (87%), 344 (100%), 355 (45%), 435 (13%), 436 (6%), 479 (51%, mass ion), 
480 (19%, mass ion). 
 
3-((6-Phenethyl-2,3-dihydro-1H-inden-1-yl)methyl)-1H-indole (196) 
 
A stirred solution of benzyl 3-[(E/Z)-[6-(2-phenylethynyl)indan-1-
ylidene]methyl]indole-1-carboxylate (194, 23 mg, 0.05 mmol) and palladium on charcoal 
(2 mg) in tetrahydrofuran (5 mL) was placed under an atmosphere of hydrogen gas. The 
solution was stirred until no starting material was present by TLC (approximately 42 
hours). The hydrogen atmosphere was then replaced with nitrogen gas. The solution was 
filtered through a celite plug to remove any palladium on charcoal, and concentrated 
under reduced pressure. The crude material was purified using prep-scale HPLC 
(acetonitrile/water, 50% to 95%, 20 minutes), to give the product as a light brown solid 
(3 mg, 18%) 
 
1H NMR (500 MHz, CDCl3) δ 7.92 (1H, s, 18-NH), 7.65 (1H, d, J = 7.9 Hz, 22-CH), 
7.38 (1H, d, J = 8.1 Hz, 25-CH), 7.33 – 7.28 (2H, m, 13/17-CH), 7.23 – 7.18 (4H, m, 
14/16-CH, 15-CH, 19-CH), 7.17 – 7.13 (2H, m, 6-CH, 24-CH), 7.03 (2H, s, 5-CH, 23-
CH), 6.92 (1H, s, 8-CH), 3.60 – 3.50 (1H, m, 7-CH), 3.23 (1H, dd, J = 14.6, 5.5 Hz, 18-
CHH), 2.91 – 2.73 (7H, m, 3-CH2, 10-CH2, 11-CH2, 18-CHH), 2.25 – 2.17 (1H, m, 2-
CHH), 1.89 – 1.78 (1H, m, 2-CHH); 13C NMR (126 MHz, CDCl3) δ 147.6 (4-C), 142.0 
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(12-C), 141.7 (9-C), 139.6 (7-C), 136.3 (26-C), 128.4 (14/16-CH), 128.2 (13/17-CH), 
126.6 (21-C), 125.8 (15-CH), 124.2 (6-CH), 124.0 (5-CH), 121.9 (19-CH), 121.8 (8-CH), 
119.2 (22-CH), 119.0 (24-CH), 115.3 (23-CH), 113.2 (20-C), 111.0 (25-C), 45.4 (1-CH), 
38.2 (10-CH2), 37.8 (11-CH2), 32.4 (3-CH2), 30.8 (2-CH2, 18-CH2); IR (neat, νmax, cm-1) 
3641 (w), 2959 (s), 2926 (s), 2871 (m), 1724 (m), 1435 (m), 1383 (w), 1351 (w), 1273 
(m), 1160 (m), 1121 (m), 1059 (w), 970 (w), 753 (w);  MS (EI): m/z 91 (57%), 120 
(37%), 129 (34%), 219 (100%), 243 (26%), 337 (24%), 352 (85%, mass ion). 
 
6.3 Biochemical Procedures 
6.3.1 Circular Dichroism 
Circular dichroism was carried out on a JASCO J-715 series CD spectrometer. The 
protein was suspended as a 1.2 mg/mL solution in deionised water. This solution was 
diluted to a 0.3 mg/mL solution using deionised water, then placed in a 0.5 mm cuvette. 
The spectrum was recorded between 300 nm and 180 nm, and baseline-corrected by 
subtraction of a spectrum of deionised water. The data was then converted to deg. 
Cm2.dmol-1 for analysis. 
6.3.2 Miniprotein Refolding General Procedure 
A lyophilised sample of 1.0 mg peptide sequence was suspended in phosphate buffer (3 
mL, pH 8.0). This solution was mixed with trifluoroethanol (6 mL), and TCEP solution 
added (0.5 M, 30 μL, pH 7.0) before being allowed to stir for three hours. DMSO (1 mL) 
was then added to quench any remaining TCEP, and the solution stirred in oxygen for 48 
hours to promote the formation of disulphide bridges. The resulting solution was 
concentrated under a stream of pressurised air at 30 °C, giving a solid residue ready to be 
desalted using Waters Sep-Pak C-18 200mg cartridges. 
6.4 Computational Procedures 
6.4.1 Small Molecule Mimetics: Markush Enumeration 
Aim: To generate a database of structures designed to mimic BRCA2, with filters to 
remove any structurally unstable or unwanted functionalities generated. 
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Software Package(s): KNIME version 2.9.1 (KNIME AG, 8005 Zurich, Switzerland, 
https://www.knime.org), Infocom JchemExtentions 2.6.3.v0200 (Infocom Corp., 
Shibuya-ku, Tokyo, 150-0001, https://www.infocom.co.jp/bio/knime/) 
General Procedure: 
 
Details and Parameters: 
Markush Structures 
Markush structures were constructed in the ChemAxon ‘Marvin Sketch’ node. The ‘atom 
list’ and ‘link node’ tools were used to define parameters for each atomic centre. The 
information was output as the ChemAxon ‘MrvCell’ format. An example of a typical 
Markush structure is shown below. 
L
[C;N]
L [C;N]
(L1-2)
HN
L
[C;N;O];(L1-2)
 
Figure 6.1: A typical Markush structure for enumeration. 
Markush Enumeration 
The Infochem/Chemaxon ‘Markush Enumeration’ node was used for enumeration, with 
the following parameters: 
x Calculation: Sequential enumeration. 
x Calculation: Generate all enumerations. 
Markush 
structures were 
constructed in 
MarvinSketch 
input nodes in 
KNIME 
Enumeration 
carried out by 
ChemAxon 
/Infocom 
‘Markush 
Enumeration’ 
Unstable and 
unwanted 
structures 
removed by 
ChemAxon/Infoco
m MolSearch 
Unstable and 
unwanted 
structures defined 
in MarvinSketch 
input node. 
Resulting 
database exported 
as .sdf file. 
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x Output: MrvCell 
Structure Filters 
The Infochem/Chemaxon ‘MolSearch’ node was used in combination with the ‘Marvin 
Sketch’ node for structure filtering, with the following parameters: 
x Search type: Substructure 
The functionalities specified in ‘Marvin Sketch’ nodes for removal were the aliphatic 
heteroatom-heteroatom bonds O-N, N-N and O-O. 
6.4.2 Small Molecule Mimetics: Conformer Generation And Alignment To 
BRCA2 
Aim: To generate conformers of BRCA2 mimetic designs, aligning them to the hotspot 
residues on the BRCA2 helix, and determining the best aligning structures. 
Software Package(s): KNIME version 2.9.1, RDKit (Greg Landrum, RDKit: Open-
source cheminformatics, http://www.rdkit.org), PyMOL 1.7.6.6 (Schrodinger, LLC, 
Cambridge, Cambridgeshire, UK, CB1 2JD, https://www.pymol.org). 
General Procedure: 
 
Database of 
structures 
imported from 
.sdf file. 
Conformers 
generated using 
looped ‘RDKit 
Add Conformers’ 
Node. 
Conformers 
aligned to BRCA2 
structure using 
‘RDKit open 3D 
Alignment’ node. 
Structure of 
BRCA2 edited to 
only leave hot-
spot residues, and 
imported as .sdf 
structure. 
Results sorted by 
alignment score, 
and filtered to 
only contain the 
best results. 
The best aligning 
conformers 
exported to .sdf 
database for 
further analysis. 
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Details and Parameters: 
Import of databases 
A database of BRCA2 mimetic designs was imported to the KNIME workflow in .sdf 
format. The database was previously manually curated, or generated using Markush 
enumeration (6.4.1). 
Conformer Generation 
Conformers were generated for each structure using the ‘RDKit Add Conformers’ node. 
The node was placed into a variable loop, with each iteration of the loop containing one 
structure for conformer generation. The conformers were concatenated into a single 
database at the loop end. The ‘RDKit Add Conformers’ node was configured with the 
following parameters: 
x Number of conformers: 5000 
x Maximum number of tries to generate conformers: 200 
x Random seed: -1 
x RMS threshold for keeping a conformer: -1.0 
x Use random co-ordinates as a starting point for distance geometry: No 
x Perform a clean-up using universal forcefield after calculation: Yes 
Importing BRCA2 Hotspot residues 
The necessary BRA2 hotspot residues for the alignment, as well as their backbone 
connecting atoms, were extracted from the PALB2/BRCA2 crystal structure (3EU7). 
This was done in PyMOL using the structure editing tools, and saved as an .sdf file for 
import into the KNIME workflow.  
 
Figure 6.2: Extraction of i, i+1 residues for mimetic alignment studies. 
Aligning Conformers to BRCA2 Hotspots 
193 
 
 
The conformers generated using the ‘RDKit Add Conformers’ node were aligned to the 
modified helix residues using the ‘RDKit Open 3D Alignment’ node. The parameters set 
were: 
x Allow reflection: No 
x Maximal number of iterations: 50 
x Accuracy (0 – most accurate, 3 – least accurate): 0 
When the alignment was done, the results were sorted by score, and the top 200 results 
exported to .sdf database format for further analysis. 
6.4.3 Small Molecule Mimetics: MOE E_Strain 
Aim: To calculate the strain that the best aligning conformers are under using MOE 
E_Strain tools, to help remove any highly strained conformers. 
Software Packages: MOE 2015.1001 (Chemical Computing Group, Montreal, Quebec, 
Canada, H3A 2R7, https://www.chemcomp.com/). 
General Procedure: 
 
Details and Parameters: 
The E_Strain calculations were carried out in the MMFF94x environment in MOE. The 
MOE database viewer was then used to calculate E_Strain, found in Compute > 
Descriptors > Calculate > E_Strain. The database could then be manipulated in MOE, or 
exported an .sdf with E_Strain values for manipulation in KNIME. 
6.4.4 Small Molecule Mimetics: Small Molecule Docking in MOE 
Aim: To dock the best aligning BRCA2 mimetics into the binding site on PALB2 as a 
second prediction for binding affinity.  
Software Package(s): MOE 2015.1001. 
Import .sdf file of best aligning 
conformers into MOE .mdb 
format. 
Calculate E_Strain for each 
database entry in MOE. 
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General Procedure: 
 
Details and Parameters: 
Import of Protein Crystal Structure into MOE 
The 3EU7 crystal structure was downloaded from the protein data bank, and opened in 
MOE. Before docking was carried out, the structure was prepared using the ‘Structure 
Preparation’ and ‘Protonate 3D’ tools. The BRCA2 helix was redefined as a ligand rather 
than a protein by isolating the structure and then exporting as a .mol2 file. The .mol2 file 
was then opened into MOE, causing it to recognise the structure as a small molecule. The 
session with the modified BRCA2 and the PALB2 structure from 3EU7 was then 
exported as a .pdb file, so that when it was imported MOE recognised the structure as a 
protein/ligand rather than a protein/protein interaction. 
Preparation of Pharmacophore Parameters for Docking 
Pharmacophores were generated from the structure of BRCA2 bound to PALB2. 4 
pharmacophores were used to direct the i and i+1 groups from the designed mimetics into 
the correct position in the PALB2 binding site. These were two aromatic rings and a 
nitrogen atom for the i indole ring, and an aromatic ring for the i+1 phenyl group (Figure 
6.3) 
BRCA2/PALB2 
3EU7 .pdb 
structure 
imported into 
MOE and 
prepared. 
Pharmacophore 
parameters 
developed based 
on the BRCA2 
hot-spot residues 
Conformers 
docked into 
PALB2 using the 
pharmacophore to 
guide the i and 
i+1 positions.  
Best aligning 
conformers with 
low E_Strain 
imported into 
MOE. 
Results of 
docking study 
exported as .sdf 
database for 
analysis. 
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Figure 6.3: Use of pharmacophores to guide the docking of BRCA2 mimetics 
Docking Designed BRCA2 Mimetics into PALB2 
The best BRCA2 mimetic from alignment studies were imported into MOE as an .sdf 
database. These were then docked into the PALB2 binding site using the ‘Dock’ function 
in MOE with the following parameters: 
x Forcefield: Amber10:EHT 
x Receptor: Receptor+Solvent 
x Site: Ligand atoms 
x Placement: α-Triangle 
o Minimum iterations: 300 000 
o Maximum Iterations: 10 000 000 
o Timeout: 600 seconds 
x Refinement: Induced fit 
o Termination criterion: Gradient = 0.01, iterations = 500 
o Pharmacophore restraint: Force constant = 100, radius offset = 0.4 
6.4.5 Small Molecule Mimetics: 4-Substituted Indole Docking in MOE 
Aim: To dock a database of 4-substituted indoles into the PALB2 binding site, to 
determine whether the Leu binding site can be targeting with these structures.  
Software Package(s): MOE 2015.1001. 
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General Procedure: 
 
Details and Parameters: 
Import of Protein Crystal Structure into MOE 
The 3EU7 crystal structure was downloaded from the protein data bank, and opened in 
MOE. Before docking was carried out, the structure was prepared using the ‘Structure 
Preparation’ and ‘Protonate 3D’ tools. The BRCA2 helix was redefined as a ligand rather 
than a protein by isolating the structure and then exporting as a .mol2 file. The .mol2 file 
was then opened into MOE, causing it to recognise the structure as a small molecule. The 
session with the modified BRCA2 and the PALB2 structure from 3EU7 was then 
exported as a .pdb file, so that when it was imported MOE recognised the structure as a 
protein/ligand rather than a protein/protein interaction. 
Preparation of Pharmacophore Parameters for Docking 
Pharmacophores were generated from the structure of BRCA2 bound to PALB2. A 
pharmacophore was specified to detail each of the 9 atoms in the indole ring, as well as 
the two aromatic ring centres. It was found that this allowed MOE to place the indole 
structures into the correct position, allowing it to optimise the conformation of the 4-
position. This resulted in a total of 11 pharmacophores overall. 
BRCA2/PALB2 
3EU7 .pdb 
structure 
imported into 
MOE and 
prepared. 
Pharmacophore 
parameters 
developed based 
on the tryptophan 
indole ring. 
Indoles docked 
into PALB2 using 
the 
pharmacophore to 
guide the i and 
i+1 positions.  
Library of 4-
substituted indoles 
generated by 
Markush 
enumeration 
imported to MOE. 
Results of 
docking study 
exported as .sdf 
database for 
analysis. 
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Figure 6.4: Use of pharmacophores to guide the docking of 4-substituted indoles. 
Docking Designed BRCA2 Mimetics into PALB2 
The 4-substituted indoles generated by Markush enumeration (procedure 6.4.1) were 
imported into MOE as an .sdf database. These were then docked into the PALB2 binding 
site using the ‘Dock’ function in MOE with the following parameters: 
x Forcefield: Amber10:EHT 
x Receptor: Receptor+Solvent 
x Site: Ligand atoms 
x Placement: α-Triangle 
o Minimum iterations: 80 000 
o Maximum Iterations: 500 000 
o Timeout: 600 seconds 
x Refinement: Induced fit 
o Termination criterion: Gradient = 0.01, iterations = 500 
o Pharmacophore restraint: Force constant = 100, radius offset = 0.4 
 
6.4.6 Miniprotein Design: Homology Modelling in MOE 
Aim: To build homology models of modified miniprotein sequences, so that they can be 
analysed for compatibility with PALB2.  
Software Package(s): MOE 2015.1001. 
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General Procedure: 
 
Details and Parameters: 
Manually Align Sequences to Each Other 
The sequence viewer in MOE was used to manually align the sequences to each other. 
This was done simply by dragging the modified sequence (middle mouse button) so that 
it was in line with the parent sequence, 
Build Homology Model of Modified Sequence 
The ‘Homology Model’ tool in MOE was used to build a model of the modified sequence. 
The parameters used were: 
x Forcefield: Amber10:EHT (Fixed charges) 
x Mainchain models: 10 
x Sidechain models: 4, at temperature: 300 
x Intermediate refinement: Medium 
x Final model: Fine 
x Model scoring: GB/VI 
Once the model had been built, it was exported in .sdf format for later analysis. 
6.4.7 Miniprotein Design: Alignment and Superposition of Miniprotein 
Homology Models to Test For Steric Incompatibilities 
Aim: To superpose the miniprotein homology models with the BRCA2 WFXXL motif, 
so that they can be analysed for steric overlap.  
Software Package(s): MOE 2015.1001. 
Import modified 
sequence and 
parent .pdb 
structure into 
MOE. 
Manually align 
sequences to 
each other. 
Build homology 
model of 
modified 
sequence based 
on parent 
sequence. 
Export as .sdf file 
for analysis. 
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General Procedure: 
 
Details and Parameters: 
Manually Align Sequences to Each Other 
The sequence viewer in MOE was used to manually align the sequences to each other, by 
manually dragging them (middle mouse button) so that the WFXXL motif was in the 
same position in each case.  
Superpose Sequences To The WFXXL Motif 
The superpose tool in the MOE sequence editor was used to superpose the miniproteins 
to the WFXXL motif. The Trp, Phe and Leu residues for each miniprotein were selected, 
and the align tool was set to superpose to ‘Selected Residues’, and ‘Use Current 
Alignment’. 
Check for Steric Overlap 
The MOE ‘contacts’ tool was used to check for steric overlap. The ‘clash’ functionality 
was turned on, showing parts of the miniprotein where steric clash occurred with orange 
disks (Figure 6.5). The residues where clashing occurred were manually listed, in order 
to aid the selection of miniproteins for synthesis. 
  
Figure 6.5: Left: Superposed WFXXL miniprotein based on 1WQD291, with minimal steric clashing. 
Right: Superposed WFXXL miniprotein based on 2RTZ, showing significant steric clashing denoted by 
orange disks. 
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An atom-eﬃcient and convergent approach to the
preparation of NS5A inhibitors by C–H activation†
Thomas O. Moore,* Michael Paradowski and Simon E. Ward
A novel approach of the convergent functionalisation of aryl dibromides to form NS5A type inhibitors
using C–H activation is reported. The focus of investigation was to reduce the formation of homodimeric
side product, as well as to investigate the scope of diﬀerent aryl dibromides that were tolerated under the
reaction conditions. The C–H activation methodology was found to give a viable synthetic route to NS5A
inhibitors, with late stage functionalisation of the core portion of the molecule, albeit with some chemical
functionalities not tolerated.
Introduction
The hepatitis C virus (HCV) is estimated to aﬀect 170 million
people worldwide and, without treatment, may lead to cirrho-
sis, hepatocellular carcinoma, liver failure and ultimately
death.1–4 Until recently, the standard of care for HCV patients
was a combination of lengthy regimens of pegylated interferon
α (pegIFN-α) and ribavirin.5 Those poorly tolerated and mode-
rately eﬃcacious therapies contributed to the urgent need to
identify improved treatments by oral administration. One
major focus to achieve this was targeted at the nonstructural
protein 5A (NS5A) which is enabled in the HCV genome and
plays an essential role for the viral RNA replication.6–8 Those
eﬀorts led to the discovery of daclatasvir (BMS) (Fig. 1), a non
‘rule of 5’ compliant NS5a inhibitor exhibiting picomolar
activity against HCV genotypes 1a and 1b.9 Subsequently, there
have been over 70 patents and publications describing novel
NS5A inhibitors related to Daclatasvir.9–14 Of these, many have
maintained its symmetrical biphenylimidazole core with
diﬀerentiation arising from key structural aryl alterations.15–18
The existing strategy for the preparation of dimeric NS5A
inhibitors is by chain elongation from an aryl bis acetate core.
However, this methodology is linear and does not allow rapid
exploration of the central core unit. A number of reports and
patents have also described the preparation of symmetrical
aryl-imidazoles by a late stage cross coupling of bis-metalated
aryl core to the required halogenated imidazole fragments.17–20
This methodology oﬀers the advantage of a late diversification
of the central core units but suﬀers from the lengthy, expens-
ive and poor atom-eﬃcient processes to install the pre-
requisite organometallic reagents. However, to the best of our
knowledge, none of the late stage cross coupling methodo-
logies reported had the key pharmacophores comprising of a
pair of (S)-methoxycarbonylvaline capped pyrrolidines already
in place and required further synthetic steps to prepare the
reported NS5A inhibitors.
Our search for methodology that allowed us to form this
bond as late as possible highlighted the opportunity to con-
sider a double C–H activation strategy. The C–H activation of
imidazoles in the desired C-5 position is one that has under-
gone much development in recent years.21–25 Arguably the key
development was the establishment of broadly applicable con-
ditions for the C–H activation of heterocycles by Fagnou,24
where the use of pivalic acid as an additive was found to
greatly increase the rate and overall yield of reaction due to
transition state stabilisation.26 Given that the SEM group has
been found to be well tolerated under C–H activation con-
ditions,27 a synthetic route based around the reaction between
SEM-protected imidazoles and aryl dibromides was developed.
Results and discussion
N-Boc-L-prolinal 3 was obtained from the corresponding proli-
nol 2 under mild copper/TEMPO mediated aerobic oxidation
conditions (Scheme 1). Although the Swern oxidation con-
ditions gave 3 in quantitative yields, we had concerns about
Fig. 1 Structure of daclatasvir.
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c6ob00340k
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the potential racemisation of the carbonyl α-carbon due to the
presence of triethylamine, and thus opted for milder con-
ditions on scale up. Cyclisation of the prolinal 3 under glyoxal
and ammonia conditions followed by removal of the BOC pro-
tecting group gave pyrrolidine 5 in 85% yield over three steps.
Methyl carbamate-L-valine 6, obtained via reported Schotten–
Bauman conditions from L-valine,28 was then coupled to
imidazole pyrrolidine 5 by peptide bond formation, although
this proved challenging due to high aqueous solubility of the
product formed and its instability when purified by silica
chromatography. Mild coupling reagents such as guanidinium
salts and carbodiimides were found to be unsuitable mainly
due to the diﬃculty separating the product and byproducts
formed. The respective acid chloride was found to react cleanly
with pyrrolidine 5, however we were concerned with the possi-
bility of ketene formation from HCl elimination, leading to
racemisation of the chiral valyl carbon as reported by Sauer.29
Pyridine was used instead of triethylamine to reduce the likeli-
hood of racemisation and gave 7 in 97% yield. D-Valine-carb-
amate was also coupled with 5 and both NMR and HPLC
experiments confirmed the lack of racemisation under the
reaction conditions. Subsequent protection of imidazole 7
with 2-(trimethylsilyl)ethoxymethyl (SEM) chloride in THF
with sodium hydride as a base gave the key C–H activation
precursor 8 in 47% yield.
Pleasingly, 10 was obtained in moderate yields on first
attempt by double C–H activation of 8 with 4-4′-dibromobiphenyl
under the conditions reported by Fagnou (Pd(dppf)Cl2, PivOH,
DMA, 100 °C, 4 h, Table 1).24 Unfortunately however a homo-
coupled by-product 11 was produced, which proved diﬃcult to
separate from the product by standard purification techniques.
In proof of concept studies on a simplified imidazole reagent
carried out by our group, it was shown that optimisation of
conditions focusing on the base, solvent and reaction tempera-
ture had the greatest eﬀect on formation of this homo-coupled
by-product. We therefore set about modifying these conditions
to test whether it was possible to prevent any by-product for-
mation. It was found that the previously established con-
ditions30 were not only the highest yielding, but also exhibited
very low amounts of homo-coupled product by LCMS analysis.
When the reaction was carried out in dioxane at 100 °C, or in
DMA at 60 °C (Table 1, entries 2 and 6), no homo-coupled
product was observed by LCMS, but the drop in overall yield
and rate of reaction in both of these cases made them imprac-
tical. As such, the Fagnou conditions were deemed the best
suited for use in the double C–H activation. The 78% yield
observed by LCMS for condition 5 equated to an 84% yield
upon scale up and purification by column chromatography.
Scheme 1 Preparation of the key (S)-methoxycarbonylvaline capped pyrrolidine 7.
Table 1 Optimisation conditions for the C–H activation
Entry Base Solvent Temperature Yield 9a 10 : 9a
1 K2CO3 DMF 100 °C 65% 0.13
2 K2CO3 Dioxane 100 °C 10% 0
3 K2CO3 NMP 100 °C 38% 0.05
4 K2CO3 THF 100 °C 25% 0.11
5 K2CO3 DMA 100 °C 78% 0.03
6 K2CO3 DMA 60 °C 1% 0
7 K2CO3 DMA 80 °C 5% 0.15
8 K2CO3 DMA 120 °C 69% 0.07
9 Cs2CO3 DMA 100 °C 21% 0.10
10 KOAc DMA 100 °C 3% 0.23
11 K3PO4 DMA 100 °C 72% 0.06
a Yield of 9 and ratio of 10 : 9 determined by LCMS peak integration
measured by adsorption at 254 nm. Conditions: (i) Pd(dppf)Cl2,
PivOH, base, 4 hours.
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Removal of the SEM protecting group post C–H activation
using organic solubilised fluoride ions proved unsuccessful
even at elevated temperatures and extended reaction times.
However, conditions involving trifluoroacetic acid at room
temperature cleaved the SEM group slowly but in quantitative
yield (Scheme 2). Despite some initial stability concerns, the
methyl carbamate functionality proved to be stable under the
TFA deprotection conditions.
With the synthesis for 1 optimised, we turned our attention
to the scope of this methodology for the rapid synthesis of
potential symmetrical NS5A inhibitors (Table 2). Under the
reaction conditions developed above, bis-CH activated pro-
ducts were obtained in moderate to good yields over 2 steps.
Purification of deprotected product was carried out by prep-
scale LCMS mass directed auto purification, giving better
separation of the product and homo-dimer by-product.
Overall, of 16 diﬀerent aryl dibromides tested, 9 successfully
underwent double C–H activation. The yields of successful
couplings consistently ranges from moderate to good on a
0.1 mmol scale. The proportion of homo-dimer to product,
however, was found to vary greatly, with a tendency to be
highest in electron rich aryl di-bromides, such as entries 4
and 7.
Several functional groups were found to not be compatible
with the reaction conditions used. The presence of an alkyne
(entry 5) seemed to prevent formation of the anticipated
product, and instead produced many unidentifiable side-
products. Coordination of alkynes to palladium centres through
an η-2 binding mode is well precedented to undergo a wide
variety of reactions, and as such this seems likely to be respon-
sible for the lack of desired reactivity observed.31 Aryl di-
bromides containing a 2-phenylpyridine (entries 6 and 15)
functionality also did not allow the reaction to proceed as
hoped, with the reaction mixture containing starting materials
and a mixture of side products after prolonged heating. There
is much precedent for the C–H activation directing capability
of pyridyl nitrogen’s onto 2-phenyl groups,32 possibly account-
ing for the loss of desired reactivity, however there was no
identifiable side product proving this hypothesis. Further-
more, no reaction was observed in the presence of aryl di-
bromides containing an N–H functionality (entries 11, 12, 14
and 16). However, when the amide group in entry 12 was
Table 2 Scope of double C–H activation
Entry Aryl dibromide Yielda (%) HD : Pb
1 78% 0.13
2 80% 0
3 64% 0.37
4 37% 0.72
5 0% —
6 0% —
7 42% 0.68
8 67% 0.12
9c 45% 0.26
10c 58% 0.23
11 0% —
12 0% —
13 67% 0
14 0% —
Scheme 2 Deprotection step under protolytic conditions.
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masked with an N-methyl functionality the reaction proceeded
well (entry 13). This is particularly surprising considering the
presence of a carbamate N–H bond within the imidazole start-
ing material, which is tolerated in the reaction conditions.
Subsequent deprotection under TFA conditions led to the
preparation of the NS5A-like analogues. To our surprise, the
furan and thiophene (entries 9 and 10) were found to decom-
pose upon exposure to TFA during the deprotection. As they
were also found to be unreactive towards milder TBAF con-
ditions, they were purified and characterised as the SEM-
protected analogue instead.
Conclusions
In summary, we have described a novel, green and eﬃcient
approach to the synthesis of symmetrical NS5A-like com-
pounds such as daclatasvir. The overall synthesis was accom-
plished using a novel double C–H activation as a key step that
allows for a rapid synthesis of analogues and late stage struc-
tural diversification, which is to our knowledge the first time
that palladium catalysed C–H activation has been used to con-
struct symmetrical molecules in such a way. However, we
found that intolerance of some co-ordinating functionalities in
the reaction conditions gave some limitation to the methodo-
logy, and this must be considered when hoping to attempt this
strategy.
Experimental section
General procedure for C–H activated cross coupling for
compound without deprotection
The appropriate aryl dibromide (0.10 mmol), (S)-tert-butyl 2-(1-
((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-
1-carboxylate (7, 100 mg, 0.240 mmol), pivalic acid (6.1 mg,
0.060 mmol), K2CO3 (41 mg, 0.30 mmol) and Pd(ddpf)Cl2
(7.3 mg, 0.010 mmol) were placed in a sealed reaction vial. The
reaction vial was placed under reduced pressure then purged
with nitrogen, repeating the process 5 times. The contents of
the sealed vial were dissolved in dimethylacetamide (1 mL),
and the solvent was deoxygenated by bubbling with nitrogen
for 20 minutes. The solution was then irradiated in a micro-
wave at 100 °C for 4 hours. The resulting solution was
quenched with water (15 mL), and extracted with EtOAc
(2 × 10 mL). The organic phase was washed with concentrated
sodium bicarbonate solution (2 × 15 mL) water (2 × 15 mL),
and brine (2 × 15 mL), before being concentrated to a solid
under reduced pressure. This solid was then purified to the
desired product by mass-directed auto purification.
Dimethyl(2S,2′S)-1,1′-((2S,2′S)-2,2′-(5,5′-(biphenyl-4,4′-diyl)
bis(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-5,2-diyl))
bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl)
dicarbamate (10). 1H NMR (500 MHz, CD3OD) 7.79 (4H, d,
J 7.8 Hz, ArH), 7.59 (4H, d, J 7.9 Hz, ArH), 7.04 (2H, s, ArH),
5.79 (2H, d, J 10.9 Hz, CH2), 5.32 (2H, d, J 10.9 Hz, CH2), 5.24
(2H, s, CH), 4.22 (2H, d, J 7.5 Hz, CH), 4.11–4.03 (2H, m, CH2),
3.95–3.86 (2H, m, CH2), 3.66 (6H, s, CH3), 3.61–3.44 (4H, m,
CH2), 2.37 (4H, m, CHAB), 2.21–1.96 (6H, m, CHAB), 0.90 (16H,
m, CH2, CH3), −0.03 (18H, s, Si(CH3)3); 13C NMR (126 MHz,
CD3OD) 171.7 (CO), 158.0, OC(O)N), 150.9 (NCN), 140.0 (ArC),
133.1 (ArC), 129.4 (ArCH), 128.8 (ArC), 127.0 (ArCH), 125.4
(ArCH), 72.1 (CH2), 65.6 (CH2), 58.3 (CH), 53.2 (CH), 51.3
(CH3), 47.6 (CH2), 31.6 (CH2), 30.1 (CH), 24.7 (CH2), 18.4
(CH3), 17.30 (CH2), −2.84 (Si(CH3)3); IR (neat, νmax, cm−1) 3276
(bw), 2959 (m), 1719 (s), 1631 (s), 1507 (m), 1441 (s), 1248 (s),
1189 (m), 1178 (s), 1033 (m), 820.21 (s), 693 (m); HRMS (ESI):
calcd for C52H78N8Na1O8Si2 [M + H]+ 1021.5368, found
1012.5373; [α]D −39.4 (c 0.6 in CHCl3, T 21.0 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-(furan-2,5-diylbis(4,1-
phenylene))bis(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imid-
azole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-
2,1-diyl))dicarbamate (12). 1H NMR (500 MHz, CDCl3) δ 7.80
(4H, d, J 8.0 Hz, ArH), 7.49 (4H, d, J 8.1 Hz, ArH), 7.05 (2H, s,
FurylH), 6.82 (2H, s, ArH), 5.79 (2H, d, J 10.6 Hz, CH2), 5.29
(2H, d, J 9.1 Hz, NH), 5.24–5.16 (4H, m, CHAB, CH), 4.35 (2H,
dd, J 9.2, 6.4 Hz, CH), 3.98–3.87 (4H, m, CH2), 3.67 (6H, s,
CH3), 3.59–3.46 (4H, m, CH2), 2.55–2.42 (2H, m, CHAB),
2.39–2.26 (4H, m, CH2), 2.15–1.91 (4H, m, CHAB, CH),
1.01–0.87 (10H, m, CH3, CH2), 0.80 (6H, d, J 6.7 Hz, CH3), 0.00
(18H, s, Si(CH3)3); 13C NMR (126 MHz, CDCl3) δ 170.9 (CO),
157.1 (OC(O)N), 153.3 (ArC), 151.6 (ArC), 150.7 (ArC), 133.8
(ArC), 132.8 (ArC), 129.3 (ArCH), 124.0 (ArCH), 108.0 (ArCH),
88.3 (FurylCH), 65.9 (CH2), 57.6 (CH), 52.9 (CH), 52.2 (CH3),
47.6 (CH2), 31.8 (CH2), 31.1 (CH), 25.2 (CH2), 19.3 (CH3), 18.0
Table 2 (Contd.)
Entry Aryl dibromide Yielda (%) HD : Pb
15 0% —
16 0% —
a Yield of product determined by LCMS peak integration measured by
adsorption at 254 nm. Characterisation was carried out on the fully
deprotected product (see Experimental section). b Ratio of homo-dimer
to product. c Product decomposed under deprotection and
characterisation was carried out on the SEM-protected product.
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(CH2), 17.3 (CH3), −1.4 (Si(CH3)3); IR (neat, νmax, cm−1) 2955
(m), 1719 (s), 1640 (s), 1503 (m), 1440 (m), 1249 (s), 1188 (m),
1082 (s), 1030 (w), 837 (s), 697 (w); HRMS (ESI): calcd
for C56H81N8O7Si2 [M + H]+ 1065.5660, found 1065.5642;
[α]D −102.1 (c 0.3 in CHCl3, T 22.5 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-(thiophene-2,5-diylbis-
(4,1-phenylene))bis(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imid-
azole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-
2,1-diyl))dicarbamate (13). 1H NMR (500 MHz, CDCl3) δ 7.71
(4H, d, J 7.8 Hz, ArH), 7.47 (4H, d, J 8.0 Hz, ArH), 7.38 (2H, s,
thiopheneH), 7.12 (2H, s, ArH), 5.81 (2H, d, J 10.6 Hz, CHAB),
5.29–5.14 (6H, m, CHAB, CH, NH), 4.39–4.31 (2H, m, CH),
4.21–4.05 (2H, m, CHAB), 3.99–3.84 (2H, m, CHAB), 3.66 (6H, s,
CH3), 3.59–3.43 (4H, m, CH2), 2.58–2.28 (6H, m, CHAB, CH2),
2.17–1.93 (4H, m, CHAB, CH), 1.01–0.85 (10H, m, CH3, CH2),
0.79 (6H, d, J 6.7 Hz, CH3), 0.00 (18H, s, Si(CH3)3); 13C NMR
(126 MHz, CDCl3) δ 171.4 (CO), 157.1 (OC(O)N), 150.3 (NCN),
143.2 (ArC), 134.5 (ArC), 134.1 (ArC), 132.9 (ArC), 129.7 (ArCH),
125.9 (ArCH), 124.8 (thiopheneCH), 118.4 (ArCH), 72.9 (CH2),
66.4 (CH2), 57.7 (CH), 52.8 (CH), 52.2 (CH3), 47.7 (CH2), 31.7
(CH2), 30.6 (CH), 25.4 (CH2), 19.4 (CH3), 18.0 (CH2), 17.2
(CH3), −1.4 (Si(CH3)3); IR (neat, νmax, cm−1) 3681 (bw), 2967
(m), 2844 (m), 1718 (m), 1637 (m), 1508 (w), 1455 (m), 1429
(m), 1055 (s), 1033 (s), 1015 (s), 838 (m); HRMS (ESI): calcd
for C56H81N8O6Si2S [M + H]+ 1081.5431, found 1081.5449;
[α]D −69.1 (c 1.2 in CHCl3, T 22.7 °C).
General procedure for C–H activated cross coupling and
subsequent SEM-removal
The appropriate aryl dibromide (0.10 mmol), (S)-tert-butyl 2-(1-
((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)pyrrolidine-
1-carboxylate (7, 100 mg, 0.240 mmol), pivalic acid (6.1 mg,
0.060 mmol), K2CO3 (41 mg, 0.30 mmol) and Pd(ddpf)Cl2
(7.3 mg, 0.010 mmol) were placed in a sealed reaction vial. The
reaction vial was placed under reduced pressure then purged
with nitrogen, repeating the process 5 times. The contents of
the sealed vial were dissolved in dimethylacetamide (1 mL),
and the solvent was deoxygenated by bubbling with nitrogen
for 20 minutes. The solution was then irradiated in a micro-
wave at 100 °C for 4 hours. The resulting solution was
quenched with water (15 mL), and extracted with EtOAc
(2 × 10 mL). The organic phase was washed with concentrated
sodium bicarbonate solution (2 × 15 mL) water (2 × 15 mL),
and brine (2 × 15 mL), before being concentrated to a solid
under reduced pressure. This solid material was then re-
dissolved in dichloromethane (0.5 mL) and trifluoroacetic acid
(0.50 mL, 6.5 mmol) was added. The solution was then stirred
in inert atmosphere for 4 hours, before being diluted with
dichloromethane (15 mL). The solution was then washed with
concentrated sodium bicarbonate solution (2 × 30 mL), taking
care due to the production of gas as the solution is neutral-
ised. The organic phase was then concentrated to a solid
under reduced pressure. This solid was then purified to the
desired product by mass-directed auto purification.
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-([1,1′-biphenyl]-4,4′-diyl)
bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-
oxobutane-2,1-diyl))dicarbamate (1). 1H NMR (500 MHz,
CD3OD) 7.73 (4H, d, J 8.2 Hz, ArH), 7.66 (4H, d, J 8.0, Ar), 7.37
(2H, s, ArH), 5.19 (2H, dd, J 8.0 Hz, 6.3 Hz, CH), 4.24 (2H, d,
J 7.4 Hz, CH), 4.05–3.95 (2H, m, CHAB), 3.92–3.84 (2H, m,
CHAB), 3.66 (6H, s, CH3), 2.41–2.17 (6H, m, CH2, CHAB),
2.11–2.04 (4H, m, CHAB, CH), 0.93 (12H, dd, J 22.0 Hz, 6.8 Hz,
i-PrCH3); 13C NMR (126 MHz, CD3OD) 172.0 (CO), 158.0
(NCN), 149.6 (OC(O)N), 139.0 (ArC), 136.1 (ArC), 130.9 (ArC),
126.6 (ArCH), 125.0 (ArCH), 116.2 (ArCH), 58.4 (CH), 54.8 (CH),
51.3 (CH3), 47.4 (CH2), 30.9 (CH2), 30.1 (CH), 24.7 (CH2), 18.4
(i-PrCH3), 17.0 (i-PrCH3); IR (neat, νmax, cm−1) 2964 (w), 2875
(w), 1705 (s), 1632 (s), 1446 (s), 1393 (s), 1258 (w), 1035 (m),
829 (m), 773 (m); HRMS (ESI): calcd for C40H51N8O6 [M + H]+
739.3926, found 739.3937; [α]D −170.0 (c 0.6 in CHCl3,
T 22.2 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-(1,4-phenylene)bis(1H-
imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxo-
butane-2,1-diyl))dicarbamate (14). 1H NMR (500 MHz,
CD3OD) 7.88 (4H, s, Ar), 7.48 (2H, s, ArH), 5.29–5.19 (2H, m,
CH), 4.29–4.17 (2H, m, CH), 4.14–3.97 (2H, m, CHAB),
3.93–3.77 (2H, m, CHAB), 3.66 (6H, s, CH3), 2.60–2.46 (CHAB, m,
2H), 2.32–1.95 (8H, m, CHAB, CH2, CH), 0.96–0.85 (12H, m,
i-PrCH3); 13C NMR (126 MHz, CD3OD) 172.7 (CO), 158.1
(NCN), 149.4 (OC(O)N), 147.5 (ArC), 126.0 (ArC), 118.7 (ArCH),
115.3 (ArCH), 58.5 (CH), 53.7 (CH), 53.2 (CH2), 51.4 (CH3), 29.8
(CH), 24.9 (CH2), 18.4 (CH2), 16.7 (i-PrCH3); IR (neat, νmax,
cm−1) 3284 (bw), 2962 (w), 1711 (s), 1625 (s), 1521 (s), 1444 (s),
1370 (w), 1264 (s), 1192 (m), 1098 (m), 1037 (m), 846 (m), 734
(s); HRMS (ESI): calcd for C34H47N8O6 [M + H]+ 663.3613,
found 663.3608; [α]D −288.6 (c 0.3 in CHCl3, T 22.6 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-((E)-ethene-1,2-diylbis(4,1-
phenylene))bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))
bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate (15). 1H NMR
(500 MHz, CD3OD) 8.16 (2H, s, alkeneH), 7.92 (2H, d, J 8.6 Hz,
ArCH), 7.82 (2H, d, J 8.3 Hz, ArCH), 7.66 (2H, s, ArCH), 5.24
(2H, dd, J 8.1 Hz, 6.2 Hz, CH), 4.26 (2H, d, J 7.3 Hz, CH),
4.09–4.02 (2H, m, CHAB), 3.97–3.81 (2H, m, CHAB), 3.67 (6H, s,
CH3), 2.52–2.41 (2H, m, CHAB), 2.32–2.02 (8H, m, CHAB, CH2,
CH), 0.94 (12H, dd, J 24.3, 6.7, i-PrCH3); 13C NMR (126 MHz,
CD3OD) 172.4 (CO), 163.2 (NCN), 158.1 (ArC), 149.6 (OC(O)N),
133.0 (ArC), 128.5 (ArC), 125.0 (alkeneCH), 123.7 (ArCH), 123.0
(ArCH), 115.8 (ArCH), 58.5 (CH), 54.4 (CH), 51.4 (CH3), 47.5
(CH2), 30.9 (CH2), 30.0 (CH), 24.8 (CH2), 18.4 (CH3), 16.9
(i-PrCH3); IR (neat, νmax, cm−1) 2966 (w), 2876 (w), 1701 (s),
1631 (s), 1521 (m), 1443 (m), 1264 (w), 1201 (s), 1132 (m), 1033
(w), 799 (w), 719 (m); HRMS (ESI): calcd for C42H53N8O6
[M + H]+ 765.4083, found 765.4118; [α]D −538.3 (c 0.3 in
CHCl3, T 22.6 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-(naphthalene-2,6-diyl)
bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-
1-oxobutane-2,1-diyl))dicarbamate (16). 1H NMR (500 MHz,
CD3OD) 7.64–7.54 (4H, m, ArH), 7.41 (2H, s, ArH), 7.20–7.13
(2H, m, ArCH), 5.19 (2H, t, J 7.0 Hz, CH), 4.24 (2H, d, J 7.3 Hz,
CH), 4.06–3.97 (2H, m, CHAB), 3.92–3.83 (2H, m, 22/26-CHAB),
3.66 (6H, s, CH3), 2.43–2.32 (2H, m, CHAB), 2.31–1.97 (8H,
m, CHAB, CH2, CH), 0.93 (12H, dd, J 22.8 Hz, 6.9 Hz, i-PrCH3);
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13C NMR (126 MHz, CD3OD) 172.2 (CO), 158.0 (NCN), 149.4
(OC(O)N), 136.7 (ArC), 135.6 (ArC), 130.0 (ArC), 127.8 (ArCH),
126.7 (ArCH), 124.8 (ArCH), 115.9 (ArCH), 58.4 (CH), 54.6 (CH),
51.4 (CH3), 47.5 (CH2), 30.9 (CH2), 30.1 (CH), 24.7 (CH2), 18.4
(i-PrCH3), 16.9 (i-PrCH3); IR (neat, νmax, cm−1) 3287 (bw), 2962
(w), 2875 (w), 1711 (s), 1628 (w), 1517 (m) 1443 (m), 1370 (w),
1264 (m), 1181 (m), 1131 (m), 1035 (m), 947 (w), 841 (m), 775
(m), 732 (s); HRMS (ESI): calcd for C38H49N8O6 [M + H]+
713.3770, found 713.3779; [α]D −222.1 (c 0.6 in CHCl3,
T 22.1 °C).
Dimethyl((2S,2′S)-((2S,2′S)-2,2′-(5,5′-(oxybis(4,1-phenylene))
bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-
1-oxobutane-2,1-diyl))dicarbamate (17). 1H NMR (500 MHz,
CD3OD) 8.13 (2H, s, NH), 7.68 (4H, d, J 8.1 Hz, ArH), 7.48 (2H,
s, ArH), 7.08 (4H, d, J 8.0 Hz, ArH), 5.20 (2H, t, J 7.1 Hz, CH),
4.24 (2H, d, J 7.2 Hz, CH), 4.09–3.99 (2H, m, CHAB), 3.92–3.82
(2H, m, CHAB), 3.66 (6H, s, CH3), 2.50–2.35 (2H, m, CHAB),
2.31–1.97 (8H, m, CHAB, CH2, CH), 0.91 (12H, dd, J 20.4 Hz,
6.8 Hz, i-PrCH3); 13C NMR (126 MHz, CD3OD) 172.3 (CO),
163.5 (NCN), 158.1 (OC(O)N), 156.9 (ArC), 149.1 (ArC), 134.9
(ArC), 126.6 (ArCH), 118.9 (ArCH), 114.8 (ArCH), 58.4 (CH),
54.3 (CH), 51.4 (CH3), 47.5 (CH2), 30.9 (CH2), 30.0 (CH), 24.8
(CH2), 18.4 (i-PrCH3), 16.8 (i-PrCH3); IR (neat, νmax, cm−1) 3294
(bw), 2962 (w), 2875 (w), 1712 (m), 1627 (s), 1497 (m), 1424
(m), 1237 (s), 1199 (m), 1198 9m), 1130 (m), 1033 (m), 798 (m),
733 (s), 701 (m); HRMS (ESI): calcd for C40H51N8O7 [M + H]+
755.3875, found 755.3882; [α]D −114.3 (c 0.6 in CHCl3,
T 22.0 °C).
Methyl N-[(2S)-1-[(2S)-2-{5-[4-(5-{2-[(2S)-1-[(2S)-2-[(methoxy-
carbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imid-
azol-5-yl}-1,3-benzoxazol-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-
1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (18). 1H NMR
(500 MHz, CD3OD) δ 8.33–8.20 (2H, m, ArH), 8.02 (1H, d, J 8.3
Hz, ArH), 7.94–7.84 (2H, m, ArH), 7.83–7.70 (2H, m, ArH),
7.72–7.59 (2H, m, ArH), 5.27–5.18 (2H, m, CH), 4.25 (2H, t, J =
7.3 Hz, CH), 4.13–3.98 (2H, m, CHAB), 3.95–3.84 (2H, m, CHAB),
3.66 (6H, s, CH3), 2.57–2.35 (2H, m, CHAB), 2.32–2.02 (8H, m,
CHAB, CH2, CH), 0.99–0.89 (12H, m, iPrCH3); 13C NMR
(126 MHz, CD3OD 3) δ 173.7 (CO), 165.0 (ArC), 159.5 (OC(O)N),
152.9 (ArC), 152.4 (Ar–C), 152.0 (Ar–C), 151.5 (ArC), 150.3
(NCN), 136.6 (ArC), 136.0 (ArC), 129.3 (ArCH), 126.5 (ArCH),
124.5 (ArCH), 118.0 (ArCH), 117.5 (ArCH), 116.4 (ArCH), 112.5
(ArCH), 59.9 (CH), 55.4 (CH3), 52.8 (CH2), 49.0 (CH2), 32.4
(CH2), 31.5 (CH), 26.3 (CH2), 19.8 (iPrCH3), 18.3 (iPrCH3);
IR (neat, νmax, cm−1) 3284 (bw), 2966 (w), 2875 (w), 1699 (m),
1628 (s), 1517 (m), 1424 (m), 1368 (w), 1265 (m), 1180 (s), 1132
(s), 1039 (m), 825 (m), 798 (m), 732 (s); HRMS (ESI): calcd for
C41H50N9O7 [M + H]+ 780.3828, found 780.3804; [α]D −446.6
(c 0.3 in CHCl3, T 22.4 °C).
Methyl N-[(2S)-1-[(2S)-2-(5-{4-[(4-{2-[(2S)-1-[(2S)-2-[(methoxy-
carbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-
5-yl}phenyl)(methyl)carbamoyl]phenyl}-1H-imidazol-2-yl)pyrro-
lidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate (19). 1H NMR
(500 MHz, CDCl3) δ 7.51–7.39 (2H, m, ArH), 7.35–7.26 (2H, m,
ArH), 7.26–7.20 (2H, m, ArH), 7.15–7.04 (2H, m, ArH), 6.98 (2H,
d, J 8.2 Hz, ArH), 5.58 (2H, s, NH), 5.18 (2H, s, CH), 4.30 (2H, t,
J 8.1 Hz, CH), 3.90–3.77 (2H, m, CHAB), 3.74–3.63 (8H, m,
CHAB, CH3), 3.46 (3H, s, CH3), 2.35–2.11 (4H, m, CHAB, CHAB),
2.09–1.85 (6H, m, CHAB, CHAB, CH), 0.88–0.77 (12H, m,
i-PrCH3); 13C NMR (100 MHz, CDCl3) δ 172.6 (CO), 170.2 (CO),
157.1 (OC(O)N), 148.5 (NCN), 143.6 (ArC), 138.5 (ArC), 134.3
(ArC), 132.3 (ArC), 129.3 (ArCH), 127.1 (ArCH), 125.5 (ArCH),
124.6 (ArC), 123.9 (ArCH), 115.3 (ArCH), 57.7 (CH), 54.2 (CH),
52.3 (CH3), 47.8 (CH2), 38.4 (CH3), 30.8 (CH), 28.4 (CH2), 25.2
(CH2), 19.2 (i-PrCH3), 17.43 (i-PrCH3); IR (neat, νmax, cm−1)
3227 (bw), 2958 (w), 1698 (s), 1630 (s), 1532 (m), 1445 (m),
1396 (m), 1203 (m), 1137 (m), 1038 (w), 847 (w); HRMS (ESI):
calcd for C41H50N9O7 [M + H]+ 796.4141, found 796.4240;
[α]D −243.3 (c 0.6 in CHCl3, T 22.4 °C).
Acknowledgements
Thanks to Dr Iain Day for his help with NMR spectroscopy,
and Dr Alaa Abdul-Sada for his help with mass spectroscopy.
Thanks to all members of the SDDC who have helped support
this project.
Marvin was used for drawing, displaying and characterizing
chemical structures, substructures and reactions and Calcula-
tor Plugins were used for structure property prediction and
calculation, Marvin 15.8.10.0, 2015, ChemAxon (http://www.
chemaxon.com).
References
1 R. S. Brown, Nature, 2005, 436, 973–978.
2 D. Lavanchy, Liver Int., 2009, 29, 74–81.
3 T. K. H. Scheel and C. M. Rice, Nat. Med., 2013, 19, 837–
849.
4 D. L. Thomas, Nat. Med., 2013, 19, 850–858.
5 F. J. Torriani, M. Rodriguez-Torres, J. K. Rockstroh,
E. Lissen, J. Gonzalez-García, A. Lazzarin, G. Carosi,
J. Sasadeusz, C. Katlama, J. Montaner, H. Sette, S. Passe,
J. De Pamphilis, F. Duﬀ, U. M. Schrenk and D. T. Dieterich,
N. Engl. J. Med., 2004, 351, 438–450.
6 R. Bartenschlager and V. Lohmann, J. Gen. Virol., 2000, 81,
1631–1648.
7 K. L. LeMay, J. Treadaway, I. Angulo and
T. L. Tellinghuisen, J. Virol., 2013, 87, 1255–1260.
8 M. Hughes, S. Griﬃn and M. Harris, J. Gen. Virol., 2009, 90,
1329–1334.
9 M. Belema and N. A. Meanwell, J. Med. Chem., 2014, 57,
5057–5071.
10 M. Belema, O. D. Lopez, J. A. Bender, J. L. Romine,
D. R. St. Laurent, D. R. Langley, J. A. Lemm, D. R. O’Boyle,
J. H. Sun, C. Wang, R. A. Fridell and N. A. Meanwell,
J. Med. Chem., 2014, 57, 1643–1672.
11 M. Belema, V. N. Nguyen, C. Bachand, D. H. Deon,
J. T. Goodrich, C. A. James, R. Lavoie, O. D. Lopez,
A. Martel, J. L. Romine, E. H. Ruediger, L. B. Snyder,
Paper Organic & Biomolecular Chemistry
3312 | Org. Biomol. Chem., 2016, 14, 3307–3313 This journal is © The Royal Society of Chemistry 2016
Op
en
 A
cc
ess
 A
rti
cle
. P
ub
lis
he
d o
n 2
5 F
eb
rua
ry 
20
16
. D
ow
nlo
ad
ed
 on
 01
/08
/20
16
 14
:10
:46
. 
 T
his
 ar
tic
le 
is 
lic
en
sed
 un
de
r a
 C
rea
tiv
e C
om
mo
ns
 A
ttr
ibu
tio
n 3
.0 
Un
po
rte
d L
ice
nc
e.
View Article Online
D. R. S. Laurent, F. Yang, J. Zhu, H. S. Wong, D. R. Langley,
S. P. Adams, G. H. Cantor, A. Chimalakonda, A. Fura,
B. M. Johnson, J. O. Knipe, D. D. Parker, K. S. Santone,
R. A. Fridell, J. A. Lemm, D. R. O’Boyle, R. J. Colonno,
M. Gao, N. A. Meanwell and L. G. Hamann, J. Med. Chem.,
2014, 57, 2013–2032.
12 D. R. St. Laurent, M. H. Serrano-Wu, M. Belema, M. Ding,
H. Fang, M. Gao, J. T. Goodrich, R. G. Krause, J. A. Lemm,
M. Liu, O. D. Lopez, V. N. Nguyen, P. T. Nower,
D. R. O’Boyle, B. C. Pearce, J. L. Romine, L. Valera,
J. H. Sun, Y. K. Wang, F. Yang, X. Yang, N. A. Meanwell and
L. B. Snyder, J. Med. Chem., 2014, 57, 1976–1994.
13 M. Belema, V. N. Nguyen, D. R. St. Laurent, O. D. Lopez,
Y. Qiu, A. C. Good, P. T. Nower, L. Valera, D. R. O’Boyle,
J. H. Sun, M. Liu, R. A. Fridell, J. A. Lemm, M. Gao,
J. O. Knipe, N. A. Meanwell and L. B. Snyder, Bioorg. Med.
Chem. Lett., 2013, 23, 4428–4435.
14 M. Belema, V. N. Nguyen, J. L. Romine, D. R. St. Laurent,
O. D. Lopez, J. T. Goodrich, P. T. Nower, D. R. O’Boyle,
J. A. Lemm, R. A. Fridell, M. Gao, H. Fang, R. G. Krause,
Y. K. Wang, A. J. Oliver, A. C. Good, J. O. Knipe,
N. A. Meanwell and L. B. Snyder, J. Med. Chem., 2014, 57,
1995–2012.
15 D. A. DeGoey, J. T. Randolph, D. Liu, J. Pratt, C. Hutchins,
P. Donner, A. C. Krueger, M. Matulenko, S. Patel,
C. E. Motter, L. Nelson, R. Keddy, M. Tufano, D. D. Caspi,
P. Krishnan, N. Mistry, G. Koev, T. J. Reisch, R. Mondal,
T. Pilot-Matias, Y. Gao, D. W. A. Beno, C. J. Maring,
A. Molla, E. Dumas, A. Campbell, L. Williams, C. Collins,
R. Wagner and W. M. Kati, J. Med. Chem., 2014, 57, 2047–
2057.
16 O. D. Lopez, V. N. Nguyen, D. R. St. Laurent, M. Belema,
M. H. Serrano-Wu, J. T. Goodrich, F. Yang, Y. Qiu,
A. S. Ripka, P. T. Nower, L. Valera, M. Liu, D. R. O’Boyle,
J.-H. Sun, R. A. Fridell, J. A. Lemm, M. Gao, A. C. Good,
N. A. Meanwell and L. B. Snyder, Bioorg. Med. Chem. Lett.,
2013, 23, 779–784.
17 I. K. Mangion, C. Chen, H. Li, P. Maligres, Y. Chen,
M. Christensen, R. Cohen, I. Jeon, A. Klapars, S. Krska,
H. Nguyen, R. A. Reamer, B. D. Sherry and I. Zavialov, Org.
Lett., 2014, 16, 2310–2313.
18 F. Wakenhut, T. D. Tran, C. Pickford, S. Shaw, M. Westby,
C. Smith-Burchnell, L. Watson, M. Paradowski, J. Milbank,
D. Stonehouse, K. Cheung, R. Wybrow, F. Daverio,
S. Crook, K. Statham, D. Leese, D. Stead, F. Adam, D. Hay,
L. R. Roberts, J.-Y. Chiva, C. Nichols, D. C. Blakemore,
G. H. Goetz, Y. Che, I. Gardner, S. Dayal, A. Pike,
R. Webster and D. C. Pryde, ChemMedChem, 2014, 9, 1387–
1396.
19 M. Zhong, E. Peng, N. Huang, Q. Huang, A. Huq, M. Lau,
R. Colonno and L. Li, Bioorg. Med. Chem. Lett., 2014, 24,
5738–5742.
20 T. D. Tran, F. Wakenhut, C. Pickford, S. Shaw, M. Westby,
C. Smith-Burchnell, L. Watson, M. Paradowski, J. Milbank,
R. A. Brimage, R. Halstead, R. Glen, C. P. Wilson, F. Adam,
D. Hay, J.-Y. Chiva, C. Nichols, D. C. Blakemore, I. Gardner,
S. Dayal, A. Pike, R. Webster and D. C. Pryde, ChemMed-
Chem, 2014, 9, 1378–1386.
21 F. Bellina, S. Cauteruccio, L. Mannina, R. Rossi and S. Viel,
J. Org. Chem., 2005, 70, 3997–4005.
22 F. Bellina, S. Cauteruccio, L. Mannina, R. Rossi and S. Viel,
Eur. J. Org. Chem., 2006, 693–703.
23 F. Bellina, S. Cauteruccio, A. Di Fiore and R. Rossi,
Eur. J. Org. Chem., 2008, 5436–5445.
24 B. Liégault, D. Lapointe, L. Caron, A. Vlassova and
K. Fagnou, J. Org. Chem., 2009, 74, 1826–1834.
25 R. Goikhman, T. L. Jacques and D. Sames, J. Am. Chem.
Soc., 2009, 131, 3042–3048.
26 S. I. Gorelsky, D. Lapointe and K. Fagnou, J. Am. Chem.
Soc., 2008, 130, 10848–10849.
27 J. M. Joo, B. B. Touré and D. Sames, J. Org. Chem., 2010, 75,
4911–4920.
28 I. H. Bae, J. K. Choi, C. Chough, S. J. Keum, H. Kim,
S. K. Jang and B. M. Kim, ACS Med. Chem. Lett., 2014, 5,
255–258.
29 J. C. Sauer, J. Am. Chem. Soc., 1947, 69, 2444–2448.
30 B. Liégault, D. Lapointe, L. Caron, A. Vlassova and
K. Fagnou, J. Org. Chem., 2009, 74, 1826–1834.
31 R. Chinchilla and C. Nájera, Chem. Rev., 2014, 114, 1783–
1826.
32 D. Alberico, M. E. Scott and M. Lautens, Chem. Rev., 2007,
107, 174–238.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2016 Org. Biomol. Chem., 2016, 14, 3307–3313 | 3313
Op
en
 A
cc
ess
 A
rti
cle
. P
ub
lis
he
d o
n 2
5 F
eb
rua
ry 
20
16
. D
ow
nlo
ad
ed
 on
 01
/08
/20
16
 14
:10
:46
. 
 T
his
 ar
tic
le 
is 
lic
en
sed
 un
de
r a
 C
rea
tiv
e C
om
mo
ns
 A
ttr
ibu
tio
n 3
.0 
Un
po
rte
d L
ice
nc
e.
View Article Online
